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Abstract
Human Enterovirus 71 Infection in Sarawak, Malaysia Mong How Ooi
Introduction: Hand, foot and mouth disease (HFMD) is a childhood exanthema 
caused by enteroviruses, such as coxsackie virus A (CVA) 16. However since 1997 
large epidemics of HFMD caused by human enterovirus (EV) 71 and associated 
with severe and sometimes fatal neurological complications have occurred across 
Asia.
Aims: To examine: (i) the diagnostic approach for detection of EV71, (ii) the 
clinical and molecular epidemiology of the virus in Sarawak, (iii) the clinical 
predictors for neurological involvement, and (iv) the viral determinants for clinical 
phenotype of EV71 infection.
Methods: A prospective study was set up to examine children with HFMD 
presenting to Sibu Hospital, Sarawak, Malaysia between January 2000 and 
December 2006. Detailed history and clinical examination was performed and 
recorded on standardised forms. Throat and rectal swabs, and swabs from skin 
vesicles and mouth ulcers, if present, were taken from every patient. Lumbar 
puncture was performed in patients with suspected neurological involvement. Virus 
isolation and RT-PCR for enteroviruses were performed on all specimens. Isolated 
enteroviruses were typed by nucleotide sequencing of VP1 and VP4 genes and 
genogrouped by phylogenetic analysis.
Results: Throat and vesicle swabs were the most useful samples for detection of 
EV71. Using virus culture results as the reference, an EV71-specific assay originally 
developed for molecular typing of EV71 clinical isolates had a sensitivity of 76.9% 
(258/337), specificity of 82.6% (133/161), positive predictive value of 90.2% 
(259/287) and negative predictive value of 63.0% (133/211) when evaluated with 
337 EV71-positive, 161 non-EV71 culture-positive clinical specimens. Epidemics of 
EV71 -associated HFMD occurred every 3 years in Sarawak, and were caused by 
genogroups B4 and B5, and Cl. The genogroups of EV71 differ in their risk of 
causing neurological disease and family clusters. Total duration of fever >3 days, 
peak temperature >38.5°C and history of lethargy were identified and validated as 
independent risk factors for neurological involvement. EV71-positive children were 
more likely to have neurological disease when compared to CVA16-positive 
children.
Discussion: EV71 has become a major public health problem in Asia and may 
continue to spread globally. The transmission dynamic of the virus is poorly 
understood. The public health intervention measure to date has been empirical and 
generic, but they have considerable socioeconomic implication. There is neither 
specific antiviral nor vaccine for EV71. Intravenous immunoglobulin is now used 
presumptively for severe EV71 infection in many Asian countries, although there 
are little data on its efficacy. Early diagnosis of neurological involvement may help 
reduce the mortality. A better understanding on diagnosis and management of this 
neurological infectious disease can help public health doctors and clinicians manage 
the epidemic caused by the virus when it spread to a new territory.
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Chapter 1: Introduction
1.1 Overview
Enteroviruses are small single stranded positive sense RNA viruses from 
the genus Enterovirus in the family Picomaviridae (Pallansch et al. 
2001). They are responsible for a very wide range of clinical 
manifestations, including cutaneous, visceral and neurological disease. 
For many years polioviruses were the most important enteroviruses, on 
account of the large outbreaks of paralytic disease that they caused; 
however in the last few decades polio has all but disappeared from 
Europe, the Americas, and much of Africa and Asia, secondary to the 
global polio eradication campaign. However, over the last 10 years, a 
related virus, human enterovirus (EV) 71 has emerged across Asia, where 
it threatens to become the “new polio” (Prager et al. 2003). The virus is a 
member of the enterovirus genus, which includes coxsackie viruses, 
echoviruses. Being a more recently identified enterovirus serotype, it is 
assigned a type number. EV71 first appeared in California in the 1960s, 
subsequently causing sporadic cases, or small outbreaks of hand foot and 
mouth disease (HFMD), neurological disease, or both (Pallansch et al. 
2001). However, in 1997 the virus caused an unexpected large and severe 
outbreak in Sarawak, Malaysia, with many fatalities (Cardosa et al. 1999;
28
Chan et al 2000). Since then countries of the Asia Pacific Region have 
been hit by regular epidemics of EV71, including an epidemic in Taiwan, 
in which millions of people were thought to be infected (Ho et al. 1999) 
(Table 1.1). Whilst the virus circulates across most of the globe, the 
largest outbreaks of disease have so far mostly been confined to the Asia- 
Pacific region, for reasons that are incompletely understood (Cardosa et 
al. 1999; Ho et al. 1999; Komatsu et al. 1999; Chan et al. 2000; McMinn 
et al. 2001; Cardosa et al. 2003; Chan et al. 2003; Jee et al. 2003; Shimizu 
2004; Chen et al. 2007; Tu et al. 2007; Zhang et al. 2009; Zhang et al. 
2010). During outbreaks, tens of thousands of children can develop 
HFMD, and whilst most will have a self-limiting illness, a small 
proportion can rapidly develop neurological and systemic complications 
which may be fatal. The neurological manifestations range from aseptic 
meningitis, to acute flaccid paralysis and a brainstem encephalitis, which 
is often associated with systemic features such as severe pulmonary 
oedema and shock, which are thought to be neurogenic in origin (Chang 
et al. 1998; Huang et al. 1999).
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1.1 Virology
1.1.1 Classification of human enterovirus
As well as the Enterovirus genus, the large Picomaviridae family, 
includes Hepatovirus (e.g. human hepatitis A virus), Parechovirus (e,g. 
human parechovirus 1-14), and nine important animal virus genera 
Cardiovirus (e.g. encephalomyocarditis virus), Aphthovirus (foot and 
mouth disease virus), Avihepatovirus (e.g. Duck hepatitis A virus), 
Erbovirus (e.g. Equine rhinitis B virus), Kobuvirus (e.g. Bovine 
kobuvirus), Sapelovirus (e.g. Avian sapelovirus), Senecavirus (e.g.
Seneca Valley virus), Teschovirus (e.g. Porcine teschovirus), Tremovirus 
(e.g. Avian encephalomyelitis virus) (Virus Taxonomy: 2009 Release, 
http://www. ictvonline. org/virusT axonomy. asp?version=2009&bhcp= 1). 
The human enteroviruses were traditionally classified into four subgroups 
according to their pathogenicity in humans and experimental animals, and 
their cytopathic effects in tissue culture; these subgroups were 
polioviruses (3 serotypes), coxsackie virus A (23 serotypes) and B (6 
serotypes), and echoviruses (28 serotypes) (Pallansch et al. 2001). 
However, because of the limitations of this system newer serologically 
distinct human enteroviruses, isolated since 1970, have been designated 
by serotype numbers, beginning with EV68. More recently the original 
classification of human enteroviruses has been substituted by a new 
taxonomical scheme based on molecular and biological properties of the
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viruses (King et al. 2000; Nasri et al. 2007). This revised classification 
recognises at least 90 types, and divides them into 4 species, which tend 
to be associated with particular clinical presentations, though there is 
considerable overlap (Table 1.2)
(http://www.picornaviridae.com/enterovirus/enterovirus.htmT Of note, 
polioviruses have been designated as members of human enterovirus 
species C because they are genetically closely related to other members of 
human enterovirus species C (Brown et al. 2003).
1.1.2 Physicochemical properties
The human enteroviruses are small non-enveloped icosahedral spherical 
particles (approximately 30nm) containing a single-stranded, positive- 
sense polyadenylated virus RNA of approximately 7.4 kilo base pairs.
The virus capsid is made of 60 identical subunits (protomers); each of 
which comprises a copy of the four structural viral proteins (VP1 to VP4) 
(Figure 1.1) (Brown et al. 1995). The VP1, VP2, and VP3 form the 
mature virion surface, while VP4 is completely internalised within the 
capsid, and is not exposed to the immune pressure from the host antibody 
response (Pallansch et al. 2001). The property of the lack of a lipid 
envelope confers the human enterovirus ’ considerable stability in the 
environment, and hence the viruses remain stable on exposure to human 
gastric acid, and can survive at room temperature for several days
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(Pallansch et al. 2001). EV71 and other enteroviruses have also been 
detected in surface and ground water and hot spas (Chen et al. 2008; Hsu 
et al. 2008). Enteroviruses are resistant to organic solvents (such as ether 
and chloroform) and alcohol, and freezing, but may be inactivated by 
temperatures above 56° C, chlorination, formaldehyde and ultraviolet 
irradiation (Pallansch et al. 2001).
1.1.3 Virus life cycle
Humans are the only known natural hosts of human enteroviruses. The 
viruses are ubiquitous and transmitted primarily through the faeco-oral 
mode. In addition, they may spread from person to person through contact 
of virus-contaminated oral secretion or vesicular fluid, as well as via 
respiratory droplets (Pallansch et al. 2001). Like most other enteroviruses 
the replication cycle of EV71 is generally considered to be similar to that 
of polioviruses which have been studied extensively. A comprehensive 
review on replication cycle on polioviruses is available (Jesus 2007).
Viral entry into susceptible host cells is dependent on the presence of 
specific receptors. Seven distinct receptors for different enteroviruses 
have been identified in humans to date (Nasri et al. 2007). The specific 
receptors include the poliovirus receptor (PVR; CD 15 5), three integrins 
(a2f31, av|33, and av^h), decay-accelerating factor (DAF; CDS5), the 
coxsackievirus-adenovirus receptor (CAR), and intracellular adhesion
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molecule 1 (ICAM-1). Some enteroviruses are able to use more than one 
receptor to infect a host cell, but the specific receptor for EV71 has yet to 
be identified.
After the binding of enteroviruses with a specific receptor on the cell 
surface, a series of structural changes occur at the vims capsid, yet to be 
defined in EV71, and pores are formed in the cell membrane through 
which the virion RNA is released into the host cell cytoplasm (Pallansch 
et al. 2001; Jesus 2007). Being a positive-sensed RNA vims, the parent 
vims RNA acts directly as a messenger RNA and is translated into a large 
polypeptide, which is promptly cleaved by the viral proteases into a total 
of 11 mature stmctural and non-structural proteins. The replication of the 
vims genome takes place in a vesicle membrane structure (viral 
replication complex) in the host cell cytoplasm, and is carried out by the 
error-prone RNA-dependent RNA polymerase (3Dpol). It is estimated 
that the polymerase mis-incorporates 1 to 2 bases in every genome 
copying event, which explains why this RNA vims mutates and evolves 
rapidly when compared to the DNA viruses (Pallansch et al. 2001). 
Mutation occurs during the process of viral replication when there is a 
faulty deletion, insertion or an exchange of nucleotide in a gene encoding 
a specific protein. Such changes to the nucleotide sequence of the gene 
may lead to a change in the stmcture and function of the protein product. 
Substitution is a type of point mutation involving replacement of a single
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nucleotide base with a different nucleotide. It is considered a synonymous 
substitution when such replacement causes no change in the resultant 
protein because the altered codon continues to encode the same amino 
acid. On the other hand a non-synonymous substitution occurs when the 
replacement result in a codon that encodes a different amino acid. The 
newly synthesized protein with altered amino acid sequence may be 
ineffective in its structure and function. Within the VP1 gene there are 
estimated to be 4.2-4.6 xlO'3 nucleotide substitutions per site per year, 
which is similar to that of poliovirus and greater than that of influenza 
viruses (0.5-2.6 xlO'3 nucleotide substitutions per site per year) (Kew et 
al. 1998; Nobusawa et al. 2006; Tee et al. 2010). While the machinery of 
the host cellular protein synthesis is shut down by the viral protease (2A), 
the viral protein synthesis remains unaffected. An infectious virus particle 
is formed following the packaging of a progeny viral RNA into a virus 
capsid in the cytoplasm of the infected cells. Mature infectious virus 
particles are released to infect new susceptible cells when an infected cell 
is lysed.
1.2 Clinical features
EV71 infection may present with a board spectrum of clinical 
manifestations, although central nervous system (CNS) infection and
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HFMD are the two most commonly recognised disease associations 
(Pallansch et al. 2001).
1.2.1 Mucocutaneous and respiratory manifestations
HFMD is a common childhood exanthema characterised by a brief, 
usually mild, febrile illness with papulovesicular rashes over the palms 
and soles and multiple oral ulcers (Figure 1.2). Herpangina, a closely 
related childhood enanthema, is characterised by a febrile illness and the 
presence of multiple oral ulcers predominantly affecting the posterior 
aspect of the oral cavity including the anterior pharyngeal folds, uvula, 
tonsils and soft palate. Although the classical HFMD picture is typically 
seen in older children with EV71, in children aged 2 years and below 
more widespread and atypical rashes occur. Of the many enteroviruses 
that can cause HFMD or herpangina, EV71 and coxsakie virus (CV) A16 
are the most common, both causing epidemic disease. CVA16 is not 
normally associated with neurological disease (Pallansch et al. 2001), but 
the rash it causes is indistinguishable from that caused by EV71. Other 
respiratory manifestations in young children include exacerbation of 
bronchial asthma, bronchiolitis, and pneumonia (Merovitz et al. 2000).
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1.2.2 Neurological and systemic manifestations
Like other enteroviruses, EV71 can cause aseptic meningitis, acute flaccid 
paralysis, encephalitis and other rarer manifestations (Table 1.3)
(McMinn 2002); in EV71 encephalitis is typically a brainstem 
encephalitis (or rhombencephalitis) and unlike most other enteroviruses, 
this is often accompanied by marked cardiorespiratory problems; these 
are also seen in poliomyelitis, and have been attributed to neurogenic 
pulmonary oedema.
Myoclonic jerks are seen more often in EV71 than other enteroviruses, 
and may be an early indicator of neurological involvement, particularly in 
the brainstem (Huang et al. 1999; Lu et al. 2004); however myoclonus has 
also been reported in other virus CNS infection including Japanese 
encephalitis, Nipah virus, subacute sclerosing panencephalitis, herpes 
simplex virus, HIV and varicella-zoster virus. In addition, myoclonic 
jerks are not uncommonly seen in otherwise healthy young infants 
particularly when they are asleep and may occur spontaneously or be 
provoked by a loud noise.
Seizures, if they occur at all in EV71 infection, tend to be seen in younger 
children, and are short lived with good recovery of consciousness, 
suggesting that they are febrile seizures, rather than due to CNS infection 
itself; Unlike other viral encephalitides, recurrent and prolonged seizures
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are very rare, probably reflecting the fact that this is a brainstem, rather 
than a cortical encephalitis (Huang et al. 1999).
Brainstem encephalitis with associated pulmonary oedema has been the 
hallmark of EV71 CNS infection in Asia since the late 1990s (Chang et 
al. 1998; Chang et al. 1999; Huang et al. 1999). This distinctive clinical 
syndrome is characterised by a prodromal illness of HFMD in followed 
by a sudden deterioration that typically occurs after 3 to 5 days of fever. 
Children then develop acute rapidly progressing acute cardiorespiratory 
failure which presents as shock and pulmonary oedema or haemorrhages. 
Without intensive care support, the vast majority of such children die 
within 24 hours of hospital admission, and some may die before reaching 
hospital.
Magnetic resonance (MR) imaging findings of children with brainstem 
encephalitis correlated well with those of postmortem examination; both 
of which shows frequent involvement of the medulla oblongata, reticular 
formation, pons and midbrain in several studies (Figure 1.3) (Shen et al. 
1999; Chen et al. 2000; Wong et al. 2000). Acute flaccid paralysis is the 
primary presenting feature of a number of neurological syndromes caused 
by EV71 including poliomyelitis-like anterior horn cell destruction 
(anterior myelitis), Guillian-Barre syndrome and transverse myelitis. 
Anterior hom cell destruction is probably the most common of these,
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though it may be less severe that that caused by polioviruses, with a 
higher recovery rate (McMirm 2002).
During the 1998 Taiwan epidemic the severity of brainstem encephalitis 
was categorised into Grade I disease with myoclonic jerks and tremor or 
ataxia, or both; Grade II disease with cranial nerve palsies evident by eye 
movement disorders (nystagmus, strabismus, or gaze paresis), facial 
weakness and bulbar palsy (dysphagia, dysarthria and dysphonia); Grade 
III disease, the acute onset of intractable cardiorespiratory failure, which 
is often fatal as described above (Huang et al. 1999). A separate clinical 
staging system of stage 1 through to stage 4 has been used by other 
clinicians to help monitor progress through the clinical course of EV71 
infection, and management, from febrile illness through CNS 
involvement to cardiorespiratory failure and development of sequelae 
(Lin et al. 2002; Chang et al. 2004).
1.2.3 Outcome
Published reports on acute outcome showed that many children developed 
neurological sequelae (Huang 2001). Long term outcome is still unknown 
involving those with mild CNS infection. It is not known if children with 
mild EV71 CNS infection will have complete recovery like those affected 
by other enteroviruses such as echoviruses.
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1.3 Clinical management and diagnosis
During outbreaks of EV71 tens of thousands of children develop 
symptoms, and whilst most of them will have mild self limiting illness, a 
small proportion of apparently well children can rapidly deteriorate to 
severe and fatal neurological and systemic complications over days or 
even hours. Whereas in the past children with mild HFMD tended to be 
looked after at home, with increasing public awareness about the 
potentially fatal complications, many are now brought directly to hospital, 
and health services can easily become swamped. The challenge for the 
front-line clinician is to recognise which patients are likely to deteriorate, 
to know which investigations give the best diagnostic yield, and to 
understand which treatments might be appropriate, given the lack of 
controlled clinical trials.
1.3.1 Differential diagnosis
The rash of HFMD can be caused a range of enteroviruses in addition to 
EV71, the most common being CVA16 (Table 1.4). There are many other 
childhood exanthamata that can be confused with HFMD, particularly 
measles, rubella, and chicken pox. Two particularly important causes to 
consider are meningococcus, because of the need for antimicrobial
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treatments, and dengue, because of the risk of developing dengue 
haemorrhagic fever, which in severe forms requires careful fluid 
resuscitation. Herpangina, on the other hand, can be confused with 
apthous ulcer and herpetic gingivostomatitis. For aseptic meningitis, 
which is a common neurological manifestation of EV71, the differential is 
broad, and includes other viruses, especially echoviruses and other 
enteroviruses, adenoviruses, mumps and occasionally Japanese 
encephalitis virus; partially treated bacterial meningitis, and tuberculous 
meningitis should also be considered. Most patients with severe CNS 
disease due to EV71, also have features of shock and collapse, and 
septicaemia is an important differential; however other causes of 
encephalopathy need to be excluded, particularly malaria. Where acute 
flaccid paralysis is the predominant feature, the differential includes 
poliomyelitis due to wild type polioviruses or vaccine associated disease, 
other enteroviruses, flaviviruses, rabies, Guillain-Barre syndrome, and 
bacterial toxins, such as diphtheria.
1.3.2 Virological diagnosis
Laboratory diagnosis of EV71 is established primarily through virus 
isolation or molecular detection of the virus nucleic acid in appropriate 
clinical specimens.
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Choice of sample
A wide range of samples may be available, depending on the disease 
manifestations; these include throat and rectal swabs, serum, urine, and 
when taken, cerebrospinal fluid (CSF), as well as fluid from vesicles and 
swabs from ulcers, if they are present. Prolonged viral shedding from the 
gastrointestinal tract (throat, rectum or stool) may occur after complete 
resolution of EV71 infection, as it does for other enterovimses.
Virus isolation, serotyping and nucleic acid detection
Traditionally the gold standard for diagnosis of enterovirus infection is 
virus isolation; several human and non-human primate cell lines may be 
used including rhabdomyosarcoma (RD), which is most efficient, human 
lung fibroblast cells (MRC5), and African green monkey kidney cells 
(Vero) (Pallansch et al. 2001). In RD cells a characteristic cytopathic 
effect is observed typically 7 to 10 days after inoculation. However, to 
improve the yield, blind passage may necessary before cytopathic effects 
become apparent. Once a cytopathic effect is observed, the virus is 
identified by neutralization tests using intersecting pools of type-specific 
anti-sera, EV71 type-specific anti-sera, or by an indirect 
immunofluorescence assay using EV71 type-specific monoclonal 
antibodies (Pallansch et al. 2001). More recently a molecular “serotyping” 
approach has been developed by amplifying part of the VP1 gene of the 
cultured virus, using the polymerase chain reaction (PCR) and pan-
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enterovirus specific primers and then sequencing the product (Nasri et al. 
2007). To this end, several sets of primers directed at different regions of 
the VP1 gene of human enterovirus have been developed (Brown et al. 
2000; Perera et al. 2004).
Serology
Serological diagnosis of an acute virus infection is classically established 
by demonstrating a four-fold rise in specific neutralizing antibody 
between the acute and convalescent samples (Pallansch et al. 2001). 
However, in the case EV71, very high levels of neutralizing antibodies 
are often detectable within the first few days of illness, and thus a four­
fold rise cannot be demonstrated (Chumakov et al. 1979; Nagy et al. 
1982). Furthermore, although homologous antibody is produced when 
young children encounter their first enterovirus infection, heterologous 
cross-reacting IgG and IgM antibodies are produced by older children and 
adults following repeated infection with different enterovirus serotypes; 
this reduces their usefulness in diagnosis. A rapid IgM ELISA test for 
EV71 has recently been developed to try to overcome some of these 
limitations (Wang et al. 2004); however the possibility of cross reactivity 
still remains an issue (Xu et al. 2010), and the duration of detectable 
EV71-specific IgM following an infection is also uncertain.
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1.3.3 Other laboratory diagnosis
In mild disease the full blood count is usually normal, but in severe 
disease the white cell count is often elevated with a neutrophilia (Chang 
et al. 1999). The urea and electrolytes are typically unchanged, but there 
may be hyperglycaemia in severe disease (Chang et al. 1999). Among the 
cardiac enzymes, creatine kinase is sometimes elevated in patients with 
cardiac involvement (Fu et al. 2004), and elevated cardiac tropinin I has 
been reported as a predictor of imminent cardiopulmonary failure in 
children with brainstem encephalitis (Huang et al. 2003). If there is 
pulmonary oedema it will usually be obvious on a chest X-ray, and the 
normal heart size will suggest this is not cause by an acute viral 
myocarditis, or congenital heart disease. The ECG often shows non­
specific changes (Fu et al. 2004), and continuous monitoring can 
demonstrate abnormal beat to beat variability, which may predict 
imminent cardiovascular collapse (Lin et al. 2006). In children that are 
haemodynamically unstable with tachycardia, hypotension or pulmonary 
oedema, an echocardiogram shows generalised left ventricular 
hypokinesia which may be accompanied by mitral regurgitation (Fu et al. 
2004); pericardial effusion is not usually seen. The lumbar puncture is 
essential in children who are unwell with suspected CNS involvement. In 
some patients the clinical features, such as meningism or myoclonic jerks, 
may clearly point to the CNS. However in other children particularly 
those less than two years old, there may just be high fever, vomiting or
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lethargy, but a lumbar puncture reveals CNS disease. There is typically a 
mild CSF lymphocytic pleocytosis of 10 to 100 cells per mm3, but 
occasionally there may be none (Perez-Velez et al. 2007). The CSF to 
plasma glucose ratio is usually normal, but can be low.
1.3.4 Imaging
Computer tomography scans can be helpful to exclude other pathologies, 
but in EY71 encephalitis, where the pathology is mostly in the brainstem, 
CT scans are almost always normal. MR imaging in these patients shows 
characteristic high signal intensities on T2 weighted images in the dorsal 
pons and medulla, most of the midbrain, and the dentate nuclei of the 
cerebellum. Similar high signal lesions may also be found in the anterior 
horn cells of cervical spinal cord (Figure 1.3) (Huang et al. 1999; Shen et 
al. 1999). However, the usefulness of these changes, in terms of 
sensitivity, specificity, positive and negative predictive value has yet to be 
demonstrated. In children with acute flaccid paralysis magnetic resonance 
imaging typically shows unilateral high signal lesions in the anterior horn 
cells of spinal cord on T2-wieghted images and contrast-enhancing 
ventral root on T1 weighted images (Huang et al. 1999; Shen et al. 2000; 
Chen et al. 2001).
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1.3.5 Predictors of severe disease
Several clinical features and laboratory abnormalities have been 
associated with neurological and fatal EV71 disease, but few have been 
prospectively validated (Chang et al. 1999; Huang et al. 2003; Hsia et al. 
2005). Young age at disease onset is associated with increased risk of 
severe disease (Chang et al. 2007). Hyperglycemia and leucocytosis were 
also associated fatal EV71 disease in a retrospective evaluation of the 
fatal cases (Chang et al. 1999).
1.4 Epidemiology
1.4.1 Clinical Epidemiology
EV71 was first isolated from the stool of a 9-month-old infant with 
encephalitis in California, USA in 1969 (Schmidt et al. 1974). Before 
long small outbreaks of neurological infection including encephalitis and 
aseptic meningitis attributed to the newly identified neurotrophic virus 
were reported in New York, Melbourne and Sweden in the early 1970s 
(Blomberg et al. 1974; Kennett et al. 1975; Deibel et al. 1979).
The dermotrophic properties of EV71 were first recognised when the 
vims caused epidemics of HFMD in Japan in 1973 (Hagiwara et al. 1978; 
Ishimam et al. 1980). In the 1970s, two large and severe EY71 epidemics
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occurred in Europe. The first was in Bulgaria, and was initially attributed 
to polioviruses because the epidemiological, clinical and pathological 
characteristics mimicked that disease (Chumakov et al. 1979; Shindarov 
et al. 1979). Indeed country-wide administration of Sabin’s live- 
attenuated poliovirus vaccine was one of the public health measures 
instituted at the height of the epidemic. EV71 infection, confirmed by 
either virus isolation or neutralization test, was later determined to be the 
causative agent in 347 (77%) of 451 children who presented with non­
specific febrile illness, or neurological disease; forty-four children died. 
Three years later, the second major European EV71 epidemic took place 
in Hungary, with 1550 cases (826 aseptic meningitis, 724 encephalitis), 
with 47 deaths; unlike the Bulgarian epidemic, the Hungarian one also 
had a small number of patients with HFMD (Nagy et al. 1982).
Recent EV71 activity in the Asia-Pacific region
After the Australian and Japanese EV71 epidemics of the 1970s, further 
small epidemics and sporadic clusters occurred in Hong Kong (1985) and 
Australia (1986) (Samuda et al. 1987; Gilbert et al. 1988). Then in 1997 a 
large outbreak of EV71 in Sarawak, Malaysia heralded the start of a new 
series of large outbreaks across the Asia-Pacific region, which is still 
ongoing; these epidemics have confirmed EV71 as a major public health 
problem across the region, and have provided setting for the work in this 
thesis (Table 1.1) (Figure 1.4) (Brown et al. 1999; McMinn et al. 2001;
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Cardosa et al. 2003; Shimizu 2004; Li et al. 2005; Lin et al. 2006; Chua et 
al. 2007; Tu et al. 2007; Huang et al. 2008; Huang et al. 2009; Zhang et 
al. 2009; Chatproedprai et al. 2010; Jeong et al. 2010; Zhang et al. 2010).
During the 1997 Sarawak outbreak, a total of 2618 HFMD cases and 34 
deaths were recorded between May and July; around the same time EV71 
caused four deaths in peninsular Malaysia and a number of severe 
neurological diseases in Japan (Lum et al. 1998; Cardosa et al. 1999; 
Komatsu et al. 1999). In 1998, the largest ever EV71 epidemic to date 
occurred in Taiwan (Ho et al. 1999). Four hundred and five children were 
hospitalised for serious neurological complications, 78 of whom died; but 
epidemiological studies estimated that almost 1.5 million people were 
infected with the virus.
The clinico-epidemiological features of the EV71 epidemics in Asia in 
recent years differ from earlier epidemics in that in addition to HFMD, 
aseptic meningitis, and flaccid paralysis, a brainstem encephalitis 
associated with cardiopulmonary dysfunction also occurs, which has been 
the primary cause of death in most fatal cases in Asia (Cardosa et al.
1999; Huang et al. 1999; Prager et al. 2003; Tu et al. 2007; Zhang et al. 
2010). Children so affected typically present with a brief febrile illness 
with subtle neurological signs, following which they develop signs of 
tachycardia, poor perfusion and tachypnoea, which rapidly develops into
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acute intractable cardiac dysfunction and fulminant often fatal pulmonary 
oedema or haemorrhage (Chang et al. 1998; Chang et al 1999). Imaging 
and autopsy findings indicate this is associated with encephalitis in the 
brainstem, especially the medulla, and neurogenic pulmonary oedema is 
thought to be the main pathogenic process (Chang et al. 1998; Lum et al. 
1998; Lum et al. 1998; Huang et al. 1999). Such rapidly fatal HFMD was 
not observed in epidemics caused by EV71 in the 1970’s and 1980’s, 
where aseptic meningitis was the most commonly observed neurological 
involvement (Blomberg et al. 1974; Kennett et al. 1975).
EV71 circulation outside the Asia-Pacific region
Outside the Asia-Pacific region, EV71 has continued to circulate in 
America, Europe, and Africa at a low level causing sporadic cases or 
small outbreaks. During a one-year prospective study in Canada in 1998, 
20 children with EV71 were admitted to a tertiary hospital, most during 
the summer or fall; half had aseptic meningitis, and a third had respiratory 
symptoms, but none was severe and all improved rapidly (Merovitz et al. 
2000).
Clearly EV71 circulates across most of the globe. Why the large 
outbreaks have been confined to the Asia-Pacific region, and whether 
they might be seen elsewhere is not completely understood, though recent 
molecular epidemiological work on of the evolution of the different
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genotypes of virus has given some key insights into this important 
question.
1.4.2 Molecular epidemiology of enterovirus 71
Virus genogroup, evolution and geographical distribution
Before 1999 there was relatively little information about the molecular 
epidemiology of EV71. However, systematic laboratory surveillance 
established in several Asian countries following the first epidemics in the 
late 1990’s has provided invaluable information on the geographical 
distribution, spread and evolution of the virus.
The first complete phylogenetic analysis of EV71 based on the structural 
VP1 gene identified three independent lineages of EV71, and designated 
them genogroup A, B and C (Brown et al. 1999). A sequence diversity of 
at least 15% in the VP1 gene was used to distinguish genogroups. 
Genogroup A consists of a single member, the prototype BrCr strain, 
which was first identified in California in 1970 and until very recently 
never been reported outside the USA (see Final discussion and overall 
conclusion chapter). The genogroup B viruses, subdivided into 
subgenogroups B1 and B2 with divergence of 12% at the nucleotide level, 
were the predominant circulating strains in the 1970’s and 1980’s. The
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genogroup C viruses, also similarly subdivided into Cl and C2, were only 
identified later in the mid-1980’s (Figure 1.5).
Recombination
Recombination events occur frequently within an enterovirus species 
(Simmonds et al. 2006). Recombination between EV71 viruses, and 
occasionally between EV71 and other enteroviruses, such as CVA16 or 
CVA8 has been reported (Chan et al. 2004; Huang et al. 2009); most 
often this is in the non-structural gene regions or untranslated region, 
rather than structural genes, and so diagnostics PCR based on VP1 gene is 
thought to be robust.
1.5 Pathogenesis
1.5.1 Viral determinants of virulence
The factors that determine whether EV71 infection will be asymptomatic 
or result in HFMD or severe neurological disease are not known. For 
poliovirus, the 5’ untranslated region (UTR) and VP1 genes are known to 
contain virulence determinants (Jesus 2007). Several studies have 
therefore examined the nucleotide sequence of these genes, or the whole 
genome, comparing isolates from fatal and non-fatal cases, but in most 
cases the isolates have been identical, or near identical, and significant
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changes have not been found (Shih et al. 2000; Singh et al. 2002). The 
incidence of CNS disease and other severe complications of EV71 
infection appear to have varied among the recent outbreaks in Asia, 
leading to the suggestion that differences in the virulence of the various 
subgenogroups may have a role. However, comparisons between 
outbreaks have been hampered by the retrospective nature of many of the 
studies, and differences in inclusion criteria, definitions of severity, and 
viral diagnostic capabilities. Perhaps the strongest data supporting the 
hypothesis that strain virulence determinants play an important role in the 
pathogenesis of severe neurological disease come from a study in Perth. 
During the EV71 epidemic in Perth in 1999, two subgenogroups, B3 and 
C2, co-circulated, thus providing a unique opportunity to examine the role 
of virulence determinants in a single epidemic setting (McMinn et al. 
2001; McMinn 2002). In this outbreak, subgenogroup C2 viruses linked 
to the Taiwan epidemic of 1998 were almost exclusively isolated from 
children with severe neurological disease, and only a single isolate came 
from a case of uncomplicated HFMD. In contrast, subgenogroup B3 
viruses, similar to those from the Sarawak 1997 epidemic, were isolated 
mainly from children with uncomplicated HFMD. aseptic meningitis, or 
post-infectious neurological disease, none of whom died (McMinn et al. 
2001).
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1.5.2 Dual infection
During the first of the recent EV71 outbreaks in Sarawak in 1997, which 
was due to subgenogroup B3, an adenovirus type 21 was also implicated 
in the fatal cases as well as in some cases with acute flaccid paralysis 
(Cardosa et al. 1999; Ooi et al. 2003). The virus was isolated from sterile 
sites such as CSF, brain and heart in fatal cases, and indeed was more 
frequently detected than EV71 itself; this led to the suggestion that in this 
early outbreak the fatalities were due to dual infection, rather than EV71 
alone (Cardosa et al. 1999).
1.5.3 Host susceptibility
A range of host factors may affect pathogenesis, particularly partial cross 
protective immunity from prior outbreaks; this may partially explain why 
young age is a risk factor for severe disease (Chang et al. 2002; Lu et al. 
2002; Chang et al. 2004).
1.6 Pathophysiology of severe disease
1.6.1 Viral entry and spread
EV71 is transmitted predominantly via the faeco-oral route, with 
respiratory spread also implicated (Pallansch et al. 2001). As for other 
enteroviruses, initial viral replication is presumed to occur in the
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lymphoid tissues of the oropharyngeal cavity (tonsils) and small bowel 
(Peyer’s patches), with further multiplication in the regional lymph nodes 
(deep cervical nodes, mesenteric nodes), giving rise to a mild viraemia. 
The majority of infections are controlled at this point, and are 
asymptomatic. However in vivo studies show that if enteroviruses 
disseminate further they reach target organs, particularly the 
reticuloendothelial system (liver, spleen, bone marrow and lymph nodes), 
heart, lung, pancreas, skin, mucous membranes and central nervous 
system, coinciding with the onset of clinical features.
1.6.2 Pathological findings
CNS inflammation is observed predominantly in the spinal cord gray 
matter, and the whole medulla oblongata including the dorsal nucleus of 
the vagus, tractus solitarius, and nucleus, and reticular formation; in 
addition the hypothalamus and subthalamic and dentate nuclei, and to a 
lesser degree motor cortex of the cerebrum are involved (Figure 1.6) 
(Lum et al. 1998; Huang et al. 1999; Shen et al. 1999; Hsueh et al. 2000; 
Shieh et al. 2001; Wong et al. 2008). Inflammatory changes were absent 
in cerebellar cortex, thalamus, basal ganglia, peripheral nerve and 
autonomic ganglia. The histopathological changes, characterised by 
perivascular cuffs, variable edema, neuronophagia and microglia nodules, 
are similar to encephalitis caused by other viruses (German et al. 2006).
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However, virus inclusion has not been observed, and viral antigens and 
RNA can only be seen in a small number of neuronal processes and 
phagocytic cells (Wong et al. 2008).
1.7 Prevention and control
1.7.1 Surveillance and prevention
The only measures available currently for disease control are public 
health approaches. Outbreak control measures are primarily targeted at 
interrupting the virus transmission and spread from person-to-person 
through contact with throat and nose secretions, saliva, stool and vesicular 
fluid; in addition contact with virus contaminated surfaces, toys or 
fomites is important. Hence health education focuses on personal hygiene 
and good sanitation including frequent hand washing, proper disposal of 
soiled diapers and disinfection of soiled surfaces with chlorinated (bleach) 
disinfectants.
1.7.2 Vaccine development
There are currently no vaccines against EV71, but by analogy with 
poliomyelitis, vaccines probably offer the strong best for future disease 
control.
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1.8 Treatment
There are no established antiviral treatments for EV71, and there have 
been no clinical trials of antiviral or ancillary treatments.
1.8.1 Antiviral agents
Pleconaril is an antiviral drug that inhibits entry into cells for a number of 
enteroviruses by blocking viral attachment and uncoating, which has been 
used in clinical trials of aseptic meningitis (Rotbart et al. 1998; Rotbart 
2000; Rotbart et al. 2001); however it is not active against EV71 
(McMinn 2002; Chen et al. 2008).
1.8.2 Intravenous Immunoglobulin
During the initial large outbreaks of EV71 in Asia, clinicians in Sarawak 
and Taiwan used intravenous immunoglobulin on the presumptive basis 
that it might prove beneficial because of anti-EV71 neutralizing 
antibodies and non-specific anti-inflammatory properties (Wang et al. 
1999; Ooi et al. 2007).
1.8.3 Fluid balance and ionotrope support
In routine paediatric practice the most common cause for shock and 
peripheral shut down is hypovolaemia and dehydration, for example
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following gastrointestinal infections, which are treated with rapid fluid 
resuscitation. However when similar approaches were used in the early 
EV71 outbreaks in Asia, this often precipitated pulmonary oedema. Once 
it became clear that impaired cardiac function is an important contributor 
to shock, clinicians were more judicious in their use of intravenous fluids, 
and used additional inotrope support. Where possible fluid management 
should be guided by central venous pressure monitoring. In Taiwan, 
management algorithms based on this approach appear to have improved 
outcome (Lin et al. 2002; Chang et al. 2004).
1.9 Scope of this thesis
EV71 has become a major emerging virus across Asia, and has become 
responsible for frequent explosive epidemics of HFMD with severe 
neurological complications. A better understanding of which clinical 
samples are best for the detection of the neurotrophic virus will help in 
the laboratory diagnosis. Rapid laboratory identification of the virus is 
critical in guiding public health doctors to institute appropriate 
intervention and outbreak response measures because EV71 can spread 
very rapidly in a susceptible population. Clearly a rapid and reliable 
detection assay of EV71 in primary clinical samples such as an RT-PCR 
approach would be an ideal alternative to the classical time-consuming 
tissue culture technique. EV71 infection has emerged as a growing public
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health concern in Asia with new clinical manifestations. In the absence of
a rapid diagnostic test clinicians will have to depend on their clinical 
skills to identify children at risk of severe disease. Early recognition of 
children at risk of severe disease may be the key to reducing acute 
mortality and morbidity. However which clinical features predict severe 
disease is not known. Molecular epidemiological studies of the virus 
indicate that the virus is undergoing rapid evolution as it spreads across 
Asia in recent years. However the role of the vims genogroup in the viral 
transmission dynamics and neurovirulence is still poorly understood.
This thesis therefore focuses on the clinical and laboratory diagnosis, case 
management and pathogenesis of EV71 infection that has emerged in 
Sarawak, Malaysia. In particular the thesis sets out to answer the 
following questions:
1. Which type of clinical samples are best for detection of EV71?
2. Can RT-PCR techniques be a rapid diagnostic approach to detect 
enterovims 71 in primary clinical samples?
3. What are the clinical features, virological characteristics and 
molecular epidemiology of enterovims 71 infection in Sarawak? Is 
viral genogroup an important determinant of the disease phenotype?
4. How to recognise and manage children at risk of neurological disease 
and death?
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5. What are the differences between cases of hand, foot and disease
caused by CVA16 and that by enterovirus 71?
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Table 1.3 Neurological syndromes association with enterovirus 71 
infection
Purely neurological manifestations:
Encephalitis, especially brainstem Common
Acute flaccid paralysis (anterior myelitis) Common
Encephalomyelitis Common
Aseptic meningitis Very common
Cerebellar ataxia Uncommon
Transverse myelitis Rare
Neurological plus systemic manifestations:
Brainstem encephalitis with cardiorespiratory failure Common
Manifestations indicative of immune-mediated (para-infectious) mechanisms
Guillain-Barree syndrome Uncommon
Opsoclonus-myoclonus syndrome Rare
Benign intracranial hypertension Rare
. Modified from (McMinn 2002)
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Table 1.4 Differential Diagnosis of enterovirus 71 infection
Rash
Viral Infections
*Coxsackie virus A16, and other enteroviruses
^Measles
*Rubella
*Chicken pox (varicella zoster virus)
Roseola infantum (human herpes viruses 6 & 7)
Erythema infectiosum ("slapped cheek disease", parvovirus B19) 
Dengue Hemorrhagic fever ( and other flavivirus infections, e.g. West 
Nile virus)
Chikungunya (and other alphavirus infections, e.g. O’nyong nyong, 
Western equine encephalitis)
Epstein Barr virus 
Primary HIV infection 
Non-specific viral rashes
Bacterial Infections
Meningococcemia {Neisseria meningitides)
Scarlet fever (Streptococcus pyogenes)
Leptospirosis (Weil’s disease;Leptoy/?zra Spp)
Relapsing fever {Borrelia recurrentis)
Lyme Disease {Borrelia burgdorferi)
Syphilis {Treponema pallidum)
Typhus and other Rickettsial infections
Other diseases
* Scabies {Sarcoptes scabei)
Drug reaction 
Allergy
Paraneoplastic syndrome
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Aseptic Meningitis
Viral Infections
*Echoviruses, Coxsackie viruses and other enteroviruses,
Herpes simplex virus type 2
HIV
Mumps
Flaviviruses (Japanese encephalitis virus, West Nile virus, Tick-borne 
encephalitis virus)
Alphaviruses (Western Eastern and Venezuelan encephalitis virus) 
Bunyaviruses (eg La Cross virus)
Lymphocytic choriomeningitis
Bacterial Infections
*Bacterial meningitis (partially treated)
Tuberculous meningitis 
Parameningeal bacterial infections 
Listeria {Listeria monocytogenes)
Syphilis
Lyme disease {Borrelia burgdorferi)
Weil’s disease (Leptospira spp)
Mycoplasma pneumoniae
Other
Drug reactions (antibiotics, non-steroidal anti-inflammatory drugs) 
Fungi (e.g. Cryptococcus spp, Candida spp, Aspergillus spp)
Flaccid paralysis
Viral Infections
♦Poliomyelitis and other enteroviruses 
Vaccine-associated paralytic poliomyelitis
Flaviviruses (Japanese encephalitis virus, West Nile virus, Tick-borne 
encephalitis virus)
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Rabies
Adenoviruses
Bacterial Infections
Botulism
Diphtheria
Other
Intramuscular injection into buttock causing sciatic nerve damage 
Guillain-Barre syndrome (esp acute motor axonal neuropathy)
Brainstem encephalitis
Viral Infections
^Poliomyelitis and other enterovimses
*Flaviviruses (Japanese encephalitis virus. West Nile vims, Tick- 
bome encephalitis vims)
Nipah virus
Bacterial Infections
Listeria {Listeria monocytogenes)
Tuberculosis {Mycobacterium tuberculosis)
Brucellosis {Brucella abortens)
Lyme disease {Borrelia burgdorferi)
Other
Paraneoplastic syndromes
NB the relative importance of the pathogens listed in the differential varies 
greatly according to the age of the patient, and the geographical location 
*Those which are especially likely to be confused with enterovirus 71 infection 
are marked with an asterix. Modified from (Solomon 2009)
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Figure 1.1 Enterovirus 71: three dimensional structure and genome 
structure
VP1, VP2, VPS and VP4 are viral structural proteins, coded for by the PI 
region of the genome; P2 and PS regions encode seven non-structural 
proteins 2A-2C and 3A-SD, UTR is untranslated region. VPg is virus 
encoded protein. Modified from
http://www.expasv.ch/viralzone/all by species/97.html and (Brown et al. 
1995).
5 UTR PI P2 P3 3 UTR
■4 — ■ » 4 >
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Figure 1.2 Mucocutaneous lesions in hand, foot and mouth disease
This Malaysian child has ulcers are seen inside the upper lip (top), and
vesicular and macular lesions on the wrists (middle) and soles 
(bottom).Photo credit: T Solomon
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Figure 1.3 MRI changes in enterovirus 71 encephalomyelitis
T-2 weighted images of a 10 month old female who presented three
months earlier with somnolence tachycardia, tachypnea and coma, and 
who recovered consciousness but remained ventilator dependent. A. 
sagital section showing high signal intensity in the posterior portion of the 
pons and medulla (black arrows) and anterior cervical cord (white 
arrows). B. Axial section showing the high signal intensity in the two 
anterior horns of the cervical cords (black arrows), modified from (Shen 
et al. 1999).
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Figure 1.4 Map of Southeast Asia
The map shows the geographical location of the state of Sarawak, 
Malaysia. The country consists of two regions, West and East Malaysia, 
which are separated by the South China Sea. Sarawak is situated at the 
Northern region of the Borneo Island, where it shares its borders with 
Brunei and Kalimantan, Indonesia. Sibu Hospital (the study site) is 
situated at Sibu, which was the epicentre of the Sarawak 1997 epidemic. 
All the virological investigations performed in the thesis were carried out 
at Institute of Health and Community Medicine, Universiti Malaysia 
Sarawak at Kuching (the capital city of Sarawak).
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Figure 1.5 Phylogenetic tree of enterovirus 71 isolated between 1970 
and 1998
The dendrogram was generated by the neighbor-joining method with the 
DNADIST distance measure program (PHYLIP, version 3.5). The 
phylogram was calculated based on the nucleotide divergence of the VP1 
gene (position 2442 to 3332). The last four or five characters of each 
strain name indicate the state or country and year of isolation. Branch 
lengths are proportional to the number of nucleotide differences; the 
frequencies with which the branches for genotypes A, B, and C appeared 
in 1,000 bootstrap replications were 898, 543, and 999, respectively. 
Clades with bootstrap numbers are expressed in percentile. The marker 
denotes a measurement of the relative phylogenetic distance. (A) The 
branch length for the outgroup, CA16-G10-51, was reduced by 0.75 to 
save space.
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A CA16-G10-51
« ---------Genogroup A
— Genogroup C
—2- Genogroup B
Genogroup B Genogroup C
0,1
Adapted from (Brown et al. 1999)
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Figure 1.6 Pathological findings in enterovirus 71 encephalitis
Parenchymal inflammation (arrows) and perivascular cuffing in the the
medulla (A); more severely inflamed areas (B), with edema (*) and 
neuronophagia (C, arrows). More subtle inflammation in the motor cortex 
with mild perivascular cuffing (arrow) and parenchymal inflammatory 
cells (circle) (D). Numerous CD68-positive macrophages/microglial (E), 
CD8-positive lymphocyte adjacent to a neuron (F). Viral RNA in the 
anterior horn cells of the spinal cord (G). (A—D: hematoxylin and eosin 
stains; E, F: immunohistochemistry / peroxidise / DAB; G: in situ 
hybridization / nitroblue tetrazolium/ 5-bromo-4-chloro-3-indolyl 
phosphate stains. Original magnification: (A) 4x; (B, D) lOx; (C, F) 40x; 
(G) 20x.
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Chapter 2: The usefulness of different clinical 
samples in laboratory diagnosis of enterovirus 
71
Abstract
Human enterovirus 71 and coxsackie virus A16 are important causes of 
hand, foot and mouth disease (HFMD). Like other enteroviruses they can 
be isolated from a range of sterile and non-sterile sites, but which clinical 
sample, or combination of samples is the most useful is not clear. Virus 
culture was attempted on 2916 samples from 628 of 725 children with 
HFMD studied over a VA year period (between January 2000 and July 
2003), which included 2 large outbreaks. Overall, throat swabs were the 
single most useful specimen, being positive for any enterovirus for 288 
(49%) of 592 patients with a full set of samples. Vesicle swabs were 
positive for 169 (48%) of 333 patients with vesicles, the yield being 
greater if two or more vesicles were swabbed. The combination of throat 
plus vesicle swabs identified virus for 224 (67%) of the 333 patients with 
vesicles; for this patient group, the addition of rectal and ulcer swabs 
diagnosed just 27 (8%) extra patients. Of 259 patients without vesicles, 
the combination of throat plus rectal swab identified virus for 138 (53%).
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60 patients had virus isolated from both vesicle and rectal swabs, but for 
12 (20%) of these, the isolate differed. Such discordance occurred for just 
11 (10%) of 112 patients with virus isolated from vesicle and throat 
swabs. During large HFMD outbreaks it is recommended to collect swabs 
from the throat plus one other site: vesicles, if these are present (at least 
two should be swabbed), or the rectum if there are no vesicles. Vesicle 
swabs give a high diagnostic yield, with the added advantage they are 
from a sterile site.
2.1 Introduction
Hand, foot and mouth disease (HFMD) is a common febrile illness in 
young children characterised by lesions on the skin, and oral mucosa. The 
skin rash, which may be maculopapular or vesicular, typically occurs on 
the palms and soles, but can also involve the buttocks, elbows and knees. 
Mouth ulcers are the most common enanthema, but some patients have 
herpangina (multiple oral ulcers predominantly affecting the posterior 
part of the oral cavity), and others have no oral lesions (Pallansch et al. 
2001; McMinn 2002).
Many human enteroviruses (family Picornoviridae, genus enterovirus) 
can cause HFMD, but human enterovirus (EV) 71 and the closely related 
coxsackie virus (CV) A16 are the most important (Pallansch et al. 2001;
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McMinn 2002). Since the late 1990’s, EV71 has caused a series of large 
HFMD epidemics in the Asia-Pacific region, associated with a rapid 
fulminant course, severe neurological complications and a large number 
of fatalities (Cardosa et al. 1999; Ho et al 1999; Komatsu et al. 1999; 
McMinn et al. 2001). CVA16 causes a similar clinical illness initially, but 
neurological and other severe complications are extremely rare (Chang et 
al. 1999). In much of Asia there is now epidemiological and virological 
surveillance for HFMD so that effective public health measures, such as 
closing nurseries and schools, can be instituted early. However, because 
of the similar clinical presentation, establishing the actual cause of HFMD 
cases relies on laboratory identification of the virus. Diagnostic 
techniques include isolating the virus in susceptible continuous cell lines 
or detecting viral RNA using the polymerase chain reaction (PCR) (Lina 
et al. 1996; Yerly et al. 1996). Though laborious and time consuming, 
virus isolation remains the gold standard for enterovirus diagnosis; it is a 
relatively cheaper than PCR, and is the most widely used method, 
particularly in developing countries such as in Sarawak, Malaysia.
There is a wide range of samples from which virus isolation can be 
attempted, including rectal and throat swabs, serum, and CSF (when 
taken) and vesicles and ulcers when they are present. However for EV71 - 
associated HFMD outbreaks there has been relatively little work 
examining which samples or combination of samples are the most useful.
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This question becomes especially important in the context of large 
outbreaks with many thousands of patients. Rectal and throat swabs are 
available for all patients, and do not require the presence of 
mucocutaneous stigmata. However, they have the disadvantage that, 
because these are not sterile sites, isolation of vims here may represent 
coincidental asymptomatic carriage, rather than the causative agent 
(Rotbart et al. 1995): many enterovirus infections are asymptomatic, and 
viral shedding may persist for up to 2 weeks from the throat and up to 11 
weeks from the rectum (Chung et al. 2001; Pallansch et al. 2001). In the 
absence of vims isolation from a sterile site, isolates from non-sterile sites 
are usually accepted as surrogate markers for enterovirus infections 
(Rotbart 1995; Pallansch et al. 2001). There is little data available on the 
validity of this approach for EV71-associated HFMD. I therefore set out 
to answer three important clinical microbiological questions during a 3!4 
year prospective clinical and diagnostic study of HFMD, which included 
two large outbreaks: firstly which single specimen is most often positive 
for the different HFMD patient groups; secondly, which combination of 
samples is the most efficient in terms of diagnostic yield; and thirdly how 
reliable are samples from non-sterile sites, compared with sterile sites.
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2.2 Materials and methods
2.2.1 Clinical and laboratory methods
Between January 2000 and July 2003 all children with HFMD in the 
paediatric ward and intensive care unit at Sibu Hospital, Sarawak, 
Malaysia were included into the study.
Case definitions
a. Hand, foot and mouth disease
A child was defined as having HFMD if they had new onset of at least 
one of the following: maculopapular and/or vesicular rash on the palms 
and/or soles; vesicles or ulcers in the oral cavity; herpangina (defined as 
multiple oral ulcers predominantly affecting the posterior parts of the oral 
cavity).
b. Suspected central nervous system involvement
A child with HFMD was suspected of having central nervous system 
(CNS) involvement if he or she had a history of fever, or fever on 
examination (> 38°C), and at least one of the following: toxic and ill in 
appearance, recurrent vomiting (at least twice), tachycardia (heart rate 
>150/min) breathlessness, poor perfusion (cold clammy skin), reduced 
consciousness (irritability, lethargy, drowsiness, coma), limb weakness, 
meningism (neck stiffness or positive Kemig’s sign), seizures.
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Collection of clinical samples
All children with HFMD admitted into the hospital were assessed by the 
paediatricians of the study team. A detailed history and clinical 
examination, including for mucocutaneous lesions, was recorded on 
standardised forms. A rectal and throat swab was taken for each child.
The skin was examined carefully for vesicles, and the oral cavity for 
ulcers, and if they were present swabs were taken from at least one of 
each (usually the largest and most accessible lesions). Rectal swabs were 
taken with a gentle circular motion on the rectal wall. Throat swabs were 
taken with the aid of a tongue depressor, by carefully swabbing the lateral 
and posterior pharynx without touching the tongue or buccal mucosa. For 
vesicle swabs the skin was cleaned gently with 0.9% sterile normal saline, 
but not alcohol which kills viruses. A sterile 24G needle was used to 
rupture the vesicle, and the fluid absorbed onto a swab. Alternatively the 
swab was gently rolled over the vesicle to squeeze out fluid. Mouth ulcers 
were sampled by rolling the swab over the floor of the ulcer. When more 
than one vesicle or ulcer was swabbed, a fresh swab was used for each 
lesion and put into a separate tube of viral transport material, because I 
was interested in the yield from each swab. Swab samples were collected 
by study team members or nursing staff, after training. Cerebrospinal 
fluid (CSF) and serum were collected from children with suspected 
central nervous system (CNS) involvement. The clinical samples were 
stored immediately in a “70°C freezer until further testing. Out of hours,
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when immediate storage at -70°C was not possible, clinical samples were 
stored at 4°C overnight, and were transferred to a -70°C freezer the 
following morning.
Virological method
Virus isolation was attempted on all swabs, CSF and any serum which 
had adequate volume. Specimens were inoculated into 
rhabdomyosarcoma (RD) and 293 (human embryonal kidney) cells, and 
observed daily for cytopathic effects. Cell cultures were harvested when 
the monolayer showed extensive cytopathic effect. A blind passage was 
done in the same cell line with all cultures showing no cytopathic effect 
after 10 to 14 days. Enteroviruses isolated were typed by nucleotide 
sequencing of the VP1 or the VP4 genes (McMinn et al. 2001; Cardosa et 
al. 2003).
For the purposes of analysis, swabs from herpangina lesions were 
grouped with other mouth ulcers. Vesicles, serum and CSF were 
considered to be sterile sites, and swabs from the throat, mouth ulcers and 
rectum to be from non-sterile sites. All samples were investigated, 
irrespective of the results of other samples from the same patient.
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2.2.2 Analytical approach
The patients were divided into 4 groups according to their presenting 
mucocutaneous lesions, and thus the availability of samples: those with a 
papulovesicular rash and mouth ulcers (referred to hereafter as HFMD 
with vesicles and ulcers); those with a papulovesicular rash only (HFMD 
with vesicles); those with a maculopapular rash and mouth ulcers only 
(HFMD with ulcers), and patients with maculopapular rash only (HFMD 
with maculopapular rash). To determine which combination of samples 
gives the best diagnostic yield, a stepwise approach was adopted to the 
analysis for each patient group. First I determined which sample type 
gave the most positives. Then I looked at the remaining undiagnosed 
patients, and determined which of the remaining samples gave the most 
positives. I continued like this until all sample types had been assessed. I 
decided to use data from the first outbreak to determine the usefulness of 
different samples, and combinations of samples. I then applied these 
findings to the second outbreak to see if the predicted samples remained 
useful. However, the sample analysis was not begun until the end of the 
study, to avoid any bias in sample collection.
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2.2.3 Statistical analysis
Statistical analysis was performed by using statistical software Statview 
4.02 Abacus Concepts Inc. Sensitivity, specificity, positive predictive 
value and negative predictive value were calculated from a 2 X 2 table.
2.2.4 Ethical approval
The study was approved by the Director of Health for Sarawak (Malaysia) 
and the Ethics Committee of the Liverpool School of Tropical Medicine 
(Liverpool, United Kingdom). Informed consent was obtained from each 
child’s accompanying parent or guardian.
2.3 Results
Seven-hundred-and-twenty-five patients were entered into the study: 471 
(299 [63%] males, median [range] age 28 [4-120] months) were enrolled 
in the first half (the majority in an outbreak between January 2000 and 
March 2001), and 254 (158 [62%] males, median [range] age 28 [2-153] 
months) were enrolled in the second half (mostly during an outbreak 
between January and July 2003). The 471 patients in the first half of the 
study included 110 with vesicles and ulcers, 112 patients with vesicles 
only, 78 patients with ulcers only, and 171 patients with a maculopapular 
rash only. Of the 254 patients in the second half of the study 98 had
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vesicles and ulcers, 29 had vesicles only, 87 had ulcers only, and 40 had a 
maculopapular rash only. The median (range) duration of illness before 
admission was 2 (0-8) days, and did not differ significantly between 
patient groups.
2.3.1 Virology results
Viral isolation was attempted on a total of 2916 samples: 1666 from 389 
(83%) of the 471 patients in the first half of the study, and 1250 from 239 
(94%) of the 254 patients in the second half of the study. Most patients 
had a single throat swab and single rectal swab cultured. In addition, 127 
patients with vesicles had at least one (median 2; range 1-10) vesicle 
investigated, and 185 patients with ulcers had at least one (median 2; 
range 1-6) sample investigated. For a single swab, 35% of vesicles and 
17% of ulcers were positive (Table 2.1), but the percentages increased as 
more swabs were taken.
The number of patients tested for each sample type, and the number that 
were positive for any enterovirus, for EV71, and for CVA16 are shown in 
Table 2.2. During the first half of the study a throat swab was most likely 
to be positive (being positive for any enterovirus for 191 [52%] of 367 
patients), followed by vesicle, ulcer and then rectal swabs. During the 
second half, vesicle swabs were most likely to be positive (positive for
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any enterovirus for 63 [50%] of 127 patients), followed by throat, rectal 
and then ulcer swabs. Most (>95%) viruses were isolated following a 
single passage.
In the first half of the study, 167 (65%) of 255 patients with positive viral 
isolation were EV71 positive (11 of whom were also infected with 
CVA16, 2 with CVA4, 2 with CVA24 and 1 with adenoviruses [Ad]-7); 
CVA16 was isolated from a further 69 patients (2 of whom were also 
infected with another virus). In addition 19 patients were infected with 
other enteroviruses, adenoviruses or unidentified viruses (6 of whom had 
multiple viruses isolated). In the 2nd half of the study, 106 (44%) of 239 
patients had EV71 isolated, 10 of whom had a second virus isolated: 3 
with CVA16, 2 with CVA5, and 1 each with CVA10, Poliovirus 1 Sabin 
vaccine strain, Adi, an untypeable enterovirus, and an unidentified virus. 
CVA16 was isolated from 16 further patients (2 of whom were also 
infected with a second virus, Ad2 and Ad4). In addition 31 patients were 
infected with other enteroviruses, adenoviruses or unidentified viruses (4 
of whom had multiple viruses isolated). For most patients with multiple 
isolates the viruses came from different clinical samples, however in 20 
cases two viruses were isolated from the same clinical sample. These 
comprised 9 rectal swabs, 5 throat swabs, and 2 ulcer swabs, which gave 
different isolates in different cell lines; in addition four patients with mild 
HFMD had two different viruses grown from different vesicles (three
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with EV71 and CVA16, and one with EV71 and poliovirus Sabin strain 
type 1). The serotyping of enterovirus isolates was repeated and verified.
Across the whole study 79 (51%) of 156 patients who required CSF 
examination had elevated CSF cell counts (>5/mm3), but only 3 had virus 
cultured (two EY71 and one other). Enteroviruses were isolated from the 
serum of 7(9%) of 81 patients, 2 were EV71, 2 were CVA16, and there 
was a single CVA6, CVA9, and CVA10.
2.3.2 Analysis of sample combinations during first outbreak
Figure 2.1a shows for each patient group, the possible incremental 
increases in number of patients diagnosed viro logically, by different 
combinations of samples assessed stepwise according to the analytical 
plan. For this part of the analysis, only patients with full sets of samples 
were studied. For vesicles and ulcer swabs, the results for multiple swabs 
of a single type were treated as a single result, so that if at least one swab 
was positive, this was taken as a positive result for that sample type.
For the 105 patients with vesicles and ulcers in the first half of the study, 
the throat swab alone diagnosed 63 (60%) patients, whereas the vesicle 
swabs alone would have diagnosed 54 patients, the rectal swab alone 29 
patients, and the ulcer swab alone 26 patients. Throat swabs were
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therefore taken as the first sample (Figure 2.1a). The number of patients 
with a virological diagnosis (the diagnostic yield) would increase to 73 
patients if the results of vesicle swabs were added next, 70 if rectal swabs 
were added, or 68 if ulcer swabs were added. The vesicle swab results 
were therefore added as a next step. From here the addition of the rectal 
swab results would increase the yield to 79 patients, whereas ulcer swab 
results would increase it to 75 patients; so the rectal swab was therefore 
added next, and the ulcer swab was added last, increasing the yield to 82 
(78%) patients.
For patients with HFMD and a vesicular rash, a throat swab was again the 
most useful single sample, diagnosing 57 (52%) of 109 patients. The 
addition of the rectal swab result would increase the diagnostic yield to 70 
(64%), whereas the addition of the vesicle swab result would increase it to 
72 (66%). The vesicle swab result was therefore used as the second 
investigation; finally the addition of the rectal swab result increased the 
number of patients diagnosed to 79 (72%). For patients with ulcers only, a 
throat swab diagnosed virologically 33 (48%) of 69 patients; addition of 
either the rectal or vesicle swab increased the diagnostic yield to 38 
(55%) patients, and combining all three samples diagnosed 42 (61%) 
patients. Finally, for patients with a maculopapular rash only, a throat 
swab alone diagnosed 35 (43%) of 82 patients, whereas a rectal swab 
alone diagnosed 22 patients. A throat swab was therefore used as the first
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sample, followed by the rectal swab, which increased the number of 
patients diagnosed to 44 (54%) of 82 patients.
In figure 2.2a, the proportion of patients diagnosed at each step, using the 
best combination of samples as determined above, is compared with the 
total number of samples analyzed at each step. It is clear that although the 
detection rate increased as more clinical sample types were included, the 
number of samples analyzed increased to a much greater extent. For 
example for the patients with vesicles and ulcers, 63 patients were 
diagnosed by throat swab samples alone (105 samples, 1.7 samples per 
patient diagnosed); adding the vesicle swab results diagnosed a further 10 
patients, but required the processing of a further 264 samples (26.4 
samples per patient); adding the rectal swab results diagnosed 6 more 
patients for a further 105 samples (17.5 per patient), and adding ulcer 
swab diagnosed 3 more patients for 213 samples (71 per patient). Thus 
the total the number of samples needed to be analyzed to diagnose each 
additional patient increased dramatically for each additional sample type 
included.
2.3.3 Recommendation based on the first outbreak
Based on these observations, it was decided that during a large outbreak, 
if one wanted to limit the number of samples, the following could be
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recommended. For patients with both vesicles and ulcers, investigation of 
throat and vesicle swabs diagnosed most patients (70%), and the addition 
of rectal or ulcer swabs added little value, for the extra work and cost 
involved. Similarly for patients with vesicles only, the combination of 
throat swabs and vesicles gave a good diagnostic yield, and the addition 
of rectal swabs only increased the yield marginally (6%). For patients 
with ulcers only, throat and ulcer swabs, or throat and rectal swabs were 
equally useful, but combining all three swabs only increased the 
diagnostic yield by 6%. For patients with a maculopapular rash only, both 
throat and rectal swabs should be tested.
2.3.4 Application of findings to the second outbreak
The validity of these recommendations was tested on data from the 
second outbreak. The same analytic process was applied to determine 
which combination of samples gave the best diagnostic yield and to see if 
the recommended combinations would prove to be the most useful. 
Figures 2. lb and 2.2b show that, for the most part, the approach remained 
valid. For patients with vesicles plus ulcers, and for patients with vesicles 
only, the combination of throat and vesicle swabs gave a good diagnostic 
yield (66 and 67% respectively), with further samples not improving the 
yield greatly. Interestingly, though, for the first patient group vesicles, 
rather than throat swabs, were the single most useful sample. For patients
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with a maculopapular rash only, throat swabs and then rectal swabs were 
most useful. However, for those with ulcers only, the addition of rectal 
swabs to throat swabs proved more useful than the addition of ulcer 
swabs, increasing the yield to 41 (48%) of 85 patients, as compared to 36 
(42%).
Thus, summarising the data from both outbreaks together, the 
combination of throat swabs plus vesicle swabs was the most useful 
approach for patients with vesicles (whether or not they also had ulcers), 
identifying vims for 134 (64%) of 208 patients with vesicles and ulcers, 
and 90 (66%) of 136 patients with vesicles only; the combination of 
throat swab and rectal swab was most useful for patients without vesicles 
(whether or not they had ulcers), identifying vims for 79 (51%) of 154 
patients with ulcers only, and 59 (56%) of 105 patients with 
maculopapular rash only.
2.3.5 Concordance of viral diagnosis between samples
To examine the concordance of vims isolates from non-sterile sites 
(rectal, throat and ulcer swabs), with those from a sterile site (vesicle 
swabs), all HFMD patients with swabs taken from vesicles plus another 
site were studied (Table 2.3). The isolation results from 212 (63%) of 337 
patients with throat swabs, 187(55%) of 342 with rectal swabs and 112
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(54%) of 208 with ulcer swabs were in agreement with the results from 
vesicle swabs of the same patients (either the same virus isolated or no 
virus isolated). However, a different virus was isolated for 11 (10%) of 
112 patients with positive throat and vesicle swabs, 4 (12%) of 33 patients 
with positive ulcer and vesicle swabs, and 12 (20%) of 60 patients with 
positive rectal and vesicle swabs. Overall taking the vesicle swab as a 
reference, the sensitivity of the throat swabs for isolating the same virus 
was 67%, the specificity 63%, and the positive and negative predictive 
values were 61% and 69%. Equivalent values for the rectal swabs were 
31%, 79%, 56%, and 57%, and for ulcer swabs were 28%, 81%, 60% and 
53%. The detailed viral isolation results of these patients with different 
viruses isolated from vesicle and non-sterile sites are shown in Table 2.4.
2.4 Discussion
The outbreaks of EV71-associated hand foot and mouth disease which 
have swept across the Asia Pacific region since 1997 have posed a great 
economic and social burden, not least on the health care facilities and 
laboratories that have to diagnose and manage such patients. The three 
large outbreaks in Sarawak (1997, 2000 and 2003) are estimated to have 
affected several thousand children, whilst the 1998 Taiwanese outbreak 
was estimated to have affected 1.5 million children (Ho et al. 1999; Chan 
et al. 2000; Cardosa et al. 2003). To diagnose EV71 infection, clinicians
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are faced with a wide range of samples to choose from, but there has been 
relatively little work comparing them. Whilst for the occasional patient, 
taking every sample might be possible, faced with a large outbreak with 
hundreds to thousands of patients, a more rational approach is needed.
Most of the recent studies of EV71 infection have relied on stool culture 
and throat swabs, and have found the latter to have greater sensitivity, 
with throat swabs being positive in 90 to 95% compared to stool culture 
being positive in 40-65% of patients tested (Chang et al. 1999; Wang et 
al. 1999; Wang et al. 2000). Few studies have looked systematically at all 
samples from a large patient group. One report of 175 patients with 
HFMD during the 2000 outbreak in Singapore found that rectal swabs 
most often yielded virus, followed by stool samples, vesicle swabs, and 
then throat swabs (Chan et al. 2003). However, throat swab was the single 
specimen most likely to be positive in most patient groups in this study, 
being positive for 288 (49%) of the 592 patients with a full set of samples, 
and 292 (49%) of all 598 patients studied. Approximately half of the 
patients had skin vesicles, and the result showed that vesicle swabs were 
also very useful. In patients with vesicles, they gave the second highest 
yield, being positive for 169 (48%) of 333 patients studied and in one 
patient group (during the second outbreak) they were the single most 
sensitive specimen (positive for 50%). Vesicle swabs have not been 
widely used to diagnose HFMD previously. One study from the EV71
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outbreak in Taiwan in 1998 reported virus isolation from four children 
who had vesicle swabs investigated, all of which were positive (Chang et 
al. 1999). But for most outbreaks vesicle fluid was not investigated 
(Komatsu et al. 1999; Wang et al. 1999; Fujimoto et al. 2002; Nolan et al. 
2003; Prager et al. 2003). However, in the report from the Singapore 2000 
outbreak, vesicles were positive for 50% of 62 HFMD patients with 
vesicles (Chan et al. 2003).
To examine the optimal number of lesions to sample, separate swabs were 
taken from each vesicle. Swabs from single vesicle were positive 35% of 
the time, but increased to 49% with two vesicles and 60% with 3 vesicles 
were sampled. Based on this observation, applying a single swab to two 
or more vesicles is recommended. This maximises the chance of isolating 
virus, without doubling the number of samples to be processed. In the 
study approximately half the patients had vesicles. They usually appeared 
early in the illness, and resolved after a few days, so that their presence 
may depend on the time of presentation. Like previous reports for EV71 
(Chang et al. 1999; Chang et al. 1999; Wang et al. 1999; McMinn et al. 
2001; Fujimoto et al. 2002; Chan et al. 2003; Nolan et al. 2003) and other 
human enteroviruses (Rotbart 1995; Pallansch et al. 2001), the isolation 
rate of CSF was low in this study. Less than 3% (3 of 102) of HFMD 
patients with aseptic meningitis had a positive CSF culture. The yield 
would likely have been higher if PCR had been used (Rotbart et al. 1997)
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but this investigation is not available in most developing countries. The 
isolation rate for rectal swabs was not as high as that of throat and vesicle 
swabs. This could be a reflection of the timing of the samples: the median 
time of presentation was just 2 days, which may be before viral shedding 
in the stool has become fully established.
In addition to looking at individual samples, I examined which 
combinations of samples were the most useful. This was achieved by 
determining the extent to which the addition of a sample type increased 
the number of patients diagnosed; this is different to asking how 
frequently a sample is positive. Thus, for example in the first half of the 
study, although ulcer swabs were positive more often than rectal swabs, 
they were less useful diagnostically, because most of the patients in 
whom they were positive had already been diagnosed by a throat swab. 
Determining the “added diagnostic value” of a sample type allowed us to 
produce predictions about which combinations of samples should prove 
useful, that I were then able to test in the second outbreak. Although the 
two outbreaks differed in size, and the proportion of patients in the 
different groups, they were similar in terms of demographics and 
causative agents, with EY71 being the predominant virus followed by 
CVA16. The predictions were basically sound. The combination of throat 
swabs plus vesicle swabs was the most useful for patients with vesicles, 
whether or not they also had ulcers, identifying virus for 224 (67%) of
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333 such patients across the whole study. For these patients, the addition 
of rectal and ulcer swabs diagnosed just 27 (8%) extra patients. For 
patients without vesicles (whether or not they had mouth ulcers), the 
combination of throat swab and rectal swab was most useful, identifying 
virus for 138 (53%) of 259 such patients. Thus during large outbreaks it is 
recommended that a throat swab plus one other sample type should be 
taken for each patient: if no vesicles are present, this should be a rectal 
swab; but if there are vesicles a swab should be applied to as many of 
these as possible (but at least 2). Although a limited sampling particularly 
for community surveillance and during large outbreaks is advocated, for 
individual patients, especially those that are critically ill, physicians will 
want to maximise the chance of obtaining a diagnosis. One approach 
might be to collect all sample types, but to investigate them in a stepwise 
manner, starting with the most useful samples, until a diagnosis has been 
made.
The study also examined the concordance of virus isolates from non- 
sterile sites (rectal, throat and ulcer swabs), with those from a sterile site 
(vesicle swabs). Twenty percent of rectal isolates differed from vesicle 
isolates (in individual patients with isolates from both sites), where-as 
such discordance with vesicle isolates occurred for only 10% of throat 
isolates. While most would accept the virus isolated from a vesicle as the 
causative pathogen, the significance of other viruses concomitantly
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detected from throat and/or rectum is not always clear. The data show that 
in the majority of patients with HFMD throat and rectal isolates do reflect 
viruses isolated from sterile sites, but in a minority they may be co­
incidental infections. However, it may not be correct to assume that virus 
isolated from vesicle is always the most important pathogen. For example 
one patient (HFM-178, Table 2.4) with severe HFMD and CNS disease 
had CVA16 isolated from a vesicle swab, but CVB1 from the throat. 
CVA16, a common cause of HFMD, is not known to cause CNS disease; 
in contrast CVB1, is not known to cause HFMD, and being a species B 
human enterovirus is a more likely neuropathogen (Thivierge et al. 1982). 
So in this patient with dual infection, the two virus isolates may have 
been responsible for two clinical syndromes: the throat isolate CVB1 
causing CNS disease and the vesicle isolate CVA16 causing HFMD. For 
four patients I also isolated different viruses from different vesicles: three 
with EV71 and CVA16, and one (with mild HFMD) with EV71 and 
Poliovirus 1 Sabin strain. These patients clearly demonstrate that systemic 
infection with two vimses can occur simultaneously. In addition, the latter 
case suggests the possibility that occasionally during dual infection, 
viruses may cross tissue barriers that they would not normally be able to 
(Poliovirus Sabin strain type 1 does not itself cause HFMD, and thus is 
not normally found in vesicles (Pallansch et al. 2001). The findings on 
dual infection underscore the need to look for a possible second pathogen,
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before attributing pathogenesis to a virus rarely associated with a severe 
disease phenotype.
EV71 looks likely to continue causing large outbreaks across the Asia 
pacific region. In summary I have shown that the throat swab is the single 
most useful sample from patients with HFMD during an EV71 outbreak. 
Vesicle swabs, which have been relatively neglected until now, can also 
be extremely useful. Although they are not as easy to obtain as throat and 
rectal swabs, and are not available for approximately half the patients, the 
viral yield is almost as good as that of throat swabs, with the added 
advantage that they come from sterile sites. Whilst virological culture is 
the standard method of diagnosis of enterovirus infection, rapid detection 
with PCR may offer new approach to laboratory detection of the virus.
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Table 2.1 The relationship between the numbers of swabs collected 
and the number positive, for vesicles and ulcers.
The relationship between the numbers of swabs collected and the number 
positive, for vesicles and ulcers.
Sample No. of swabs per No. of patients with at least one
type patient swab positive
Vesicle 1 62/177 (35)
2 40/81 (49)
3 18/30 (60)
>4 46/61 (75)
1 26/152 (17)
Ulcer 2 21/103 (20)
3 37/77 (48)
>4 13/40 (33)
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Table 2.2 Detection rate of different clinical sample types
Positive isolation rates of different clinical sample types according to
virus [No. (%)] for different viruses according to sample type. The 
number of patients positive for each sample type is shown as a proportion 
of the EV71 positive patients, the CVA16 positive patients, all 
enterovirus positive patients, and all patients (whether positive or 
negative).
Note:
* 11 patients in the 1st half of the study, and 3 in the 2nd half of the study 
had co-isolation of EV71 and CVA16.
EV=human enterovirus, CVA=Coxsackie virus A, CSF=cerebrospinal 
fluid.
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Table 2.3 Comparison of virus isolates grown from sterile sites with 
those from non-sterile sites
Pair-wise comparison [No.(%)] of virus isolates grown from vesicles (sterile site) 
with isolates grown from throat, rectum, or ulcers (non-sterile sites) in the same
patient*
Concordance findings with that of Throat Rectal Ulcer
vesicle swab (sterile site) swab swab swab
Same virus was isolated from vesicle swab 101 (30) 48 (14) 29 (14)
No virus was isolated from either swab 111 (33) 139(41) 83 (40)
Total 212(63) 187 (55) 112(54)
Discordance findings with that of Throat Rectal Ulcer
vesicle swab (sterile site) swab swab swab
Different virus was isolated from vesicle 11(3) 12(4) 4(2)
swab
Vesicle swab negative but sample positive 65 (19) 37 (11) 19(9)
Vesicle swab positive but sample negative 49(15) 106 (31) 73 (35)
Total 125 (37) 155 (45) 96 (46)
Grand total 337 342 208
* Many patients had swabs from multiple sites. The total number of patients 
represented here is 349.
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Figure 2.2 Diagnostic yields of different combination of clinical 
sample types
Histograms showing the proportion of patients diagnosed at each step, for 
the different patient groups, using the optimum combination of samples as 
determined in figure 2.1, and the total number of samples analysed at 
each step. Figure 2.2a shows the first half of the study and figure 2.2b 
shows the 2nd half. T-throat swab, V-vesicle swab, R-rectal swab, U-ulcer 
swab 
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Chapter 3: Rapid detection of enterovirus 71 
in primary clinical specimens
Abstract
A human enterovirus 71 (EV) 71 type-specific RT-PCR was developed in 
Institute of Health and Community Medicine, University Malaysia 
Sarawak, Malaysia for molecular typing of EV71 clinical isolates. In this 
chapter, I evaluated the diagnostic performance of the EV71 type-specific 
RT-PCR when tested with clinical specimens collected from children with 
hand, foot and mouth disease (HFMD) admitted at hospitals and at 
sentinel surveillance clinics during an outbreak of HFMD in 2006. 
Without altering PCR conditions originally optimised for typing of 
clinical isolates, and using virus culture results as the reference standard, 
the EV71 type-specific assay had a sensitivity of 76.9% (258/337), 
specificity of 82.6% (133/161), positive predictive value of 90.2% 
(259/287) and negative predictive value of 63.0% (133/211) when 
evaluated with a total of498 (337 EV71 positive, 161 non-EV71 virus) 
culture positive clinical specimens. The sensitivity of the assay in 
detection of EV71 from EV71 culture-positive clinical specimens was 
lower than that of pan-enterovirus RT-PCR [73.4% (152/207) versus 
97.6% (202/207)]. By lowering the PCR stringency, the sensitivity of the
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assay improved to 94.9% (297/313) and 95.1% (176/185) when compared 
to virus culture method and pan-enterovirus RT-PCR, respectively. The 
evaluation indicated that the application of the EV71 type-specific RT- 
PCR can be extended to be used as a rapid diagnostic assay for direct 
detection of EV71 from primary clinical specimens. As a single step PCR 
assay with no additional step of amplicon sequencing, the EV71 type- 
specific assay may be a useful alternative to clinical laboratories that have 
limited access to the conventional virus culture and neutralization test 
method, and nucleotide sequencing facilities.
3.1 Introduction
Hand, foot, and mouth disease (HFMD) is a common febrile illness in 
young children, and is characterised by maculopapular or vesicular skin 
lesions on the palms and soles, and mouth ulcers. Many species A human 
enteroviruses (EV-A, family Picornaviridae, genus Enterovirus) can 
cause HFMD, but human enterovirus 71 (EV) 71 and coxsackievirus 
(CV) A16 are the most common (Pallansch et al. 2001). A series of 
EV71-associeted HFMD outbreaks have occurred in Asia in the past 
decade, and some of these were associated with severe neurological 
manifestations and many deaths (Cardosa et al. 1999; Ho et al. 1999; 
McMinn et al. 2001; Chan et al. 2003; Ooi et al. 2007). In contrast, 
CVA16 infection is a benign disease (Pallansch et al. 2001). In many
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parts of Asia, there is now epidemiological and virological surveillance 
for HFMD so that effective public health measures, such as closing 
nurseries and schools, and broadcasting messages about personal hygiene 
can be instituted early to control outbreaks (Podin et al. 2006; Chen et al. 
2007). However, because the clinical presentations of these virus 
infections are indistinguishable clinically, establishing the aetiological 
diagnosis of HFMD cases relies on laboratory identification of the 
infecting virus. Hence, it is important to develop an accurate diagnostic 
method that can rapidly discriminate these two viruses particularly at the 
start of an outbreak in order to guide public health interventions.
The gold standard method for the identification of human enterovirus 
infection is to isolate the virus from the patient using susceptible cell lines 
followed by typing using the neutralization test (Pallansch et al. 2001). 
However, the method is slow and labour-intensive. In addition, it is 
dependent on the availability of the Lim-Benyesh-Melnick antiserum 
pools that are not available to every clinical virology laboratory. Indirect 
immunofluorescence employing commercially available monoclonal 
antibodies is an often used alternative, but some commercially available 
monoclonal antibodies do not have the specificity claimed. Therefore, a 
molecular diagnostic assay is more useful to allow rapid and sensitive 
detection of EV71. A universal enterovirus (pan-enterovirus) primer sets 
targeting the highly conserved 5’ untranslated region (5’UTR) of the
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enterovirus genome were developed in the late 1980’s and the early 
1990’s to detect enterovirus from primary clinical specimens (Rotbart et 
al. 1995). The pan-enterovirus primer sets have substantially higher 
sensitivity than virus culture in the detection of enterovirus, and are used 
widely on primary clinical specimens for rapid virological diagnosis 
(Romero 1999). However, the major drawback of the pan-enterovirus 
primers is that the method does not distinguish enterovirus serotypes 
(Rotbart et al. 1995). More recently, a molecular typing method based on 
sequencing a segment of the VP1 gene, which codes for the most 
immunodominant region of viral capsid protein, has been shown to be a 
useful and rapid approach to typing of human enterovirus (Oberste et al. 
1999). This method, however, requires access to a DNA sequencing 
facility and is therefore more expensive and less accessible in resource 
limited situations.
Several EV71 type-specific RT-PCR assays directed at different regions 
of the VP1 gene of human enterovirus have been developed following the 
large outbreaks of HFMD in Malaysia and Taiwan (Brown et al. 2000; 
Yan et al. 2001; Singh et al. 2002; Tsao et al. 2002). Although all the 
published primer sets have been shown to be highly sensitive and specific 
when tested with virus isolates, only one of these sets has been evaluated 
for its utility in the detection of EV71 from primary clinical specimens 
(Singh et al. 2002). Furthermore, misidentification of CVA16 as EV71
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has been observed with some primer sets (Singh et al. 2002; Perera et al. 
2004). A set of EV71 type-specific primer (MAS01A and MAS02S) was 
developed in Institute of Heath and Community Medicine, Universiti 
Malaysia Sarawak, Sarawak, Malaysia. The EV71 type-specific primers 
were designed to only amplify a part of the VP1 gene of EV71 but not 
other enteroviruses, including CVA16. The utility of these primers on 
identification of clinical isolates has been reported (Perera et al. 2004). 
The diagnostic performance of the MAS01S/MAS02A primer set when 
its application was extended to direct detection of EV71 from primary 
clinical specimens was evaluated during an outbreak of HFMD in 
Sarawak in 2006. The performance of this type specific primer set was 
compared with a widely used pan-enterovirus primer set in detection of 
EV71 from primary clinical specimens.
3.2 Materials and methods
3.2.1 Setting and Clinical specimens
Clinical specimens including throat swabs, rectal swabs, ulcer swabs, 
vesicular fluid, urine, serum and cerebrospinal fluid (CSF) were collected 
from the hospitalised patients with HFMD as well as patients treated in 
the sentinel surveillance clinics during an outbreak of HFMD in 2006. A 
sentinel surveillance clinic programme for HFMD was established in
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Sarawak in 1998 (Podin et al. 2006). The doctors of the sentinel clinics in 
this study have actively participated in the surveillance programme since 
1998. They were provided with a standard reporting and specimen 
collection form, sterile swabs and virus transport medium, a telephone 
number for obtaining assistance for transport of specimens to the 
laboratory and a facsimile number to report cases to the Sarawak Health 
Department. The clinical specimens from the hospitalised patients were 
stored immediately in a “70°C freezer until transported to the laboratory. 
When immediate storage at -70°C was not possible, the specimens were 
stored at 4°C overnight and were transferred to a -70°C freezer the 
following morning. Specimens from the sentinel clinics were stored at 4 
°C after collection and transported on ice to the laboratory. Swabs in virus 
transport medium were vortexed and aliquoted before testing.
3.2.2 Virus isolation
Specimens were inoculated into human rhabdomyosarcoma (RD) and 
human embryonal kidney (293) cell lines as described in the section of 
materials and methods of Chapter 2.
3.2.3 Nucleic acid extraction
In this chapter RNA was extracted fi'om infected tissue culture 
supernatants and from primary clinical specimens using Chemagic Viral
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RNA/DNA kits (Chemagen, Baesweiler, Germany) according to the 
manufacturer’s instructions. An automated magnetic particle separator 
(Kingfisher mL, Thermo Electron Corporation) was used to separate the 
magnetic beads from eluted viral RNA. The extracted RNA was stored at 
-80°C until use.
3.2.4 Pan-enterovirus RT-PCR for identification of 
enterovirus
The presence of any enterovirus in primary clinical specimens was 
determined by the pan-enterovirus RT-PCR using the primer MD90 and 
MD91 as described previously (Romero et al. 1993). The expected PCR 
product for pan-enterovirus PCR was 154 base pairs.
3.2.5 Enterovirus 71 type specific RT-PCR
The presence of EV71 RNA in primary clinical specimens was 
determined by using the MAS01S (5*-
ATAATAGCA(C/T)T(A/G)GCGGCAGCCCA -3’) and MAS02A (5’ - 
AGAGGGAG(A/G)TCTATCTC(C/T)CC -3’) primer set that flank a 
region within the VP1 gene unique to EV71 and amplify an expected 
product size of 376 base pairs (Perera et al. 2004). Briefly, first strand of 
cDNA was prepared in a 10 pi reaction mixture containing 5.5 pi RNA
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template, 0.5 mM dNTP, 200 U Moloney murine leukemia virus reverse 
transcriptase (M-MuLV RT) (Fermentas), IX M-MuLV RT buffer 
(Fermentas) and the antisense primer MAS02A. cDNA synthesis was 
performed for 1 hour at 37°C. In the PCR step, the VP1 gene was 
amplified using 10 pi of cDNA in a 20 pi reaction volume containing 1.5 
mM MgCl2,1 pM each of primer MAS01S and MAS02A, 0.3 mM dNTP 
(Fermentas), 2.5 U Taq DNA polymerase (Fermentas) and IX Taq 
polymerase buffer with (NFL^kSCU (Fermentas). DNA amplification was 
performed by initial denaturation at 94°C for 5 minutes and followed by 
35 cycles of denaturation at 95°C, annealing at 55°C and extension at 
72°C for 30 seconds each. A final extension at 72°C for 5 minutes was 
performed after the last cycle. The PCR products were analyzed by 
electrophoresis on 2% agarose gel containing 0.5 pg/ml ethidium 
bromide.
3.2.6 Nucleotide sequencing of enterovirus isolated
Enterovirus VP4 gene nucleotide sequencing was used to screen, and to 
identify clinical isolates according to enterovirus species (Ishiko et al. 
2002; Cardosa et al. 2003). Further typing of EV-A isolates was provided 
by VP4 gene sequencing as it has been previously shown that the results 
of the VP4 gene were 100% in concordance with that provided by the 
VP1 gene for EV-A (Tu et al. 2007). Sequencing reactions were
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performed using the Big Dye Terminator Cycle Sequencing Kit version 
3.1 (Applied Biosystems, Foster City, CA, USA).
3.2.7 Statistical analysis
Differences between proportions were tested using the Chi-Square test 
with Yates’ correction or Fisher’s exact test (Epi Info version 6 CDC, 
Atlanta, USA). The diagnostic accuracy of the EV71 specific assay was 
compared with two reference standards - virus isolation and Pan- 
enterovirus RT-PCR. Using the results of virus culture (the conventional 
gold standard) as the reference standard, the sensitivity of EV71 specific 
assay was defined as the percent of EV71 PCR positive specimens that 
also yielded an EV71 isolate by virus culture, and the specificity was 
defined by the percent of EV71 PCR negative specimens that yielded a 
non-EV71 virus by virus culture. Likewise, using the results of pan­
enterovirus RT-PCR using MD90/MD91 primer set (a widely used RT- 
PCR method for enteroviruses) as the reference standard, the sensitivity 
of EV71 specific assay in the detection of EV71 from EV71 isolate 
positive specimens was defined as the percent of EV71 PCR positive 
specimens that also were positive by pan-enterovirus RT-PCR, and the 
specificity was defined by the percent of EV71 PCR negative specimens 
that were also negative by pan-enterovirus RT-PCR. The sensitivity, 
specificity, positive predictive value (PPV), negative predictive value
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(NPV) of the EV71 specific assay were calculated from a 2 X 2 table, and 
reported according to the guideline of The STARD statement (Bossuyt et 
al. 2003).
3.3 Results
A total of 1515 clinical specimens (1256 throat swabs, 100 vesicle swabs, 
56 rectal swabs, 30 CSF, 30 ulcer swabs, 23 serum, 9 endotracheal 
aspirate, 6 urine, 2 brain tissue and 3 swabs from unknown site) from 
hospitals, and 311 samples (180 throat swabs, 86 ulcer swabs and 45 
vesicle swabs) from 2 sentinel clinics were tested (Figure 3.1). All the 
clinical specimens were subjected to virus isolation. EV71 type-specific 
RT-PCR and Pan-enterovirus RT-PCR on the primary clinical specimens 
were performed before the results of the virus isolation became available.
3.3.1 Virus isolation
Virus was isolated from 498 (27.3%, 449 from the hospitals, 49 from 
sentinel clinics) of 1826 specimen tested. Three hundred and twelve 
(69.5%) of 449 hospital specimens had EV71, and 3 of these specimens 
also had a second non-EV71 virus. The remaining 137 (30.5%) hospital 
isolates were not EV71 and included EV-A and EV-B with some 
adenoviruses, herpes simplex virus and human rhinovirus. At least 3 of
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these specimens also yielded more than one virus isolate. Of the 49 
culture positive specimens from the sentinel clinics, only 25 (51%) 
yielded EV71 and the remaining yielded other EV-A. No specimen from 
the sentinel clinics yielded more than one virus isolate. Table 3.1 shows 
the distribution of the viruses according to specimen types. EV71 was 
more likely to be isolated from specimens collected from hospitalised 
children than that from children treated at sentinel clinics [312 (69.5%) of 
449 versus 25 (51%) of 49, Odds ratio (95% confidence interval) 2.19 
(1.16-4.13), p=0.0138].
3.3.2 The diagnostic accuracy of enterovirus 71 type 
specific RT-PCR compared to virus isolation followed by 
serotype identification
Table 3.2 shows the results of the EV71 type-specific assay when tested 
with a total of 498 culture positive clinical specimens. The 
MAS01A/MAS02S primers correctly identified 259 (76.9%) of the 337 
specimens that subsequently cultured EV71 isolates (true positive), but 
failed to amplify the remaining 78 specimens (false negative). The 
MAS01S/MAS02A primers also generated a PCR product of the expected 
size in 28 (17.4%) of the 161 primary specimens from which a non-EV71 
isolate was obtained (false positive). Using the results from virus culture 
as the reference standard, the type specific RT-PCR had a sensitivity of
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76.9% (259/337), specificity of 82.6% (113/161), PPV of 90.2% 
(259/287) and NPV of 63.2% (113/211). When the performance of the 
primers was analyzed according to the samples collected from 2 different 
clinical settings, the primer set had a sensitivity of 76.9% (240/312), 
specificity of 82.5% (113/137)), PPV of 89.6% (240/264) and NPV of 
61.1% (113/185) when tested with the hospital samples, and a sensitivity 
of 76% (19/25), specificity of 83.3% (20/24), PPV of 82.6% (19/23) and 
NPV of 76.9% (20/26) when tested with the sentinel clinic samples.
In addition, nearly a third (415/1328) of the culture negative clinical 
specimens was also positive with the EV71 type-specific assay (Table 
3.2). To exclude the likelihood of non-specific amplification in the 
primary clinical specimens, the PCR products obtained from 16 of the 
415 culture negative specimens were sequenced, and confirmed as EV71.
3.3.3 Reason for the non-detection of enterovirus 71 by 
enterovirus 71 type specific RT-PCR
The possible reasons for the failure of EV71 PCR product amplification 
in a total of 78 EV71 culture-positive clinical specimens (72 from 
hospitals, 6 from sentinel clinics) may be due to multiple reasons 
including (a) degradation of viral RNA because of prolonged storage, (b)
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primer-template sequence mismatch, (c) low viral load or low RT-PCR 
assay sensitivity.
The information on the duration of template storage before RT PCR was 
available in 314 of 337 EV71 isolate positive specimens. There was no 
difference in the median duration of template storage (days, range) before 
the assay was performed between the true positive group (24, 0-193) and 
the false negative group (18, 3-86) (Mann-Whitney U test, p=0.1729).
I attempted to exclude the likelihood of primer-template mismatch in the 
false negative group by investigating 68 (87.2%) of 78 EV71-infected 
tissue culture supernatants that were available for testing with the 
MAS01A/MAS02S primers. A PCR product of expected size was 
obtained in all the 68 (100%) infected tissue culture supernatants tested 
indicating that the failure of PCR amplification was unlikely due to 
primer-template mismatch in the primary clinical specimens, although the 
availability of large amount of templates that would normally be present 
in tissue culture supernatants may have overcome the inefficiency of the 
PCR reaction with mismatched target.
Fifty five (70.5%) of the 78 primary clinical specimens in the false 
negative group were tested with pan-enterovirus PCR to determine if the 
universal enterovirus primer set could detect the presence of EV71 that
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were missed by the EV71 type specific primers (Figure 3.1). Apart from 5 
(4 throat, 1 mine) samples that were negative by both pan-enterovirus 
RT-PCR and EV71 type specific RT-PCR, 90.9% (50/55) of the samples 
were positive using the pan-enterovirus RT-PCR suggesting that the non­
detection of EV71 was not due to low viral load but lower sensitivity of 
the EV71 type-specific assay compared to the pan-enterovirus primer set.
3.3.4 Comparison of enterovirus 71 type-specific RT-PCR 
results with pan-enterovirus rt-PCR results in enterovirus 
71 culture-positive clinical specimens
Table 3.3 compares the performance of EV71 type-specific RT-PCR with 
pan-enterovirus RT-PCR in the detection of EV71 from a total of 207 
(195 from hospitals, 12 from sentinel clinics) EV71 culture-positive 
clinical specimens. Of the 202 EV71 culture-positive specimens that were 
positive by pan-enterovirus RT-PCR, the MAS01A/MAS02S primers 
correctly identified 152 (75.2%) but missed the remaining 50 (24.8%) 
specimens. The primer set failed to identify EV71 in 5 culture positive 
specimens that were also missed by pan-enterovirus RT-PCR.
127
3.3.5 Further improvement in the sensitivity of EV71 
specific assay
Compared with virus isolation followed by serotype 
identiHcation
The stringency of the PCR conditions was reduced to improve the 
sensitivity of EV71 specific assay - the annealing temperature was 
lowered from 55°C to 50°C. Fifty four (69.2%) of the 78 false negative 
specimens were available for re-testing using the modified RT-PCR 
protocol (Figure 3.1), and PCR product was obtained in 38 (70%) of the 
54 specimens tested (Figure 3.2). Repeating the analysis based on the 
repeat assay results of the 54 specimens, with the assumption that all the 
PCR positive samples would remain positive when they were assayed 
with the modified RT-PCR protocol, the sensitivity of the primer set 
when compared to virus culture improved from 76.9% (259/337) to 
94.9% (297/313).
Compared with Pan-enterovirus RT-PCR
Thirty four of 50 samples that were negative by the EV71 type-specific 
RT-PCR but positive by the pan-enterovirus RT-PCR, as well as 3 of 5 
samples that were negative by both PCR methods were also retested using 
the modified protocol. By lowering the annealing temperature to 50° C, 
the primer set detected EV71 in 25 (73.5%) of the 34 samples that were
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previously EV71 RT-PCR negative, but continued to fail to amplify EV71 
in all 3 samples that were negative earlier by both PCR methods. Using a 
similar analytical approach and assumption, the sensitivity of the primer 
set, when compared to pan-enterovirus PCR improved from 75.2 
(152/202) to 95.1% (176/185).
3.4 Discussion
Two consecutive epidemics of EV71 associated HFMD in Sarawak and 
Taiwan in the late 1990’s heralded the emergence of EV71 as the most 
important non-polio enterovirus in children in the Asia Pacific region 
(Cardosa et al. 1999; Ho et al. 1999). The memory of the previous 
massive outbreaks in Sarawak and Taiwan has led the general public in 
Asia, including in Sarawak, to perceive HFMD as a potentially fatal 
infection. It often causes panic among the parents of the affected children, 
as well as the doctors, and attracts widespread media publicity. Previous 
experience in Sarawak, Malaysia showed the epidemic activity of EV71 
can rise exponentially and reach its height within 4 weeks after its first 
appearance (Podin et al. 2006). However, enterovirus typically takes 7 to 
10 days to grow and produce cytopathic effect on the RD cell culture, 
which was developed for the detection of enteroviruses belonging to 
species A including EV71 (Schmidt et al. 1975). Therefore to meet the 
primary objectives of providing an early alert for an impending outbreak,
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and to guide public health intervention, an effective virological 
surveillance programme for HFMD requires not only virus culture, but 
also a rapid and accurate molecular diagnostic tool for the identification 
of EV71. Although preventive measures such as dissemination of health 
information including the importance of personal hygiene and avoidance 
of crowded public areas, disinfection and cleaning of areas are useful and 
inexpensive, more aggressive approaches such as closure of childcare 
centres and schools or extension of school vacation may be necessary to 
effectively prevent further transmission of EV71 in a community. Due to 
the socio-economic impact of some of these measures, the identification 
of the infecting virus is critical in guiding the public health doctors to 
institute appropriate public health interventions. In addition, timely 
clinical intervention including use of intravenous immunoglobulin in 
children with severe EV71 infection may reduce acute mortality (Chang 
et al. 2004; Wang et al. 2006). Nonetheless, intravenous immunoglobulin 
treatment is expensive, and not completely free of serious side effects. As 
a result, clinical laboratories are often under tremendous pressure to 
provide a timely diagnosis to public health doctors, clinicians and the 
community when there is a cluster of HFMD in the community.
Several nested and semi-nested PCR assays had been developed for direct 
identification of enterovirus serotypes from primary clinical specimens. 
The assays, however, require a panel of primer sets and involve the
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additional step of PCR product sequencing (Miren et al. 2006; Nix et al. 
2006; Oberste et al. 2006). At least four sets of EV71 type specific 
primers have been published previously, but only one set developed by 
Singh et al had been evaluated on clinical specimens (Brown et al. 2000; 
Yan et al. 2001; Singh et al. 2002; Tsao et al. 2002). The reported 
sensitivity of the primers was less than 5% (1/21) when used as a single­
round RT-PCR and 53% (17/32) as a semi-nested PCR. A two-step 
duplex real-time RT-PCR assay for rapid detection of enteroviruses and 
parechoviruses has been shown to have superior diagnostic sensitivity 
over virus isolation when tested on CSF and throat swab samples (Corless 
et al. 2002). In this chapter, a set of EV71 type-specific primers originally 
developed for molecular typing of EV71 clinical isolates, for rapid 
detection of EV71 from clinical specimens was evaluated. Without 
altering the thermal cycling conditions that were originally optimised for 
typing of enterovirus isolates, the MAS01A/MAS02S primer set had a 
sensitivity of 76.9% and a specificity of 82.6% when tested with 498 
culture positive clinical specimens. The assay performed equally well 
when tested with clinical specimens collected from hospitals and primary 
care clinics.
The false negative rate of theEV71 specific assay was 23.1%. The reason 
for non-detection in EV71 culture positive specimens is likely related to 
lower assay sensitivity when compared to the pan-enterovirus RT-PCR.
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The study showed that the sensitivity of the assay can be improved 
significantly by lowering the PCR stringency. Nonetheless, the overall 
negative predictive value (NPV) is only 63% (133/211) and it is important 
to exercise caution in the interpretation of negative results (Table 3.2).
In this study, there were 28 specimens that were EV71 PCR-positive but 
subsequently obtained a non-EV71 isolate. It is notable that there were at 
least 6 specimens that yielded more than one virus. Three of these had 
both EV71 as well as another enterovirus or adenovirus isolate. The most 
plausible explanations for the non-cultivation of EV71 may be related to 
low viral load, non-viable virus, virus interference or other reasons. EV71 
was detected in a significant proportion (415/1328) of culture negative 
specimens. The ability of the primer set in detecting EV71 from such 
clinical specimen types indicates that the primer set can be a valuable 
back-up diagnostic method to virus culture in clinical settings where a 
definitive aetiological diagnosis is crucial. Although there is no doubt that 
real time RT-PCR methods may also provide similar information rapidly, 
a higher cost associated with this technology render it less useful in 
Sarawak, Malaysia, which is that of a developing country setting.
A number of EV71-associated HFMD outbreaks have been reported in 
the past decade in Asia, and some of these were linked epidemiologically 
(McMinn et al. 2001; McMinn et al. 2001; Fujimoto et al. 2002; Cardosa
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et al. 2003; Chan et al. 2003; Jee et al. 2003; Shimizu et al. 2004; Lin et 
al. 2006; Hosoya et al. 2007). The vims can cause cyclical outbreaks and 
may have established an endemic circulation in some countries (Podin et 
al. 2006; Chen et al. 2007). There is also concern that it may spread 
globally. The MAS01A/MAS02S primer set may be used to provide rapid 
genogroup information about EV71 (Perera et al. 2004). Molecular 
epidemiological linkage of outbreaks may be established through the 
sequenced PCR product obtained directly from clinical specimens before 
clinical isolates become available through vims culture. Indeed, the 
detection of partial sequence of VP1 of EV71 through this approach has 
helped the laboratory in Universiti Malaysia Sarawak to issue early 
warning of an impending outbreak, and provide preliminary information 
about the molecular epidemiology of the outbreak vims strains in 
Sarawak in early 2006
f http: //www2. ichr .uwa. edu.au/apnet/news/index. lasso ?q=/apnet/news/ind
ex. lasso&news=current_ev71 and
http://www2.ichr.uwa.edu.au/apnet/news/docs/Sarawak_EV71_2006.pdf)
. As WHO is close to eradicating wild polio vims from the world, there is 
great concern that EV71 may emerge as the most important neurotrophic 
enterovims in children (Prager et al. 2003; Modlin 2007; Perez-Velez et 
al. 2007), and thence underscores the need for a reliable diagnostic tool 
for EV71 infection. Although all recent major EV71 epidemics in Asia 
were closely associated with HFMD (McMinn 2002), a valuable clinical
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cue for the clinicians who manage children with suspected neurological 
infection, the cutaneous stigmata of the virus may be absent in some 
cases, as reported in a recent outbreaks of EV71 in Colorado, USA in 
2003 and 2005 (Perez-Velez et al. 2007). To heighten the index of 
suspicion in the laboratory and to improve the detection rate of EV71, the 
authors proposed an algorithm that considers the results of pan- 
enterovirus RT-PCR on CSF, throat swab and rectal swab, followed by 
further tests such as nucleotide sequencing and virus isolation. A single 
step type-specific EV71 assay is therefore a useful and practical 
alternative for most clinical laboratories that have limited access to 
nucleotide sequencing and virus isolation facilities, and may indeed even 
be a useful screening tool for the most well-resourced laboratories.
There were some limitations in the study. The molecular diagnostic 
approaches in this study were developed to detect enteroviruses in the 
clinical samples. Children with CNS involvement were not tested for 
human parechoviruses. Human parechoviruses are increasingly 
recognized as important cause of viral CNS infection in children. Apart 
from gastrointestinal and respiratory infections, human parechovirus type 
1 has been associated with encephalitis and paralysis, while human 
parechovirus type 3 has been found to be an important cause of aseptic 
meningitis in young infants (Harvala et al. 2009).
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In summary, the study evaluated a single step EV71 type-specific RT- 
PCR method for an extended application of direct detection of EV71 from 
primary clinical specimens. The primers performed satisfactorily when 
tested with a large set of clinical specimens from 2 different clinical 
settings, and has compared very favourably to a previously published type 
specific semi-nested PCR method. The performance of the assay 
improved further with a lower annealing temperature, and was 
comparable to that of pan-enterovirus RT-PCR. A lower stringency may 
be employed when the primer set is used to analyze primary clinical 
specimens, but the higher stringency conditions should be maintained 
when used to type isolates.
Until RT-PCR become part of routine diagnostic practice, virus isolation 
will remain the mainstay of laboratory diagnosis of enterovirus infection. 
Both virus isolation and PCR allow determination of the genogroup of the 
infecting virus, and thus examination of possible clinical difference 
between different subgenogroups, as addressed in the next chapter.
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Table 3.1 Distribution of vims isolates according to specimen types 
and clinical settings
Hospital Sentinel clinic
Specimen type EV71
isolated
Non-
EV71
virus
isolated
Negative
EV71
isolated
Non-
EV71
virus
isolated
Negative
Total
Throat Swabs 277* 116** 863 10 7 163 410
Vesicle 16 9 75 1 1 43 27
Mouth ulcer 3 1 26 14 16 56 34
Rectal swabs 13 8 35 - - - 21
Swab (site
unknown)
1 0 2 - - - 1
CSF 1 2 27 - - - 3
Urine 1 1 4 - - - 2
Total 312 137 1032 25 24 262 498
Notes:
* 3 specimens yielded both EV71 and a second virus (1 each with EV 
species A, B and C)
** 3 specimens yielded 2 different non-EV71 isolates 
- no sample tested
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Table 3.2 Enterovirus 71 type-specific RT PCR results on clinical 
specimens from which virus isolates were obtained
Non-EV71 Total number
EV71 virus No virus of specimens
isolated isolated isolated tested
EV71 type-
specific RT-
PCR positive
259 28 415 702
EV71 type-
specific RT- 78 133 913 1124
PCR negative
Total 337 161 1328 1826
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Table 3.3 Comparison of the performance of enterovirus 71 type- 
specific RT-PCR with pan-enterovirus RT-PCR in the detection of 
enterovirus 71 from enterovirus 71-culture positive clinical samples
Pan-enterovirus RT-
PCR positive
Pan-enterovirus RT-
PCR negative
Total
EV71 type-
specific RT-PCR
positive
152 0 152
EV71 type-
specific RT PCR 50 5 55
negative
Total 202 5 207
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Figure 3.1 Evaluation of a total of 1826 clinical specimens collected 
from the patients with hand, foot and mouth disease.
A flowchart showing the evaluation of a total of 1826 clinical specimens 
collected from the patients with hand, foot and mouth disease.
HFMD: hand, foot and mouth disease; EV71 spec RT-PCR: enterovirus 71 type- 
specific RT-PCR; EV71 spec RT-PCR AT50: enterovirus 71 type-specific RT- 
PCR with an annealing temperature of 50°C; Pan-enterovirus RT-PCR: universal 
enterovirus RT-PCR.
Specimens from patients 
with HFMD, n=l 826
RT-PCR
Pan-EV
pos, n=152
RT-PCR
Pan-EV
nee, n=0
Pan-EV
RT-PCR
Pan-EV
EV71 spec RT- 
PCR AT50 
neg, n= 16
EV71 spec RT- 
PCR AT50 pos, 
n=38
EV71 isolated 
by virus 
culture, n=78
EV71 spec RT- 
PCR AT50 pos, 
n=25
EV71 spec RT- 
PCR AT50 neg, 
n=3
No virus 
isolated by virus 
culture, n=913
EV71 detected by EV71 
spec RT-PCR, n=702
EV71 isolated 
by virus culture, 
n=259
Non-EV71 virus 
isolated by virus 
culture, n=133
EV71 not detected by EV71 
spec RT-PCR, n=1124
Clinical specimens 
tested with
Pan-EV RT-PCR,
Clinical specimens 
tested with
Pan-EV RT-PCR.
Clinical specimens 
tested with EV71 spec 
RT-PCR AT50, n=3
Clinical specimens 
tested with EV71spec 
RT-PCR AT50, n=34
Clinical specimens 
tested with EV71spec 
PCR AT50, n=54
EV71 spec RT- 
PCR AT50 neg, 
n=9
EV71 spec RT- 
PCR AT50 pos, 
n=0
Non-EV71 virus 
isolated by virus 
culture, n*=28
No virus isolated 
by virus culture, 
0=415
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Figure 3.2 Amplification of enterovirus 71 from primary clinical 
material using re-optimised PCR cycling conditions with primer pair 
MAS01S/MAS02A.
Lanes, 1-16, primary clinical material previously not positive for EV71 
using published PCR conditions (Perera et al, 2004); H, water control; P, 
EV71 positive control; M, 100 bp DNA ladder (Fermentas). ‘+’ indicates 
samples that were tested positive for EV71. The expected position of the 
amplicon is indicated by the arrow.
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Chapter 4: Clinical features, virological 
characteristics and molecular epidemiology of 
enterovirus 71 disease in Sarawak, Malaysia
Abstract
Human enterovirus (EV) 71 causes large outbreaks of hand, foot and 
mouth disease with neurological complications, but the role of EV71 
genogroups or dual infection with other viruses, in causing severe disease 
is unclear. Children with suspected EV71 infection (hand, foot and mouth 
disease, central nervous system disease, or both) were studied over VA 
years, with detailed virological investigation and genogrouping of all 
isolates. A total of 773 children were recruited, 277 of whom were EV71 
positive, including 28 co-infected with other vimses. Risk factors for 
central nervous system disease in EV71 included young age, fever, 
vomiting, mouth ulcers, breathlessness, cold limbs, and poor urine output. 
Genogroup analysis for the EV71-infected patients showed 168 were 
infected with genogroup B4, 68 with Cl, and 41 with a newly emerged 
genogroup B5. Children with EV71 genogroup B4 were less likely to 
have central nervous system complications than those with other 
genogroups [26 (15%) of 168 versus 30 (28%) of 109, odds ratio (OR) 
[95% Cl] 0.48 [0.26 - 0.91], p=0.0223] and less likely to be part of a
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family cluster [12 (7%) of 168 versus 29 (27%) of 109, OR 0.21 [0.10- 
0.46], pO.OOOl]; family clusters were more likely with genogroup B5 
(OR 6.26 [2.77-14.18], p<0.0001). Children with EV71 and co-infection 
with another enterovirus or adenovirus were no more likely to have CNS 
disease. In conclusion genogroups of EV71 may differ in their risk of 
causing CNS disease, and family clusters. Dual infections are common, 
and all possible causes should be excluded before accepting that the first 
virus identified is the causal agent.
4.1 Introduction
Since 1997 countries of the Asia-Pacific rim have been affected by large 
outbreaks of human enterovirus (EV) 71 associated hand foot and mouth 
disease (HFMD), with hundreds of thousands of cases, and many deaths 
(Cardosa et al 1999; Ho et al. 1999; Komatsu et al. 1999; Chan et al. 
2000; McMinn 2002; Chan et al. 2003; Nolan et al. 2003). HFMD is a 
common exanthema of young children, characterised by fever, rash on the 
palms and soles, and ulcers in the oral cavity. Most patients have mild 
disease, but some patients develop severe neurological complications 
(aseptic meningitis, acute flaccid paralysis and encephalitis) or systemic 
disease (shock, cardiac dysfunction). HFMD is caused by enteroviruses 
(genus enterovirus, family Picomoviridae), particularly Coxsackie virus 
(CV) A10, CAV16 and EV71, which are mostly transmitted by the faeco-
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oral route. Phylogenetic studies have divided EV71 strains into 
genogroups A, B and C, which have been further sub-divided (Brown et 
al. 1999; McMinn et al. 2001; McMinn 2002; Cardosa et al. 2003). The 
incidence of CNS disease, and of other severe complications, appears to 
have varied between outbreaks. The reason for this is unclear, but 
differences between genogroups (Dolin 1999; McMinn et al. 2001; Wang 
et al. 2002), and co-infection with other viruses, such as a newly 
characterised adenovirus (Cardosa et al. 1999; Ooi et al. 2003), have been 
postulated. However making comparisons between outbreaks has been 
hampered by the retrospective nature of many studies, and differences in 
inclusion criteria, in definitions of severe disease, and in viral diagnostic 
capabilities. A prospective clinical, diagnostic and molecular virological 
study of EV71-associated HFMD in one setting was conducted over 31/2 
years focusing on risk factors for neurological disease, and the putative 
role of different EV71 genogroups and dual infections in pathogenesis.
4.2 Materials and methods
Setting
The study was conducted on the paediatric wards and intensive care unit 
at Sibu Hospital, Sarawak, Malaysia, from January 2000 for 3 'A years. 
This 550 bed hospital serves Sibu town (population 200,000) and receives 
referrals from district hospitals in the Rejang basin (total population
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approximately 650,000). The study was approved by the Director of 
Health for Sarawak (Malaysia) and the Ethics Committee of the Liverpool 
School of Tropical Medicine (Liverpool, UK). Informed consent was 
obtained from each child’s accompanying parent or guardian.
Case definitions
Because enteroviruses can cause HFMD, CNS infection, or both, children 
(age 1 month to <12y) were screened for both these conditions. Children 
with HFMD were classified according to an algorithm as having Mild 
HFMD, Severe non-CNS HFMD, or HFMD with CNS complications 
(Figure 4.1). Children with suspected CNS infections, but no HFMD, 
were classified as having aseptic meningitis (ASM) or viral encephalitis, 
based on the clinical and CSF findings; however there were no children 
with enterovirus infection in this last group, so they are not discussed 
further.
Clinical methods
A detailed history was taken, and a clinical examination performed by a 
paediatrician in the study team, looking especially for mucocutaneous 
lesions, cardiovascular and neurological signs; all details were recorded 
on standardised forms. For viral culture, swabs were taken from the 
throat, and rectum of every patient, as well as at least one swab from 
vesicles on the skin and oral ulcers (if present). Blood was taken for viral
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studies. In patients with severe disease full blood count, urea, electrolytes, 
glucose, electrocardiogram and echocardiogram was performed. CSF was 
examined for cell count and differential, protein, glucose, Gram stain, 
bacterial culture and viral studies; lumbar puncture was repeated if there 
was a strong clinical suspicion of viral CNS infection, but the initial 
examination was not confirmatory. Lumbar punctures were delayed in 
those severely unwell. Patients were examined daily or more frequently as 
indicated, by a member of the study team. Children with HFMD and CNS 
complications were treated with intravenous immunoglobulin (IVIG, 
Intragam P, CSL which is derived from local Malaysian blood donors) on 
a presumptive basis (Cardosa et al. 1999; Lin et al. 2002), at the 
discretion of the treating physician.
Virological methods
Virus isolation was attempted on all swabs, CSF and any serum 
remaining after other investigations had been completed, by inoculating 
into rhabdomyosarcoma (Rd) and 293 cells (Ooi et al. 2003). 
Enteroviruses isolated were typed by nucleotide sequencing of VP1 and 
VP4 genes (Brown et al. 1999; Ishiko et al. 2002), and genogrouped by 
phylogenetic analysis (Brown et al. 1999; McMinn et al. 2001; Cardosa et 
al. 2003). Adenoviruses were cultured and typed as described previously 
(Ooi et al. 2003). Paired sera (taken on admission and day 7 or discharge) 
and CSF were also tested for IgM against dengue and Japanese
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encephalitis virus (JEV) in parallel, using an IgM capture ELISA 
(Cardosa et al, 2002). Seroconversion from a negative sample to a 
positive 2nd sample or a rising IgM optic density (OD) was considered 
evidence of acute infection; antibody in the CSF was diagnostic of 
flavivirus CNS infection (Solomon et al. 1998; Solomon et al. 2000). A 
falling IgM OD was considered evidence of a recent infection, and low 
IgM OD in serum of children recently vaccinated against JEV was 
ascribed to vaccination.
Statistical analysis
Normally distributed data were compared using Student’s t-test; data that 
were not normally distributed were compared by the Mann-Whitney U 
test (Staview 4.02 Abacus Concepts Inc). Differences between 
proportions were tested using the chi-square test with Yates’ correction or 
Fisher’s exact test (Epi-info Version 6). Variables that might relate to 
disease pathogenesis that were associated with CNS disease in univariate 
analyses were also examined in a stepwise logistic regression (SPSS 
version 9).
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4.3 Results
4.3.1 Epidemiology
During the study 773 children (485, 63% males) were recruited. Five- 
hundred-and-forty (70%) had mild HFMD, 83 (11%) had severe HFMD 
with no CNS complications, 102 (13%) had HFMD with CNS disease, 
three of whom died, and 48 (6%) had ASM, one of whom died. Most 
children were recruited during two large outbreaks of EV71 associated 
HFMD, during 2000/1 and 2003 (Figure 4.2). Both outbreaks began in the 
months of January/February and peaked around the months of May and 
June, which coincided with the dry season of Sarawak. Genogroup 
analysis showed that in the 2000/1 outbreak most EV71 isolates belonged 
to genogroup B4 (McMinn et al. 2001; Cardosa et al. 2003), with some in 
Cl. In 2003 as well as genogroup Cl strains, a previously un-described 
genogroup emerged during the outbreak which has been named B5 (see 
below).
Most patients entered the study just once, but four boys were admitted to 
the study twice. For the purposes of analysis, each hospitalization was 
considered as a separate entity. Thirteen other children had also been 
hospitalised in the past history with HFMD (outside the study). For 211 
(27%) children, there was a history of contact with another HFMD case. 
103 children (13%) children had at least one other child in the family
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(sibling or cousin; maximum 4) admitted into the study, and were 
considered to be part of a family cluster. Seventy-seven of the children in 
these 44 family clusters had mild disease, 9 had severe non-CNS HFMD, 
and 17 had HFMD with CNS complications. Where the index case in a 
family cluster could be identified clearly, they were no more or less likely 
to have CNS disease than subsequent cases. Forty-one of the children in 
clusters had EV71 isolated (with only one genogroup isolated from each 
family), 3 of these children also had CVA16 isolated, so that in two 
families both CVA16 and EV71 were isolated. Twelve other children had 
CVA16, and three had other viruses.
4.3.2 Virology
Dual infections
Virus isolation was attempted on 3006 samples (622 throat swabs, 631 
rectal swabs, 768 mouth ulcer swabs, 706 vesicle swabs, 91 serum and 
188 CSF samples) from 672 (87%) of the 773 patients seen over the study 
period. There were no important demographic differences between those 
investigated and those not investigated. Two-hundred-and-seventy-seven 
(41%) patients had EV71 isolated. Twenty eight of these EV71 patients 
had a second virus isolated, including 14 patients coinfected with CVA16, 
and 9 co-infected with other enteroviruses (including CVA4, CVA5, 
CVA16, CVA10, Echo 25, CVB1, CVA24) and one each co-infected
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with an oral polio vaccine vims, an untyped enterovirus, adenovirus (Ad)
1 (isolated from the rectum), Ad7 (rectum), and an unidentified vims 
(isolated irom the CSF). CVA16 was isolated from a further 85 patients, 
four of whom had co-infection: two with CVB1 (isolated from the throat) 
and two with adenovimses isolated from the rectum (one Ad2 and one 
Ad4). Fifty-eight patients were infected with other enterovimses, 
adenovimses or unidentified vimses (12 of whom had multiple vimses 
isolated). The EY71 positive and vims isolation-negative patients were 
similar in most of the presenting clinical features, except that 26 (10%) of 
the 252 patients with no vims isolated had seizures, compared with only 6 
(2%) of the 263 EV71 positive patients [OR 0.20 [0.07-0.53], pO.001].
Seven-hundred-and-sixteen patients had semm, and when available CSF 
(233 patients) tested for antibodies to JEV and dengue. Three had 
serological evidence of acute JEV infection: a girl with mild HFMD and 
EV71 isolated from vesicles and the throat, and a boy with mild HFMD 
and fever who had EV71 isolated from vesicles, and CVA16 isolated 
from the throat had acute peripheral JEV infection (seroconversion in the 
semm); in addition An 18m old boy with HFMD and CNS disease 
(manifested by a generalised seizure and a CSF pleocytosis of 10 
cells/juL) had CVA16 isolated from a vesicle, but seroconverted to JEV in 
both the semm and CSF; he made a full recovery. Three patients had 
acute dengue. All had HFMD and CNS disease (lethargy, instability, CSF
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pleocytosis), and EV71 isolated: one from the CSF, one from the throat 
and vesicles, and one from vesicles and the rectum. Dengue was 
diagnosed by IgM seroconversion, but there was no dengue antibody in 
the CSF. Two HFMD patients had serological evidence of a recent JEV 
infection or recent vaccination, and 6 patients had serological evidence of 
recent dengue. Only two of the CYA16 children with HFMD had CNS 
disease: one of these was the child co-infected with JEV, described 
above; for the other child, CVA16 was isolated from rectal and vesicle 
swabs, and CVB1 was isolated from the throat.
4.3.3. Enterovirus 71 genogroups
Phylogenetic analysis of all 277 EV71 isolates showed that 168 (61%) of 
the isolates belonged to genogroup B4 (165 from 2000, 1 from 2002, and 
2 from 2003); 68 (25%) of the isolates belonged to Cl (4 of these were 
isolated in 2000 and 64 in the 2003 outbreak); in addition, 41 (15%)
EV71 strains isolated in 2003 were from a new genogroup (B5) that 
emerged during the course of the study (Cardosa et al. 2003; Mizuta et al. 
2005; Podin et al. 2006). Neighbour-joining trees of the VP1 [Figure 
4.3a] genes showed that representative Sibu EV71 strains belonging to 
B4, B5 and Cl genogroups clustered tightly with their respective 
genogroup reference strains with a bootstrap value 93.6%, 100% and 
100%, respectively.
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4.3.4 Clinical features of enterovirus 71 infection
Nearly two thirds of the EV71 patients had mild HFMD; 13% had severe 
non-CNS disease, 20% had HFMD with CNS disease, and only 1% had 
ASM (Table 4.1). For the purposes of analysis, those with CNS infection, 
defined by a CSF pleocytosis (with or without HFMD) were compared 
with the patients with no CNS disease (including mild and severe non- 
CNS HFMD). Patients with CNS disease were younger, and were more 
likely to give a history of fever, vomiting, mouth ulcers, breathlessness, 
cold limbs, poor urine output, and neurological features including altered 
sensorium, and seizures (Table 4.1). On examination patients with CNS 
disease were more likely to look toxic, be dehydrated and febrile, have 
altered consciousness, and neck stiffness, but they were less likely to have 
mouth ulcers (Table 4.2). Excluding the four patients with ASM and no 
rash did not significantly alter these findings. The CSF was examined in 
90 (34%) children infected with EV71, of whom 56 (62%) had a CSF 
white cell count > 5/pL. For these patients the median (range) white cell 
count was 75 (6-1090) cells/pL. Typically this was a lymphocytic CSF 
with a normal glucose ratio, but 12 (21%) had neutrophil predominance, 
and 10 (18%) had a CSF to plasma glucose ratio < 50%.
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Three children had HFMD complicated by acute flaccid paralysis; one 
had EV71 B4 genogroup isolated from his throat; the two others were 
culture negative. Sixty-two children with severe HFMD had cardiac 
enzymes measured (27 EV71 positive). Seventy-eight of the 233 more 
severe HFMD cases were treated with IVIG on a presumptive basis, 
including 42 that were EV71 positive. Five EV71 positive patients 
required ionotropic support, and three required ventilation. Four children 
died, including two that had EV71 isolated (one genogroup B4, one Cl).
4.3.5 Pathogenesis of neurological enterovirus 71 disease
Children from whom EV71 plus another virus was isolated were no more 
likely than those with EV71 alone, to have neurological involvement [2 
(7%) of 28, versus 54 (22%) of249, OR 0.28 (0.04 to 1.26), p=0.1167]. 
Repeating this analysis excluding children with only rectal isolates (which 
could represent continued carriage rather than acute pathogenic infection) 
did not alter these findings [2 (7%) of 28, versus 47 (21%) of 226, OR 
0.29 (0.05 to 1.34) p=0.1407]. All three children with EV71 and 
serological evidence of acute dengue infection, had HFMD with CNS 
disease, compared with 52 (20%) of 264 EV71-infected children with no 
dengue (p =0.008). In contrast the two EV71-infected children with 
serological evidence of JEV infection (as shown by seroconversion in the
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serum) had HFMD with no CNS disease, compared with 55 (21%) of 266 
with no JEV infection (p^l).
To examine the possible role of different EV71 genogroups in the clinical 
phenotype of EV71 infection, the likelihood of CNS disease for each 
genogroup was determined. Children with B4 genogroup were less likely 
to have CNS infection that those with other genogroups: 26 (15%) of 168 
children infected with genogroup B4 had CNS infection, compared with 
30 (28%) of 109 with other genotypes (OR [95% Cl] 0.48 [0.26 - 0.91], p 
= 0.0223) (Table 4.2). Pair wise comparisons of the genogroups showed 
that genogroup B4 was associated with less risk of CNS disease than Cl 
[26 (15%) of 168, versus 19 (28%) of 68, OR 0.47 (0.23-0.98) p=0.0429]. 
There was also a trend showing that genogroup B4 was associated 
reduced incidence of CNS disease when compared to B5 [26 (15%) of 
168, versus 11 (27%) of 41, OR 0.50 (0.21-1.21) p=0.139]. The observed 
difference did not reach the statistical significance likely because of the 
small sample size. There was no altered risk for B5 compared with Cl [11 
(27%) of 41, versus 19 (28%) of 68 (28%) OR 0.95 (0.36-2.45) 
p=0.9240]. Children with EV71 genogroup B4 were also less likely to be 
part of a family cluster: 12 (7%) of 168 B4 positive were in clusters, 
versus 29 (27%) of 109 with other genogroups (OR 0.21 [0.10-0.46], p 
<0.0001). In contrast those with B5 genogroup were more likely to be 
part of a cluster: 17 (41%) of 41 B5 positive children were in a cluster,
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versus 24 (10%) of 236 with other genogroups (OR 6.26 [2.77-14.18], 
pO.OOOl). Genogroup, age, and being part of a family cluster were 
initially entered into a multiple logistic regression model: increasing age 
and genogroup B4 versus Cl were associated with a reduced risk of CNS 
infection (Table 4.3), whereas being in a family cluster did not affect risk.
4.4 Discussion
Since 1997, EV71 has become a major public health problem in both 
developed and developing countries in the Asia-Pacific region, and has 
the potential to spread further. Molecular epidemiological studies have 
documented remarkable changes in the circulating EV71 genogroups in 
the Asia-Pacific region during this time (McMinn et al. 2001; Cardosa et 
al. 2003; Jee et al. 2003; Shimizu 2004; Lin et al. 2006). However, 
whether such genetic differences explain the differing clinical 
presentations is not clear (McMinn et al. 2001; McMinn 2002). Other 
postulated factors include differences in pre-existing immunity of the 
paediatric population (Lu et al. 2002), in host genetic susceptibility (Dolin 
1999; Yang et al. 2001; Lin et al. 2003), and co-infection with other 
viruses (Cardosa et al. 1999). The detailed investigation of 773 patients, 
including 277 with EV71 infection has produced intriguing clinic- 
epidemiological evidence suggesting that genogroups of EV71 may differ 
in their behaviour in humans. Children infected with genogroup B4 were
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less likely to present with CNS infection than those infected with Cl or 
B5, and were also less likely to be part of a family cluster. In contrast 
children infected with B5 were more likely to be part of a family cluster, 
and there was a trend towards a greater incidence of CNS disease in these 
patients.
However, these findings must be interpreted with caution. Although I 
attempted to minimise confounding variables, there were factors beyond 
my control. In particular the likelihood of children presenting to the 
hospital with HFMD may have varied during the study, although altered 
referral rates would be unlikely to explain the different risk of family 
clustering for the different genogroups. There may also have been other 
inherent features that differed between the cohort studied in 2000 and 
2003, through the basic demographic features were similar (data not 
shown).
This study has also confirmed those of earlier reports that young age, 
fever, vomiting and hyperglycaemia are associated with severe EV71 
infection (Chang et al. 1999; Wang et al. 1999); in addition, tachycardia, 
breathlessness, and absence of mouth ulcers were noted to have 
associated with CNS disease. Overall, the incidence of severe disease was 
milder in this study than previous series, with just four fatal cases, all of
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whom had pulmonary oedema. In addition, the study was unusual in 
having just four patients with pure aseptic meningitis.
This study has also made an important contribution to the debate about 
the role of dual infections in viral CNS disease. As others have shown 
previously (Hooi et al. 2002), several enteroviruses were co-circulating 
during the HFMD outbreaks in Sarawak. Instances of co-infection of 
EV71 with other enteroviruses in individual patients were documented. 
There was no evidence for an increased likelihood of CNS disease in such 
patients, though there was an intriguing association of co-infection with 
dengue viruses and neurological presentation. Nevertheless the findings 
must be interpreted with cautions in view of small number of cases with 
proven co-infection. Previously a new adenovirus type-21 was postulated 
to have made an important contribution to fatal disease during an EV71- 
associated HFMD outbreak (Cardosa et al. 1999; Ooi et al. 2003), 
however adenoviruses was isolated from only 4 patients in this study, and 
none was adenovirus type-21. Rigorous investigations for multiple viral 
agents in the study showed the importance of pursuing all possible 
avenues before attributing causation to the first pathogen encountered.
For example in two children, CNS disease would have been attributed to 
CVA16, which is an unusual cause of CNS disease, had the thorough 
diagnostic work-up not revealed alternative more likely viral causes (JEV 
in one child, CBV1 in the other). Whether unsuspected dual infections lie
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behind other “unusual manifestations” of common relatively benign 
enteroviruses, such as acute flaccid paralysis recently attributed to 
CVA24 is not known (Chaves et al. 2001).
In summary the study provides clinical epidemiological evidence for 
different biological behaviour of EY71 genogroups, in terms of 
transmissibility within families, and risk of CNS disease. It also 
highlights the importance of detailed investigations for multiple 
pathogens during HFMD outbreaks. Only with such thorough 
investigations will the pathophysiology of EV71 be fully determined.
Clearly neurological disease is one of the most important manifestations 
of EV71 infection. Clinical predictors of such disease, as described in the 
next chapter can help clinicians focus their attention on patients who most 
need it.
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Table 4.3 Multivariate logistic regression analysis of variables associated 
with neurological disease in enterovirus 71 infection
Variable B-coefficient Odds Ratio (95% Cl) P
Age -0.022 0.978 (0.962-0.996) 0.015
Genogroup Cl versus B4 0.751 2.12(1.070-4.202) 0.031
Genogroup B5 versus B4 0.795 2.215 (0.972-5.048) 0.058
Genogroup, age, and being part of a family cluster were initially entered into 
a multiple logistic regression model. Terms were entered into the model and 
remained in only if they were statistically associated with CNS disease 
(p<0.05). Both forward selection and backward elimination methods were 
used. Increasing age and genogroup B4 versus Cl were associated with a 
reduced risk of CNS infection where-as being in a family cluster did not 
affect risk. Forward selection and backward elimination procedures generated 
the same model, indicating its robustness. The Hosmer-Lemeshow statistic 
indicated a non-significant lack of fit (Chi2 8.338, p=0.401).
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Figure 4.1 Algorithm showing the classification of patients in the 
study.
Because EV71 can cause HFMD, CNS infection or both, children with HFMD 
or suspected CNS infections were studied. Children with HFMD were classified 
into mild HFMD, Severe non-CNS HFMD, and HFMD complicated by CNS 
disease; those with viral CNS infection were classified as aseptic meningitis 
(ASM), or viral encephalitis, but there were no children in the latter group 
infected with enteroviruses during this study. The final number of EV71 positive 
patients in each diagnostic group is shown in the figure. * Herpangina was 
defined as multiple oral ulcers predominantly affecting the posterior parts of the 
oral cavity.
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Suspected Viral 
CNS infection
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(n-0)
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encephalopathy
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One of:
• Rash of palms &/or 
soles &Jor buttock
• Mouth vesicles/ulcers
• Herpangina*
Encephalitis syndrome?
One or more of
• Coma score <13
• Upper motor neuron signs
• Prolonged seizure
HFMD
complicated by 
CNS Disease 
(n=52)
Aseptic
meningitis
(ASM)
<n=4)
Suspected CNS Infection
•T &37.5C or history of fever 
AND one or more of:
• Reduced consciousness
(irritability, lethargy, 
drowsiness, coma)
• Severe headache
• Neck stiffness
• Limb paralysis
• Tense fontanelle
• Seizures
Severe?
• T Z38C or history of fever 
AND one or more of:
• Toxic/ill
• Recurrent vomiting
(at least twice),
• Tachycardia
(>150/mi n)
■ Breathlessness
• Poor perfusion
(coid dammy skin),
• Reduced consciousness
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Figure 4.3 Neighbor-joining phylogenetic trees of human enterovirus 71 
strains isolated in this study
(a) Tree based on the alignment of a partial VP1 (nucleotide positions 2442- 
3281) or complete VP1 (nucleotide positions 2442-3332) gene sequences. 
The tree show 14 representative strains isolated in this study (boxed), and 
representative EV71 strains for other genogroups.
(b) Tree based on the alignment of a partial VP4 (nucleotide positions 744- 
950). The trees shows 7 representative strains isolated in this study (boxed), 
and representative EV71 strains for other genogroups.
For both trees sequence from the prototype CVA16-G10 was used as an 
outgroup. The year of isolates is given as a suffix, and Genbank accession 
numbers are in parentheses. Horizontal branch lengths are proportional to the 
number of nucleotide changes between viruses, and a scale shown, and the 
bootstrap values in 1,000 pseudoreplicates for major lineages within the 
dendrogram are shown as percentages. PCR products were sequenced using 
Big Dye ver3.0 and run on an ABI377 automated sequencer (Applied 
Biosciences, Foster City, CAV, USA), and nucleotide sequences were 
aligned (DNASTAR Inc., Madison WI, USA).
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Chapter 5: Clinical predictors for the risk of 
neurological involvement in hand, foot and 
mouth disease
Abstract
Human enterovirus (EV) 71 can cause Hand, foot, and mouth disease 
(HFMD) with neurological complications, which may rapidly progress to 
fulminant cardiorespiratory failure, and death. Early recognition of children 
at risk is the key to reduce acute mortality and morbidity. Data collected 
through a prospective clinical study of HFMD conducted between 2000 and 
2006 that included 3 distinct outbreaks of EV71 were examined to identify 
risk factors associated with neurological involvement in children with 
HFMD. Total duration of fever >3 days, peak temperature >38.5°C and 
history of lethargy were identified as independent risk factors for 
neurological involvement (evident by CSF pleocytosis) in the analysis of 725 
children admitted during the first phase of the study. When they were 
validated in the second phase of the study, two or more (>2) risk factors were 
present in 162 (65%) of 250 children with CSF pleocytosis compared with 56
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(30%) of 186 children with no CSF pleocytosis (OR 4.27, 95% Cl 2.79-6.56, 
p<0.0001). The usefulness of the three risk factors in identifying children 
with CSF pleocytosis on hospital admission during the second phase of the 
study was also tested. Peak temperature >38.5°C and history of lethargy had 
the sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of 28%(48/174), 89%(125/140), 76%(48/63) and 
50%( 125/251), respectively in predicting CSF pleocytosis in children that 
were seen within the first 2 days of febrile illness. For those presented on the 
3rd or later day of febrile illness, the sensitivity, specificity, PPV and NPV of 
>2 risk factors predictive of CSF pleocytosis were 75% (57/76), 59% (27/46), 
75% (57/76) and 59% (27/46), respectively. In summary three readily elicited 
clinical risk factors were identified to help detect children at risk of 
neurological involvement. These risk factors may serve as a guide to 
clinicians to decide the need for hospitalization and further investigation, 
including cerebrospinal fluid examination, and close monitoring for disease 
progression in children with HFMD.
5.1 Introduction
Hand, foot and mouth disease (HFMD) is a common childhood exanthema 
caused by species A human enteroviruses (EV-A), particularly
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coxsackievirus (CV) A16 (Pallansch et al. 2001). In most instances, this is a 
mild self-limiting illness. The affected children are often given out-patient 
care with symptomatic treatment. However over the last decade HFMD has 
emerged as a growing public health problem in Asia following frequent 
outbreaks of death-associated HFMD caused by a more virulence member of 
EVA, human enterovirus (EV) 71, in a number of countries in the region 
(Cardosa et al. 1999; Komatsu et al. 1999; Chan et al. 2003). This was first 
recognised with large outbreaks of HFMD associated with neurological 
disease and alarming fatalities in Sarawak, Malaysia in 1997 and in Taiwan 
in 1998 (Cardosa et al. 1999; Ho et al. 1999). Fatal cases typically presented 
with a brief duration of febrile illness, subtle neurological signs and died 
dramatically of acute refractory cardiac dysfunction and fulminant pulmonary 
oedema within hours of developing signs of tachycardia, poor peripheral 
perfusion and tachypnea. Indeed, most of them died shortly after hospital 
admission, and some even before or on arrival at hospital (Cardosa et al.
1999; Chang et al. 1999; Wang et al. 1999; Huang et al. 2002). Although 
severe neurological complications and death only occur in a small minority 
of children with HFMD, the fulminant disease course of the fatal cases has 
caused great public alarm in Asia. Experience from recent outbreaks of EV71 
associated HFMD in Asia showed that primary care doctors are often 
overwhelmed with large number of children with HFMD seeking medical
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attention for the fear of neurological complications and death. Because of the 
risk of sudden death, coupled with tremendous parental pressure to admit 
children with HFMD into hospital for observation, children with HFMD are 
often routinely admitted into hospital for observation in Sarawak, which has 
imposed a huge burden on the healthcare system. Cerebrospinal fluid (CSF) 
pleocytosis has so far been the universal finding in fatal cases even though 
many have no obvious neurological signs prior to sudden onset of 
cardiorespiratory failure and death (Cardosa et al. 1999; Chang et al. 1999; 
Wang et al. 1999). In the absence of clear neurological sign, CSF pleocytosis 
(indicative of neurological involvement) has thus been considered an 
objective marker of complicated disease, allowing clinicians to focus their 
attention and provide timely intervention in these patients before they 
develop fatal cardiorespiratory failure. Data collected through a prospective 
study of HFMD were examined to identify and validate risk factors 
associated with neurological involvement in children with HFMD that may 
be used by clinicians managing children with HFMD.
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5.2 Materials and methods
5.2.1 Setting and study period
A prospective clinical study from January 2000 through December 2006, 
which included 3 distinct outbreaks that occurred in 2000/1, 2003 and 2006, 
was conducted at the paediatric wards and intensive care unit at Sibu 
Hospital (Sarawak, Malaysia). The study was approved by the Director of 
Health for Sarawak and the Ethics Committee of the Liverpool School of 
Tropical Medicine (UK). Informed consent was obtained verbally from each 
child’s accompanying parent or guardian.
5.2.2 Case definitions
Figure 5.1 shows the algorithm of the investigation and the classification of 
the disease severity of children with HFMD in the study, as described in 
Chapter 4. Briefly a child was defined as having HFMD if they had new 
onset of at least one (>1) of the following: maculopapular or vesicular rash 
on the palms and/or soles; vesicles or ulcers in the mouth or herpangina 
(defined as multiple oral ulcers predominantly affecting the posterior parts of 
the oral cavity). Children with HFMD were considered to have more serious 
illness if they have the following features: a history of fever, or fever on
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examination (>38°C), and >1 of the following features indicative of more 
serious illness: toxic and ill in appearance, recurrent vomiting (at least twice), 
tachycardia (heart rate >150/min) breathlessness, poor perfusion (cold 
clammy skin), reduced consciousness (irritability, lethargy, drowsiness, 
coma), limb weakness, meningism (neck stiffness or positive Kernig’s sign), 
seizures. They were subjected to CSF examination after written consent to 
exclude central nervous system (CNS) involvement. Children with >5 
cells/pL (i.e. CSF pleocytosis) and negative microscopy and culture for 
bacteria were classified as “HFMD with CNS complications” (HFMD-CNS), 
while those with normal CSF examination were considered to have “severe 
HFMD without CNS involvement” (HFMD-Non-CNS). Children with 
HFMD-CNS were diagnosed to have aseptic meningitis (ASM) if they were 
fully conscious, had headache, meningism, and no focal neurological signs. 
Encephalitis was defined by the presence of impaired consciousness 
including lethargy, drowsiness or coma, seizures or myoclonus. Acute flaccid 
paralysis (AFP) was characterised by the acute onset of areflexic limb 
weakness. Cardiorespiratory failure was defined by the presence of 
tachycardia, respiratory distress, pulmonary oedema, poor peripheral 
perfusion requiring inotropes, pulmonary congestion on chest radiography 
and reduced cardiac contractility on echocardiography. Children without 
features of more serious illness were classified as “mild HFMD”, and were
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observed in hospital until they became afebrile for at least 12-24 hours. A 
child was considered to be positive for EV71 if EV71 was isolated by tissue 
culture or EV71 RNA was detected by EV71 type-specific RT-PCR from >1 
clinical sample, as described in Chapter 3.
5.2.3 Clinical methods
All children with HFMD admitted into the hospital were assessed by 
paediatricians of the study team. A detailed history and clinical examination 
was performed with special attention to mucocutaneous lesions, 
cardiovascular and neurological signs. All details were recorded on 
standardised forms. Swabs were taken from the throat and rectum of every 
patient, as well as >1 swab from vesicles on the skin and oral ulcers (if 
present). The clinical samples were stored immediately in a -70°C freezer 
until further testing. Blood was taken for flavivirus serology, and in patients 
with suspected CNS involvement for full blood count, urea, electrolytes, and 
glucose. Electrocardiogram and echocardiogram was also performed on 
children with suspected CNS involvement. CSF was examined for cell count 
and differential, protein, glucose, Gram stain, bacterial culture and processed 
for viral studies. If there was a strong clinical suspicion of viral CNS 
infection, but the initial CSF examination was acellular, a second lumbar
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puncture was performed. Lumbar punctures were delayed in those with 
unstable vital signs. Patients were examined daily or more frequently as 
indicated, by a member of the study team. Children with HFMD-CNS 
complications (particularly those with encephalitis and acute flaccid 
paralysis) were treated with intravenous immunoglobulin (IVIG) at the 
discretion of the treating physician (Lin et al. 2002).
5.2.4 Virological methods
Virus isolation was attempted on all swab specimens, CSF specimens, and 
any serum samples remaining after other investigations had been completed 
through the inoculation of human rhabdomyosarcoma and human embryonic 
kidney cells. Isolated enteroviruses were typed by nucleotide sequencing of 
VP 1 and VP4 genes and genogrouped by phylogenetic analysis (McMinn et 
al. 2001; Cardosa et al. 2003). During the 2006 outbreak, in addition to virus 
isolation, all swab specimens were also tested for presence of EV71 RNA 
using a EV71 type-specific RT-PCR (Perera et al. 2004). Paired serum 
samples (obtained on the day of admission and on day 7, or on the day of 
discharge or after death) and CSF specimens were also tested for IgM against 
dengue and Japanese encephalitis virus (JEV) in parallel, using an IgM-
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capture ELISA that distinguishes responses to these two viruses (Cardosa et 
al. 2002).
5.2.5 Statistical analysis
Data from HFMD patients recruited in the first phase of the study (mostly 
during 2 outbreaks that occurred between January 2000 and July 2003) were 
used to identify risk factors for neurological involvement (evident by CSF 
pleocytosis). The primary analysis was for variables associated with 
neurological involvement by comparing children with HFMD-CNS (i.e. with 
CSF pleocytosis) to those with HFMD-Non-CNS (i.e. no CSF pleocytosis). 
Variables that were considered potentially useful to primary care doctors in 
identifying children with neurological involvement were included in a 
multiple logistic regression analysis to look for independent risk factors for 
neurological involvement (i,e. CSF pleocytosis). Variables were selected 
backward and remained in the model only if they were statistically associated 
with neurological involvement (p<0.05). (SPSS software, Version 13.0; 
SPSS). The association between the independent risk factors identified and 
neurological involvement were validated in the second phase of the study, 
where most patients were admitted during the 2006 outbreak. The utility of 
the identified risk factors as clinical predictors for neurological involvement
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at the point of first contact for care was also examined. Normally distributed 
data were compared using Student’s t test; data that were not normally 
distributed were compared by the Mann-Whitney U test (Statview 4.02; 
Abacus Concepts). Differences between proportions were tested using the 
Chi-square test with Yates’s correction or Fisher’s exact test as appropriate 
(Epi Info, version 6; Centers for Disease Control and Prevention). A p value 
<0.05 was considered statistically significant.
5.3 Results
A total of 725 children (457, 63% males) were recruited between 1st January 
2000 and 31st July 2003 (Figure 5.1) Most children were recruited during 2 
large outbreaks of EV71-HFMD that occurred during 2000/2001 and 2003. 
Five hundred and forty (74%) children had mild HFMD. One hundred and 
eighty five (26%) children had suspected CNS involvement and required 
CSF examination; 102 (55%) of them had CSF pleocytosis (HFMD-CNS) 
and the remaining 83 (45%) had normal CSF findings (HFMD-Non-CNS). 
Of the 102 children with HFMD-CNS, 63 (62%) had ASM, 33 (32%) had 
encephalitis, 3 (3%) had AFP, and 3 (3%) had encephalitis associated with 
cardiorespiratory failure (all of the 3 died). Of the 273 EV71 culture positive 
children, 187 (69%) had mild HFMD, 34 (13%) had HFMD-Non-CNS, and
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52 (19%) had HFMD-CNS (30 had ASM, 19 had encephalitis, 1 had AFP 
and 2 had encephalitis with cardiorespiratory failure). Detailed results of the 
epidemiology, diagnostic virology and molecular epidemiology of this phase 
of the study have been described in the earlier chapters.
5.3.1 Clinical features
Comparison of patients with HFMD with CNS complications 
with those had more serious HFMD without CNS involvement 
(January 2000 to July 2003)
The clinical features of the children with HFMD-CNS (i.e. with CSF 
pleocytosis) are compared to those with HFMD-Non-CNS (i.e. no CSF 
pleocytosis) (Table 5.1). Children with HFMD-CNS were more likely to be 
male and of Chinese ethnic group. Children of Iban ethnic group, however, 
were less likely to have HFMD with CNS complications. Children with 
HFMD-CNS complications were more likely to have higher mean peak 
temperature, peak temperature >38.5°C, longer mean total duration of fever 
and total duration of fever >3 days. Findings of lethargy (from the parent’s 
history or physical examination), faster mean heart rate, mean heart rate 
>150/min and limb weakness on examination were more frequently present 
in children with HFMD-CNS. There was no difference in the proportion of
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children with positive EV71 isolation between children with HFMD-CNS 
and those with HFMD-Non-CNS.
To look for independent risk factors that could be used to predict 
neurological involvement evident by CSF pleocytosis, total duration of fever 
>3 days, peak temperature >38.5°C, being lethargic (from the parent’s history 
or physical findings), history of breathlessness, history of vomiting, history 
of or witnessed myoclonus, neck stiffness were included in a multiple logistic 
regression analysis. Total duration of fever >3 days, peak temperature 
>38.5°C and history of lethargy were found to be independent risk factors of 
neurological involvement after multivariate analysis (Table 5.2). Table 5.3 
shows the number and type of the risk factors that were present in the 725 
children with HFMD seen during the first phase of the study according to the 
disease severity. Two or more (>2) risk factors were present in 83% (85/102) 
of patients that had HFMD-CNS when compared to 43% (36/83) of patients 
with HFMD-Non-CNS (OR 6.53, 95% Cl 3.15-13.66, pO.OOOl). Further 
analysis on the EV71-positive subset showed that >2 risk factors were 
present in 82% (43/52) of children with HFMD-CNS when compared to 32% 
(11/34) patients with HFMD-Non-CNS (OR9.99, 95%CI 3.26-31.82). A 
separate analysis on children with mild HFMD showed that >2 risk factors
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were present in 6% of cases with mild HFMD (32/540)(Table 2), and EV71- 
postive mild HFMD (11/187), respectively.
5.3.2 Validation of the association between the risk factors and 
neurological involvement in children with HFMD in 2006 
outbreak
The association between the identified risk factors (total duration of fever >3 
days, peak temperature >38.5°C and history of lethargy) and neurological 
involvement were validated in the 2006 outbreak. A total of 730 children 
with HFMD were admitted between January and December 2006. Two 
hundred and ninety four (40%) children had mild HFMD. Four hundred and 
thirty six (60%) children had features of more serious illness and warranted 
CSF examination; 250 (34%) of them had HFMD-CNS and the remaining 
186 (26%) had HFMD-Non-CNS. Of the 250 children with HFMD-CNS, 65 
(26%) had ASM, 172 (69%) had encephalitis, 2 (0.8%) had encephalitis 
associated with AFP, and 11 (4.4%) had encephalitis associated with 
cardiorespiratory failure (6 of them died). EV71 was isolated from 157 (27%) 
of 586 children who had virus isolation done. A further 44 (7%) children had 
other species A enteroviruses (n=29) and species B EV (n=15). No patient 
had CVA16 isolated. EV71 RNA was detected in 239 (50%) of 477 children
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that were tested with EV71 type-specific RT-PCR. In short, 291 (45%) of 
653 children were positive for EV71. Of the 291 EV71-positive children, 104 
(36%) had mild HFMD, 73 (25%) had HFMD-Non-CNS, 114 (39%) had 
HFMD-CNS (22 had ASM, 83 had encephalitis, 2 had encephalitis 
associated with AFP, 7 had encephalitis associated with cardiorespiratory 
failure). EV71 was detected in 4 (67%) of the 6 fatal case children that had 
encephalitis associated with cardiorespimtory failure. The table 5.4 shows the 
clinical features of the 730 children that were admitted during the 2006 
outbreak according to the disease severity. Total duration of fever >3 days, 
peak temperature >38.5°C and history of lethargy were similarly more 
frequently present in children with HFMD-CNS than those with HFMD-Non- 
CNS. Two or more risk factors were present in 65% (162/250) of children 
that had HFMD-CNS when compared with 30% (56/186) of children with 
HFMD-Non-CNS (OR 4.27, 95%CI 2.79-6.56, pO.0001) (Table 5.3). 
Among children with EV71-positive HFMD, >2 risk factors were present in 
61% (69/114) of children with HFMD-CNS when compared with 26% 
(19/73) of children with HFMD-Non-CNS (OR 4.36, 95%CI 2.19-8.75, 
pO.OOOl). A separate analysis on children with mild HFMD showed that 
history of lethargy, total duration of fever >3 days and peak temperature 
>38.5°C was present in 6.4% (19/294), 11% (33/294) and 14% (42/294) of 
the children with mild HFMD, respectively (table 5.4). Two or more 2 risk
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factors were found in only 5 (2%) of294 with mild HFMD (Table 5.3) and in 
1 (1%) of 104 of children with EV71-positive mild HFMD.
5.3.3 The usefulness of the risk factors in predicting 
neurological involvement in children with HFMD in the 2006 
outbreak
The utility of the three clinical risk factors in predicting neurological 
involvement in children with HFMD at the point of first contact for care was 
assessed. While a febrile illness >3 day was an important risk factor for 
severity, primary care physicians often see many children on the first 2 days 
of HFMD illness. To determine if peak temperature >38.5°C and history of 
lethargy are useful in identifying children who sought treatment within the 
first 2 days of the febrile illness a separate analysis for children who 
presented within the first 2 days of the illness during the 2006 outbreak was 
performed. Figure 5.2 shows the distribution and classification of disease 
severity of 730 children with HFMD in the 2006 outbreak according to the 
duration of febrile illness and the risk factors that were present when they 
first presented to hospital. Five hundred and seventy nine (79%) of 730 
children were admitted within the first 2 days of febrile illness. Sixty five 
(11%) of the 579 children had history of lethargy plus peak temperature
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>38.5C, All but two (97%) of the 65 children had features of more serious 
illness and warranted CSF examination. About three quarter of them had CSF 
pleocytosis and was classified as HFMD-CNS. Only 2 (3%) of the 65 
children were labelled as mild HFMD. Two hundred and twenty (38%) 
children had only either history of lethargy or peak temperature >38.5C. Of 
the 167 (76%) children who warranted a CSF examination, 102 (61%) of 
them had CSF pleocytosis, and were classified as HFMD-CNS. The 
remaining 53 (24%) children without feature of more serious illness were 
considered as mild HFMD. Two hundred and ninety four (51%) children had 
neither of the two risk factors. Eighty four (29%) of the 294 children, 
however, had other features of more serious illness, and hence underwent 
CSF examination. CSF pleocytosis was found in 24 (29%) of the 84 children, 
and were classified as HFMD-CNS. Two hundred and ten (71%) of the 294 
children without features of more serious illness were labelled as mild 
HFMD. In summary CSF pleocytosis was found in 48(74%) of 65 children 
with 2 risk factors (temperature >38.5°C and history of lethargy) on hospital 
admission compared with that in 126 (25%) of 514 children with <1 risk 
factors (OR 8.69; 95%CI 4.66-16.37, pO.OOOl).
One hundred and fifty one (21%) of the 730 children were seen on the 3rd or 
later days of their febrile illness. Twenty two (15%) of the 151 children had
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all the 3 risk factors associated with neurological involvement. All the 22 
children warranted CSF examination. Seventeen (77%), including 4 fatal 
cases, of the 22 children had CSF pleocytosis and were classified as HFMD- 
CNS. Of the 55 (36%) children that had 2 risk factors, all except one child 
required CSF examination to exclude CNS involvement. Forty (74%) of the 
54 children had CSF pleocytosis and were classified as HFMD-CNS. Being 
febrile for >3 days was the sole risk factor in 74 (49%) of the 151 children. 
Forty six (62%) children had features of more serious illness, and underwent 
CSF examination — 19 (41%) had CSF pleocytosis and were classified as 
HFMD-CNS. The remaining 28 (38%) children were labelled as mild 
HFMD. In short CSF pleocytosis was found in 57(74%) of 77 children that 
had >2 risk factors on hospital admission compared with in 19 (26%) of 74 
children with isolated risk factor of being febrile >3 days (OR 8.25; 95%CI 
3.75-18.38, pO.OOOl). Further analysis on the EV71-positive subset showed 
that 24% (21/86) of children with HFMD-CNS presented within the first 2 
days of febrile illness had >2 risk factors compared with 10% (6/60) of 
children with HFMD-Non-CNS (OR 2.91; 95% Cl 1.03-9.38, p=0.0464). For 
the EV71-positive children presented on the 3rd or later days of febrile illness 
,71% (20/28) of children with HFMD-CNS had >2 risk factors compared 
with 31% (4/13) of children with HFMD-Non-CNS (OR 5.63; 95% Cl 1.11- 
31.35, p=0.0341). The sensitivity, specificity, positive predictive value and
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negative predictive value of the risk factors in predicting CSF pleocytosis in 
children with HFMD at presentation in the 2006 outbreak is shown in Table 
5.5.
Between 2000 and 2006, a total of 352 children with CNS involvement were 
admitted into the study. One hundred and twenty eight (36%) children had 
ASM (a mild and benign CNS involvement) and 224 (64%) had severe and 
potentially fatal CNS complications (205 had encephalitis, 14 had 
encephalitis associated with cardiorespiratory failure, 2 had encephalitis 
associated with AFP, 3 had AFP). Among the 224 children that had severe 
CNS complications, 204 (95%) of 215 children that survived had timely 
hospital admission and IVIG treatment compared to one (11%) of 9 children 
that died (OR 148.36, 95% Cl 16.34-6609.04, pO.OOOl) (Figure 5.3). Table 
5.6 shows the clinical details and the risk factors that were present in the 9 
fatal case children on hospital admission. Two or more risk factors associated 
with neurological involvement were present in all the 9 fatal case children, 
and were noted for >24-48 hours before hospital admission. Three of the fatal 
case children had repeated white cell counts and serum glucose examination, 
which showed leucocytosis and hyperglycaemia were observed on the day or 
the day after the onset of cardiorespiratory failure (Figure 5.4)
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5.4 Discussion
Early recognition of children at risk of neurological involvement and death 
(particularly those with encephalitis and encephalomyelitis) is critical as the 
disease progression from the onset of neurological involvement to fulminant 
cardiorespiratory failure may be remarkably rapid (Chang et al). However 
the clinical manifestations of neurological involvement may be very subtle, 
particularly in young children with early CNS disease (Chang et al. 1999; Lin 
et al. 2006). While the signs of cardiorespiratory distress such as 
breathlessness, tachypnea, tachycardia, poor perfusion are easy to recognise, 
they invariably appear late and only shortly before most fatal case children 
collapsed. The results of this work and other published studies showed that 
timely diagnosis and intervention, including the use of IVIG infusion, may 
reduce acute mortality (Lin et al. 2002; Chang et al. 2004; Wang et al. 2006; 
Wang et al. 2006). Hence the primary care doctors are confronted with a 
clinical challenge of identifying a small fraction of children who are at risk of 
neurological complication from an overwhelmingly large number of children 
who would have uncomplicated course of HFMD. For this reason it is 
important to find clinical predictors for neurological involvement that can 
guide primary care doctors perform a proper patient triage, which should be 
aimed to admit high risk children into hospital early for close observation and
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further management, while those at low risk of neurological complication 
may be given out-patient care after parental education and advice. Few 
studies have systemically examined how to identify children at risk early 
before they develop cardiorespiratory failure, particularly at the primary care 
setting where the majority of children with HFMD would first seek treatment 
during a community outbreak of HFMD. A history of lethargy, mean peak 
temperature >38.5°C and total duration of fever >3 days were identified and 
validated as important risk factors for neurological involvement in this study. 
The study also showed that neurological involvement occurs at early course 
of complicated HFMD, and may be detectable within the first 2 days of the 
febrile illness because CSF pleocytosis was present in 174 (30%) of 579 
children seen within the first 2 days of febrile illness, where they also formed 
70% (174/250) of children with HFMD-CNS in the 2006 outbreak (Figure 
5.2). Since CSF pleocytosis may be detectable within the first 2 days of the 
febrile illness and fulminant cardiorespiratory failure seen in the fatal case 
children typically occurred on the 3rd or later day of febrile illness, it is 
imperative to attempt to identify children at risk of neurological involvement 
before the 3rd day of febrile illness so that they can be admitted into hospital 
early for close monitoring and investigation, and intervention may be 
instituted when necessary.
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Examination of body temperature and careful enquiry into history of 
lethargy, duration of fever and home record of body temperature should form 
an integral part of HFMD patient triage at the primary care level. The three 
risk factors are readily elicited, and can also be used after minimal training 
by paramedics, who are the key primary care providers in many developing 
countries including in Sarawak (Malaysia) in Asia. The parents of children 
with HFMD can also play an important role in early diagnosis of 
neurological complication in children with HFMD. They should be educated 
about the 3 risk factors, and be encouraged to monitor the children’s body 
temperature regularly and observe the children’s physical activity closely. 
Body temperature >38.5°C and history of lethargy may be particularly useful 
clinical clues for neurological involvement during the first 2 days of febrile 
illness since at this time the presentation of complicated HFMD is typically 
undifferentiated and subtle, even to the experienced clinicians (Chang et al. 
1999). Indeed both history of lethargy and temperature >38.5°C were 
observed for 24-48 hours in all the 9 fatal case children before they 
succumbed to unexpected fulminant cardiorespiratory failure (Table 5.6). 
Primary care doctors should have high index of suspicions of neurological 
complication when they are presented with children with HFMD who have 
been febrile >3 days. The children should be admitted into hospital for close 
observation and investigated for CNS involvement, if necessary. This study
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showed that 92 (31%) of 293 children with total duration of fever >3 days in 
the 2000/3 outbreak, and 183 (61%) of 300 children in the 2006 outbreak had 
neurological involvement (Table 5.3). CSF pleocytosis was present in 25% 
(19/74) of children with a single risk factor of being febrile >3 days on 
hospital admission (Figure 5.2). The risk of CNS complication is increased 
significantly when there are added risk factors of having history of lethargy 
and temperature >38.5°C. In contrast children who have a brief duration of 
low grade fever (<38.5°C) and no history of lethargy are of low risk of 
neurological disease, and may be provided with out-patient care and parental 
reassurance.
The results of this study are in keeping with findings reported by Chang and 
co-authors where fever >39°C, fever duration >3 days and lethargy were 
more frequently observed in children with CNS involvement and in children 
with EY71-HFMD than in those with CVA16-HFMD (Chang et al. 1999). 
Although several other clinical features and laboratory abnormalities have 
been associated with fatal EV71-HFMD, they have yet been validated, and 
been shown useful in detecting neurological disease or disease progression 
(Huang et al. 1999; Huang et al. 2003) (Chong et al. 2003). For example, 
Chong and co-authors reported that absence of mouth ulcers predicted a more 
complicated or fatal HFMD, and have recommended that children without
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mouth ulcers should be monitored closely (Chong et al. 2003). However, 
children without mouth ulcers were more likely than children with mouth 
ulcers to have features of more severe HFMD or develop neurological 
complication in this study. Not all the risk factors identified in these 
published studies can readily be translated into clinical practice, particularly 
at primary care settings. Hyperglycaemia and leucocytosis have been shown 
as risk factors for fatal EV71 disease (Chang et al. 1999). However, in this 
study hyperglycaemia and leucocytosis were late laboratory changes in 
children with fulminant cardiorespiratory failure, and thus are not helpful 
clinically in identifying children at high risk of complication and death. 
Elevated cardiac troponin I, a sensitive cardiac-specific biomarker for 
myocardial injury, has been noted in children who subsequently developed 
left ventricular failure, and may be useful in identifying patients at risk of left 
ventricular failure and pulmonary oedema (Huang et al. 2003). Although 
cardiac troponin I has been used widely in developed countries for early 
diagnosis of acute coronary syndrome, it is expensive and not widely 
available in many developing countries, including in Sarawak. Screening for 
heart rate variability abnormalities, an index of autonomic nervous system, 
through non-invasive continuous electrocardiography monitoring may 
provide early warning of impending cardiorespiratory failure about 7 hours 
before its onset (Lin et al. 2006). The labour-intensive approach is most
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suited in a critical care setting for children already diagnosed of CNS 
involvement because it requires the use of expensive and sophisticated 
device, and close monitoring for the heart rate abnormalities.
Children of Chinese ethnic group were more likely to develop CNS 
complication while children of Iban ethnic group were less likely to have 
CNS disease. Host genetic susceptibility may be a possible explanation for 
the observed difference in the risk of developing HFMD-CNS among 
children of different ethnic group. HLA-A33 has been reported to have 
significant association with increased susceptibility to EV71 infection in a 
genetic study in Taiwan (Chang et al. 2008). The authors also reported that 
HLA-A2 was closely associated with the risk of cardiorespiratory failure 
often observed in fatal cases (Chang et al. 2008).
A limitation of this study is that the clinical predictors developed for use at 
primary care setting were identified and tested using data collected through a 
hospital-based study. Clinical characteristics of children treated at primary 
care settings may differ from hospitalised children. However, as a large 
number of children with mild HFMD were admitted into the study, it 
provided an opportunity to systemically examine the clinical feature of 
HFMD of varying severity, including children with mild disease that would
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normally be treated at primary care clinics, where history of lethargy, peak 
temperature 38.5C and total duration of fever 3 days were reported 
infrequently in children with mild HFMD.
Currently there is no vaccine against EV71 infection. Early recognition of 
children at risk of fulminant pulmonary oedema and cardiac dysfunction may 
be the key to reduce acute mortality and morbidity. The three clinical risk 
factors identified in this study may help detect children at risk of neurological 
involvement and death at primary care settings, which may guide primary 
care doctors decide if hospital admission is warranted when they see with 
children with HFMD. These risk factors are readily elicited through history 
taking and measurement of body temperature. They may also provide useful 
guide to help clinicians to decide the need for CSF examination, as well as to 
monitor disease progression in children with HFMD.
Whilst EV71 remains the most important cause of HFMD with severe 
manifestations, the related enterovirus, coxsackie virus A16 also causes 
HFMD. Whether it too can cause neurological disease has been a subject of 
some controversies.
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Figure 5.1 The algorithm of the investigation and the classification of the 
disease severity of children with hand, foot and mouth disease
The flow chart shows the algorithm of the investigation and the classification 
of the disease severity of children with HFMD used in the study 
HFMD: Hand, foot, and mouth disease, CSF: Cerebrospinal fluid, CNS: 
Central nervous system
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Mild HFMD 
N=540
HFMD with CNS 
complication 
N=102
CSF examination 
Cell count >5 white cells/pL
Severe HFMD without 
CNS involvement 
N=83
HFMD
One of:
• rash on palms &/or soles
• mouth vesicles &/or ulcers
• herpangina
History of fever, or fever on 
examination (>380C), and si of:
• toxic and ill
• recurrent vomiting (at least twice)
• tachycardia (sl50/min)
• breathlessness
• poor perfusion
• reduced consciousness 
(irritability, lethargy, drowsiness, 
coma)
• limb weakness
• meningism
• seizures
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Figure 5.2 Classification of 730 Children with hand, foot and mouth 
disease
The flow chart shows the distribution and classification of disease severity of 
730 children with HFMD in the 2006 outbreak according to the duration of 
fever and the risk factors that were present when they first presented to the 
hospital. CSF examination is indicated if the children have features indicative 
of more serious illness of HFMD (see case definition in main text)
Hx lethargy: History of lethargy, Temp >38.5°C: body temperature >38.5°C, 
CSF exam: cerebrospinal fluid examination, HFMD: Hand, foot, and mouth 
disease, HFMD-CNS: Hand, foot, and mouth disease with central nervous 
system complication, HFMD-Non-CNS: Severe HFMD without central 
nervous system involvement, BENC: brainstem encephalitis, ASM: aseptic 
meningitis.
a. Of the 48 children with HFMD-CNS, 40 had BENC, 6 had ASM and 2 
had BENC associated with cardiorespiratory failure (1 of whom died).
b. Of the 102 children with HFMD-CNS, 74 had BENC, 26 had ASM, 1 
had encephalitis and 1 had fatal BENC associated with cardiorespiratory 
failure.
c. Of the 24 children with HFMD-CNS, 13 had BENC, 8 had ASM, 1 each 
had BENC associated with cardiorespiratory failure, encephalitis, and 
encephalitis associated with acute flaccid paralysis.
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d. Of the 17 children with HFMD-CNS, 11 had BENC, 5 had BENC 
associated with cardiorespiratory failure (4 of whom died) and 1 had 
ASM
e. Of the 40 children with HFMD-CNS, 22 had BENC, 17 had ASM and 1 
had fatal BENC associated with cardiorespiratory failure.
f Of the 19 children with HFMD-CNS, 10 had BENC, 7 had ASM and 1 
each had encephalitis with acute flaccid paralysis, and BENC associated 
with cardiorespiratory failure.
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Had >5 cells/ul?
'Had CSF exam?
Had >5 cells/uL? Had >5 cells/gL? Had >5 cells/uL?Had >5 cells/gL?
'Had CSF exam?'Had CSF exam?
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Had 1 risk factor 
(Hx lethargy OR 
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N=220
Presented on 3,d or 
later day of illness 
N=151
Had neither 
Hx lethargy nor 
temp &38.50C 
N=294
Had 2 risk factors 
(Hx lethargy PLUS 
tempa385#C) 
N=65
Had 1 risk factor 
(Had only 
fever >3D) 
N=74
'Had CSF exam? 'Had CSF exam? 'Had CSF exam?
Had 2 of the 3 risk 
factors (Had fever a3D 
PLUS Hx lethargy OR 
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N=55
Had 3 risk factors 
(Had fever S3D PLUS 
Hx lethargy PLUS 
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199
Figure 5.3 Use of intravenous immunoglobulin treatment and the clinical 
outcome
Between 2000 and 2006 there were 1455 children with hand, foot and mouth disease 
were admitted; 352 of those had central nervous system (CNS) involvement. One 
hundred and twenty eight (36%) children had aseptic meningitis, a mild and benign 
CNS disease, and were not treated with intravenous immunoglobulin. The other 224 
(64%) children had severe and potentially fatal CNS complications, including 205 
had encephalitis, 14 had encephalitis associated with cardiorespiratory failure, 2 had 
encephalitis associated with acute flaccid paralysis, 3 had isolated acute flaccid 
paralysis, and were treated with intravenous immunoglobulin. There were a total of 
20 deaths occurred during the Sarawak 1997 (April - June) epidemic (Cardosa et al. 
1999).
HadIVIG
n = 1
NoIVIGHadIVIG 
ii = 204
HFMD-CNS
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Severe CNS 
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Figure 5.4 White cell counts and serum glucose of three children with 
fatal hand, foot and mouth disease caused by enterovirus 71
The line graphs show the white cell counts (top panel, Y axis indicates the 
number of white cells per uL) and serum glucose (bottom panel, Y axis 
indicates the measurement unit in mmol/L) of three patients (Pt) with fatal 
hand, foot and mouth disease the day before (day -1), on the day (day 0) and 
the day after the onset of cardiorespiratory failure.
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Table 5.1 Clinical features of 725 children with hand, foot, and mouth 
disease that were admitted between January 2000 and July 2003 
according to the clinical severity
Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-
CNS (no CSF
pleocytosis)
p value*
Mild HFMD
Number of
children
History
102 83 540
Median age in
months (range)
25 [5-120] 25 [5-104] 0.7582 29 [2-153]
Male, no (%) 73 [71.6%] 47 [56.6%] 0.0497 337 [62.4%]
Chinese 44 [43.1%] 22 [26.5%] 0.0282 209 [38.7%]
Iban 28 [27.5%] 46 [55.4%] 0.0002 188 [34.8%]
Malay/Melanau 30 [29.4%] 15 [18.1%] 0.1062 125 [23.1%]
Fever at home 100 [98%] 77 [92.8%] 0.1425 402 [74.4%]
Mean duration of
fever at home
(days)
2.6 [0-8] 2.0 [0-7] 0.0078 1.6 [0-7]
Mean total
duration of fever
(days)
4.5 [1-12] 2.9 [0-8] <0.0001 1.8 [0-10]
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-
CNS (no CSF
pleocytosis)
p value*
Mild HFMD
Total duration of 92 [90.2%] 48 [57.8%] <0.0001 153 [28.3%]
fever > 3 days
Past history of 3 [2.9%] 3 [3.6%] >0.9999 12 [2.2%]
HFMD
Had history of 34 [33.3%] 21 [25.3%] 0.3044 156 [28.9%]
contact with
children with
HFMD
Rash 92 [90.2%] 70 [84.3%] 0.3279 486 [90%]
Mouth ulcers 85 [83.3%] 76 [91.6%] 0.1502 491 [90.9%]
Coryza 33 [32.4%] 33 [39.8%] 0.3722 165 [30.6%]
Cough 35 [34.3%] 32 [38.6%] 0.6571 146 [27%]
Breathlessness 7 [6.9%] 1 [1.2%] 0.0759 2 [0.4%]
Cold peripheries / 9 [8.8%] 3 [3.6%] 0.2306 2 [0.4%]
poor perfusion
Vomiting 49 [48%] 29 [34.9%] 0.0996 59 [10.9%]
Poor feeding 79 [77.5%] 70 [84.3%] 0.3217 303 [56.1%]
Diarrhea 7 [6.9%] 6 [7.2%] >0.9999 17 [3.1%]
Constipation 8 [7.8%] 2 [2.4%] 0.1890 20 [3.7%]
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-
CNS (no CSF
pleocytosis)
p value*
Mild HFMD
Reduced urine 24 [23.5%] 20 [24.1%] >0.9999 48 [8.9%]
output
Irritability 36 [35.3%] 29 [34.9%] >0.9999 36 [6.7%]
Lethargy 65 [63.7%] 36 [43.4%] 0.0089 51 [9.4%]
Seizures 7 [6.9%] 8 [9.6%] 0.6755 0
Reduced limb 6 [5.9%] 1 [1.2%] 0.1318 0
movement
Headache 14 [13.7%] 8 [9.6%] 0.5315 7 [1.3%]
Examination
Toxic looking 69 (67.6) 53 (63.9) 0.6994 7(1.3)
Dehydration 18 [17.6%] 10 [12%] 0.3944 22 [4.1%]
Mean peak body 38.6 38.1 <0.0001 37.2
temperature (°C, [36.8-40.9] [36.8-40.5] [36.4-39.8]
range)
Mean peak body 60 [58.8%] 32 [38.6%] 0.0094 20 [3.7%]
temperature >
38.5°C
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-
CNS (no CSF
pleocytosis)
p value*
Mild HFMD
Mean heart rate 132 [72-219] 124 [80-160] 0.0038 123 [80-
(per min, range) 238]
Mean heart rate 12 [11.8%] 1 [1.2%] 0.0069 6 [1.1%]
>150/min
Rash 97 [95.1%] 78 [94%] 0.9915 516 [95.6%]
Mouth ulcers 90 [88.2%] 78 [94%] 0.2785 496 [91.9%]
Lethargy/drowsy 35 15 0.0210 1
Instability 21 [20.6%] 13 [15.7%] 0.5025 0
Limb weakness 9 [8.8%] 0 0.0046 0
Neck stiffness 7 [6.9%] 1 [1.2%] 0.0759 0
History of or 21 [20.6%] 9 [10.8%] 0.1121 4 [0.7%]
witnessed
myoclonus
Cerebellar signs 2 [2%] 0 0.5026 0
Abnormal lung 7 [6.9%] 3 [3.6%] 0.5157 0
examination
Abnormal 4 [3.9%] 2 [2.4%] 0.6925 9 [1.7%]
cardiovascular
examination
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-
CNS (no CSF
pleocytosis)
p value*
Mild HFMD
Hepatomegaly 16 [15.7%] 10 [12%] 0.6195 34 [6.3%]
Splenomegaly 1 [1.8%] 0 >0.9999 4 [0.7%]
Vesicle present 49 [48%] 39 [47%] 0.9953 367 [68%]
Viral isolation
EV71 isolated 52 [51%] 34 [41%] 0.2258 173 [32%]
CVA16 isolated 2 [2%] 9 [10.8%] 0.0102 74 [13.7%]
Both EV71 and
CVA16 isolated
0 0 14 [2.6%]
Other virus
isolated
8 [7.8%] 11 [13.3%] 0.3360 31 [5.7%]
Negative isolation 35 [34.3%] 24 [28.9%] 0.5320 161 [29.8%]
No virus isolation
done
Laboratory
results
5 [4.9%] 5 [6%] 0.7551 87 [16.1%]
206
Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-
CNS (no CSF
pleocytosis)
p value*
Mild HFMD
Mean 11.5 [8.9-15.1] 11.3 [8.5-13.4] 0.4866 11.6
haemoglobin [7.3-17.3]
(g/dL, range)
Mean white cell 13247 13300 0.9543 12010
count (cells/jaL, [5200-264000] [5700-283000] [5100-
range) 31100]
Mean platelet 387537 353220 0.1473 356336
count [152000-994000] [180000- [125000-
(platelelt/pL, 504000] 775000]
range)
Mean serum 138 [130-146] 137 [131-145] 0.6392 138
sodium (mmol/L, [131-148]
range)
Mean blood 5.9 [2.8-24.1] 5.4 [1.9-13.4] 0.1618
glucose (mmol/L,
range)
Median CSF cell 41[0-1090] 2 [0-5]
count (cells/|iL,
range)
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-
CNS (no CSF
pleocytosis)
p value*
Mild HFMD
CSF neutrophilia 17 0
Median CSF 0.28 [0.06-1.26] 0.18 [0.06- <0.0001
protein 0.57]
concentration
(g/dL, range)
CSF protein 22 2
concentration >
0.45
Mean CSF: 0.66 [0.2-1.1] 0.67 [0.14-1.1] 0.7374
plasma glucose
ratio
Note:
* Comparison between children with HFMD-CNS and those with HFMD-Non-CNS 
HFMD: Hand, foot and mouth disease 
CSF: Cerebrospinal fluid
HFMD-CNS: HFMD with central nervous system complication 
HFMD-Non-CNS: Severe HFMD without central nervous system involvement 
EV71: human enterovirus 71 
CVA16: Coxsackie virus A16
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Table 5.2 Risk factors that were significantly associated with 
cerebrospinal fluid pleoytosis in children with hand, foot and mouth in 
the first phase of the study (2000 to 2003).
Risk factors p value Odds ratio 95% Cl
Total duration of fever >3 days <0.0001 6.52 2.83 - 14.99
Peak temperature >38.5°C 0.0192 2.27 1.14-4.51
History of lethargy 0.001 3.18 1.60-6.35
Note; The Hosmer-Lemeshow statistics indicated a non-significance of lack 
of fit (x2 = 2.163, p=0.904).
CSF: Cerebrospinal fluid
HFMD: Hand, foot, and mouth disease
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Table 5.4 Clinical features of 730 children with hand, foot, and mouth 
disease that were admitted during the 2006 outbreak according to 
clinical severity
Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-CN S
(no CSF
pleocytosis)
P
value*
Mild HFMD
Number of children 250 186 294
History
Median age in 23.9 27.8 0.1456 31.2
months (months, (0.3-126.0) (2.2-134.2) (1.6-128.0)
range)
Male, no (%) 152 (60.8) 97 (52.2) 0.0878 163 (54.9)
Chinese 97 (38.8) 52 (28.0) 0.0239 64(21.5)
Iban 106 (42.4) 88 (47.3) 0.3559 166 (55.9)
Malay/Melanau 40(16) 42 (22.6) 0.1063 63(21.2)
Fever at home 247 (98.8) 178 (95.7) 0.0610 253 (85.2)
Mean duration of 2 (0-6) 1.9 (0-7) 0.2095 1.3 (0-10)
fever
at home (days)
Duration of fever at 76 (30.4) 46 (24.7) 0.2316 29 (9.8)
home > 3 days
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HFMD-CNS HFMD-Non-CN S Mild HFMD
P
Severity (with CSF (no CSF
value*
pleocytosis) pleocytosis)
Mean total duration
of fever (days)
3.6 (0.5-9.5) 2.7 (0-7.5) <0.0001 1.5 (0-10)
Total duration of
fever > 3 days
183 (73.2) 84 (45.2) <0.0001 33 (11.1)
Past history of
HFMD
2 (0.8) 0 0.5096 4(1.3)
Had history of
contact with
children with
HFMD
103 (41.2) 50 (26.9) 0.0027 96 (32.3)
Rash 191 (76.4) 114(61.3) 0.0010 213 (71.7)
Mouth ulcers 218 (87.2) 158 (84.9) 0.5926 272 (91.6)
Coryza 42 (16.8) 28(15.1) 0.7194 41 (13.8)
Cough 48 (19.2) 37(19.9) 0.9535 36(12.1)
Breathlessness 5 (2.0) 3(1.6) >0.9999 1 (0.3)
Cold peripheries /
poor perfusion
5 (2.0) 2(1.1) 0.7039 2 (0.7)
Vomiting 62 (24.8) 35(18.8) 0.1710 14 (4.7)
Poor feeding 203 (81.2) 154 (82.8) 0.7625 185 (62.3)
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-CNS
(no CSF
pleocytosis)
P
value*
Mild HFMD
Diarrhoea 11 (4.4) 10(5.4) 0.8066 8 (2.7)
Constipation 3(1.2) 0 0.2645 0
Reduced urine 92 (36.8) 68 (36.6) 0.9610 72 (24.2)
output
Irritability 54(21.6) 41 (22.0) 0.9948 15(5.1)
Lethargy 90 (36.0) 36 (19.4) 0.0002 19 (6.4)
Seizures 13 (5.3) 9 (4.8) 0.9595 0
Reduced limb 1 (0-4) 0 >0.9999 0
movement
Headache 17 (6.8) 8 (4.3) 0.3672 16(5.4)
Examination
Toxic looking 52 (20.8) 14(7.5) 0.0002 1 (0.3)
Dehydration 85 (34.0) 50 (26.9) 0.1375 38 (12.8)
Mean peak body 38,7 38.3 <0.0001 37.6 (36.4-
temperature (°C, (36.8-40.3) (36.8-40.4) 39.9)
range)
Mean peak body 170 (68) 83 (44.6) <0.0001 42(14.1)
temperature >38.5°C
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-CN S
(no CSF
pleocytosis)
P
value*
Mild HFMD
Mean heart rate 145 141 0.0607 130
(bears per min, (86-204) (82-209) (80-199)
range)
Mean heart rate 105 (42) 69 (37.1) 0.3497 49 (16.5)
>150/min
Rash 222 (88.8) 147 (79.0) 0.0077 250 (84.2)
Mouth ulcers 235 (94.0) 181 (97.3) 0.1605 287 (96.6)
Lethargy 74 (29.6) 31 (16.7) 0.0026 5 (1.7)
Irritability 37 (14.8) 34(18.3) 0.3997 6 (2.0)
Limb weakness 2 (0.8) 0 0.5096 0
Neck stiffness 17 (6.8) 4 (2.2) 0.0438 0
History of or 176 (70.4) 91 (48.9) <0.0001 31 (10.4)
witnessed
myoclonus
Abnormal lung 19 6 0.0828 1
findings
Abnormal 1 (0.4) 1 (0.5) >0.9999 0
cardiovascular
findings
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-CN S
(no CSF
pleocytosis)
P
value*
Mild HFMD
Hepatomegaly 20 (8) 7 (3.8) 0.1064 4(1.3)
Splenomegaly 3(1.3) 1 (0.5) 0.6394 0
Vesicle present 41 (16.4) 22(11.8) 0.2281 61 (20.5)
Viral isolation
EV71 isolated 53 46 58
CVA16 isolated 0 0 0
Other EV isolated 12 19 13
Negative isolation 123 114 148
Pan-enterovirus
PCR
positive 163 (65.2) 133 (71.5) 188
negative 57 (22.8) 18(9.7) 35
EV7X specific PCR
positive 96 (38.4) 60 (32.3) 83
negative 63 (25.2) 88 87
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Severity
HFMD-CNS
(with CSF
pleocytosis)
HFMD-Non-CNS
P
(no CSF
value*
pleocytosis)
Mild HFMD
Number of EV71 114 73 104
positive children
Number of EV71 109 109 144
negative children
Note:
* Comparison between children with HFMD-CNS and those with HFMD-Non-CNS 
HFMD: Hand, foot, and mouth disease 
CSF: Cerebrospinal fluid
HFMD-CNS: HFMD with central nervous system complication 
HFMD-Non-CNS: Severe HFMD without central nervous system involvement 
EV71: human enterovirus 71 
CVA16: Coxsackie virus A16
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Chapter 6: Neurological disease in children 
infected with coxsackie virus A16 in Sarawak: 
cause or coincidence?
Abstract
Coxsackievirus (CV) A16 infection commonly causes a mild self-limiting 
illness, and neurological complications are rarely reported. Recent reports of 
neurological disease and deaths associated with CVA16 infection have raised 
concerns about the possible emergence of a more virulent strain of CVA16. 
Data collected through a prospective study of hand, foot, and mouth disease 
(HFMD) conducted between 2000 and 2003 were examined to investigate 
for possible severe CVA16 infection in Sarawak, Malaysia, and review 
whether any CVA16 infection was likely to be co-incidental or causal. The 
clinical features and disease severity of the CVA16-positive children were 
compared to the human enterovirus (EV) 71-positive children. CV Alb- 
positive children with neurological disease were identified, and the results of 
laboratory investigation for the aetiology of the children^ neurological 
disease were reviewed. CVA 16-positive children were more likely to have
221
mild HFMD than HFMD with central nervous system complications when 
compared to EV71-positive children. There were two CVA16-positive 
children who had encephalitis in the study. While Japanese encephalitis, 
confirmed by the intrathecal Japanese encephalitis virus-specific IgM 
production, was determined to be the cause of encephalitis in the first child, 
the co-isolation of coxsackie virus B1 and an adenovirus from the second 
child has raised doubts about CVA16 being the aetiology of the second 
child’s encephalitis.
6.1 Introduction
Hand, foot, and mouth disease (HFMD) is a common childhood illness 
characterised by a short febrile illness and the development of oral ulcers and 
typical skin rashes over the palms and soles of the affected children. The 
disease is most commonly caused by human enterovirus (EV) species A, 
particularly coxsackie virus (CV) A16 and EV71 (Pallansch et al. 2001). 
While CVA16 and EV71 are genetically very closely related and often co- 
circulate during outbreaks of HFMD and result in clinically indistinguishable 
skin lesions, the outcome and disease severity associated with the two 
viruses may be remarkably different. In most instances, CVA16 infection 
causes a mild self-limiting illness, and neurological complications are rarely
222
reported. EV71 infection, however, has been associated with severe 
neurological complications and fulminant cardiorespiratory failure (Huang et 
al. 1999). There have been two case reports of fatal CVA16 infections 
involving young infants in the literature between 1960 and 1997 (Wright et 
al. 1963) (Goldberg et al. 1963). Further cases of severe CVA16 infection 
associated with neurological complication and fatal myocarditis in older 
children during an outbreak of HFMD, as well as fatal pneumonitis in an 
adult have been reported more recently (Chang et al. 1999) (Wang et al. 
2004) (Legay et al. 2007). This has raised some concerns about the possible 
emergence of a new, more virulent strain of CVA16 (Legay et al. 2007). 
However, in many parts of Asia where these outbreaks have occurred, other 
neurotrophic viruses, such as JEV co-circulate (Solomon 2004). In addition 
an adenovirus has been associated with unexpected neurological disease 
during a large HFMD outbreak in Sarawak in 1997 (Cardosa et al. 1999). In 
this chapter data collected through a prospective clinical study of HFMD 
conducted between 2000 and 2003, a period which included 2 large 
epidemics of HFMD caused by EV71 and CVA16, were examined for 
possible severe CVA16 infection in Sarawak, Malaysia, and review whether 
any CYA16 infection was likely to be co-incidental or causal.
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6.2 Materials and methods
6.2.1 Setting and study period
A prospective clinical study of HFMD was conducted between 2000 and 
2003 at Sibu Hospital (Sarawak, Malaysia). The study was approved by the 
Director of Health for Sarawak and the Ethics Committee of the Liverpool 
School of Tropical Medicine (UK). Informed consent was obtained from 
each child’s accompanying parent or guardian.
6.2.2 Case definitions and clinical methods
The case definitions and clinical methods of the study have been described in 
earlier chapters. Briefly clinical data obtained through history taking and 
clinical examination were recorded on standardised forms. Swabs were taken 
from the throat and rectum of every patient, as well as skin vesicles and oral 
ulcers (if present). The clinical samples were stored immediately in a -70°C 
freezer until further testing. Blood was taken for flavivirus serology, and in 
patients with suspected CNS involvement for full blood count, urea, 
electrolytes, and glucose. Cerebrospinal fluid (CSF) was examined for cell 
count and differential, protein, glucose, Gram stain, bacterial culture. If there 
was a strong clinical suspicion of viral CNS infection, but the initial CSF
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examination was acellular, a second lumbar puncture was performed.
Lumbar punctures were delayed in those with unstable vital signs. Patients 
were examined daily or more frequently as indicated, by a member of the 
study team.
6.2.3 Virological methods
Virus isolation was attempted on all swab specimens and CSF specimens and 
any available serum samples through the inoculation of human 
rhabdomyosarcoma (RD) and human embryonic kidney cells (293). Isolated 
enterovimses were typed by nucleotide sequencing of VP1 and VP4 genes as 
described in earlier chapters. Adenoviruses were isolated in 293 cells.
6.2.4 Serological diagnosis of flaviviruses
All children with suspected CNS infection were routinely investigated for 
Japanese encephalitis (JE) in the hospital (Ooi et al. 2008; Wong et al. 2008). 
JEV shares cross reactive epitopes with dengue virus (DENY). Both CSF 
and serum samples were tested by an IgM-capture ELISA that distinguishes 
between responses to these 2 viruses (Cardosa et al. 2002). Paired serum 
samples (obtained at hospital admission and at day 7, at discharge from the 
hospital, or after death) and either one CSF specimen or paired CSF
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specimens were tested for IgM against DENY and JEV in parallel. As JEV- 
specific IgM may be undetectable in the CSF at the early stage of JE, a 
second CSF examination is routinely performed in the hospital to provide 
laboratory confirmation of JEV by demonstrating JEV-specific IgM 
seroconversion in the CSF (WHO 2006). A sample was considered to be 
IgM positive for JEV if the optical density against JEV was higher than that 
against DENV in the same test run (Cardosa et al. 2002; Ooi et al. 2008).
6.2.5 Statistical analysis
Normally distributed data were compared using Student’s t test; data that 
were not normally distributed were compared by the Mann-Whitney U test 
(Statview 4.02; Abacus Concepts). Differences between proportions were 
tested using the Chi-square test with Yates’s correction or Fisher’s exact test 
as appropriate (Epi Info, version 6; Centers for Disease Control and 
Prevention). A p value <0.05 was considered statistically significant.
6.3 Results
A total of 725 patients were recruited into the study. Five hundred and forty 
(74%) patients had mild HFMD, 83 (11%) had severe HFMD without CNS
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involvement and 102 (14%) patients had HFMD with CNS complication. 
EV71 and CVA16 were the two most frequently isolated enteroviruses 
during the study. The detailed results of epidemiological, diagnostic virology 
and molecular epidemiology of EV71 isolated in the study have been 
reported in Chapter 4.
Of 628 (87%) of the 725 patients tested in the study, 259 (41%) patients had 
EV71 isolated (14 of these patients also had other non-CVA16 vimses 
isolated), 85 (14%) had CVA16 isolated (4 of whom also had another non- 
EV71 virus isolated), 14 (2%) had both EV71 and CVA16 co-isolated and a 
further 50 (8%) had other viruses isolated. The remaining 220 (35%) patients 
had no virus isolated. For the purpose of the analysis, children with CVA16 
isolation were compared to those with EV71 isolation. The 14 children that 
had co-isolation of EV71 and CVA16 (all of whom had mild HFMD) were 
excluded in the analysis. Compared to EV71-positive children, CVAlb- 
positive children were more likely to have mild HFMD. They were less 
likely to have a total duration of fever >3 days, history or examination 
findings lethargy and myoclonus, and hepatomegaly (Table 6.1). There was 
also a trend to suggest that recurrent vomiting was less frequently seen in 
children with CVA16. Interestingly, two (2%) of the 85 children with 
CVA16-positive HFMD developed neurological disease. The detailed
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clinical presentation and investigation results of the 2 children with CVA16- 
positive HFMD complicated by neurological disease are presented here.
Case 1
A previously healthy 18-month old boy was admitted into hospital in 
September 2000 with a 5-day history of fever, painful mouth ulcers and skin 
rash. He fed poorly and became increasingly irritable and lethargic during 
the illness. On the day of admission, he developed a generalised seizure. 
There was no history of limb weakness, vomiting, diarrhoea or respiratory 
symptoms. His parents reported that his elder brother had just recovered 
from a febrile illness associated with similar skin lesions a few days before 
he was admitted. On examination at hospital admission, he looked ill, 
drowsy and was febrile (39°C). There were multiple papulovesicular skin 
lesions over the palms, soles, buttocks and knees, and multiple oral ulcers. 
Apart from the altered state of consciousness there was no sign of meningism 
or focal neurological deficit. The rest of the systemic examination, including 
heart, lung and abdomen, was unremarkable. His first CSF examination on 
admission showed an elevated cell count of 10 lymphocytes/pL, a protein 
level of 0.1 g/dL and a CSF-to-plasma glucose ratio of 0.57. A second CSF 
examination performed 4 days after the first showed that the CSF cell counts 
raised further to 39 cells/pL (90% were lymphocytes); an elevated protein
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level of 0.69 g/dL. Bacterial cultures for blood and CSF were sterile. CVA16 
was isolated from a vesicle in the RD cell culture. JEV-specific IgM was 
absent in the fust CSF specimen but the JEV-specific IgM seroconversion 
was demonstrated in the second CSF specimen taken 4 days after the first 
(Figure 6.1). This child was thus considered infected with both CVA16, and 
JEV.
Case 2
A previously healthy 14-month old boy presented to the hospital in October 
2000 with a 2-day history of fever, painful mouth ulcers and skin rash. He 
fed poorly, became less active and cried inconsolably. There was no history 
of seizures, limb weakness, vomiting, diarrhoea, respiratory symptoms or 
contact with cases of HFMD. On examination at hospital admission, he 
appeared ill and lethargic, and was febrile (38°C). There were multiple 
papulovesicular skin lesions over the palms and soles, as well as multiple 
oral ulcers. There was no sign of meningism or focal neurological deficit 
apart from increased irritability. The other systemic examinations, including 
heart, lung and abdomen, were unremarkable. His CSF examination on 
admission showed a marginally elevated cell count of 6 cells/pL (all were 
lymphocytes); a protein level of 0.22g/dL and a CSF glucose level of 3.1. 
CVA16 was isolated from a vesicle and rectum in the RD cell cultures while
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coxsackie virus B1 and an adenovirus was cultured from the throat in the RD
and 293 cell cultures, respectively. JEV-specific IgM was negative in both 
serum and CSF samples. These results confirmed that this child was infected 
with CVA16, coxsackie virus B1 and an adenovirus.
6.4 Discussion
The study confirms that CVA16-associated HFMD is a brief uncomplicated 
virus infection. Although there were two children with CVA16-associated 
HFMD who developed encephalitis in the study, the concurrent detection of 
other neurotrophic viruses (JEV in the first, coxsackie virus B1 and an 
adenovirus in the second case) has raised doubts if CVA16, which is not 
normally known to cause neurological disease, was the plausible cause of 
neurological disease in the two children.
In Case 1 the intrathecal production of JEV-specific IgM, demonstrated by 
JEV-specific IgM seroconversion in the paired CSF samples, provided strong 
evidence to support JEV infection as the underlying cause of the 18-month- 
old boy’s acute neurological symptoms. Fatal JEV infection during an 
epidemic of EV71-associated HFMD has been reported previously. Shieh 
and co-workers documented a case of fatal JEV infection in a child presented
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with HFMD and fulminant neurogenic pulmonary oedema during the largest 
ever EV71-associated HFMD epidemic in Taiwan in 1998 (Shieh et al.
2001). JEV, the causative agent of JE, is the principal cause of virus 
encephalitis in children in Asia, including in Sarawak, Malaysia (Ooi et al. 
2008; Wong et al. 2008). The neurotrophic flavivirus is transmitted naturally 
among birds, pigs and other vertebrae hosts by Cidex spp mosquitoes that 
breed in rice fields and stagnant water. In Sarawak the flavivirus encephalitis 
occurs sporadically throughout the year with a seasonal peak during the rainy 
season that lasts between the months of September and December, which 
coincide with the seasonal increase in Culex tritaeniorynchus population 
(Wong et al. 2008). The first case is a good example to show that during a 
virus epidemic a patient may be simultaneously infected by the outbreak 
virus and the endemically circulating virus. Therefore it is important to 
always consider endemic encephalitis viruses as possible causes of CNS 
infection in the diagnostic work-up of patients with acute neurological 
syndrome even during an epidemic of an unrelated virus. The 18-month-old 
boy could have been misdiagnosed as having an unusually severe CVAlb- 
associated HFMD had I failed to consider JEV, the most important endemic 
neurotrophic virus in Sarawak, as a cause of the encephalitis.
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Apart from CVA16, coxsackie virus B1 and an adenovirus were also isolated 
from the 14-month-old boy described in Case 2. The serotyping of coxsackie 
virus B1 isolated in Case 2 was performed by nucleotide sequencing of YP4 
gene. Coxsackie virus B1 is a member of enterovirus species B. A recent 
study compared the VP4 with VP1 gene regions for its usefulness in typing 
human enterovirus species B (Perera et al. 2010). The authors showed that a 
VP4-based approach often did not provide the same serotype identification 
as that obtained through VP 1-based nucleotide sequencing, although the 
species identity was correct. Therefore it is possible that the coxsackie virus 
identified as B1 during the study, using VP4 nucleotide sequencing, might 
actually be a different species B enterovirus. Although the three viruses were 
isolated from the throat, which may not necessarily represent acute infection 
but only related to asymptomatic carriage state or continuing shedding from 
a recent virus infection, the pathogenic role of these viruses isolated in the 
second case could not be discounted. The isolation finding is particularly 
relevant because both enterovirus species B and adenovirus are well- 
recognised possible CNS pathogens while neurological CVA16 infection is 
rarely reported. Pre-existing immunodeficiency may predispose a susceptible 
individual to multiple concurrent virus infection, which in turn lead to 
unusually severe infection caused by viruses that normally only cause mild 
illness. However this is less likely in this case because the child’s subsequent
232
follow-up examination showed that he recovered fully from the neurological 
infection and has since remained healthy. Alternatively transient 
immunosuppression due to multiple concurrent virus infections may have 
predisposed the child to neurological CVA16 infection.
Cases of serious and fatal CVA16 infection have been published by several 
authors previously; though they were varied in the diagnostic rigour in 
investigating for co-infecting vimses. The first two reports of fatal CVA16 
infection in the literature were published in 1963, and involved two infants 
who died of encephalitis and myocarditis, respectively (Goldberg et al. 1963; 
Wright et al. 1963). CVA16 was isolated from the intestinal content of both 
fatal cases, and also from the blood and heart tissues of the first infant. More 
recently CVA16 has been implicated as the pathogen responsible for a fatal 
case of HFMD complicated by CNS (i.e. seizures and CSF pleocytosis) and 
cardiac involvement, and for a further 4 cases of HFMD complicated by 
aseptic meningitis (Chang et al. 1999), during the same HFMD outbreak in 
1998 where Shieh and co-workers showed JEV infection was the cause of 
death in a child presented with HFMD and fulminant neurogenic pulmonary 
oedema (Shieh et al. 2001). It was not clear, however, from the two reports 
that JEV infection has been considered in the investigation of the patients. 
Legay and co-workers reported a fatal case of CVA16 pneumonitis in a 76-
233
year-old man who had history of contact with HFMD. CVA16, isolated from 
bronchoalveolar lavage, was determined to be the cause of death following 
extensive investigation for other common respiratory pathogens (Legay et al.
2007) . Apart from the advanced age, an important risk factor for mortality in 
community-acquired pneumonia, it is not clear from the report if there were 
underlying co-morbid conditions that may have contributed to the fatal 
outcome of this normally benign virus infection (Janssens 2005; Chong et al.
2008) .
Conclusions
In conclusion, CVA16-associated HFMD is a brief uncomplicated virus 
infection and rarely associated with neurological disease. During a virus 
epidemic concurrent infection caused by the outbreak virus and other 
endemically circulating virus can occur in an individual. It is particularly 
important for clinicians to consider common and endemically circulating 
encephalitis viruses being the possible aetiological agents before ascribing 
the neurological disease observed in children with CVA16-associated HFMD 
to CVA16 infection.
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Figure 6.1 Serological diagnosis of Japanese encephalitis in a child with 
CVA16-associated hand, foot and mouth disease
The bar chart shows the adjusted optic density (adj. OD) values against 
Japanese encephalitis virus (JEV) and dengue virus (DENY) of serum and 
cerebrospinal fluid samples of an 18-month old boy (Case 1) that were tested 
on the same IgM-capture ELISA run. The cutoff adj. OD values for JEV and 
DENY were 0.210 and 0.395, respectively. Coxsackie virus A16 was 
isolated from a vesicle in the human rhabdomyosarcoma cell culture.
Senxn Fiist CSF Second CSF
(Day 5 of the illness) (Day 5 of the illness) (Day 9 of the illness)
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Chapter 7: Final discussion and overall 
conclusion
Human enterovirus 71 continues to cause large cyclical epidemics of hand, 
foot and mouth disease over the last 14 years, and is now considered the 
most important non-polio enterovirus in children in Asia. Of note the virus 
often sweeps across the affected countries very rapidly causing an alarming 
number of deaths or patients with neurological sequelae, not to mention the 
marked socioeconomic disruption. The neurotrophic virus, which first 
emerged in Sarawak, Malaysia in 1997 with new clinical manifestations of 
hand, foot and mouth disease complicated by brainstem encephalitis and 
potentially fatal cardiorespiratory failure, has become a major public health 
problem in Asia, and had posed many clinical and public health challenges to 
clinicians, public health doctors and virologists in the region.
7.1 The usefulness of different clinical samples in 
laboratory diagnosis of enterovirus 71
A wide range of samples may be used to detect EV71 infection, depending 
on the disease manifestations; these include throat and rectal swabs, serum,
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urine, and when taken, cerebrospinal fluid (CSF), as well as fluid from 
vesicles and swabs from ulcers, if they are present. The results in Chapter 2 
have shown that the sensitivity, specificity and usefulness vary according to 
the sample. In particular virus detection in sterile sites such as vesicular 
fluid, CSF, serum, urine, serum, or autopsy material more reliably indicates a 
causative organism, than detection from non-sterile sites such as throat or 
rectum, which may indicate coincidental carriage. However many of the 
sterile sites only occasionally yield virus. For example virus was isolated 
from less than 3% of the CSF of patients with neurological disease, and the 
low yield from CSF in this work is consistent with other published reports 
(Kennett et al. 1975; Chumakov et al. 1979; Ishimaru et al. 1980; Nagy et al. 
1982; Gilbert et al. 1988; Chang et al. 1999; Ooi et al. 2007; Ooi et al. 2009), 
because, as for poliomyelitis, the viral load in the CSF is very low (Fujimoto 
et al. 2008). The yield for serum is similarly low. Vesicular fluid, when 
present, is more useful, though care is needed to collect it (Figure 7.1). 
Although throat and rectal swabs are more likely to have an enterovirus 
detected, the virus isolated from the non-sterile sites was not always the 
same enterovirus as that isolated from a sterile site: using the isolate from 
vesicle swabs as a reference, 10% of positive throat swabs gave a different 
isolate, and for rectal swabs the figure was 20%. Presumably the isolate from
242
the non-sterile site represented coincidental carriage, where-as that from the 
vesicles was actually pathogenic.
Prolonged viral shedding from the gastrointestinal tract (throat, rectum or 
stool) may occur after complete resolution of EV71 infection, as it does for 
other enteroviruses; a study in Taiwan showed that EV71 may be detected in 
the throat up to 2 weeks after recovery from HFMD or herpangina; in the 
stool it can be detected up to 11 weeks (Chung et al. 2001; Han et al. 2010). 
Given that there are so many potential samples which could be positive, 
during an outbreak, laboratories can soon become overwhelmed. The results 
Chapter 2 have shown that the most efficient approach was to examine throat 
swabs for all patients, plus swabs from at least two vesicles, if they were 
present, or from the rectum for patients with no vesicles.
7.2 Rapid diagnostic assay for direct detection of 
enterovirus 71 from primary clinical specimens
The gold standard for diagnosis of enterovirus infection is virus isolation, but 
PCR has increasingly become diagnostic method of choice in routine viral 
diagnostics. The advantage of PCR is that it provides quicker results and 
less labour intensive than virus culture. The evaluation of the application of
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an EV71 type-specific RT-PCR (MAS01S/MAS02A) as a rapid diagnostic 
assay for direct detection of EV71 from primary clinical specimens was 
shown in Chapter 3. The EV71 type-specific RT-PCR was originally 
developed for rapid molecular typing of EV71 clinical isolates. The 
evaluation indicated that the EV71 type-specific RT-PCR can be extended to 
be used as a rapid diagnostic assay for direct detection of EV71 from 
primary clinical specimens. As a single step PCR assay with no additional 
step of amplicon sequencing, the EV71 type-specific RT-PCR may be a 
useful alternative to clinical laboratories that have limited access to the 
conventional virus culture and neutralization test method, and nucleotide 
sequencing facilities. This can be especially useful in providing rapid 
diagnostics given the explosive nature of some EV71 outbreaks, and the need 
for urgent public health interventions. The disadvantage is that such an 
approach will only detect the virus looked for, and thus will miss the chance 
to identify other unexpected causes (Perera et al. 2004; Chen et al. 2006; Tan 
et al. 2008; Xiao et al. 2009). Other diagnostic platforms have been explored 
for the need for rapid diagnosis of EV71 in recent years. DNA microarray is 
a powerful, though expensive, new tool designed to detect multiple pathogen 
targets by hybridization of pathogen-specific probes. Two groups have 
recently reported such an approach to distinguish EV71 and CVA16 
infection in primary clinical specimens (Shih et al. 2003; Chen et al. 2006).
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7.3 Clinical predictors for neurological disease
While there are advances in the rapid laboratory detection method for EV71 
as alternative to the laborious time-consuming tissue culture technique there 
is still lack of a point-of-care diagnostic kit for EV71 to help clinicians 
identify children with EV71 infection who may at risk of neurological 
disease and death. Hence clinicians still need to rely on good clinical history 
and examination skill to identify children at risk of neurological disease and 
death. In Chapter 5 nearly 1500 children recruited through three EV71 
outbreaks over 7 years were studied. Peak temperature of 38* 5°C or more, 
duration of fever for 3 or more days, and a history of lethargy were found to 
be useful clinical predictors for neurological involvement. The presence of at 
least two of these factors was strongly associated with the subsequent 
development of neurological disease. The results of Chapter 5 confirmed the 
findings from early retrospective studies. However other findings from 
earlier studies, such as an association between the absence of mouth ulcers 
and development of complicated or fatal disease were not confirmed (Chong 
et al. 2003). Hyperglycaemia and leucocytosis were also associated fatal 
EV71 disease in a retrospective evaluation (Chang et al. 1999), and although 
these findings were confirmed in the prospective study, they were late
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changes occurring at approximately the same time as the fulminant disease 
as have been shown in Chapter 5. Therefore they are not helpful clinically in 
identifying children at high risk of complications and death.
Not all the children with CNS involvement in EV71 infection will progress 
to cardiorespiratory collapse. A small study involving 46 patients showed 
that children developed abnormal heart rate variability, an index of 
autonomic nervous system disease, about 7 hours before the clinical onset of 
cardiorespiratory instability (Lin et al. 2006). The authors proposed that 
screening children with CNS involvement for abnormalities in heart rate 
variability may provide early warning of impending cardiorespiratory failure 
and allow timely institution of appropriate interventions. Cardiac troponin I 
is a cardiac-specific biomarker for myocardial injury, used for early 
diagnosis of acute coronary syndrome in adults. Elevated cardiac troponin I 
has been observed in children with EV71 infection, brainstem encephalitis 
cardiac dysfunction and pulmonary oedema (Huang et al. 2003); in some 
cases it was elevated prior to the development of cardiopulmonary failure, 
suggesting that serial measurement of cardiac troponin may be helpful in 
identifying children at risk of left ventricular failure. However neither 
measurement of heart rate variability nor troponin I level evaluations have 
become routine clinical practice in the management of EV71, probably
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because the former requires relatively sophisticated equipment which is not 
widely available, and the latter, though more widely available, is relatively 
expensive in developing countries. Even in wealthier Asian countries such as 
Taiwan these measures have not entered routine clinical practice. Overall 
simple clinical parameters such as length of illness, height of fever, and 
lethargy are probably more useful indicators of potentially severe disease.
7.4 Clinical feature of EV71 infection
Similar to many enteroviruses most of the infection caused by EV71 are 
either mild or asymptomatic. More than 20% of adult contacts during one 
Taiwanese outbreak had symptoms of an upper respiratory tract infection, 
whilst asymptomatic infection occurred in more than 50% (Chang et al. 
2004). EV71 and CVA16 are the most important causative agents for 
HFMD. While EV71 has caused massive outbreaks with alarming number of 
deaths in Asia, CVA16 has rarely been associated with neurological disease 
and deaths. Although both viruses cause indistinguishable skin lesion there 
may be other clues that may suggest a child’s HFMD is due to EV71 rather 
than CVA16. In Chapter 6, children with EV71 were shown to be more 
likely to have a fever for longer than 3 days, a peak temperature greater than 
38-5oC, lethargy and myoclonus. The study confirmed the findings observed
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in a retrospective study by Chang et al. In Chapter 6, two cases of HFMD 
caused by CA16 who also had neurological disease were investigated in 
detail. The investigation showed that there were other plausible explanations 
for the neurological disease in these two children, underscoring the 
importance of thorough diagnostic investigation for common aetio logical 
agents before attributing severe disease manifestations to CVA16 infection.
Although brainstem encephalitis severity grading and clinical staging has 
been proposed shortly after the 1998 Taiwan epidemic, the grading and 
staging systems have not come into widespread usage in clinical practice 
during the ongoing Asian EV71 epidemics, possibly because they are not 
always easy to remember, and imply sequential progression through the 
various disease grades or stages, which does not always occur. A WHO 
Informal Consultation on Hand Foot and Mouth disease which met in Kuala 
Lumpur in March 2010 discussed the use of simple clinical descriptions of 
disease manifestations (Ooi et al. 2010).
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7.5 Epidemiology
7.5.1 Clinical Epidemiology of EV71
EV71 continues to cause large epidemics of HFMD with deaths across Asia. 
The most recent large epidemic in Asia occurred in China in 2008. 
Approximately 490,000 children including 126 deaths were reported 
nationwide; at the epicentre in Anhui Province, more than 6,000 HFMD 
cases and 22 deaths were reported (Zhang et al. 2010). In addition to these 
very large outbreaks, many areas, including Sarawak in Malaysia, Taiwan, 
Singapore, Vietnam and Japan have experienced cyclical epidemics that 
occur at 2 to 3 year intervals (Figure 7.2) (Mizuta et al. 2005; Hosoya et al. 
2006; Podin et al. 2006).
Outside the Asia-Pacific region two small community outbreaks of 
neurological EV71 disease, with no HFMD, occurred in 2003 and 2005 in 
Denver, USA, and affected 16 children, aged 4 weeks to 9 years, with 1 
fatality (Perez-Velez et al. 2007). A retrospective analysis of stool samples 
collected from children with aseptic meningitis in Austria showed that EV71 
was detected in 16 (9%) of 181 patients admitted between 2001 and 2004 
(Ortner et al. 2009). A similar study identified 32 sporadic cases of EV71 
infection in the UK between 1998 and 2006, presenting primarily as
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neurological disease and/or HFMD (Bible et al. 2008). A cluster of 58 
hospitalised cases with predominant clinical manifestations of fever, 
gastrointestinal symptoms and CNS infections was observed in 2007 
following a period of 21 years of low endemicity (Van der Sanden et al. 
2009). Widespread asymptomatic circulation of EV71 was also noted 
between October 2002 and October 2003 in Norway where the virus was 
isolated from 19 (17%) of 113 children who were completely well (Witso et 
al. 2007). EV71 was among a range of enteroviruses detected by screening 
blood donations in Scotland over 22 months; the pick-up rate for any 
enterovirus was 1 in 4000 donations, and the significance remains uncertain 
(Welch et al. 2003). In Nairobi Kenya, there were two small institutional 
outbreaks of EV71 infection in an HIV-orphanage in 1999 and 2000 
(Chakraborty et al. 2004). Although EV71 was first isolated in 1969 in 
California, a retrospective analysis of samples from the Netherlands shows 
that EV71 was circulating as early as 1963 (Van der Sanden et al. 2009).
7.5.2 Molecular epidemiology
Chapter 4 describes the emergence of two new subgenogroups B4 and B5 in 
Sarawak during the two consecutive epidemics in 2000 and 2003, 
respectively. A number of new subgenogroups within genogroup B and C
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have emerged in the Asia-Pacific region over the last 12 years (Table 7.1) 
Phylogenetic studies of the virus isolated from the ongoing epidemics in 
Asia showed that subgenogroup B3 and B4 viruses are likely to have co­
circulated in the region since 1997 (McMinn et al. 2001; Cardosa et al. 2003; 
Shimizu 2004). Subgenogroup B5, was first isolated in Sarawak and Japan in 
2003, and was responsible for epidemics in Sarawak, Taiwan and Brunei in 
2006 (Mizuta et al. 2005; Podin et al. 2006; Huang et al. 2008; AbuBakar et 
al. 2009). Except for the major community outbreak in Sydney in 1986, 
subgenogroup Cl viruses have mostly been isolated from sporadic cases 
since the mid-1980, suggesting a low level of endemic circulation across the 
globe (Brown et al. 1999; Sanders et al. 2006). Subgenogroup C2 viruses 
were responsible for the large EV71 epidemic in Taiwan in 1998, and the 
Perth outbreak in 1999 (McMinn et al. 2001; McMinn 2002; Cardosa et al. 
2003; Lin et al. 2006). Subgenogroup C3 was isolated in Japan in 1994 and 
Korea in 2000 (Cardosa et al. 2003; Jee et al. 2003; Iwai et al. 2009). 
Subgenogroup C4 has been the predominant circulating genogroup in 
mainland China since 2000, including the most recent epidemic in 2008, as 
well as occurring in Japan, Vietnam and Taiwan (Shimizu 2004; Lin et al. 
2006; Tu et al. 2007; Zhang et al. 2010). Subgenogroup C5 has been reported 
from Southern Vietnam and Taiwan (Tu et al. 2007; Huang et al. 2008). A 
genetically distinct EV71 strain (R13223, Genbank accession no. AY179600
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to AY 179602), when compared to other EV71 strains isolated in the Asia- 
Pacific region in recent years, was isolated from a single child who with 
acute flaccid paralysis in India in 2001 (Deshpande et al. 2003). Thus, two 
major EV71 genogroups (B and C) have co-circulated and co-evolved into 
subgenogroups in the Asia-Pacific region over the past 14 years. In Malaysia 
and Singapore, the genogroup B viruses have dominated, where-as in East 
Asia, particularly in mainland China and Vietnam, genogroup C viruses have 
dominated (Figure 7.3).
Recently isolates of genogroup A have been reported from 5 of 22 children 
presenting with HFMD in Anhui province of Central China during the 2008 
outbreak - the first ever report of genogroup A viruses, since the original 
prototype was isolated in America (Yu et al. 2010). Sequencing of the 
complete VP1 gene shows the isolates cluster with the prototype genogroup 
A virus, with very little divergence. This highly unexpected occurrence 
might indicate that the virus has been circulating undetected in central China, 
with very little evolutionary change for 40 years, or raises queries about the 
source of the virus templates that were sequenced, which may be from 
laboratory contamination or perhaps be related to laboratory-acquired 
infection. Surveillance from the same outbreak by the Chinese Centre for 
Disease Control does not appear to have identified any genogroup A viruses
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(Zhang et al. 2010). Clearly, good surveillance programs need to be 
implemented in many different geographical regions to provide accurate and 
relevant information about EV71 transmission and evolution and it would be 
prudent to await confirmation by other laboratories before concluding that 
genogroup A viruses have re-emerged. A recent phylogenetic analysis 
suggests that EV71 may have emerged from the genetically closely related 
coxsackie virus A16 as recently as 1940 (Tee et al. 2010).
7.6 Transmission and epidemic potential of 
genogroupsO O JL
Surveillance systems for EV71 have been established in a number of 
countries in the Asia-Pacific region; whilst primarily aimed at monitoring 
transmission and spread, they have also provided invaluable insights into 
how the virus evolves in the community during outbreaks. For example, data 
from a virological surveillance system in Sarawak, Malaysia has shown 
increased viral activity every 3 years (1997, 2000,2003, 2006 and 2008/09) 
which is closely associated with an increased incidence of HFMD in the 
community (Podin et al. 2006) (Solomon et al. 2010). The phenomenon of 
cyclical epidemics that take place at regular intervals has also been observed 
in Fukushima Prefecture, Japan (Hosoya et al. 2006). Such cyclical activity
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is presumed to relate to the availability of new birth cohorts of children who 
have not been exposed to the virus during the earlier epidemics (Chang et al. 
2002; Lu et al 2002). Trying to make predictions about the epidemic 
potential of particular subgenogroups has proved difficult, beyond the 
observation that some subgenogroups, such as Cl, appear to be less virulent, 
causing endemic disease, rather than the large epidemics, whereas other 
subgenogroups, particularly those that appear to have emerged in Asia in 
recent years, are associated with large epidemics.
More than one subgenogroup may co-circulate, and during outbreaks in 
Sarawak and Vietnam shift from one dominant genogroup to another has 
been described (Cardosa et al. 2003; Podin et al. 2006; Tu et al. 2007). In 
Japan and Taiwan subgenogroup B and C viruses have caused epidemics at 
different times (Table 7.1) (Wang et al. 2002; Lin et al. 2006; Huang et al. 
2008). In contrast in the Netherlands a permanent shift appears to have 
occurred, from genogroup B viruses before 1986 to genogroup C viruses 
since 1987; cross-neutralization among the genogroup B viruses, but not 
with genogroup C viruses is postulated as one explanation for this, though 
other experimental cross neutralization data would not appear to support it 
(Kung et al. 2007; Mizuta et al. 2009; Van der Sanden et al. 2009; Van der 
Sanden et al. 2010). Whilst the older subgenogroups of virus have been
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circulating and causing low levels of disease for many years, some of the 
more recently evolved subgenogroups such as genogroup B5, which possess 
distinctive antigencity from other viruses may have the potential to cause 
very large outbreaks (Huang et al. 2009; Van der Sanden et al. 2010). 
Although these have been confined to the Asia-Pacific region, the fact these 
viruses are carried by human, and that there is increasing global travel means 
that every region should consider itself potentially at risk.
7.7 Pathogenesis
7.7.1 Viral determinants of virulence
Subgenogroups may indeed vary in their biological behaviour with regard to 
risk of neurological disease and transmissibility within families, as depicted 
in Chapter 4. Children infected with subgenogroup B4 viruses were less 
likely to present with CNS infection than those infected with Cl or B5 
viruses, and that they were also less likely to be part of a family cluster. In 
contrast, children infected with B5 viruses were more likely to be part of a 
family cluster, and there was a trend towards a greater incidence of CNS 
disease in these patients.
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7.7.2 Dual infection
Co-infection with adenovrus 21 has been postulated as an important factor 
for the development of systemic complications and death during HFMD 
epidemic in Sarawak in 1997 (Cardosa et al. 1999). Nevertheless I did not 
find in this longitudinal study evidence of adenovirus 21 infection in other 
HFMD or neurological cases, though dual infection of EV71 with other 
viruses, including dengue and Japanese encephalitis, has been found but with 
no increase in disease severity or mortality.
7.7.3 Host susceptibility
The potential for host genetic variants to explain the variability in clinical 
epidemiological patterns of EV71 has also been studied. One genetic study in 
Taiwan reported that HLA-A33 is associated with increased susceptibility to 
EV71 although the role of the major histocompatibility complex in the virus 
infection is still unknown (Chang et al. 2008). The authors noted that HLA- 
A33 is more frequently found in the Asian population than that in the 
Caucasian population, and this may help explain frequent occurrence of 
EV71 epidemics in Asia. The authors also reported that HLA-A2, in a 
mechanism yet to be defined may be linked to the risk of cardiopulmonary 
failure often observed in fatal cases (Chang et al. 2008). Cytotoxic T 
lymphocyte antigen-4 (CTLA-4) gene is an important regulator of T cell
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cytotoxicity, and it has a role in the regulation of an immune response. In a 
study of 78 children with EV71 infection in Taiwan, those with 
meningoencephalitis were found to have a higher frequency of G/G genotype 
at position 49 of exon 1 in the CTLA-4 gene, than those without 
meningoencephalitis and control subjects (Yang et al. 2001). However a 
subsequent study found no such association (Chang et al. 2008).
7.4 Pathophysiology of severe disease
7.4.1 Viral entry and spread
The mechanism by which enteroviruses enter the CNS is not completely 
understood. A number of epidemiological and experimental animal studies 
on poliovimses indicate that the virus can invade the CNS system by 
permeation through a disrupted blood-brain barrier, or retrograde axonal 
spread along cranial or peripheral nerves. For EV71, this latter route has 
been implicated both from mouse models, and by examining the distribution 
of virus and inflammation in fatal human cases (Chen et al. 2007; Ong et al. 
2008; Wong et al. 2008).
257
7.4.2 Pathogenesis of severe pulmonary oedema and heart 
failure
While it is clear that fulminant pulmonary oedema is closely associated with, 
and preceded by CNS involvement, there is no consensus on its cause, 
especially the relative contributions of neurogenic pulmonary oedema, 
cardiac dysfunction, increased vascular permeability and a cytokine storm 
(Chang et al. 1998; Chang et al. 1999; Lin et al. 2002; Fu et al. 2003; Lin et 
al. 2003; Wang et al. 2003; Fu et al. 2004; Wang et al. 2007; Wang et al. 
2008)(Figure 7.4).
Neurogenic pulmonary oedema is classically seen following a head injury, 
where the associated raised intracranial pressure is thought to be important. 
Although the pathogenesis is not completely understood, studies from animal 
models suggest that the hypothalamus, and vasomotor centres of the medulla, 
and nuclei in the cervical spinal cord are important; lesions to various nuclei 
in these regions can increase activity along the sympathetic trunk, resulting 
in profound systemic and pulmonary hypertension and consequent 
pulmonary oedema (Hoff et al. 1981). Pulmonary oedema was also seen in 
poliomyelitis, and because it was associated with damage to brainstem 
nuclei, was thought to be neurogenic in origin (Baker 1957). Thus when 
severe pulmonary oedema was first seen in EV71 encephalitis, and brainstem
258
inflammatory changes were observed too, the oedema was thought to be due 
to neurogenic causes. Post-mortem examination and magnetic resonance 
imaging studies of children with EV71 brainstem encephalitis showed that 
there was extensive inflammation of gray matter of the spinal cord and the 
whole medulla oblongata, as described above (Lum et al. 1998; Huang et al. 
1999; Shen et al. 1999; Hsueh et al. 2000; Wong et al. 2008). The 
observations of hyperglycaemia and leucocytosis were also postulated to be 
due to increased sympathetic discharges (Chang et al. 1999). However, 
detailed hemodynamic observations of children with EV71 and pulmonary 
oedema have not always shown the profound systemic and pulmonary 
hypertension that would be expected (Lin et al. 2002; Wu et al. 2002; Fu et 
al. 2004). This may be because the changes in vascular pressures in 
neurogenic pulmonary oedema are only transient, as was shown for one child 
with EV71 (Wu et al. 2002). Others have argued that cardiac dysfunction is a 
major contributor to the pulmonary oedema. Although there is no 
histological or virological evidence of a viral myocarditis, elevated levels of 
the cardiac specific troponin I suggest a degree of cardiac damage (Chang et 
al. 1998; Lum et al. 1998; Huang et al. 2003; Fu et al. 2004). One detailed 
echocardiographic study of cardiac function in 11 children with EY71 
brainstem encephalitis show that it was impaired, with significantly reduced 
left ventricular ejection fraction (Fu et al. 2004). Two children whose cardiac
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output was supported with a left ventricular assist device survived, whereas 
all the others died (Fu et al. 2003). Interestingly, in a separate report the 
same authors described very high levels of norepinephrine and epinephrine 
in 3 of the 17 children with left ventricular dysfunction (Fu et al 2004). 
Although there is no myocardial inflammation, histological examination of 
cardiac ventricular tissue from six fatal cases and one survivor, obtained 
though a biopsy, revealed significant coagulative myocytolysis, myofibrillar 
degeneration, and cardiomyocyte apoptosis which are the characteristic 
features of catecholamine cardiotoxicity (Fu et al. 2004; Fu et al. 2006).
Thus it is argued by some that the high catecholamine levels caused by 
brainstem encephalitis may have a direct effect on cardiac function, as well 
as causing pulmonary oedema via raised pulmonary pressures.
The other potential contributor to pulmonary oedema is increased vascular 
permeability which is postulated to occur secondary to the systemic 
inflammatory response. A series of studies have examined cytokine and 
chemokine profiles in EV71: interleukin (IL)-6, IL-1B, IL-10, IL-13, tumour 
necrosis factor (TNF)-a and interferon (IFN)-y are all significantly higher in 
EV71 patients with pulmonary oedema, than those with encephalitis 
uncomplicated by oedema, and several of these, including IL-1, IL-6, IL-13 
and IFN-y are known mediators of increased vascular permeability (Lin et al.
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2002; Lin et al. 2003; Wang et al. 2003). In addition increased plasma levels 
of several chemokine including interferon-gamma-induced protein (IP-10), 
monocyte chemoattractant protein (MCP)-l, monokine induced by 
interferon-gamma (MIG), and IL-8 have been found in children with 
pulmonary oedema when compared to those with uncomplicated brainstem 
encephalitis (Wang et al. 2008). Children with oedema also had depleted a 
lymphocyte population particularly in CD4 and 8 and natural killer cells 
(Yang et al. 2001; Wang et al. 2003). Thrombocytosis, neutrophilia and 
hyperglycaemia, are all thought to be indicative of a systemic inflammatory 
response (Lin et al. 2003; Wang et al. 2003). Fewer studies have looked at 
cytokines in the CSF, but one showed elevated CSF IL-lb in patients with 
encephalitis complicated by oedema, compared to those with encephalitis 
alone (Lin et al. 2003).
Because the development of pulmonary oedema in patients with EV71 
encephalitis appears to be strongly associated with a dysregulated systemic 
and CNS inflammatory response; this has formed at least part of the basis for 
treatment with the anti-inflammatory drug intravenous immunoglobulin, 
which appears to be effective as I have shown in Chapter 5 and in other 
studies (Lin et al. 2002; Chang et al. 2004; Wang et al. 2006; Ooi et al. 2007; 
Ooi et al. 2009).
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In summary, the exact mechanism for pulmonary oedema in EV71 
encephalitis is still unclear. Neurogenic mechanisms secondary to brainstem 
inflammation appear to be important, but pathologically similar changes are 
seen in other encephalitides, for example Japanese encephalitis, without 
pulmonary oedema being such a prominent feature. Cardiac dysfunction and 
the effects of the systemic inflammatory response on the vascular 
endothelium may also make an important contribution. In vivo models 
including those in mouse and non-human primates have replicated some of 
the features of severe EV71 disease, such as neuroinvasiveness with marked 
inflammatory changes; however none has yet been able to reproduce the 
severe systemic features such as pulmonary oedema (Chen et al. 2004; Wang 
et al. 2004; Arita et al. 2005; Chen et al. 2007; Ong et al. 2008; Wong et al. 
2008).
7.5 Treatment of enterovirus 71 infection 
7.5.1 Antiviral agents
Several other newer capsid-function inhibitors have been investigated and 
some have demonstrated promising anti-EV71 activities in pre-clinical 
studies (Chen et al. 2008). In vitro and in vivo studies show that both
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ribavirin and interferons, may be useful (Liu et al. 2005; Li et al. 2008), and 
RNA interference approaches are being explored (Sim et al. 2005; Tan et al. 
2007; Wu et al. 2009). Several receptors for EV71 have been identified 
recently, and may be an important step towards the development of EV71- 
specific antiviral. A ubiquitously expressed cellular receptor, scavenger 
receptor B2, and a functional receptor, human P-selectin glycoprotein ligand- 
1, found on white blood cells have recently been identified by two groups of 
Japanese investigators as specific receptors for EV71(Nishimura et al. 2009; 
Yamayoshi et al. 2009). In addition sialic acid-link glycan, expressed in 
abundance in respiratory and gastrointestinal tracts, and dendritic cell- 
specific ilntercellular adhesion molecule-3-Grabbing non-integrin (DC- 
SIGN, CD209), found exclusively in dendritic cells that are present in 
lymphoid tissues, have also been identified as receptors for EV71 by two 
groups of Taiwanese investigators (Zhou et al. 2006; Lin et al. 2009; Yang et 
al. 2009).
7.5.2 Intravenous Immunoglobulin
In Chapter 5 the effectiveness of IVIG in children with neurological disease 
who are at risk of cardiorespiratory failure was examined. Retrospective 
comparisons of patients that received IVIG with those that did not suggest
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that there may be benefit from IVIG if given early, and this is consistent with 
a study in Taiwan (Chang et al. 2004; Ooi et al. 2009). Analysis of cytokine 
profiles before and after IVIG treatment showed significant reductions in 
some pro-inflammatory cytokines in EV71 patients if they had encephalitis 
with autonomic dysfunction, but not if they had less severe disease (Lin et al. 
2002; Lin et al. 2003; Wang et al. 2003; Wang et al. 2006). IVIG has 
therefore becoming routine treatment for severe EV71 disease (Chang et al. 
2004; Wang et al. 2006; Ooi et al. 2007; Ooi et al. 2009), and in Taiwan has 
been introduced into the national treatment guidelines (Lin et al. 2002). 
However uncertainty exists over whether this treatment is really effective, 
and most accept that randomised placebo controlled trials are needed. Such 
trials would be logistically and ethically challenging to establish, given the 
extent to which the treatment is used and the strong beliefs held by some; in 
the first instance carefully designed phase II trials with surrogate end points 
of disease progression, such as failure of resolution of tachycardia would be 
needed.
7.5.3 Milrinone
Milrinone is a cyclic nucleotide phosphodiesterase inhibitor currently used in 
the treatment of congestive heart failure. Inhibition of cyclic nucleotide
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phosphodiesterase subtype III by this cardiotrophic agent results in an 
increase in intracellular cyclic adenosine monophosphate (cAMP), which in 
turn leads to increased cardiac output and decreased peripheral vascular 
resistance. A small non-randomised retrospective comparison involving 24 
children with EV71-induced pulmonary oedema showed that those treated 
with milrinone had reduced tachycardia, and a lower mortality (Wang et al. 
2005; Wang et al. 2006). Intriguingly the peripheral white cell count, platelet 
count, and plasma IL-13 were also lower (Wang et al. 2005), possibly 
suggesting an immunomodulatory as well as a cardiovascular effect of the 
drug. A clinical study examining efficacy of milrinone is said to be 
ongoing(Wang et al. 2008).
7.6 Prospects for control
7.6.1 Surveillance and prevention
The only measures available currently for disease control are public health 
approaches. Since public health intervention at an early phase of an outbreak 
may help mitigate the spread of the virus in the communities, many countries 
in the region including Malaysia, Singapore, Taiwan, Japan and Vietnam 
have implemented heightened surveillance for EV71 (Mizuta et al. 2005; 
Podin et al. 2006; Chen et al. 2007; Ang et al. 2009; 2009). HFMD has now
265
become a notifiable disease in many countries, including Malaysia, 
Singapore, Thailand, Taiwan, Vietnam and China (Anonymous 2009). 
However as HFMD may be caused by a number of other EV-A viruses 
including CVA8, 10 and 16, concurrent virological surveillance is necessary. 
Virological surveillance also provides invaluable molecular epidemiological 
data about the circulating EV71 genotype and may thus help to track the 
spread of the virus across the region.
Outbreak control measures are primarily targeted at interrupting the virus 
transmission and spread from person-to-person through contact with throat 
and nose secretions, saliva, stool and vesicular fluid; in addition contact with 
virus contaminated surfaces, toys or fomites is important. Hence health 
education focuses on personal hygiene and good sanitation including 
frequent hand washing, proper disposal of soiled diapers and disinfection of 
soiled surfaces with chlorinated (bleach) disinfectants. A good hand hygiene 
among children and their caregivers has been shown to be effective in 
reducing risk of HFMD and herpangina caused by EV71 (Ruan et al. 2011). 
Since the transmission of enteroviruses including EV71 is most efficient in 
overcrowded settings, most countries in the region including Malaysia, 
Singapore, Taiwan, Hong Kong and China have adopted “social distancing” 
measures during epidemics, such as closures of childcare facilities and
266
schools, and cancellation of public functions involving children (Ang et al. 
2009; 2009). It is unclear though whether they should be instituted as soon as 
there is a HFMD outbreak or should await proof that it is EV71-related. 
However, it is not known if the distancing measures, which carry significant 
socioeconomic implications, are effective. If EV71 is like other directly 
transmissible viruses, then controls such as school closure will decrease the 
peak incidence of disease, but this may be associated with a prolonged 
outbreak, and no reduction in the overall number of cases (Figure 7.5) 
(Solomon et al. 2010). Paradoxically, if this means that more children catch 
the infection from their siblings, rather than from the peer-group at school, 
then this could theoretically lead to an increased incidence of severe cases; 
because family transmission of EV71 between siblings may be associated 
with more severe disease (presumably from a higher inoculum) (Chang et al. 
2004). Clearly more clinical and epidemiological studies are necessary to 
guide public health specialists into instituting evidence-based interventions 
to control the spread of EV71. Although there has been little systematic 
research to examine the effectiveness of such measures, studies from 
Singapore and Hong Kong appeared to show some benefit (Ma et al. ; Ang et 
al. 2009).
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7.6 2 Vaccine development
There are currently no vaccines against EV71, but by analogy with 
poliomyelitis, vaccines probably offer the best strategy for future disease 
control. One limitation in EV71 vaccine development is the lack of a good 
mouse model of human disease. Adult mice are resistant to infection. 
Although suckling mice are susceptible, by the time potential vaccines 
inoculated into them have led to the development of immunity, the animals 
have matured and become resistant to infection anyway. One way around 
this is to vaccinate female adult mice, allow them to become pregnant, and 
then determine the level of protective maternal antibody transferred to their 
offspring, as judged by protection against lethal infection (Wu et al. 2001).
In humans the target population should be younger children, especially those 
less than three years, because they are susceptible to severe disease. One 
important issue is whether vaccines derived against one genogroup will 
provide cross protection against all genotypes: data so far are contradictory 
(Kung et al. 2007; Mizuta et al. 2009; Van der Sanden et al. 2010). Several 
comprehensive reviews on the development ofEV71 vaccine candidates 
have been published (Xu et al. 2010; Lee et al. 2010 ). A range of approaches 
to developing vaccines have been adopted including inactivated whole virus 
vaccines, live attenuated vaccines, production of subviral particles and DNA 
vaccines. They are all in relatively early stages of development, with the
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most advanced undergoing preclinical trials in murine and non-human 
primates (Lee et al. 2010).
Candidate inactivated vaccines include those derived in Taiwan from 
subgenogroup B4 viruses, EY71-075 and EV71-0117, which are highly 
immunogenic, and EV71-1207, which is a C2 virus, and is less 
immunogenic; in one study they were found to be more immunogenic in 
mice than recombinant YP1 protein, or DNA vectored vaccines (Liu et al. 
2007). Virus like particles for EV71, that resemble the vims in appearance, 
capsid stmcture, and protein have been produced and purified as potential 
vaccines (Chung et al. 2008). After immunization of BALB/c mice, the 
particles induced potent and long-lasting humoral immune responses as 
evidenced by high total IgG titer and neutralization titer. Splenocytes 
collected from the immunised mice exhibited significant cell proliferation 
and produced high levels of IFN-gamma, IL-2 and IL-4 after stimulation, 
indicating the induction of Thl and Th2-type immune responses. 
Immunization of female mice conferred protection (survival rate up to 89%) 
to neonatal mice against vims challenge with a dose 1000 times that 
normally required to kill 50% of animals (Chung et al. 2008).
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A potential DNA vaccine has been developed by inserting the VP1 gene into 
the pVAXl vector, and transforming the constructs into E coli cells, and 
expressing in a mammalian cell line (Tung et al. 2007). Immunization of 
mice with the DNA vaccine constructs resulted in the production of anti-VP 1 
IgG and neutralizing antibody against EV71. An alternative approach, 
immunizing mice orally with an attenuated Salmonella enteric serovar 
Typhimurium expressing the VP1 gene, also proved protective of newborn 
mice, following maternal immunization (Chiu et al. 2006). Transgenic 
tomatoes expressing the VP1 protein have also been developed, and used as 
an oral vaccine, again resulting in the development of VP 1-specific 
antibodies in B ALB/c mice, as well as evidence of cell mediated immunity, 
and providing protection to their offspring in the neonatal challenge models 
(Chen et al. 2006).
Linear neutralizing epitopes from the VP1 capsid protein were identified by 
raising anti-sera in mice against overlapping peptides from this protein, and 
two peptides were found to elicit neutralizing antibody responses (Foo et al. 
2007). One of them, SP70 was particularly potent, and comparison with 
sequences from other strains showed it was conserved among the different 
subgenotypes of EV71, suggesting it is a promising candidate to take 
forward.
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A live attenuated strain of EV71, EV71(Sl-3’), was derived from the 
genotype A prototype strain BrCr using genetic manipulations (Arita et al. 
2007). These were based on knowledge of the temperature sensitive 
determinants of poliovirus type 1 vaccine strain, some of which are located 
in the 5’ and 3’ untranslated regions and the 3Dpol gene. Cynomolgus 
monkeys inoculated intravenously with the EV71 vaccine strain develop 
antibodies with cross reactivity against a broad spectrum of EV71 genotypes, 
and survived challenge with intravenous virulent EV71 (BrCr-TR strain) 
which is lethal in non-immunised monkeys. However the vaccine strain itself 
causes mild neurological symptoms (tremor), and was found to be 
neurotropic, entering the spinal cord, indicating that further work on 
attenuation is needed (Arita et al. 2007).
Among the various vaccine candidates, inactivated whole virus vaccines are 
in some ways the most ready to take forward, because the principles of 
vaccines based on inactive whole virus are well established. However, 
although the technology may be the most readily adaptable, and quickest to 
develop, those developing enterovirus vaccines would do well to remember 
the lessons learnt from vaccines against Japanese encephalitis virus, another 
major neurological infection in Asia. An effective formalin inactivated
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mouse brain derived vaccine has been available since 1950s, but the vaccine 
has not been widely used in many Japanese encephalitis virus endemic 
countries until more recently because of its high cost. Therefore; ultimately, 
if a vaccine is to be used across the whole of Asia, it needs to be cheap, 
easily produced, and readily available (Solomon 2004).
7.7 Final concluding remarks
The emergence of EV71 in the Asia Pacific Region over the last 14 years has 
had a major public health impact. The virus has emerged from being a 
relatively rare and sporadic cause of HFMD to a cause of major and regular 
epidemic across the Asia-Pacific region, which is often associated with 
severe and sometimes fatal neurological complications. Of the many 
thousands who become infected with the virus there are still no good ways of 
predicting who will develop HFMD, and who will have neurological 
complications. Nor are there clear indicators of which patients, with CNS 
involvement, are at risk of disease progression. Molecular epidemiological 
studies suggest that some subgeno groups appear to have massive potential 
for explosive epidemics, whilst others have more indolent low level 
circulation. However the biological determinants of these differences are 
poorly understood. The epidemiological differences observed between EV71
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in Asia-Pacific region and that in Europe and USA is also a mystery. 
Similarly the virological and host determinants of the wide ranging clinical 
phenotypes in those infected are unclear. There is still no specific antiviral 
drug available for EV71 infection although the identification of several 
EV71 receptors may help in drug discovery. IVIG is now used presumptively 
for severe EV71 infection in many Asian countries, even though there are 
almost no data on its efficacy. Several vaccine candidates are under 
development but how to make sure they ultimately reach the paediatric 
populations that really need them remains an important issue. Public health 
intervention and control measures of EV71 epidemics so far have been 
empirical and generic in nature; but they have a significant socioeconomic 
impact.
7.8 Future Direction
Across Asia a range of approaches to diagnosis is used, with different 
techniques and different controls; standardisation via some form of 
laboratory network with proficiency panels to allow comparability between 
laboratories and ensure quality control may prove useful. There are relatively 
good animal models of neurological disease caused by EV71, but there is an 
urgent need for an animal model of cardiorespiratory dysfunction to help
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understand pathogenesis better. IVIG is an expensive and potentially 
dangerous treatment, but is being widely in Asia. A clinical trial aimed at 
examining the efficacy of IVIG is urgently required. Evidence-based clinical 
practise guidelines on best approaches to diagnosis and treatment would 
considerably help the management of this fascinating emerging neurological 
infectious disease. Further research on the transmission dynamic of the virus 
is needed to guide the best public health intervention strategies to limit the 
havoc wreaked by future EV71 outbreaks.
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Figure 7.1 Collection of vesicular fluid from palmar lesions for 
virological diagnosis of hand foot and mouth disease
The hand is gripped firmly to prevent movement, the skin stretched slight 
and a small needle is used to puncture the vesicle (left); a clean swab is then 
applied to collect the fluid released, before placing into viral transport 
medium (right). (Photos T Solomon)
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Figure 7.2 Distribution of HFMD cases, and enteroviruses isolated from 
sentinel clinics in Sarawak, Malaysia from March 1998 through 
December 2008
The top panel shows the distribution of cases of HFMD seen in sentinel 
clinics. The bottom panel shows the distribution of EV71 isolates. Adapted 
from (Podin et al. 2006; Solomon et al. 2010)
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Figure 7.3 Phylogenetic analysis of enterovirus 71 VP1 gene sequences.
A neighbor-joining tree constructed using the Kimura-2 parameter as a
model for nucleotide substitution. The robustness of the tree was determined 
by bootstrapping using 1000 pseudoreplicates.. Sequences are labeled 
according to the following convention: “GenBank accession number” - 
“Country of origin” - “Year of isolation”. The scale bar represents 
nucleotide changes per site per year.
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Figure 7.4 The postulated pathogenesis of enterovirus 71 associated 
acute pulmonary oedema
Major postulated pathogenic pathways are shown with thick lines; lesser 
contributory pathways are shown with thinner lines. The solid boxes indicate 
strong supporting evidence from human clinical or pathological studies, 
whilst the dotted boxes indicate hypothetical but unproven steps or evidence 
from animal models only.
EV71: human enterovirus 71 
BBB: Blood brain barrier 
CNS: central nervous system
It: markedly high; SYR: systemic vascular resistance 
SBP: systemic blood pressure 
HR: heart rate 
LV: left ventricular
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Figure 7.5 The effect of public health interventions on hand foot and 
mouth disease outbreaks
The effect of public health interventions on hand foot and mouth disease 
outbreaks, comparing sentinel surveillance data from the 2003 outbreak in 
Sarawak Malaysia when the public health response was limited, and the 2006 
outbreak, when more rigorous social distancing measures were encouraged.
epid week
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Human Enterovirus 71 Disease in Sarawak, Malaysia: 
A Prospective Clinical, Virological, and Molecular 
Epidemiological Study
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Background. Human enterovirus (HEV)-71 causes large outbreaks of hand-foot-and-mouth disease with cen­
tral nervous system (CNS) complications, but the role of HEV-71 genogroups or dual infection with other viruses 
in causing severe disease is unclear.
Methods. We prospectively studied children with suspected HEV-71 (i.e., hand-foot-and-mouth disease, CNS 
disease, or both) over 3.5 years, using detailed virological investigation and genogroup analysis of all isolates.
Results. Seven hundred seventy-three children were recruited, 277 of whom were infected with HEV-71, 
including 28 who were coinfected with other viruses. Risk factors for CNS disease in HEV-71 included young age, 
fever, vomiting, mouth ulcers, breathlessness, cold limbs, and poor urine output. Genogroup analysis for the HEV- 
71-infected patients revealed that 168 were infected with genogroup B4, 68 with Cl, and 41 with a newly emerged 
genogroup, B5. Children with HEV-71 genogroup B4 were less likely to have CNS complications than those with 
other genogroups (26 [15%] of 168 vs. 30 [28%] of 109; odds ratio [OR], 0.48; 95% confidence interval [Cl], 
0.26-0.91; P = .0223) and less likely to be part of a family cluster (12 [7%] of 168 vs. 29 [27%] of 109; OR, 0.21; 
95% Cl, 0.10-0.46; P< .0001); children with HEV-71 genogroup B5 were more likely to be part of a family cluster 
(OR, 6.26; 95% Cl, 2.77-14.18; P< .0001). Children with HEV-71 and coinfected with another enterovirus or 
adenovirus were no more likely to have CNS disease.
Conclusions. Genogroups of HEV-71 may differ with regard to the risk of causing CNS disease and the 
association with family clusters. Dual infections are common, and all possible causes should be excluded before 
accepting that the first virus identified is the causal agent.
Since 1997, countries of the Asia-Pacific rim have been 
affected by large outbreaks of human enterovirus 
(HEV)-71-associated hand-foot-and-mouth disease 
(HFMD), which have resulted in hundreds of 
thousands of cases and many deaths [1-7]. HFMD is 
a common exanthema of young children, characterized 
by fever, rash on the palms and bottoms of the feet, 
and ulcers in the oral cavity. Most patients have mild
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cases of disease, but some patients develop severe neu­
rological complications (i.e., aseptic meningitis, acute 
flaccid paralysis, and encephalitis) or systemic disease 
(i.e., shock and cardiac dysfunction). HFMD is caused 
by enteroviruses (genus Enterovirus, family Picornovir- 
idae), particularly Coxsackie A virus (CAV)-IO, CAV- 
16, and HEV-71, which are mostly transmitted by the 
fecal-oral route. Phylogenetic studies have divided 
HEV-71 strains into genogroups A, B, and C, which 
have been further subdivided [4, 8-10]. The incidence 
of CNS disease and other severe complications appears 
to have varied among outbreaks of HEV-71 infection. 
The reason for this is unclear, but differences between 
genogroups [10-12] and coinfection with other viruses, 
such as a newly characterized adenovirus [1, 13], have 
been postulated. However, comparisons between out­
breaks have been hampered by the retrospective nature
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of many studies and differences in inclusion criteria, definitions 
of severe disease, and viral diagnostic capabilities. We conducted 
a prospective, clinical, diagnostic, and molecular virological 
study of HEV-71-associated HFMD in 1 context for 3.5 years. 
We focused on risk factors for neurological disease and the 
putative role of different HEV-71 genogroups and dual infec­
tions in pathogenesis.
MATERIALS AND METHODS
Setting. The study was conducted at the pediatric wards and 
intensive care unit at Sibu Hospital (Sarawak, Malaysia); it 
commenced in January 2000 and continued for 3.5 years. This 
550-bed hospital serves Sibu (population, 200,000) and receives 
referrals from district hospitals in the Rejang basin (total pop­
ulation, ~650,000). The study was approved by the Director of 
Health for Sarawak (Malaysia) and the Ethics Committee of 
the Liverpool School of Tropical Medicine (Liverpool, UK). 
Informed consent was obtained from each child’s accompa­
nying parent or guardian.
Case definitions. Because enteroviruses can cause HFMD, 
CNS infection, or both, children (age 1 month to <12 years) 
were screened for both of these conditions. Children with 
HFMD were classified according to an algorithm as having mild 
HFMD, severe non-CNS-HFMD, or HFMD with CNS com­
plications (figure 1). Children with suspected CNS infection, 
but no HFMD, were classified as having aseptic meningitis 
(ASM) or viral encephalitis on the basis of clinical and CSF 
findings; however, there were no children with enterovirus in­
fection in this last group; thus, they are not discussed further.
Clinical methods. A detailed history was recorded, and a 
clinical examination was performed by a pediatrician of the 
study team who looked especially for mucocutaneous lesions 
and cardiovascular and neurological signs; all details were re­
corded on standardized forms. For viral culture, specimens were 
swabbed from the throat and rectum of every patient, as well 
as from at least 1 of the vesicles on the skin and oral ulcers (if 
present). Blood samples were obtained for viral studies. In pa­
tients with severe disease, complete blood cell count, urea level, 
electrolyte level, and glucose level were determined, and elec­
trocardiography and echocardiography were performed. CSF 
specimens were examined for cell count and differential, pro­
tein level, and glucose level, and Gram stain, bacterial culture, 
and viral studies were performed; lumbar puncture was re­
peated if there was a strong clinical suspicion of viral CNS 
infection and if the initial examination was not confirmatory. 
Lumbar puncture was delayed in patients who were severely 
unhealthy. Patients were examined daily, or more frequently 
(as indicated), by a member of the study team. Children with 
HFMD and CNS complications were treated with intravenous 
immunoglobulin (IVIG; Intragam P-CSL, which is derived
from local Malaysian blood donors), on a presumptive basis 
[1, 14], at the discretion of the treating physician.
Virological methods. Viral isolation was attempted on all 
swab specimens, CSF specimens, and any serum samples re­
maining after other investigations had been completed through 
the inoculation of rhabdomyosarcoma (Rd) and 293 cells [13]. 
Isolated enteroviruses were typed by nucleotide sequencing of 
VP1 and VP4 genes [8, 15] and genogrouped by phylogenetic 
analysis [8-10]. Adenoviruses were cultured and typed in ac­
cordance with the methods described previously [13]. Paired 
serum samples (obtained on the day of admission, on day 7, 
or on the day of discharge) and CSF specimens were also tested 
for IgM against dengue and Japanese encephalitis virus (JEV) 
in parallel, using an IgM capture ELISA [16]. Seroconversion 
from a negative result to a positive result for a second sample 
or an increasing IgM optic density was considered evidence of 
acute infection; antibody in the CSF was diagnostic of flavivirus 
CNS infection [17, 18]. A decreasing IgM optic density was 
considered evidence of a recent infection, and low IgM optic 
density in the serum of children recently vaccinated against JEV 
was ascribed to vaccination.
Statistical analysis. Normally distributed data were com­
pared using Student’s t test; data that were not normally dis­
tributed were compared by the Mann-Whitney U test (Staview 
4.02; Abacus Concepts). Differences between proportions were 
tested using the x2 test with Yates’s correction or Fisher’s exact 
test (Epilnfo, version 6; Centers for Disease Control and Pre­
vention). Variables that might relate to disease pathogenesis 
that were associated with CNS disease in univariate analyses 
were also examined in a stepwise logistic regression (SPSS soft­
ware, version 9; SPSS).
RESULTS
Epidemiology
During the study, 773 children (485 boys [63%]) were recruited. 
Five hundred forty children (70%) had mild HFMD; 83 (11%) 
had severe HFMD with no CNS complications; 102 (13%) had 
HFMD with CNS disease, 3 of whom died; and 48 (6%) had 
ASM, 1 of whom died. Most of the children were recruited 
during 2 large outbreaks of HEV-71-associated HFMD during 
2000, 2001, and 2003 (figure 2). Genogroup analysis showed 
that in the outbreak that occurred during 2000-2001, most 
HEV-71 isolates belonged to genogroup B4 [9, 10], and some 
belonged to Cl. In 2003, in addition to genogroup Cl strains, 
a previously undescribed genogroup, which has been named 
B5, emerged during the outbreak.
Most of the patients entered the study once, but 4 boys were 
admitted to the study twice. For the purposes of analysis, each 
hospitalization was considered to be a separate entity. Thirteen 
other children had also been hospitalized in the past with
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Figure 1. Algorithm showing the classification of patients in the study. Because human enterovirus (HEV)-71 can cause hand-foot-and-mouth disease 
(HFMD), CNS infection, or both, children with HFMD or suspected CNS infection were studied. Cases of HFMD were classified as mild HFMD, severe 
non-CNS HFMD, and HFMD complicated by CNS disease; children with viral CNS infection were classified as having aseptic meningitis (ASM) or 
viral encephalitis, but there were no children in the latter group infected with enteroviruses during this study. The final number of patients infected 
with HEV-71 in each diagnostic group is shown in the figure. T, temperature. *Herpangina was defined as multiple oral ulcers predominantly affecting 
the posterior parts of the oral cavity.
HFMD (outside the study). For 211 children (27%), there was 
a history of contact with another person infected with HFMD. 
One hundred three children (13%) had at least 1 other child 
in the family (sibling or cousin; maximum, 4) admitted into 
the study and were considered to be part of a family cluster. 
Seventy-seven of the children of these 44 family clusters had 
mild disease, 9 had severe non-CNS HFMD, and 17 had HFMD 
with CNS complications. When the index case of a family clus­
ter could be identified clearly, they were no more or less likely 
to have CNS disease than subsequent cases. Forty-one of the 
children in family clusters had HEV-71 isolated (with only 1 
genogroup isolated from each family); 3 of these children also 
had CAV-16 isolated; thus, in 2 families, both CAV-16 and HEV-
71 were isolated. Twelve other children had CAV-16, and 3 had 
other viruses.
Virology
Dual infections. We attempted virus isolation on 3006 sam­
ples (622 throat swab specimens, 631 rectal swab specimens, 
768 mouth ulcer swab specimens, 706 vesicle swab specimens, 
91 serum samples, and 188 CSF samples) from 672 (87%) of 
the 773 patients seen during the study period. There were no 
important demographic differences between those who were 
investigated and those who were not investigated. Two hundred 
seventy-seven patients (41%) had HEV-71 isolated. Twenty-
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Figure 2. Epidemic curve of 773 children with hand-foot-and-mouth disease (HFMD) and/or aseptic meningitis (ASM) during the period from 1 
January 2000 through 31 July 2003. The continuous line describes the total number of patients recruited into the study each month; the histogram 
below shows the number of patients with a positive virus isolate, who are grouped as follows: human enterovirus (HEV)-71, HEV-71 isolated; HEV- 
71/Coxsackie A virus (CAVH6, HEV-71 and CAV-16 isolated; CAV-16, CAV-16 isolated; CAV, other CAVs isolated, but not CAV-16 or HEV-71; CBV, 
other CBVs isolated but not CAV-16 or HEV-71; and Echo, echoviruses isolated, but not CAV-16 or HEV-71. The inset boxes show the number of 
patients with different genogroups of HEV-71 isolates during the 2000 and 2003 outbreaks.
eight of these patients with HEV-71 had a second virus isolated, 
including 14 patients coinfected with CAV-16 and 9 coinfected 
with other enteroviruses (CAV-4, CAV-5, CA-16, CAV-10, Echo 
25, CBV-1, and CAV-24); 1 of each was coinfected with an oral 
polio vaccine virus, an untyped enterovirus, adenovirus (Ad)- 
1 (isolated from the rectum), Ad7 (rectum), or an unidentified 
virus (isolated from the CSF). CAV-16 was isolated from an 
additional 85 patients, 4 of whom had coinfection; 2 had CBV- 
1 isolated from the throat, and 2 had adenoviruses isolated 
from the rectum (Ad2 in one and Ad4 in the other). Fifty- 
eight patients were infected with other enteroviruses, adeno­
viruses, or unidentified viruses (12 of whom had multiple vi­
ruses isolated). Most of the presenting clinical features of the 
HEV-71-infected and virus-isolation-negative patients were 
similar, with the exception of 26 (10%) of the 252 patients who 
had no virus isolated and had seizures, compared with only 6 
(2%) of the 263 patients infected with HEV-71 (OR, 0.20; 95% 
Cl, 0.07-0.53; Pc.OOl).
Seven hundred sixteen patients had serum samples, and, 
when available, CSF specimens (233 patients) tested for anti­
bodies to JEV and dengue. Three patients had serological evi­
dence of acute JEV infection, including a girl with mild HFMD 
and HEV-71 isolated from vesicles and the throat and a boy 
with mild HFMD and fever who had HEV-71 isolated from 
vesicles and CAV-16 isolated from the throat that had acute 
peripheral JEV infection (seroconversion in the serum). In ad­
dition, an 18-month-old boy with HFMD and CNS disease 
(manifested by a generalized seizure and a CSF pleocyte level 
of 10 cells/jiL) had CAV-16 isolated from a vesicle, which se- 
roconverted to JEV in both the serum and CSF; he made a full 
recovery. Three patients had acute dengue. All had HFMD and 
CNS disease (defined as lethargy, irritability, and CSF pleocy­
tosis) and HEV-71 isolated (1 from the CSF, 1 from the throat 
and vesicles, and 1 from vesicles and the rectum). Dengue was 
diagnosed by IgM seroconversion, but there was no dengue 
antibody in the CSF. Two patients with HFMD had serological 
evidence of a recent JEV infection or recent vaccination, and 
6 patients had serological evidence of recent dengue. Only 2 
of the children with CAV-16 and HFMD had CNS disease; 1 
of these was the child coinfected with JEV described above and
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Figure 3. Neighbor-joining phylogenetic trees of human enterovirus (HEV}-71 strains isolated in this study. A, Tree based on the alignment of a 
partial VP1 (nucleotide positions 2442-3281) or complete VP1 (nucleotide positions 2442-3332) gene sequences. The tree shows 14 representative 
strains isolated in this study (boxed) and representative HEV-71 strains for other genogroups. B, Tree based on the alignment of a partial VP4 (nucleotide 
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(DNASTAR).
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for the other child, CAV-16 was isolated from rectal and vesicle 
swab specimens, and CBV-1 was isolated from the throat.
HEV-71 genogroups. Phylogenetic analysis of all 277 HEV- 
71 isolates showed that 168 (61%) of the isolates belonged to 
genogroup B4 (165 of these were isolated in 2000,1 was isolated 
in 2002, and 2 were isolated in 2003), and 68 (25%) of the 
isolates belonged to Cl (4 of these were isolated in 2000, and 
64 were isolated in the 2003 outbreak); in addition, 41 HEV- 
71 strains (15%) isolated in 2003 were from a new genogroup 
(B5) that emerged during the course of the study [9, 19, 20]. 
Neighbor-joining trees of the VP1 (figure 371) and VP4 (figure 
3B) genes revealed that representative HEV-71 strains from all 
3 genogroups (B4, B5, and Cl), described at Sibu, clustered 
tightly with bootstrap support values >90% and >70%, 
respectively.
Clinical Features of HEV-71 Infection
Nearly two-thirds of the patients with HEV-71 infection had 
mild HFMD; 12% had severe non-CNS disease, 19% had 
HFMD with CNS disease, and only 1% had ASM (table 1). For 
the purposes of analysis, patients with CNS infection, defined 
by a CSF pleocytosis (with or without HFMD), were compared 
with patients with no CNS disease (including mild and severe 
non-CNS HFMD). Patients with CNS disease were younger 
and were more likely to give a history of fever, vomiting, mouth 
ulcers, breathlessness, cold limbs, poor urine output, and neu­
rological features, including altered sensorium and seizures (ta­
ble 1). During examination, patients with CNS disease were 
more likely to look toxic, be dehydrated and febrile, have altered 
consciousness, and experience neck stiffness, but they were less 
likely to have mouth ulcers (table 2). Excluding the 4 patients 
with ASM and no rash did not significantly alter these findings. 
The CSF was examined in 90 children (34%) infected with 
HEV-71, of whom 56 (62%) had a CSF WBC count >5 cells/ 
jaL. For these patients, the median WBC count was 75 cells/ 
fxL (range, 6-1090 cells/juL). Typically, this was a lymphocytic 
CSF with a normal glucose ratio, but 12 (21%) had neutrophil 
predominance, and 10 (18%) had a CSF to plasma glucose 
ratio <50%.
Three children had HFMD complicated by acute flaccid pa­
ralysis; 1 had HEV-71-B4 genogroup isolated from his throat, 
and the 2 others had negative culture results. Sixty-two children 
with severe HFMD had cardiac enzyme levels measured (27 
children with HEV-71). Seventy-eight of the 233 patients with 
more severe HFMD were treated with IVIG on a presumptive 
basis, including 42 patients who were infected with HEV-71. 
Five patients with HEV-71 required ionotropic support, and 3 
required ventilation. Four children died, including 2 who had 
HEV-71 isolated (1 genogroup B4 and 1 genogroup Cl).
Pathogenesis of Neurological HEV-71 Disease
Children from whom HEV-71 and another virus were isolated 
were no more likely than those with HEV-71 alone to have 
neurological involvement (2 [7%] of 28 vs. 54 [22%] of 249; 
OR, 0.28; 95% Cl, 0.04-1.26; P = .1167). Repeating this anal­
ysis excluding children with only rectal isolates (which could 
represent continued carriage rather than acute pathogenic in­
fection) did not alter these findings (2 [7%] of 28 vs. 47 [21%] 
of 226; OR, 0.29; 95% Cl, 0.05-1.34; P - .1407). All 3 of the 
children with HEV-71 and serological evidence of acute dengue 
infection had HFMD with CNS disease, compared with 52 
(20%) of 264 HEV-71-infected children with no dengue in­
fection (P = .008). In contrast, the 2 HEV-71—infected children 
with serological evidence of JEV infection (as shown by sero­
conversion in the serum) had HFMD with no CNS disease, 
compared with 55 (21%) of 266 children with no JEV infection 
(P= 1).
To examine the possible role of different HEV-71 genogroups 
in the clinical phenotype of HEV-71 infection, we determined 
the likelihood of CNS disease for each genogroup. Children 
with B4 genogroup were less likely to have CNS infection than 
were those with other genogroups; 26 (15%) of 168 children 
infected with genogroup B4 had CNS infection, compared with 
30 (28%) of 109 with other genotypes (OR, 0.48; 95% Cl, 0.26- 
0.91; P = .0223) (table 2). Pair-wise comparisons of the gen­
ogroups showed that this occurred because genogroup B4 was 
associated with less risk of CNS disease than genogroup Cl (26 
[15%] of 168 vs. 19 [28%] of 68; OR, 0.47; 95% Cl, 0.23-0.98; 
P — .0429), whereas there was no altered risk for genogroup 
B4 versus B5 (26 [15%] of 168 vs. 11 [27%] of 41; OR, 0.50; 
95% Cl, 0.21-1.21; P = .139) or for B5 versus Cl (11 [27%] 
of 41 vs. 19 [28%] of 68 (28%]; OR, 0.95; 95% Cl, 0.36-2.45; 
P — ,9240). Children with HEV-71 genogroup B4 were also 
less likely to be part of a family cluster; 12 (7%) of 168 children 
with genogroup B4 positive were in family clusters versus 29 
(27%) of 109 children with other genogroups (OR, 0.21; 95% 
Cl, 0.10-0.46; P< .0001). In contrast, those with B5 genogroup 
were more likely to be part of a family cluster; 17 (41%) of 41 
children with genogroup B5 were in a cluster versus 24 (10%) 
of 236 children with other genogroups (OR, 6.26; 95% Cl, 2.77- 
14.18; P< .0001). Genogroup, age, and being part of a family 
cluster were initially entered into a multiple logistic regression 
model; increasing age and genogroup B4 versus Cl were as­
sociated with a reduced risk of CNS infection (table 3), whereas 
being in a family cluster did not affect risk.
DISCUSSION
Since 1997, HEV-71 infection has become a major public health 
problem in developed and developing countries in the Asia- 
Pacific region, and it has the potential to spread further. Mo-
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Table 3. Multivariate logistic regression analysis of variables 
associated with CNS disease in human enterovirus (HEV)-71 
infection.
Characteristic /3 Coefficient OR (95% Cl) P
Age -0.022 0.978 (0.962-0.996) .015
Genogroup Cl vs. B4 0.751 2.12 (1.070-4.202) .031
Genogroup B5 vs. B4 0.795 2.215 (0.972-5.048) .058
NOTE. Genogroup, age, and being part of a family cluster were initially 
entered into a multiple logistic regression model. Terms were entered into the 
model and remained only if they were statistically associated with CNS disease 
(P< 05). Both forward selection and backward elimination methods were 
used. Increasing age and genogroup B4 versus Cl were associated with a 
reduced risk of CNS infection, whereas being in a family cluster did not affect 
risk. Forward selection and backward elimination procedures generated the 
same model, indicating its robustness. The Hosmer-Lemeshow statistic indi­
cated a nonsignificant lack of fit ix2. 8.338; P = 401).
lecular epidemiological studies have documented remarkable 
changes in the circulating HEV-71 genogroups in the Asia- 
Pacific region during this time (9, 10,21-23]. However, whether 
such genetic differences explain the differing clinical presen­
tations is not clear [4, 24]. Other postulated factors include 
differences in pre-existing immunity of the pediatric population 
[25], differences in host genetic susceptibility [12, 26, 27], and 
coinfection with other viruses [1]. Our detailed investigation 
of 773 patients, which included 277 patients with HEV-71 in­
fection, has produced intriguing clinical epidemiological evi­
dence and suggests that the behavior of genogroups of HEV- 
71 may differ. Children infected with genogroup B4 were less 
likely to present with CNS infection than those infected with 
Cl or B5 and were also less likely to be part of a family cluster. 
In contrast, children infected with B5 were more likely to be 
part of a family cluster, and there was a trend towards a greater 
incidence of CNS disease in these patients.
However, our findings must be interpreted with caution. 
Although we attempted to minimize confounding variables, 
there were factors beyond our control. In particular, the like­
lihood of children presenting to the hospital with HFMD may 
have varied during the study, although altered referral rates 
would be unlikely to explain the different risk of family clus­
tering for the different genogroups. There may also have been 
other inherent features that differed between the cohort studied 
in 2000 and 2003, although the basic demographic features 
were similar (data not shown).
Our study has also confirmed findings from earlier reports 
that young age, fever, vomiting, and hyperglycemia are asso­
ciated with severe HEV-71 infection [28, 29]; in addition, we 
found tachycardia, breathlessness, and the absence of mouth 
ulcers were associated with CNS disease. Overall, the incidence 
of severe disease was milder in our study than in previous 
studies, because only 4 fatalities occurred in our study, all of 
which were a result of pulmonary edema. In addition, our series
was unusual in having only 4 patients with pure aseptic 
meningitis.
Our study has also made an important contribution to the 
debate about the role of dual infections in viral CNS disease. 
As others have shown previously [30], we found several en­
teroviruses were cocirculating during the HFMD outbreaks. We 
also documented instances of coinfection of HEV-71 with other 
enteroviruses in individual patients. We found no evidence of 
an increased likelihood of CNS disease in such patients, al­
though we did find an intriguing association of coinfection 
with dengue viruses and neurological presentation. Previously, 
we postulated that a new adenovirus type 21 might make an 
important contribution to fatal disease during an HEV-71- 
associated HFMD outbreak [1, 13]; in this new study, we iso­
lated adenoviruses from only 4 patients, and none was ade­
novirus type 21. Our rigorous investigations for multiple viral 
agents showed the importance of pursuing all possible avenues 
before attributing causation to the first pathogen encountered. 
For example in 2 children, CNS disease would have been at­
tributed to CAV-16, which is an unusual cause of CNS disease, 
had our thorough diagnostic examination not revealed alter­
native, more likely viral causes (JEV in 1 child and CBV-1 in 
the other). Whether unsuspected dual infections lie behind 
other unusual manifestations of common, relatively benign en­
teroviruses, such as acute flaccid paralysis recently attributed 
to CAV-24 [31], is not known .
In summary, our detailed study provides clinical epidemi­
ological evidence for different biological behavior of HEV-71 
genogroups, with regard to transmissibility within families and 
risk of CNS disease. It also highlights the importance of detailed 
investigations for multiple pathogens during HFMD outbreaks. 
Only with such thorough investigations will the pathophysi­
ology of HEV-71 be fully determined.
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Human enterovirus 71 and coxsackievirus A16 are important causes of hand-foot-and-mouth disease 
(HFMD). Like other enteroviruses, they can be isolated from a range of sterile and nonsterile sites, but which 
clinical sample, or combination of samples, is the most useful for laboratory diagnosis of HFMD is not clear.
We attempted virus culture for 2,916 samples from 628 of 725 children with HFMD studied over a 3 1/2-year 
period, which included two large outbreaks. Overall, throat swabs were the single most useful specimen, being 
positive for any enterovirus for 288 (49%) of 592 patients with a full set of samples. Vesicle swabs were positive 
for 169 (48%) of 333 patients with vesicles, the yield being greater if two or more vesicles were swabbed. The 
combination of throat plus vesicle swabs enabled the identification of virus for 224 (67%) of the 333 patients 
with vesicles; for this patient group, just 27 (8%) extra patients were diagnosed when rectal and ulcer swabs 
were added. Of 259 patients without vesicles, use of the combination of throat plus rectal swab identified virus 
for 138 (53%). For 60 patients, virus was isolated from both vesicle and rectal swabs, but for 12 (20%) of these, 
the isolates differed. Such discordance occurred for just 11 (10%) of 112 patients with virus isolated from 
vesicle and throat swabs. During large HFMD outbreaks, we suggest collecting swabs from the throat plus one 
other site: vesicles, if these are present (at least two should be swabbed), or the rectum if there are no vesicles.
Vesicle swabs give a high diagnostic yield, with the added advantage of being from a sterile site.
Hand-foot-and-mouth disease (HFMD) is a common febrile 
illness in young children and is characterized by lesions on the 
skin and oral mucosa. The skin rash, which may be maculo- 
papular or vesicular, typically occurs on the palms and soles 
but can also involve the buttocks, elbows, and knees. Mouth 
ulcers are the most common enanthema, but some patients 
have herpangina (multiple oral ulcers affecting predominantly 
the posterior part of the oral cavity), and others have no oral 
lesions (16, 20).
Many human enteroviruses (family Picornaviridae, genus En­
terovirus) can cause HFMD, but human enterovirus 71 
(HEV71) and the closely related coxsackievirus A16 (CVA16) 
are the most important (16, 20). Since the late 1990s, HEV71 
has caused a series of large HFMD epidemics in the Asia- 
Pacific region, associated with a rapid fulminant course, severe 
neurological complications, and a large number of fatalities 
(1-4, 8-11, 14, 17, 18, 21). CVA16 causes a similar clinical 
illness initially, but neurological and other severe complica­
tions are extremely rare (5). In much of Asia, there is now 
epidemiological and virological surveillance for HFMD so that 
effective public health measures, such as closing nurseries and 
schools, can be instituted early. However, because of the sim-
* Corresponding author. Mailing address: Department of Paediatrics, 
Sibu Hospital, Ulu Oya Road, 96000 Sibu, Sarawak, Malaysia. Phone: 6 
084 343333. Fax: 6 084 337 354. E-mail: monghow@pd.jaring.my. 
v Published ahead of print on 19 April 2007.
ilar clinical presentations of the viruses, establishing the actual 
cause of HFMD cases relies on laboratory identification of the 
virus. Diagnostic techniques include isolating the virus in sus­
ceptible continuous cell lines or detecting viral RNA by PCR 
(12, 28). Though laborious and time consuming, virus isolation 
remains the gold standard for enterovirus diagnosis; it is 
cheaper than PCR and is the most widely used method, par­
ticularly in developing countries.
There is a wide range of samples from which virus isolation 
can be attempted, including rectal and throat swabs, serum, 
and cerebrospinal fluid (CSF) (when taken) and vesicles and 
ulcers when they are present. However, for HEV71-associated 
HFMD outbreaks, there has been relatively little work exam­
ining which sample, or combination of samples, is the most 
useful. This question becomes especially important in the con­
text of large outbreaks with many thousands of patients. Rectal 
and throat swabs are available for all patients and do not 
require the presence of mucocutaneous stigmata. However, 
they have the disadvantage that, because they are not sterile 
sites, isolation of virus there may represent coincidental 
asymptomatic carriage rather than the causative agent (24): 
many enterovirus infections are asymptomatic, and viral shed­
ding may persist for up to 2 weeks from the throat and up to 11 
weeks from the rectum (7, 20, 24). In the absence of virus 
isolation from a sterile site, isolates from nonsterile sites are 
usually accepted as surrogate markers for enterovirus infec-
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tions (20,22,24), but there is little data available on the validity 
of this approach for HEV71-associated HFMD. We therefore 
set out to answer three important clinical microbiological ques­
tions during a 3 1/2-year prospective clinical and diagnostic 
study of HFMD, which included two large outbreaks: first, 
which single specimen is most often positive for the different 
HFMD patient groups; second, which combination of samples 
is the most efficient in terms of diagnostic yield; and third, how 
reliable samples from nonsterile sites are compared with those 
from sterile sites.
MATERIALS AND METHODS
Clinical and laboratory methods. Between January 2000 and July 2003, we 
studied all children with HFMD in the pediatric ward and intensive care unit at 
Sibu Hospital, Sarawak, Malaysia. Children were defined as having HFMD if 
they had new onset of at least one of the following: maculopapular and/or 
vesicular rash on the palms and/or soles, vesicles or ulcers in the oral cavity, or 
herpangina (defined as multiple oral ulcers affecting predominantly the posterior 
parts of the oral cavity). All children with HFMD admitted into the hospital were 
assessed by the pediatricians of the study team. A detailed history and results of 
a clinical examination, including an examination for mucocutaneous lesions, 
were recorded on standardized forms. A rectal swab and a throat swab were 
taken for each child. The skin was examined carefully for vesicles, and the oral 
cavity for ulcers; if they were present, swabs were taken from at least one of each 
(usually the largest and most accessible lesions). Rectal swabs were taken with a 
gentle circular motion on the rectal wall. Throat swabs were taken with the aid 
of a tongue depressor, by carefully swabbing the lateral and posterior pharynx 
without touching the tongue or buccal mucosa. For vesicle swabs, the skin was 
cleaned gently with 0.9% sterile normal saline, but not with alcohol, which kills 
viruses. A sterile 24-gauge needle was used to rupture the vesicle, and a swab was 
used to absorb the fluid. Alternatively, the swab was gently rolled over the vesicle 
to squeeze out fluid. Mouth ulcers were sampled by rolling the swab over the 
floor of the ulcer. When more than one vesicle or ulcer was swabbed, a fresh 
swab was used for each lesion and put into a separate tube of viral transport 
material, because we were interested in the yield from each swab. Swab samples 
were collected by study team members or by nursing staff, after training,
CSF and serum were collected from children with suspected central nervous 
system (CNS) involvement if they had a history of fever, or fever on examination 
{&38°C), and at least one of the following: toxic and ill in appearance, recurrent 
vomiting (at least twice), tachycardia (heart rate, >150/min), breathlessness, 
poor perfusion (cold, clammy skin), reduced consciousness (irritability, lethargy, 
drowsiness, coma), limb weakness, meningism (neck stiffness or positive Kernig’s 
sign), or seizures.
The clinical samples were stored immediately in a -70°C freezer until further 
testing. Out of hours, when immediate storage at — 70I>C was not possible, clinical 
samples were stored at 4°C overnight and were transferred to a -70°C freezer 
the following morning. Five percent of samples were handled in this way, but 
their isolation rates did not differ significantly from those of other samples. Virus 
isolation was attempted for all swabs and for CSF and any serum which had 
adequate volume. Specimens were inoculated into rhabdomyosarcoma (RD) and 
293 cells as described previously (1, 19). Enteroviruses isolated were typed by 
nucleotide sequencing of the VF1 or the VP4 genes (2, 13).
For the purposes of analysis, swabs from herpangina lesions were grouped with 
those from other mouth ulcers. Vesicles, serum, and CSF were considered sterile 
sites, and the throat, mouth ulcers, and the rectum were considered nonsterile 
sites. All samples were investigated, irrespective of the results for other samples 
from the same patient.
Analytical approach. The patients were divided into four groups according to 
their presenting mucocutaneous lesions and, thus, the availability of samples: 
those with a papulovesicular rash and mouth ulcers (referred to hereafter as 
HFMD with vesicles and ulcers), those with a papulovesicular rash only (HFMD 
with vesicles), those with a maculopapular rash and mouth ulcers only (HFMD 
with ulcers), and those with maculopapular rash only (HFMD with maculopap­
ular rash). As we were interested in which combination of samples gives the best 
diagnostic yield, we adopted a stepwise approach to the analysis for each patient 
group. First, we determined which sample type gave the most positive results. 
Then we looked at the remaining undiagnosed patients and determined which of 
the remaining samples gave the most positive results. We continued in this 
manner until all sample types had been assessed. We decided to use data from 
the first outbreak to determine the usefulness of different samples and combi-
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TABLE 1. Relationship between the number of vesicle and ulcer 
swabs collected and the number positive
Sample type No. of swabs per patient
No. of patients with at least one 
swab positive/no. of patients 
tested (%)
Vesicle 1 62/177 (35)
2 40/81 (49)
3 18/30 (60)
>4 46/61 (75)
Ulcer 1 26/152 (17)
2 21/103 (20)
3 37/77 (48)
5:4 13/40 (33)
nations of samples. We then applied these findings to the second outbreak to see 
if the predicted samples remained useful. However, the sample analysis was not 
begun until the end of the study, to avoid any bias in sample collection.
Statistical analysis. Statistical analysis was performed by using the statistical 
software Statview 4.02 (Abacus Concepts, Inc.). Sensitivity, specificity, positive 
predictive value, and negative predictive value were calculated from a 2 X 2 
table.
Ethical approval. The study was approved by the Director of Health for 
Sarawak (Malaysia) and the Ethics Committee of the Liverpool School of Trop­
ical Medicine (Liverpool, United Kingdom). Informed consent was obtained 
from each child’s accompanying parent or guardian.
RESULTS
Seven hundred twenty-five patients were entered into the 
study: 471 (299 [63%] males, with a median age of 28 months 
[range, 4 to 120 months]) were enrolled in the first half (the 
majority from an outbreak between January 2000 and March 
2001) and 254 (158 [62%] males, with a median age of 28 
months [range, 2 to 153 months]) were enrolled in the second 
half (mostly during an outbreak between January and July 
2003). The 471 patients in the first half of the study included 
110 patients with vesicles and ulcers, 112 patients with vesicles 
only, 78 patients with ulcers only, and 171 patients with a 
maculopapular rash only. Of the 254 patients in the second half 
of the study, 98 had vesicles and ulcers, 29 had vesicles only, 87 
had ulcers only, and 40 had a maculopapular rash only. The 
median duration of illness before admission was 2 days (range, 
0 to 8 days) and did not differ significantly between patient 
groups.
Virology results. We attempted viral isolation for 2,916 sam­
ples: 1,666 samples from 389 (83%) of the 471 patients in the 
first half of the study and 1,250 samples from 239 (94%) of the 
254 patients in the second half of the study. For most patients, 
a single throat swab and single rectal swab were cultured. In 
addition, for 127 patients with vesicles, at least one (median, 2; 
range, 1 to 10) vesicle was investigated, and for 185 patients 
with ulcers, at least one (median, 2; range, 1 to 6) ulcer sample 
was investigated. For a single swab, 35% of vesicle and 17% of 
ulcer samples were positive (Table 1), but the percentages 
increased as more swabs were taken.
The number of patients tested for each sample type and the 
number that tested positive for any enterovirus, for HEV71, 
and for CVA16 are shown in Table 2. During the first half of 
the study, a throat swab was most likely to be positive (being 
positive for any enterovirus for 191 [52%] of 367 patients), 
followed by vesicle, ulcer, and then rectal swabs. During the
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TABLE 2. Positive isolation rates for different viruses according to sample type"
No. of patients with positive results/total no. of patients tested (%)
Sample
type
First half of study (?! = 471) Second half of study (n ~ 254)
HEV71 
(n = 167)
CVA16 
(» = 80)
Any HEV 
(n = 255)
All
(« - 389)
HEV71 
(« = 106)
CVA16 
{n = 19)
Any HEV 
(n = 153)
All
{n = 239)
Rectal 65/166 (39) 22/78 (28) 100/252 (40) 100/378 (27) 38/103 (37) 7/16 (44) 68/147 (46) 68/229 (30)
Throat 127/164 (77) 50/76 (66) 191/248 (77) 191/367 (52) 66/104 (64) 9/15 (60) 101/148 (68) 101/231 (44)
Vesicle 66/111 (60) 36/57 (63) 106/167 (63) 106/222 (47) 54/81 (67) 10/13 (77) 63/97 (65) 63/127 (50)
Ulcer 36/85 (42) 11/42(26) 53/129 (41) 53/188 (28) 28/87 (32) 7/15 (47) 44/117 (38) 44/185 (24)
Serum 0/9 (0) 1/3 (33) 1/10 (10) 1/20 (5) 2/26 (8) 1/11 (9) 6/43 (14) 6/61 (10)
CSF 2/43 (5) 0/11 (0) 2/58 (3) 2/96 (2) 0/29 (0) 0/0 (0) 1/42 (2) 1/60 (2)
" The number of patients with positive results for each sample type is shown as a proportion of the HEV71-positive patients, the CVA16-positive patients, all 
HEV-positive patients, and all patients (whether their samples tested positive or negative). Eleven patients in the first half of the study and three in the second half 
of the study had co-isolation of HEV71 and CVA16.
second half of the study, vesicle swabs were most likely to be 
positive (positive for any enterovirus for 63 [50%] of 127 pa­
tients), followed by throat, rectal, and then ulcer swabs. Most 
viruses (>95%) were isolated following a single passage.
In the first half of the study, 167 (65%) of 255 patients with 
positive viral isolation were HEV71 positive (11 of whom were 
also infected with CVA16, 2 with CVA4, 2 with CVA24, and 1 
with adenovirus 7 [Ad-7]); CVA16 was isolated from a further 
69 patients (2 of whom were also infected with another virus). 
In addition, 19 patients were infected with other enteroviruses, 
Ads, or unidentified viruses (6 of whom had multiple viruses 
isolated). In the second half of the study, 106 (44%) of 239 
patients had HEV71 isolated, 10 of whom had a second virus 
isolated: there were 3 with CVA16, 2 with CVA5, and 1 each 
with CVA10, poliovirus 1 Sabin vaccine strain, Ad-1, an un- 
typeable enterovirus, and an unidentified virus. CVA16 was 
isolated from 16 further patients (2 of whom were also infected 
with a second virus, Ad2 or Ad4). In addition, 31 patients were 
infected with other enteroviruses, Ads, or unidentified viruses 
(4 of whom had multiple viruses isolated). For most patients 
with multiple isolates, the viruses came from different clinical 
samples; however, in 20 cases, two viruses were isolated from 
the same clinical sample. These comprised nine rectal swabs, 
five throat swabs, and two ulcer swabs, which gave different 
isolates in different cell lines; in addition, four patients with 
mild HFMD had two different viruses grown from different 
vesicles (three with HEV71 and CVA16 and one with HEV71 
and PIS). The serotyping of enterovirus isolates was repeated 
and verified.
Across the whole study, 79 (51%) of 156 patients who re­
quired CSF examination had elevated CSF cell counts (>5/ 
mm3), but only 3 had virus cultured (two HEV71 and one 
other). Enteroviruses were isolated from the serum of 7 (9%) 
of 81 patients: two of these were identified as HEV71, two as 
CVA16, and one (each) as CVA6, CVA9, and CVA10.
Analysis of sample combinations during the first outbreak. 
Figure 1A shows, for each patient group, the possible incre­
mental increases in the numbers of patients diagnosed virolog- 
ically, by different combinations of samples assessed stepwise 
according to the analytical plan. For this part of the analysis, 
only patients with full sets of samples were studied. For vesicles 
and ulcer swabs, the results for multiple swabs of a single type 
were treated as a single result, so that at least one swab testing
positive was taken as a positive result for that sample type. 
Figure IB shows similar data for a later outbreak.
For the 105 patients with vesicles and ulcers in the first half 
of the study, use of the throat swab alone diagnosed 63 patients 
(60%), whereas use of the vesicle swabs alone would have 
diagnosed 54 patients, the rectal swab alone 29 patients, and 
the ulcer swab alone 26 patients. Throat swabs were therefore 
taken as the first sample (Fig. 1A). The number of patients 
with a virological diagnosis (the diagnostic yield) would in­
crease to 73 patients if the results for vesicle swabs were added 
next, 70 if results for rectal swabs were added, or 68 if results 
for ulcer swabs were added. The vesicle swab results were 
therefore added as a next step. From here, the addition of the 
rectal swab results would increase the yield to 79 patients, 
whereas ulcer swab results would increase it to 75 patients; the 
rectal swab was therefore added next, and the ulcer swab was 
added last, increasing the yield to 82 patients (78%).
For patients with HFMD and a vesicular rash, a throat swab 
was again the most useful single sample, allowing for the di­
agnosis of 57 (52%) of 109 patients. The addition of the rectal 
swab result would increase the diagnostic yield to 70 (64%), 
whereas the addition of the vesicle swab result would increase 
it to 72 (66%). The vesicle swab result was therefore used as 
the second investigation; finally, the addition of the rectal swab 
result increased the number of patients diagnosed to 79 (72%). 
For patients with ulcers only, a throat swab result diagnosed 
virologically 33 (48%) of 69 patients; the addition of either the 
rectal or vesicle swab result increased the diagnostic yield to 38 
patients (55%), and results from the combination of all three 
samples diagnosed 42 patients (61%). Finally, for patients with 
a maculopapular rash only, results from a throat swab alone 
diagnosed 35 (43%) of 82 patients, whereas results from a 
rectal swab alone diagnosed 22 patients. A throat swab was 
therefore used as the first sample, followed by the rectal swab, 
which increased the number of patients diagnosed to 44 (54%) 
of 82 patients.
In Fig. 2A, the proportion of patients diagnosed at each step,by 
use of the best combination of samples as determined above, is 
compared with the total number of samples analyzed at each step. 
It is clear that although the detection rate increased as more 
clinical sample types were included, the number of samples ana­
lyzed increased to a much greater extent. For example, for the 
patients with vesicles and ulcers, 63 patients were diagnosed by
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FIG. 1. Analysis of which combination of samples gave the greatest diagnostic yield for the four groups of HFMD patients, assessed stepwise 
according to the analytical plan during the first half of the study (A) and second half of the study (B). The number (%) of positive patients for 
each sample type at each step is shown; the boxed sample gave the greatest diagnostic yield and thus was the one used for the next step. Only 
patients with complete sets of samples were analyzed. For the first half of the study, this comprised 105 (95%) of 110 HFMD patients with vesicles 
and ulcers, 109 (97%) of 112 with vesicles only, 69 (88%) of 78 with ulcers only, and 82 (48%) of 171 with maculopapular rash. For the second 
half, this comprised 92 (94%) of 98 HFMD patients with vesicles and ulcers, 27 (93%) of 29 with vesicles, 85 (98%) of 87 with ulcers, and 23 (58%) 
of 40 with maculopapular rash. RS, rectal swab; TS, throat swab; US, ulcer swab; VS, vesicle swab.
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FIG. 2. Histograms showing the proportion of patients diagnosed at each step for the different patient groups, using the optimum combination 
of samples as determined in Fig. 1, and the total number of samples analyzed at each step. Panel A shows the first half of the study, and panel 
B shows the second half. T, throat swab; V, vesicle swab; R, rectal swab; U, ulcer swab.
throat swab samples alone (105 samples; 1.7 samples per patient 
diagnosed). The addition of the vesicle swab results enabled the 
diagnosis of a further 10 patients but required the processing of a 
further 264 samples (26.4 samples per patient), the addition of the 
rectal swab results allowed the diagnosis of 6 more patients with 
a further 105 samples (17.5 per patient) processed, and the addi­
tion of ulcer swab allowed the diagnosis of 3 more patients with 
213 additional samples (71 per patient) analyzed. Thus, the total
number of samples needed to be analyzed to diagnose each ad­
ditional patient increased dramatically for each additional sample 
type included.
Recommendation based on the first outbreak. Based on 
these observations, it was decided that during a large outbreak, 
if one wanted to limit the number of samples, the following 
could be recommended. For patients with both vesicles and 
ulcers, most patients (70%) could be diagnosed by investigat-
Dow
nloaded from
 jcm
.asm
.org by on June 4, 2007
Vol. 45, 2007 DIAGNOSIS OF HAND-FOOT-AND-MOUTH DISEASE 1863
TABLE 3. Pairwise comparison of virus isolates grown from a sterile site with isolates grown from nonsterile sites in the same patient"
Result Finding
No. (%) of swabs testing positive from:
Throat (n = 337) Rectum (n = 342) Ulcer (n = 208)
Concordance Same virus isolated as vesicle swab 101 (30) 48(14) 29 (14)
No virus isolated from either swab 111(33) 139 (41) 83 (40)
Total 212 (63) 187 (55) 112 (54)
Discordance Different virus isolated compared with vesicle swab 11(3) 12(4) 4(2)
Vesicle swab negative but sample positive 65 (19) 37 (11) 19 (9)
Vesicle swab positive but sample negative 49 (15) 106(31) 73 (35)
Total 125(37) 155 (45) 96 (46)
" Vesicles were the sterile site; throat, rectum, and ulcers were the nonsterile sites. Many patients had swabs from multiple sites. The total number of patients 
represented here is 349.
ing throat and vesicle swabs, and the addition of rectal or ulcer 
swabs added little value for the extra work and cost involved. 
Similarly, for patients with vesicles only, the combination of 
throat swabs and vesicles gave a good diagnostic yield, and the 
addition of rectal swabs only increased the yield marginally 
(6%). For patients with ulcers only, throat and ulcer swabs or 
throat and rectal swabs were equally useful, but combining all 
three swabs increased the diagnostic yield by only 6%. For 
patients with a maculopapuiar rash only, both throat and rectal 
swabs should be tested.
Application of findings to the second outbreak. The validity 
of these recommendations was tested with data from the sec­
ond outbreak. The same analytic process was applied to deter­
mine which combination of samples gave the best diagnostic 
yield and to see if the recommended combinations would 
prove to be the most useful. Figures IB and 2B show that, for 
the most part, the approach remained valid. For patients with 
vesicles plus ulcers, and for patients with vesicles only, the 
combination of throat and vesicle swabs gave a good diagnostic 
yield (66 and 67%, respectively), with further samples not 
improving the yield greatly. Interestingly, though, for the first 
patient group, vesicles, rather than throat swabs, were the 
single most useful sample. For patients with a maculopapuiar 
rash only, throat swabs and then rectal swabs were most useful. 
However, for those with ulcers only, the addition of rectal 
swabs to throat swabs proved more useful than the addition of 
ulcer swabs, increasing the yield to 41 (48%) of 85 patients 
compared to 36 (42%).
Thus, to summarize the data from both outbreaks together, 
the combination of throat swabs plus vesicle swabs was the 
most useful approach for patients with vesicles (whether or not 
they also had ulcers), identifying virus for 134 (64%) of 208 
patients with vesicles and ulcers and 90 (66%) of 136 patients 
with vesicles only; the combination of throat swab and rectal 
swab was most useful for patients without vesicles (whether or 
not they had ulcers), identifying virus for 79 (51%) of 154 
patients with ulcers only and 59 (56%) of 105 patients with 
maculopapuiar rash only.
Concordance of viral diagnosis between samples. To exam­
ine the concordance of virus isolates from nonsterile sites (rec­
tal, throat, and ulcer swabs) with those from a sterile site 
(vesicle swabs), all HFMD patients with swabs taken from 
vesicles plus another site were studied (Table 3). The isolation 
results from 212 (63%) of 337 patients with throat swabs, 187 
(55%) of 342 with rectal swabs, and 112 (54%) of 208 with
ulcer swabs were in agreement with the results for vesicle 
swabs from the same patients (either the same virus was iso­
lated or no virus was isolated). However, a different virus was 
isolated for 11 (10%) of 112 patients with positive throat and 
vesicle swabs, 4 (12%) of 33 patients with positive ulcer and 
vesicle swabs, and 12 (20%) of 60 patients with positive rectal 
and vesicle swabs. Overall, by taking the vesicle swab as a 
reference, the sensitivity of the throat swabs for isolating the 
same virus was 67%, the specificity was 63%, and the positive 
and negative predictive values were 61% and 69%, respec­
tively. Equivalent values were 31%, 79%, 56%, and 57% for 
the rectal swabs and 28%, 81%, 60%, and 53% for the ulcer 
swabs. The detailed viral isolation results of these patients with 
different viruses isolated from vesicle and nonsterile sites are 
shown in Table 4.
DISCUSSION
The outbreaks of HEV71-associated HFMD which have 
swept across the Asia-Pacific region since 1997 have posed a 
great economic and social burden, not least on the health-care 
facilities and laboratories that have to diagnose and manage 
such patients. To diagnose HEV71 infection, clinicians are 
faced with a wide range of samples to choose from, but there 
has been relatively little work comparing them.
Most of the recent studies of HEV71 infection have relied 
on stool culture and throat swabs and have found the latter to 
have greater sensitivity, with throat swabs being positive for 90 
to 95% and stool culture being positive for 40 to 65% of 
patients tested (6, 26, 27). Few studies have looked systemat­
ically at all samples from a large patient group. One report of 
175 patients with HFMD during the 2000 outbreak in Singa­
pore found that rectal swabs most often yielded virus, followed 
by stool samples, vesicle swabs, and then throat swabs (3). 
However, our study found that in most patient groups, a throat 
swab was the single specimen most likely to be positive, being 
positive for 288 (49%) of the 592 patients with a full set of 
samples and 292 (49%) of all 598 patients studied. Approxi­
mately half of our patients had skin vesicles, and we showed 
that vesicle swabs were also very useful. In patients with vesi­
cles, they gave the second highest yield, being positive for 169 
(48%) of 333 patients studied; in one patient group (during the 
second outbreak), they were the single most sensitive specimen 
(positive for 50%). Vesicle swabs have not been widely used to 
diagnose HFMD previously. One study reported virus isolation
D
ow
nloaded from
 jcm
.asm
.org by on June 4,2007
1864 OOI ET AL. J. Clin. Microbiol.
TABLE 4. Virus isolation results for patients with different viruses grown from sterile and nonsterile sites0
Virus isolated from:
Study no. Age(mo) Gender Clinical severity Sterile site Nonsterile site
Vesicle Serum CSF Rectum Throat Ulcer
HFM-4 46 Male Severe HFMD 
with CNS
HEV71 — NEG HEV71,
Ad-7*
HEV71 HEV71
HFM-9 52 Female Mild HFMD HEV71 CA16 — NEG NEG NEG
HFM-90 37 Female Mild HFMD CVA16 — — NEG CVA16 HEV71
HFM-112 16 Male Mild HFMD HEV71 — — CVA16 HEV71 NEG
HFM-152 45 Male Mild HFMD HEV71, CVA16C — — NEG HEV71 NEG
HFM-174 73 Male Mild HFMD CVA16 — — HEV71 HEV71 NEG
HFM-178 14 Male Severe HFMD 
with CNS
CVA16 — NEG CVA16 CVB1 —
HFM-193 36 Female Severe HFMD, 
no CNS
HEV71 — NEG CVA17 HEV71 —
HFM-198 16 Female Mild HFMD HEV71 — — HEV71,
CVA17rf
HEV71 —
HFM-228 11 Female Mild HFMD CVA10 — — CVA6 CVA6,
CVB5e
NEG
HFM-298 22 Female Mild HFMD CVA10 — — NEG CVB1,
CVAK/
NEG
HFM-302 15 Female Mild HFMD HEV71 — — CVA16 HEV71 HEV71
HFM-328 19 Male Severe HFMD, 
no CNS
HEV71 NEG HEV71 HEV71,
CVA244'
HEV71
HFM-337 36 Male Mild HFMD CVA16 —- — HEV71 HEV71 NEG
HFM-338 27 Male Mild HFMD Unidentified
virus
— — HEV71 CVA16 NEG
HFM-435 11 Male Mild HFMD CVA16 — — NEG NEG HEV71
HFM-489 13 Male Mild HFMD CVA16 — — Ad-4 CVA16 NEG
HFM3-7 38 Male Mild HFMD HEV71, PIS* NEG — NEG HEV71 NEG
HFM3-35 20 Female Mild HFMD HEV71 NEG — CVA5 CVA5
HFM3-63 17 Female Mild HFMD HEV71, CVA16' — — CVA16 NEG CVA16
HFM3-97 61 Male Severe HFMD, 
no CNS
HEV71 — NEG NEG HEV71, 
Untyped EV7
HFM3-161 32 Male Mild HFMD HEV71 — — NEG CVA16 NEG
HFM3464 5 Male Severe HFMD, 
no CNS
NEG — Unidentified
virus
NEG HEV71 HEV71
a Details of dual viruses isolated from a single site by using different cell lines are given below. NEG, negative; PIS, poliovirus 1 Sabin strain; with CNS, with CNS 
involvement; no CNS, no CNS involvement; —, no sample or insufficient sample for testing,
* HEV71 isolated using RD ceils; Ad-7 isolated using 293 cells.
c HEV71 isolated from right palm vesicle using RD cells; CVA16 isolated from left sole vesicle using RD cells.
^ HEV71 isolated using RD cells; CVA17 isolated using 293 cells. 
e CVA6 isolated using RD cells; CVB5 isolated using 293 cells.
^CVBl isolated using RD cells; CVA10 isolated using 293 cells. 
e HEV71 isolated using RD cells; CVA24 isolated using 293 cells.
* HEV71 isolated from right and left palm vesicles using RD cells; PIS isolated from right and left sole vesicles using RD cells.
1HEV71 isolated from right sole vesicles using RD cells; CVA16 isolated from right knee and left sole vesicles using RD cells.
J' HEV71 isolated from lip and tongue ulcers using RD cells; untyped EV isolated from right buccal ulcer using using RD cells.
from four children for whom vesicle swabs were investigated 
(5), and another reported 50% positive vesicles for 62 HFMD 
patients with vesicles (3). But for most outbreaks, vesicle fluid 
was not investigated (8, 11, 18, 21, 27).
Because we wanted to examine the optimal number of le­
sions to sample, in our study we took separate swabs from each 
vesicle. We found a single vesicle was positive 35% of the time, 
but this increased to 49% with two vesicles and 60% with three 
vesicles. Our recommended practice now is to apply a single 
swab to two or more vesicles. This maximizes the chance of 
isolating virus without doubling the number of samples to be 
processed. In our study, approximately half the patients had 
vesicles. They usually appeared early in the illness and resolved 
after a few days, so that their presence may depend on the time 
of presentation. Like previous reports for HEV71 (3, 6, 8, 10, 
15, 18, 27) and other HEVs (20, 24), our study reports a low 
isolation rate of CSF (3 of 102 HFMD patients with aseptic
meningitis). The yield would likely have been higher if PCR 
had been used (23), but this investigation is not available in 
most developing countries. We found that the isolation rate for 
rectal swabs was not as high as that for throat and vesicle 
swabs; the median time of presentation (and thus sampling) 
was just 2 days, which may be before viral shedding in the stool 
has become fully established.
In addition to looking at individual samples, we examined 
which combinations of samples were the most useful. This was 
achieved by determining the extent to which the addition of a 
sample type increased the number of patients diagnosed; this is 
different from asking how frequently a sample is positive. Thus, 
for example, in the first half of the study, although ulcer swabs 
were positive more often than rectal swabs, they were less 
useful diagnostically, because most of the patients in whom 
they were positive had already been diagnosed by a throat 
swab. Determining the “added diagnostic value” of a sample
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type allowed us to produce predictions about which combina­
tions of samples should prove useful, which we were then able 
to test in the second outbreak. We found that our predictions 
were basically sound. Results from the combination of throat 
swabs plus vesicle swabs were the most useful for patients with 
vesicles whether or not they also had ulcers, identifying virus 
for 224 (67%) of 333 such patients across the whole study. For 
these patients, the addition of rectal and ulcer swabs enabled 
the diagnosis of just 27 extra patients (8%). For patients with­
out vesicles (whether or not they had mouth ulcers), the com­
bination of throat swab and rectal swab was most useful, iden­
tifying virus for 138 of 259 such patients (53%). Thus, during 
large outbreaks, we suggest that a throat swab plus one other 
sample type be taken for each patient. If no vesicles are 
present, the second sample type should be a rectal swab, but if 
there are vesicles, a swab should be applied to as many of these 
as possible (but at least two). Although we advocate limited 
sampling, particularly for community surveillance and during 
large outbreaks, for individual patients, especially those that 
are critically ill, physicians will want to maximize the chance of 
obtaining a diagnosis. One approach might be to collect all 
sample types but to investigate them in a stepwise manner, 
starting with the most useful samples, until a diagnosis has 
been made.
During our study, we were also able to examine the concor­
dance of virus isolates from nonsterile sites (rectal, throat, and 
ulcer swabs) with those from a sterile site (vesicle swabs). We 
found that 20% of rectal isolates differed from vesicle isolates 
(in individual patients with isolates from both sites), whereas 
such discordance with vesicle isolates occurred for only 10% of 
throat isolates. While most would accept the virus isolated 
from a vesicle as the causative pathogen, the significance of 
other viruses concomitantly detected from throat and/or rec­
tum is not always clear. One plausible explanation is that the 
isolation of a virus from throat or rectum may be only a con­
founding factor related to asymptomatic carriage or ongoing 
shedding from recent enterovirus infection. Our data show that 
in the majority of patients with HFMD, throat and rectal 
isolates do reflect viruses isolated from sterile sites, but in a 
minority, they may be coincidental infections. However, it may 
not be correct to assume that virus isolated from vesicle is 
always the most important pathogen. For example, one patient 
(HFM-178) (Table 4) with severe HFMD and CNS disease had 
CVA16 isolated from a vesicle swab but CVB1 isolated from a 
throat swab. CVA16, a common cause of HFMD, is not known 
to cause CNS disease; in contrast, CVB1 is not known to cause 
HFMD and, being a species B HEV, is a more likely neuro- 
pathogen (25). So in this patient with dual infection, the two 
virus isolates may have been responsible for two clinical syn­
dromes: the throat isolate CVB1 causing CNS disease and the 
vesicle isolate CA16 causing HFMD. For four patients, we also 
isolated different viruses from different vesicles: three with 
HEV71 and CVA16 and one (with mild HFMD) with HEV71 
and poliovirus 1 Sabin strain. These patients clearly demon­
strate that systemic infection with two viruses can occur simul­
taneously. In addition, the latter case suggests the possibility 
that occasionally during dual infection, viruses may cross tissue 
barriers that they would not normally be able to (poliovirus 
Sabin strain type 1 does not itself cause HFMD and thus is not 
normally found in vesicles) (20). Our findings on dual infection
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underscore the need to look for a possible second pathogen 
before attributing pathogenesis to a virus rarely associated with 
a severe disease phenotype.
In summary, we have shown that the throat swab is the single 
most useful sample from patients with HFMD during an 
HEV71 outbreak. Vesicle swabs, which have been relatively 
neglected until now, can also be extremely useful. Although 
they are not as easy to obtain as throat and rectal swabs and are 
not available for approximately half the patients, the viral yield 
is almost as good as that of throat swabs, with the added 
advantage that they come from sterile sites.
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Abstract
Background: Human enterovirus 71 (HEV7I) can cause Hand, foot, and mouth disease (HFMD) with neurological 
complications, which may rapidly progress to fulminant cardiorespiratory failure, and death. Early recognition of children 
at risk is the key to reduce acute mortality and morbidity.
Methods: We examined data collected through a prospective clinical study of HFMD conducted between 2000 and 2006 
that included 3 distinct outbreaks of HEV7I to identify risk factors associated with neurological involvement in children 
with HFMD.
Results: Total duration of fever > 3 days, peak temperature > 38.5°C and history of lethargy were identified as 
independent risk factors for neurological involvement (evident by CSF pleocytosis) in the analysis of 725 children 
admitted during the first phase of the study. When they were validated in the second phase of the study, two or more 
(> 2) risk factors were present in 162 (65%) of 250 children with CSF pleocytosis compared with 56 (30%) of 186 children 
with no CSF pleocytosis (OR 4.27, 95% CI2.79-6.56, p < 0.0001). The usefulness of the three risk factors in identifying 
children with CSF pleocytosis on hospital admission during the second phase of the study was also tested. Peak 
temperature > 38.5°C and history of lethargy had the sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of 28%(48/l74), 89%( 125/140), 76%(48/63) and 50%( 125/251), respectively in predicting CSF 
pleocytosis in children that were seen within the first 2 days of febrile illness. For those presented on the 3rd or later day 
of febrile illness, the sensitivity, specificity, PPV and NPV of > 2 risk factors predictive of CSF pleocytosis were 75%(57/ 
76), 59%(27/46), 75%(57/76) and 59%(27/46), respectively.
Conclusion: Three readily elicited clinical risk factors were identified to help detect children at risk of neurological 
involvement. These risk factors may serve as a guide to clinicians to decide the need for hospitalization and further 
investigation, including cerebrospinal fluid examination, and close monitoring for disease progression in children with 
HFMD.
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Background
Hand, foot, and mouth disease (HFMD) is a common 
childhood exanthema caused by species A human entero­
viruses (HEVA), particularly Coxsackievirus A16 
{CVA16)[1]. In most instances, this is a mild self-limiting 
illness. The affected children are often given out-patient 
care with symptomatic treatment. However over the last 
decade HFMD has emerged as a growing public health 
problem in Asia following frequent outbreaks of death- 
associated HFMD caused by a more virulence member of 
HEVA, human enterovirus 71 (HEV71), in a number of 
countries in the region [2-5]. This was first recognized 
with large outbreaks of HFMD associated with neurologi­
cal disease and alarming fatalities in Sarawak, Malaysia in 
1997 and in Taiwan in 1998 [2,3]. Fatal cases typically 
presented with a brief duration of febrile illness, subtle 
neurological signs and died dramatically of acute refrac­
tory cardiac dysfunction and fulminant pulmonary 
oedema within hours of developing signs of tachycardia, 
poor peripheral perfusion and tachypnea. Indeed, most of 
them died shortly after hospital admission, and some 
even before or on arrival at hospital [2,6-8]. Although 
severe neurological complications and death only occur 
in a small minority of children with HFMD, the fulminant 
disease course of the fatal cases has caused great public 
alarm in Asia. Experience from recent outbreaks of HEV71 
associated HFMD (HEV71-HFMD) in Asia showed that 
primary care doctors are often overwhelmed with large 
number of children with HFMD seeking medical atten­
tion for the fear of neurological complications and death. 
Because of the risk of sudden death, coupled with tremen­
dous parental pressure to admit children with HFMD into 
hospital for observation, children with HFMD are often 
routinely admitted into hospital for observation in 
Sarawak, which has imposed a huge burden on the health­
care system. Cerebrospinal fluid (CSF) pleocytosis has so 
far been the universal finding in fatal cases even though 
many have no obvious neurological signs prior to sudden 
onset of cardiorespiratory failure and death [2,6,8]. In the 
absence of clear neurological sign, CSF pleocytosis (indic­
ative of neurological involvement) has thus been consid­
ered an objective marker of complicated disease, allowing 
clinicians to focus their attention and provide timely 
intervention in these patients before they develop fatal 
cardiorespiratory failure. We therefore examined data col­
lected through a prospective study of HFMD to identify 
and validate risk factors associated with neurological 
involvement in children with HFMD that may be used by 
clinicians managing children with HFMD.
Methods
Setting and study period
A prospective clinical study was conducted from January 
2000 through December 2006, which included 3 distinct 
outbreaks that occurred in 2000/1, 2003 and 2006, at the
paediatric wards and intensive care unit at Sibu Hospital 
(Sarawak, Malaysia). The study was approved by the 
Director of Health for Sarawak and the Ethics Committee 
of the Liverpool School of Tropical Medicine (UK). 
Informed consent was obtained verbally from each child's 
accompanying parent or guardian.
Case definitions
Figure 1 shows the algorithm of the investigation and the 
classification of the disease severity of children with 
HFMD in the study [9]. A child was defined as having 
HFMD if they had new onset of at least one (> 1) of the 
following: maculopapular or vesicular rash on the palms 
and/or soles; vesicles or ulcers in the mouth or herpangina 
(defined as multiple oral ulcers predominantly affecting 
the posterior parts of the oral cavity). Children with 
HFMD were considered to have more serious illness if 
they have the following features: a history of fever, or fever 
on examination (> 38 °C), and > 1 of the following fea­
tures indicative of more serious illness: toxic and ill in 
appearance, recurrent vomiting (at least twice), tachycar­
dia (heart rate > 150/min) breathlessness, poor perfusion 
(cold clammy skin), reduced consciousness (irritability, 
lethargy, drowsiness, coma), limb weakness, meningism 
(neck stiffness or positive Kernig's sign), seizures. They 
were subjected to CSF examination after written consent 
to exclude central nervous system (CNS) involvement. 
Children with > 5 cells/pL (i.e. CSF pleocytosis) and neg­
ative microscopy and culture for bacteria were classified as 
"HFMD with CNS complications" (HFMD-CNS), while 
those with normal CSF examination were considered to 
have "severe HFMD without CNS involvement" (HFMD- 
Non-CNS). Children with HFMD-CNS were diagnosed to 
have aseptic meningitis (ASM) if they were fully con­
scious, had headache, meningism, and no focal neurolog­
ical signs. Encephalitis was defined by the presence of 
impaired consciousness including lethargy, drowsiness or 
coma, seizures or myoclonus. Acute flaccid paralysis 
(AFP) was characterized by the acute onset of areflexic 
limb weakness. Cardiorespiratory failure was defined by 
the presence of tachycardia, respiratory distress, pulmo­
nary oedema, poor peripheral perfusion requiring ino- 
tropes, pulmonary congestion on chest radiography and 
reduced cardiac contractility on echocardiography. Chil­
dren without features of more serious illness were classi­
fied as "mild HFMD", and were observed in hospital until 
they became afebrile for at least 12-24 hours. A child was 
considered to be positive for HEV71 if HEV71 was iso­
lated by tissue culture or HEV71 RNA was detected by 
HEV71 specific RT-PCR from > 1 clinical sample.
Clinical methods
All children with HFMD admitted into the hospital were 
assessed by pediatricians of the study team. A detailed his­
tory and clinical examination was performed with special
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Mild HFMD 
N=540
HFMD with CNS 
complication 
N=102
CSF examination 
Cell count >5 white cells/pL
Severe HFMD without 
CNS involvement 
N=83
HFMD
One of:
• rash on palms &/or soles
• mouth vesicles &/or ulcers
• herpangina
History of fever, or fever on 
examination (£38°C), and £1 of:
• toxic and ill
• recurrent vomiting (at least twice)
• tachycardia (^150/min)
• breathlessness
• poor perfusion
• reduced consciousness 
(irritability, lethargy, drowsiness, 
coma)
• limb weakness
• meningism
• seizures
Figure I
Case definitions. The flow chart shows the algorithm of the investigation and the classification of the disease severity of chil­
dren with HFMD used in the study. HFMD: Hand, foot, and mouth disease, CSF: Cerebrospinal fluid, CNS: Central nervous 
system.
Page 3 of 12
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:3 http://www.biomedcentral .com/1471 -2334/9/3
attention to mucocutaneous lesions, cardiovascular and 
neurological signs. All details were recorded on standard­
ized forms. Swabs were taken from the throat and rectum 
of every patient, as well as > 1 swab from vesicles on the 
skin and oral ulcers (if present). The clinical samples were 
stored immediately in a -700 C freezer until further testing. 
Blood was taken for flavivirus serology, and in patients 
with suspected CNS involvement for full blood count, 
urea, electrolytes, and glucose. Electrocardiogram and 
echocardiogram was also performed on children with sus­
pected CNS involvement. CSF was examined for cell 
count and differential, protein, glucose, Gram stain, bac­
terial culture and processed for viral studies. If there was a 
strong clinical suspicion of viral CNS infection, but the 
initial CSF examination was acellular, a second lumbar 
puncture was performed. Lumbar punctures were delayed 
in those with unstable vital signs. Patients were examined 
daily or more frequently as indicated, by a member of the 
study team. Children with HFMD-CNS complications 
(particularly those with encephalitis and acute flaccid 
paralysis) were treated with intravenous immunoglobulin 
(IVIG) at the discretion of the treating physician [10].
Virological methods
Virus isolation was attempted on all swab specimens, CSF 
specimens, and any serum samples remaining after other 
investigations had been completed through the inocula­
tion of human rhabdomyosarcoma and human embry­
onic kidney cells. Isolated enteroviruses were typed by 
nucleotide sequencing of VP1 and VP4 genes and geno- 
grouped by phylogenetic analysis [11,12], During the 
2006 outbreak, in addition to virus isolation, all swab 
specimens were also tested for presence of HEV71 RNA 
using a HEV71 specific RT-PCR [13]. Paired serum sam­
ples (obtained on the day of admission and on day 7, or 
on the day of discharge or after death) and CSF specimens 
were also tested for IgM against dengue and Japanese 
encephalitis virus (JEV) in parallel, using an IgM-capture 
ELISA that distinguishes responses to these two viruses
[14].
Statistical analysis
Data from HFMD patients recruited in the first phase of 
the study (mostly during 2 outbreaks that occurred 
between January 2000 and July 2003) were used to iden­
tify risk factors for neurological involvement (evident by 
CSF pleocytosis). The primary analysis was for variables 
associated with neurological involvement by comparing 
children with HFMD-CNS (i.e. with CSF pleocytosis) to 
those with HFMD-Non-CNS (i.e. no CSF pleocytosis). 
Variables that were considered potentially useful to pri­
mary care doctors in identifying children with neurologi­
cal involvement were included in a multiple logistic 
regression analysis to look for independent risk factors for 
neurological involvement (i.e. CSF pleocytosis). Variables
were selected backward and remained in the model only 
if they were statistically associated with neurological 
involvement (p < 0.05). (SPSS software, Version 13.0; 
SPSS). The association between the independent risk fac­
tors identified and neurological involvement were vali­
dated in the second phase of the study, where most 
patients were admitted during the 2006 outbreak. The 
utility of the identified risk factors as clinical predictors for 
neurological involvement at the point of first contact for 
care was also examined. Normally distributed data were 
compared using Student's t test; data that were not nor­
mally distributed were compared by the Mann-Whitney U 
test (Statview 4.02; Abacus Concepts). Differences 
between proportions were tested using the Chi-square test 
with Yates's correction or Fisher's exact test as appropriate 
(Epi Info, version 6; Centers for Disease Control and Pre­
vention). A p value < 0.05 was considered statistically sig­
nificant.
Results
A total of 725 children (457, 63% males) were recruited 
between 1st January 2000 and 31st July 2003. Most chil­
dren were recruited during 2 large outbreaks of HEV71- 
HFMD that occurred during 2000/2001 and 2003. Five 
hundred and forty (74%) children had mild HFMD. One 
hundred and eighty five (26%) children had suspected 
CNS involvement and required CSF examination; 102 
(55%) of them had CSF pleocytosis (HFMD-CNS) and the 
remaining 83 (45%) had normal CSF findings (HFMD- 
Non-CNS). Of the 102 children with HFMD-CNS, 63 
(62%) had ASM, 33 (32%) had encephalitis, 3 (3%) had 
AFP, and 3 (3%) had encephalitis associated with cardi­
orespiratory failure (all of the 3 died). Of the 273 HEV71 
culture positive children, 187 (69%) had mild HFMD, 34 
(13%) had HFMD-Non-CNS, and 52 (19%) had HFMD- 
CNS (30 had ASM, 19 had encephalitis, 1 had AFP and 2 
had encephalitis with cardiorespiratory failure). Detailed 
results of the epidemiology, diagnostic virology and 
molecular epidemiology of this phase of the study have 
been reported previously [9,15].
Clinical features
Comparison of patients with HFMD with CNS complications with 
those had more serious HFMD without CNS involvement (January 
2000 to July 2003)
The clinical features of the children with HFMD-CNS (i.e. 
with CSF pleocytosis) are compared to those with HFMD- 
Non-CNS (i.e. no CSF pleocytosis) (see Additional file 1). 
Children with HFMD-CNS were more likely to be male 
and of Chinese ethnic group. Children of Iban ethnic 
group, however, were less likely to have HFMD with CNS 
complications. Children with HFMD-CNS complications 
were more likely to have higher mean peak temperature, 
peak temperature > 38.5 °C, longer mean total duration of 
fever and total duration of fever > 3 days. Findings of leth-
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argy (from the parent's history or physical examination), 
faster mean heart rate, mean heart rate > 150/min and 
limb weakness on examination were more frequently 
present in children with HFMD-CNS. There was no differ­
ence in the proportion of children with positive HEV71 
isolation between children with HFMD-CNS and those 
with HFMD-Non-CNS.
To look for independent risk factors that could be used to 
predict neurological involvement evident by CSF pleocy­
tosis, total duration of fever > 3 days, peak temperature > 
38.50 C, being lethargic (from the parent's history or phys­
ical findings), history of breathlessness, history of vomit­
ing, history of or witnessed myoclonus, neck stiffness 
were included in a multiple logistic regression analysis. 
Total duration of fever > 3 days, peak temperature > 
38.5 °C and history of lethargy were found to be inde­
pendent risk factors of neurological involvement after 
multivariate analysis (Table 1). Table 2 shows the number 
and type of the risk factors that were present in the 725 
children with HFMD seen during the first phase of the 
study according to the disease severity. Two or more (> 2) 
risk factors were present in 83% (85/102) of patients that 
had HFMD-CNS when compared to 43% (36/83) of 
patients with HFMD-Non-CNS (OR 6.53, 95% Cl 3.IS­
IS.66, p < 0.0001). Further analysis on the HEV71-posi- 
tive subset showed that > 2 risk factors were present in 
82% (43/52) of children with HFMD-CNS when com­
pared to 32% (11/34) patients with HFMD-Non-CNS 
(OR 9.99, 95%CI 3.26-31.82). A separate analysis on 
children with mild HFMD showed that > 2 risk factors 
were present in 6% of cases with mild HFMD (32/ 
540)(Table 2), and HEV71-postive mild HFMD (11/187), 
respectively.
Validation of the association between the risk factors and 
neurological involvement in children with HFMD in 2006 outbreak 
The association between the identified risk factors (total 
duration of fever > 3 days, peak temperature > 38.50 C and 
history of lethargy) and neurological involvement were 
validated in the 2006 outbreak. A total of 730 children 
with HFMD were admitted between January and Decem­
ber 2006. Two hundred and ninety four (40%) children
had mild HFMD. Four hundred and thirty six (60%) chil­
dren had features of more serious illness and warranted 
CSF examination; 250 (34%) of them had HFMD-CNS 
and the remaining 186 (26%) had HFMD-Non-CNS. Of 
the 250 children with HFMD-CNS, 65 (26%) had ASM, 
172 (69%) had encephalitis, 2 (0.8%) had encephalitis 
associated with AFP, and 11 (4.4%) had encephalitis asso­
ciated with cardiorespiratory failure (6 of them died). 
HEV71 was isolated from 157 (27%) of 586 children who 
had virus isolation done. A further 44 (7%) children had 
other HEVA (n = 29) and species B HEV (n = 15). No 
patient had CVA16 isolated. HEV71RNA was detected in 
239 (50%) of 477 children that were tested with HEV71 
specific RT-PCR. In short, 291 (45%) of 653 children were 
positive for HEV71. Of the 291 HEV71-positive children, 
104 (36%) had mild HFMD, 73 (25%) had HFMD-Non- 
CNS, 114 (39%) had HFMD-CNS (22 had ASM, 83 had 
encephalitis, 2 had encephalitis associated with AFP, 7 
had encephalitis associated with cardiorespiratory fail­
ure). HEV71 was detected in 4 (67%) of the 6 fatal case 
children that had encephalitis associated with cardiorespi­
ratory failure. The Additional file 2 shows the clinical fea­
tures of the 730 children that were admitted during the 
2006 outbreak according to the disease severity. Total 
duration of fever > 3 days, peak temperature > 38.5 ° C and 
history of lethargy were similarly more frequently present 
in children with HFMD-CNS than those with HFMD- 
Non-CNS. Two or more risk factors were present in 65% 
(162/250) of children that had HFMD-CNS when com­
pared with 30% (56/186) of children with HFMD-Non- 
CNS (OR 4.27, 95%CI 2.79-6.56, p < 0.0001) (Table 2). 
Among children with HEV71-positive HFMD, > 2 risk fac­
tors were present in 61% (69/114) of children with 
HFMD-CNS when compared with 26% (19/73) of chil­
dren with HFMD-Non-CNS (OR 4.36, 95%CI 2.19-8.75, 
p < 0.0001). A separate analysis on children with mild 
HFMD showed that history of lethargy, total duration of 
fever > 3 days and peak temperature > 38.5 ° C was present 
in 6.4% (19/294), 11% (33/294) and 14% (42/294) of 
the children with mild HFMD, respectively (Additional 
file 2). Two or more 2 risk factors were found in only 5 
(2%) of 294 with mild HFMD (Table 2) and in 1 (1%) of 
104 of children with HEV71-positive mild HFMD.
Table I: Risk factors that were significantly associated with CSF pleocytosis in children with HFMD in the first phase of the study (2000 
to 2003).
Risk factors p value Odds ratio 95% Cl
Total duration of fever > 3 days <0.000! 6.52 2.83 - 14.99
Peak temperature > 38.5°C 0.0192 2.27 1. 14 - 4.51
History of lethargy 0.001 3.18 1.60 - 6.35
Note: The Hosmer-Lemeshow statistics indicated a non-significance of lack of fit (x2 = 2.163, p = 0.904).
CSF: Cerebrospinal fluid
HFMD: Hand, foot, and mouth disease
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Table 2: The number and type of the risk factors that were present in the children with HFMD seen in the 2000/3 and 2006 outbreaks
Risk factors that were present First phase of study (2000/3) Second phase of study (2006)
HFMD-CNS HFMD-Non- Mild HFMD HFMD-CNS HFMD-Non- Mild HFMD
(N« 102) CNS (N = 83) (N = 540) (N = 250) CNS (N - 186) (N = 294)
No. of patients with none of 
the 3 risk factor
2 9 352 11 52 208
Peak temperature > 38.50C only 1 8 7 29 32 34
History of lethargy only 5 15 27 16 11 17
Total duration of fever > 3 only 9 15 122 32 35 30
No. of patients with 1 risk 
factor
IS 38 156 77 78 81
Peak temperature > 38.5°C plus 
history of lethargy
2 3 1 1 1 7 2
Peak temperature > 38.50C plus 
total duration of fever > 3 days
25 15 8 76 31 3
Total duration of fever > 3 days 
plus history of lethargy
26 12 19 21 5 0
No. of patients with 2 risk 
factors
S3 30 28 108 43 5
No. of patients with 3 risk 
factors (Peak temperature > 
38.5°C plus total duration of 
fever > 3 days plus history of 
lethargy)
32 6 4 54 13 0
Note:
HFMD: Hand, foot, and mouth disease
HFMD-CNS: Hand, foot, and mouth disease with central nervous system complication 
HFMD-Non-CNS: Severe HFMD without central nervous system involvement
The usefulness of the risk factors in predicting neurological 
involvement in children with HFMD in the 2006 outbreak 
We were particularly interested to assess the utility of the 
three clinical risk fartors in predicting neurological 
involvement in children with HFMD at the point of first 
contact for care. While a febrile illness > 3 day was an 
important risk factor for severity, primary care physicians 
often see many children on the first 2 days of HFMD ill­
ness. To determine if peak temperature > 38.5 °C and his­
tory of lethargy are useful in identifying children who 
sought treatment within the first 2 days of the febrile ill­
ness we performed a separate analysis for children who 
presented within the first 2 days of the illness during the 
2006 outbreak. Figure 2 shows the distribution and classi­
fication of disease severity of 730 children with HFMD in 
the 2006 outbreak according to the duration of febrile ill­
ness and the risk factors that were present when they first 
presented to hospital. Five hundred and seventy nine
(79%) of 730 children were admitted within the first 2 
days of febrile illness. Sixty five (11%) of the 579 children 
had history of lethargy plus peak temperature > 38.5C. All 
but two (97%) of the 65 children had features of more 
serious illness and warranted CSF examination. About 
three quarter of them had CSF pleocytosis and was classi­
fied as HFMD-CNS. Only 2 (3%) of the 65 children were 
labeled as mild HFMD. Two hundred and twenty (38%) 
children had only either history of lethargy or peak tem­
perature > 38.5C. Of the 167 (76%) children who war­
ranted a CSF examination, 102 (61%) of them had CSF 
pleocytosis, and were classified as HFMD-CNS. The 
remaining 53 (24%) children without feature of more 
serious illness were considered as mild HFMD. Two hun­
dred and ninety four (51%) children had neither of the 
two risk factors. Eighty four (29%) of the 294 children, 
however, had other features of more serious illness, and 
hence underwent CSF examination. CSF pleocytosis was
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Figure 2
Classification of 730 Children with HFMD. The flow chart shows the distribution and classification of disease severity of 
730 children with HFMD in the 2006 outbreak according to the duration of fever and the risk factors that were present when 
they first presented to the hospital. CSF examination is indicated if the children have features indicative of more serious illness 
of HFMD (see case definition in main text). Hx lethargy: History of lethargy, Temp > 38.5°C: body temperature > 38.5°C, CSF 
exam: cerebrospinal fluid examination, HFMD: Hand, foot, and mouth disease, HFMD-CNS: Hand, foot, and mouth disease 
with central nervous system complication, HFMD-Non-CNS: Severe HFMD without central nervous system involvement, 
BENC: brainstem encephalitis, ASM: aseptic meningitis, a. Of the 48 children with HFMD-CNS, 40 had BENC, 6 had ASM and 
2 had BENC associated with cardiorespiratory failure (I of whom died), b. Of the I02 children with HFMD-CNS, 74 had 
BENC, 26 had ASM, I had encephalitis and I had fatal BENC associated with cardiorespiratory failure, c. Of the 24 children 
with HFMD-CNS, 13 had BENC, 8 had ASM, I each had BENC associated with cardiorespiratory failure, encephalitis, and 
encephalitis associated with acute flaccid paralysis, d. Of the 17 children with HFMD-CNS, 11 had BENC, 5 had BENC associ­
ated with cardiorespiratory failure (4 of whom died) and I had ASM. e. Of the 40 children with HFMD-CNS, 22 had BENC, 17 
had ASM and I had fatal BENC associated with cardiorespiratory failure, f. Of the 19 children with HFMD-CNS, I0 had BENC, 
7 had ASM and I each had encephalitis with acute flaccid paralysis, and BENC associated with cardiorespiratory failure.
found in 24 (29%) of the 84 children, and were classified 
as HFMD-CNS. Two hundred and ten (71%) of the 294 
children without features of more serious illness were 
labeled as mild HFMD. In summary CSF pleocytosis was 
found in 48(74%) of 65 children with 2 risk factors (tem­
perature > 38.5“C and history of lethargy) on hospital
admission compared with that in 126 (25%) of 514 chil­
dren with > 1 risk factors (OR 8.69; 95%CI 4.66-16.37, p 
<0.0001).
One hundred and Fifty one (21%) of the 730 children 
were seen on the 3rd or later days of their febrile illness.
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Twenty two (15%) of the 151 children had all the 3 risk 
factors associated with neurological involvement. All the 
22 children warranted CSF examination. Seventeen 
(77%), including 4 fatal cases, of the 22 children had CSF 
pleocytosis and were classified as HFMD-CNS. Of the 55 
(36%) children that had 2 risk factors, all except one child 
required CSF examination to exclude CNS involvement. 
Forty (74%) of the 54 children had CSF pleocytosis and 
were classified as HFMD-CNS. Being febrile for > 3 days 
was the sole risk factor in 74 (49%) of the 151 children. 
Forty six (62%) children had features of more serious ill­
ness, and underwent CSF examination - 19 (41%) had 
CSF pleocytosis and were classified as HFMD-CNS. The 
remaining 28 (38%) children were labeled as mild 
HFMD. In short CSF pleocytosis was found in 57(74%) of 
77 children that had > 2 risk factors on hospital admission 
compared with in 19 (26%) of 74 children with isolated 
risk factor of being febrile > 3 days (OR 8.25; 95%CI 
3.75-18.38, p < 0.0001). Further analysis on the HEV71- 
positive subset showed that 24% (21/86) of children with 
HFMD-CNS presented within the first 2 days of febrile ill­
ness had > 2 risk factors compared with 10% (6/60) of 
children with HFMD-Non-CNS (OR 2.91; 95% Cl 1.03- 
9.38, p = 0.0464). For the HEV71-positive children pre­
sented on the 3rd or later days of febrile illness, 71% (20/ 
28) of children with HFMD-CNS had > 2 risk factors com­
pared with 31% (4/13) of children with HFMD-Non-CNS 
(OR 5.63; 95% Cl 1.11-31.35, p = 0.0341). The sensitiv­
ity, specificity, positive predictive value and negative pre­
dictive value of the risk factors in predicting CSF 
pleocytosis in children with HFMD at presentation in the 
2006 outbreak is shown in Table 3.
Between 2000 and 2006, a total of352 children with CNS 
involvement were admitted into the study. One hundred
and twenty eight (36%) children had ASM (a mild and 
benign CNS involvement) and 224 (64%) had severe and 
potentially fatal CNS complications (205 had encephali­
tis, 14 had encephalitis associated with cardiorespiratory 
failure, 2 had encephalitis associated with AFP, 3 had 
AFP). Among the 224 children that had severe CNS com­
plications, 204 (95%) of 215 children that survived had 
timely hospital admission and IVIG treatment compared 
to one (11%) of 9 children that died (OR 148.36, 95%CI 
16.34-6609.04, p < 0.0001). Table 4 shows the clinical 
details and the risk factors that were present in the 9 fatal 
case children on hospital admission. Two or more risk fac­
tors associated with neurological involvement were 
present in all the 9 fatal children, and were noted for > 
24-48 hours before hospital admission.
Discussion
Early recognition of children at risk of neurological 
involvement and death (particularly those with encepha­
litis and encephalomyelitis) is critical as the disease pro­
gression from the onset of neurological involvement to 
fulminant cardiorespiratory failure may be remarkably 
rapid [8]. However the clinical manifestations of neuro­
logical involvement may be very subtle, particularly in 
young children with early CNS disease [8,16]. While the 
signs of cardiorespiratory distress such as breathlessness, 
tachypnea, tachycardia, poor perfusion are easy to recog­
nize, they invariably appear very late shortly before most 
fatal case collapsed. Our results and other published stud­
ies showed that timely diagnosis and intervention, includ­
ing the use of IVIG infusion, may reduce acute mortality 
[10,17-19]. Hence the primary care doctors are con­
fronted with a clinical challenge of identifying a small 
fraction of children who are at risk of neurological com­
plication from an overwhelmingly large number of chil-
Table 3: The sensitivity, specificity, positive predictive value and negative predictive value of the risk factors.
Risk factors that were present Presented within the first 2 days of febrile illness Presented on the 3rd or later day of febrile illness
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
Both peak temperature > 28% (48/174) 89% (125/140) 76% (48/63) 50% 22% 89% (41/46) 77% (17/22) 41%
38.5°C and history of lethargy [23-33%] [86-92%] [71 -81 %] (125/251)
[44-56%]
(17/76)
[15-29%]
[83-95%] [70-84%] (41/100)
[32-50%]
Peak temperature > 38.5°C 8J 86% (150/174) 43% (60/140) 65% (150/230) 71% 75% 59% (27/46) 75% (57/76) 59%
or history of lethargy [82-90%] [38-48%] [60-70%] (60/84)
[66-76%]
(57/76)
[67-83%]
[50-68%] [67-83%] (27/46)
[50-68%]
(%, proportion, [95% confidence interval]) in predicting CSF pleocytosis in the 436 children with suspected CNS involvement seen in the 2006
outbreak
Note:
CSF: Cerebrospinal fluid 
CNS: Central nervous system
Sensitivity = The proportion of children with CSF pleocytosis that are correctly identified by the presence of the risk factors 
Specificity = The proportion of children without CSF pleocytosis that are correctly identified by the absence of the risk factors 
Positive predictive value (PPV) = The proportion of individuals with the risk factors that have CSF pleocytosis 
Negative predictive value (NPV) = The proportion of individuals without the risk factors that do not have CSF pleocytosis
Page 8 of 12
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:3 http://www.biomedcentral.eom/1471 -2334/9/3
Table 4: The clinical details and risk factors for neurological involvement of the nine fatal case children with HFMD seen in the study.
Patient Year
of the outbreak
Age (months) Day of illness at 
presentation
Risk factors that 
were present at 
presentation
Disease severity HEV7I detected? IVIG treatment Note
l 2000 I I Day 3 fever > 3D, history 
of lethargy, 
temperature > 
38.5°C
HFMD-CNS Yes No a.
2 2003 34 Day5 fever > 3D, history 
of lethargy
HFMD-CNS Yes No b.
3 2003 32 Day 3 fever > 3D, history 
of lethargy
HFMD-CNS No No a.
4 2006 9 Day I history of lethargy, 
temperature > 
38.5°C
HFMD-CNS Yes Yes c.
5 2006 8 Day 3 fever > 3D, history 
of lethargy, 
temperature > 
38.5°C
HFMD-CNS Yes No a.
6 2006 I4 Day 3 fever > 3D, history 
of lethargy, 
temperature > 
38.5°C
HFMD-CNS Yes No a.
7 2006 34 Day 4 fever > 3D, history 
of lethargy, 
temperature > 
38.5°C
HFMD-CNS Yes No a.
8 2006 25 Day 4 fever > 3D, history 
of lethargy, 
temperature > 
38.5°C
HFMD-CNS No No a.
9 2006 47 Day 4 fever £ 3D, history 
of lethargy
HFMD-CNS No No a.
Note:
a. Presented in the moribund state with fulminant cardiorespiratory failure and pulmonary oedema. The patient died within 24 hours of the 
hospitalization. The risk factors were present for > 48 hours before hospital admission.
b. Developed acute cardiorespiratory collapse and died 12 hours after hospitalization. Had peak temperature > 38.5°C in the hospital. The patient 
was lethargic for > 48 hours before hospital admission.
c. Deteriorated progressively because of cardiorespiratory failure despite intensive care support. Died on day 4 of the hospitalization. The patient 
was lethargic for 24 hours before hospital admission
HFMD-CNS: Hand, foot and mouth disease with central nervous system complication 
IVIG: Intravenous immunoglobulin
dren who would have uncomplicated course of HFMD. 
For this reason it is important to find clinical predictors 
for neurological involvement that can guide primary care 
doctors perform a proper patient triage, which should be 
aimed to admit high risk children into hospital early for 
close observation and further management, while those at 
low risk of neurological complication may be given out­
patient care after parental education and advice. Few stud­
ies have systemically examined howto identify children at 
risk early before they develop cardiorespiratory failure, 
particularly at the primary care setting where the majority 
of children with HFMD would first seek treatment during 
a community outbreak of HFMD.
In this study we identified and validated that history of 
lethargy, mean peak temperature > 38.5 °C and total dura­
tion of fever > 3 days were important risk factors for neu­
rological involvement. Our study also shows that 
neurological involvement occurs at early course of com­
plicated HFMD, and may be detectable within the first 2 
days of the febrile illness because CSF pleocytosis was 
present in 174 (30%) of 579 children seen within the first 
2 days of febrile illness, where they also formed 70% 
(174/250) of children with HFMD-CNS in the 2006 out­
break (Figure 2). Since CSF pleocytosis may be detectable 
within the first 2 days of the febrile illness and fulminant 
cardiorespiratory failure seen in the fatal case children 
typically occurred on the 3rd or later day of febrile illness, 
it is imperative to attempt to identify children at risk of 
neurological involvement before the 3rd day of febrile ill­
ness so that they can be admitted into hospital early for 
close monitoring and investigation, and intervention may 
be instituted when necessary.
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Examination of body temperature and careful enquiry 
into history of lethargy, duration of fever and home 
record of body temperature should form an integral part 
of HFMD patient triage at the primary care level. The three 
risk factors are readily elicited, and can also be used after 
minimal training by paramedics, who are the key primary 
care providers in many developing countries including in 
Sarawak (Malaysia) in Asia. The parents of children with 
HFMD can also play an important role in early diagnosis 
of neurological complication in children with HFMD. 
They should be educated about the 3 risk factors, and be 
encouraged to monitor the children's body temperature 
regularly and observe the children's physical activity 
closely. Body temperature > 38.5 °C and history of leth­
argy may be particularly useful clinical clues for neurolog­
ical involvement during the first 2 days of febrile illness 
since at this time the presentation of complicated HFMD 
is typically undifferentiated and subtle, even to the expe­
rienced clinicians [8]. Indeed both history of lethargy and 
temperature ^ 38.5 °C were observed for 24-48 hours in 
all the 9 fatal case children before they succumbed to 
unexpected fulminant cardiorespiratory failure (Table 4). 
Primary care doctors should have high index of suspicions 
of neurological complication when they are presented 
with children with HFMD who have been febrile > 3 days. 
The children should be admitted into hospital for close 
observation and investigated for CHS involvement, if nec­
essary. Our study showed that 92 (31%) of 293 children 
with total duration of fever > 3 days in the 2000/3 out­
break, and 183 (61%) of 300 children in the 2006 out­
break had neurological involvement (Table 2). CSF 
pleocytosis was present in 25% (19/74) of children with a 
single risk factor of being febrile > 3 days on hospital 
admission (Figure 2). The risk of CHS complication is 
increased significantly when there are added risk factors of 
having history of lethargy and temperature > 38.5 °C. In 
contrast children who have a brief duration of low grade 
fever (> 38.5 °C) and no history of lethargy are of low risk 
of neurological disease, and may be provided with out­
patient care and parental reassurance.
Our results are in keeping with findings reported by 
Chang and co-authors where fever > 39 °C, fever duration 
> 3 days and lethargy were more frequently observed in 
children with CNS involvement and in children with 
HEV71-HFMD than in those with CVA16-HFMD [8,20]. 
Although several other clinical features and laboratory 
abnormalities have been associated with fatal HEV71- 
HFMD, they have yet been validated, and been shown 
useful in detecting neurological disease or disease progres­
sion [8,21,22]. For example, Chong and co-authors 
reported that absence of mouth ulcers predicted a more 
complicated or fatal HFMD, and have recommended that 
children without mouth ulcers should be monitored 
closely [22]. However, in our study we did not find that
children without mouth ulcers were more likely than chil­
dren with mouth ulcers to have features of more severe 
HFMD or develop neurological complication. Not all the 
risk factors identified in these published studies can read­
ily be translated into clinical practice, particularly at pri­
mary care settings. Hyperglycemia and leucocytosis have 
been shown as risk factors for fatal HEV71 disease [8]. 
However, in our experience hyperglycemia and leucocyto­
sis are late laboratory changes in children with fulminant 
cardiorespiratory failure (unpublished observations), and 
thus are not helpful clinically in identifying children at 
high risk of complication and death. Elevated cardiac Tro­
ponin I, a sensitive cardiac-specific biomarker for myocar­
dial injury, has been noted in children who subsequently 
developed left ventricular failure, and may be useful in 
identifying patients at risk of left ventricular failure and 
pulmonary oedema [21]. Although cardiac Troponin I has 
been used widely in developed countries for early diagno­
sis of acute coronary syndrome, it is expensive and not 
widely available in many developing countries, including 
in Sarawak. Screening for heart rate variability abnormal­
ities, an index of autonomic nervous system, through 
non-invasive continuous ECG monitoring may provide 
early warning of impending cardiorespiratory failure 
about 7 hours before its onset [16]. The labour-intensive 
approach is most suited in a critical care setting for chil­
dren already diagnosed of CNS involvement because it 
requires the use of expensive and sophisticated device, 
and close monitoring for the heart rate abnormalities.
A limitation of our study is that the clinical predictors 
developed for use at primary care setting were identified 
and tested using data collected through a hospital-based 
study. Clinical characteristics of children treated at pri­
mary care settings may differ from hospitalized children. 
However, as a large number of children with mild HFMD 
were admitted into our study, we had the opportunity to 
systemically examine the clinical feature of HFMD of var­
ying severity, including children with mild disease that 
would normally be treated at primary care clinics, where 
we have shown history of lethargy, peak temperature 
38.5C and total duration of fever 3 days were reported 
infrequently in children with mild HFMD.
Conclusion
Currently there is no vaccine against HEV71 infection. 
Early recognition of children at risk of fulminant pulmo­
nary oedema and cardiac dysfunction is the key to reduce 
acute mortality and morbidity. We have identified three 
clinical risk factors that may help detect children at risk of 
neurological involvement and death at primary care set­
tings, which can guide primary care doctors decide if hos­
pital admission is warranted when they see with children 
with HFMD. These risk factors are readily elicited through 
history taking and measurement of body temperature.
Page 10 of 12
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:3 http://www.biomedcentral.eom/1471-2334/9/3
They may also provide useful guide to help clinicians to 
decide the need for CSF examination, as well as to moni­
tor disease progression in children with HFMD.
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Virology, epidemiology, pathogenesis, and control of 
enterovirus 71
Tom Solomon, Penny Lewthwaite, David Perera, Mary Jane Cardosa, Peter McMinn, Mong How Ooi
First isolated in California, USA, in 1969, enterovirus 71 (EV71) is a major public health issue across the Asia-Pacific 
region and beyond. The virus, which is closely related to polioviruses, mostly affects children and causes hand, foot, 
and mouth disease with neurological and systemic complications. Specific receptors for this virus are found on white 
blood cells, cells in the respiratory and gastrointestinal tract, and dendritic cells. Being an RNA virus, EV71 lacks a 
proofreading mechanism and is evolving rapidly, with new outbreaks occurring across Asia in regular cycles, and 
virus gene subgroups seem to differ in clinical epidemiological properties. The pathogenesis of the severe 
cardiopulmonary manifestations and the relative contributions of neurogenic pulmonary oedema, cardiac dysfunction, 
increased vascular permeability, and cytokine storm are controversial. Public health interventions to control outbreaks 
involve social distancing measures, but their effectiveness has not been fully assessed. Vaccines being developed 
include inactivated whole-virus, live attenuated, subviral particle, and DNA vaccines.
Introduction
Enteroviruses are small, single-stranded, positive-sense 
RNA viruses from the enterovirus genus in the family 
Picornaviridae.' They cause disorders with a wide range 
of clinical manifestations, including cutaneous, visceral, 
and neurological diseases. For many years polioviruses 
were the most important enteroviruses, since they led to 
large outbreaks of paralytic disease. A global campaign 
has, however, almost eradicated poliomyelitis from many 
regions worldwide. In its place, enterovirus 71 (EV71) 
causes major outbreaks of hand, foot, and mouth disease 
(HFMD), most frequently affecting children. This virus 
was first described in 1969/ although an analysis shows 
that EV71 was circulating in the Netherlands as early as 
1963.3 Although present in most countries, the largest 
outbreaks of disease have been seen in the Asia-Pacific 
region, for reasons that are incompletely understood.4-3'1 
The neurological manifestations range from aseptic 
meningitis to acute flaccid paralysis and 
brainstem encephalitis, which is associated with systemic 
features, such as severe pulmonary oedema and shock, 
in many cases.3718 The clinical features, investigations, 
and management of severe EV71 disease are discussed 
in a companion article in The Lancet Neurology.'9 In this 
Review we consider the virology, clinical and molecular 
epidemiology, pathogenesis, and prospects for control.
Virology
Classification
As well as the enterovirus genus, the large Picornaviridae 
family includes Rhinovirus spp (eg, the common cold), 
Hepatovirus spp (eg, human hepatitis A vims), 
Parechovims spp (eg, human parechovims 1 and 2), and 
two important animal vims genera, Cardiovirus spp (eg, 
encephalomyocarditis vims) and Aphthovirus spp (foot 
and mouth disease virus).3 Human enterovimses were 
traditionally separated into four classifications, according 
to their pathogenicity in human beings and experimental 
animals and their cytopathic effects in tissue culture; 
these subgroups were poliovimses (three serotypes),
coxsackievims A (23 serotypes), coxsackievims B (six 
serotypes), and echovimses (28 serotypes).3 However, 
because of the limitations of this system, serologically 
distinct human enterovimses isolated since 1970 have 
been designated by serotype numbers, beginning with 
HEV68. The original classification of human 
enteroviruses has been substituted by a taxonomic 
scheme based on molecular and biological properties of 
the viruses.20 This revised classification recognises at 
least 90 subtypes and separates them into four species 
(table 1). Poliovimses have been designated as members 
of the human enterovims C species because they are 
genetically closely related.23
Physicochemical properties
The vims capsid comprises 60 identical subunits 
(protomers), each of which contains a copy of the four 
stmctural viral proteins (figure l).22 The lack of a lipid 
envelope confers human enteroviruses stability in the 
host environment, including on exposure to human 
gastric acid, and they can survive at room temperature 
for several days. EV71 and other enteroviruses have also 
been detected in surface and ground water and in hot 
spas.23 24 Enterovimses are resistant to organic solvents 
(eg, ether and chloroform), alcohol, and freezing, but 
can be inactivated by temperatures higher than 56°C, 
chlorination, formaldehyde, and ultraviolet irradiation. 
In one study EV71 was destroyed by vimcidal 
disinfectants.25
Life cycle and replication
Human beings are the only known natural hosts of 
human enteroviruses. Like most other enterovimses the 
replication cycle of EV71 is similar to that of poliovimses.^ 
Viral entry into susceptible host cells is dependent on 
specific receptors. Seven receptors for different 
enteroviruses have been identified in human beings.20 
The specific receptors include the poliovims receptor 
(CD155), three integrins (a2(3l, avP3, and av|36), decay- 
accelerating factor (CD55), the coxsackievims-adenovims
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Serotype
A CV-A2-8, CV-A10, CV-A12, CV-A14. CV-A16, EV71, EV76, EV89-92
B CV-A9, CV-B1-6, El-7, E9, Ell-21, E24-27, E29-33, EV69, EV73, EV74-75, EV77-88, EV93, EV97, EV98, EV100, EV101, EV106, EV107
C CV-A1, CV-A11, CV-A13, CV-A17, CV-A19-A22, CV-A24, EV95. EV96, EV99. EV102, EV104, EV105, EV109, PV1-3
D EV68, EV70, EV94
The Picomavindae Study Croup and the International Committee on Taxonomy of Viruses classified the Enterovirus genus into ten species, which include four human 
enterovirus species (A-D), three human rhino virus species (A-C), bovine enterovirus, simian enterovirus A, and porcine enteroviruses (http://www.ncbi.nlm.nih.gov/ICTVdb/ 
iCTVdB/) CV-A-coxsackievirus A. CV-B*coxsackievirus B. EV-enterovirus E-echovirus. PV-poliovirus.
ToWe 1: Human enterovirus serotypes, by species
receptor, and intracellular adhesion molecule 1. Some 
enteroviruses use more than one receptor to infect a host 
cell. Several receptors for EV71 have been identified, but 
a ubiquitously expressed cellular receptor, scavenger 
receptor B2, and a functional receptor, human P-selectin 
glycoprotein ligand-1, found on white blood cells, are 
specific for EWl.*7" Sialic-acid-linked glycan, which is 
expressed in abundance in the respiratory and gastro­
intestinal tracts, and dendritic-cell-specific intercellular 
adhesion-molecule-3-grabbing non-integrin (CD209), 
which is found exclusively in dendritic cells in 
lymphoid tissues, have also been identified."-*'
After an enterovirus binds with a specific receptor on 
the cell surface, a series of structural changes occur in 
the virus capsid (yet to be defined in EV71) and pores are 
formed in the cell membrane through which the 
virion RNA is released into the host cell cytoplasm. 
Being positive-sensed, the parent virus RNA acts directly 
as a messenger RNA and is translated into a large 
polypeptide that is promptly cleaved by the viral 
proteases into 11 mature structural and non-structural 
proteins. The replication of the virus genome by the 
error-prone RNA-dependent RNA polymerase 3Dpol 
takes place in a vesicle membrane structure (viral 
replication complex). The polymerase is estimated to 
misincorporate one or two bases in every genome 
copying event, which explains why the virus mutates 
and evolves rapidly. Within the VPI gene 4-2-4-6X10-' 
nucleotide substitutions occur per site per year, which is 
similar to the number in poliovirus and greater than 
that of influenza viruses.,2-M
While the machinery of the host cellular protein 
synthesis is shut down by viral protease 2A, viral protein 
synthesis remains unaffected. An infectious virus particle 
is formed after the packaging of a progeny viral RNA into 
a virus capsid in the cytoplasm of the infected cells. 
Mature infectious virus particles are released when an 
infected cell is lysed.
Clinical epidemiology
Initial identification
EV71 was isolated from the stool of a child aged 9 months 
with encephalitis, in California, USA, in 1969,2 although 
an earlier isolate has since been identified.* Within 
5 years small outbreaks of neurological infections,
including encephalitis and aseptic meningitis, attributed 
to EV71 were reported in Australia, Japan, Sweden, and 
the USA.^’9
The dermotrophic properties of EV71 were first 
recognised when the virus caused epidemics of HFMD 
in Japan in 1973.*8 In the 1970s, two large EV71 epidemics 
occurred in Europe. The first, in Bulgaria, was initially 
attributed to polioviruses because of the epidemiological, 
clinical, and pathological characteristics.4041 EV71, 
confirmed by virus isolation or neutralisation test, was 
later identified as the causative agent in 347 (77%) of 
451 children who presented with non-specific febrile 
illness or neurological disease; 44 children died. The 
second major epidemic was 3 years later in Hungary, 
with 1550 cases (826 aseptic meningitis, 724 encephalitis) 
and 47 deaths reported; unlike the Bulgarian epidemic, 
few patients had HFMD.42
VPI
VP2
VP3
VP4
S' UTR PI P2 P3 3' UTR
AAA
0 1000 2000 3000 4000 5000 6000 7000 
Genome length in nucleotides
Figure 1: Enterovirus 71 structure and genome structure of the virion
Human enteroviruses are small (circumference around 30 nm), non-enveloped, icosahedral particles that contain 
a single-stranded, positive-sense, polyadenylated virus RNA of approximately 7-4 kb. Each protomer in the virus 
capsid contains a copy of the four structural viral proteins (VP1-VP4), of which VPI, VP2, and VP3 are external, 
whereas VP4 is completely internalised and is not, therefore, exposed to the host antibody response. All the 
structural proteins are encoded by the PI region of the genome. The P2 and P3 regions encode seven non-structural 
proteins—2A-2C and 3A-3D. Reproduced from ViralZone, with permission of Swiss Institute of Bioinformatics, and 
from reference 70, with permission of Springer. UTR=untranslated region. VPg=virus encoded protein.
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1973 1980 1986 1990 1993 1994 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Singapore B3, B4 B3.C1 B3 B4* B4 Cl, B4 B4 - - B5 - B5
Peninsular B3*, B4*, Cl B4, Cl B4\ - - - - B5\ Cl - - -
Malaysia at, C2t Cl*
Sarawak, B3* Cl Nonet B4\ Nonet a B5, Cl Nonet B5 B5
Malaysia Cl
Perth,
Australia
B3.C2 Cl Nonet Nonet - - - * - -
Japan B1 B2, Cl B2 C3 B3.B4.C2 C2 C2 B4 C2 B4, C2 C4.B5 C4 - C4 C4 -
Taiwan B1 B1 C2*, B4t B4 B4* B4 B4, C4t B4, B5t C4* C4*,C5t C5 C5, B5 B5*
Korea C3* Nonet Nonet C4 - - - - -
Brunei - - - - - B5 - -
Vietnam - - - - - C1,C4,C5 - - -
Thailand - - Cl Cl Cl - B5, Cl, B5,C1,C2, B5t,Cl.
C2.C4 C4.C5 C2t, C4*
China C3 C4 C4 C4 C4 C4 C4 - - C4 C4
‘Genotypic subgroups caused large outbreaks. tGenotypic subgroup isolated in a small number of patients. tNo enterovirus 71 detected, despite active surveillance.
Table 2: Enterovirus 71 genotypic subgroups reported to be circulating in the Asia-Pacific region between 1973 and 2008, by year9'14'45'53
Asia-Pacific region
After the Australian and Japanese EV71 epidemics of the 
1970s, further small epidemics and sporadic clusters 
occurred in Hong Kong in 1985,41 and in Australia in 1986.44 
In 1997, a large outbreak of EV71 in Sarawak, Malaysia, 
heralded the start of a new series of outbreaks across the 
Asia-Pacific region (table Z).9'1445'”
In Sarawak, 2618 HFMD cases and 34 deaths were 
recorded between May and July, 1997; around the same 
time EV71 caused four deaths in peninsular Malaysia 
and several cases of severe neurological disease in 
Japan.41154 In 1998, the largest EV71 epidemic so far 
occurred in Taiwan:7 an estimated 1-5 million people 
were infected and 405 children were admitted to 
hospital for serious neurological complications, of 
whom 78 died. The latest large Asian-Pacific epidemic 
was in China in 2008, when around 490 000 infections 
and 126 deaths in children were reported; at the 
epicentre in Anhui Province, more than 6000 HFMD 
cases and 22 deaths in children were reported.12 In 
addition to these very large outbreaks, many areas, 
including Japan, Sarawak, Singapore, Taiwan, and 
Vietnam, have experienced cyclical epidemics that occur 
every 2-3 years (figure 2).55-57
Brainstem encephalitis, especially affecting the 
medulla, associated with cardiopulmonary dysfunction 
has become a notable feature in EV71 epidemics in Asia, 
and is the primary cause of death.491217 5,1 This presentation 
is in contrast to that in the 1980s, when aseptic meningitis 
was the most frequent neurological involvement.^17 
Children typically present with a brief febrile illness and 
mild neurological signs, after which they develop signs 
of tachycardia, poor perfusion, and tachypnoea that 
rapidly develop into acute, intractable cardiac dysfunction 
and fulminant—in many cases fatal—pulmonary oedema 
or haemorrhage.19 Neurogenic pulmonary oedema is 
thought to be the main pathogenic process.171*54-59
Other regions
Outside the Asia-Pacific region, EV71 has continued to 
circulate at a low level in Africa, Europe, and the USA and 
causes sporadic cases or small outbreaks. During a 1-year 
prospective study in Canada in 1998, 20 children with EV71 
were admitted to a tertiary hospital, mostly in the summer 
or autumn months; half had aseptic meningitis, and a 
third had respiratory symptoms, but no symptoms were 
severe and all improved rapidly.60 Two small community 
outbreaks of neurological EV71 disease, without HFMD, 
occurred in 2003 and 2005 in Denver, CO, USA, affecting 
16 children aged 4 weeks to 9 years; one child died.61 A 
retrospective analysis of stool samples coUected from 
children admitted to hospital with aseptic meningitis in 
Austria between 2001 and 2004 showed that EV71 was 
detected in 16 (9%) of 181.62 A similar study identified 
32 sporadic cases of EV71 infection in the UK between
1998 and 2006, presenting primarily as neurological 
disease, HFMD, or both.61 In the Netherlands, 58 people 
were admitted to hospital with EV71-associated fever, 
gastrointestinal symptoms, and CNS infections in 2007, 
after 21 years of low endemicity.1 Widespread asymptomatic 
circulation of EV71 was also noted between October 2002 
and October 2003 in Norway, where the vims was isolated 
from 19 (17%) of 113 well children.64 EV71 was among a 
range of enterovimses detected by the screening of blood 
donations in Scotland over 22 months; the detection rate 
for any enterovims was one per 4000 donations,65 although 
the importance of this finding remains uncertain. In 
Nairobi, Kenya, two small institutional outbreaks of EV71 
infection were reported in an HIV orphanage in
1999 and 2000.“
Molecular epidemiology
Gene groups, evolution, and geographical distribution
Phylogenetic analysis suggests that EV71 emerged from 
the coxsackievirus type A 16, as recently as 1940.52 The
780 www.thelancet.com/infection Vol 10 November 2010
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first complete phylogenetic analysis of EV71 based on 
the structural VP1 gene identified three independent 
lineages of EV71. designated A, B, and C;” each group 
has at least 15% divergence from the others. Group A 
consists of one member, the prototype BrCr strain, 
which was first identified in California, USA, in 1970, 
and was not reported outside the USA until 2008, when
isolates were reported from five of 22 children presenting 
with HFMD in Anhui province of central China.67 
Sequencing of the complete VP1 gene showed very little 
divergence between isolates. The virus might, therefore, 
have been circulating undetected in central China, with 
very little evolutionary change for 40 years, although the 
source of the virus templates that were sequenced could
A
300-1
250-
200-
Epidemic year
Figure 2: Distribution of (A) hand, foot, and mouth disease and (B) enteroviruse 71 isolates identified in sentinel clinics in Sarawak, Malaysia, from March, 1998, to mid-2009
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have affected the results. Surveillance data from the 
same outbreak by the Chinese Center for Disease 
Control and Prevention do not seem to indicate any 
group A viruses.’2 Good surveillance programmes are 
needed in many different geographical regions to 
provide accurate and relevant information about EV71 
transmission and evolution, and to confirm whether 
group A viruses have re-emerged.
The B group has been predominant in Malaysia and 
Singapore, whereas the C group has been so in east Asia,
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Figure 3: Phylogenetic analysis of enterovirus 71VP1 gene sequences
A neighbour-joining tree constructed with the Kimura-2 parameter as a model for nucleotide substitution. The 
robustness of the tree was determined by bootstrapping, with use of 1000 pseudoreplicates,.
especially in mainland China and Vietnam (figure 3). 
Group B viruses, which were initially separated into 
subgroups, B1 and B2, owing to 12% divergence at the 
nucleotide level, were the predominant circulating strains 
in the 1970s and 1980s.53 Group C viruses, which were 
initially separated into the Cl and C2 subgroups, were 
identified in the mid-1980s (figure 3). Several subgroups 
have been added to groups B and C in the past 12 years, 
according to findings in the Asia-Pacific region (figure 3, 
table 2). Viruses in subgroups B3 and B4 are thought to 
have both circulated in the region since 1997.1314'45 
Subgroup B5, was first isolated in Japan and Sarawak 
in 2003, caused epidemics in Brunei, Sarawak, and Taiwan 
in 2006.16’55,5''/>8 Except for the major community outbreak 
in Sydney in 1986, subgroup Cl viruses have been isolated 
mainly from sporadic cases since the mid-1980s, 
which suggests low-level circulation worldwide.53,65 
Subgroup C2 viruses caused the outbreak in 1998, and an 
outbreak in Perth, Australia, in 1999.s'a4770 Subgroup C3 
was isolated in Japan in 1994, and in Korea in 2000.13,16,71 
Subgroup C4 has been the predominant circulating 
subtype in mainland China since 2000, and has been 
reported in Japan, Vietnam, and Taiwan.5,12,14,47 Subgroup C5 
has been reported in southern Vietnam and Taiwan.5,46 A 
genetically distinct EV71 strain (R13223, Genbank 
accession number AY179600 to AY179602), with no genetic 
relationship to other EV71 strains, was isolated in India 
in 2001 from one child with acute flaccid paralysis.72
Transmission and epidemic potential
Surveillance systems for EV71 established in several 
countries in the Asia-Pacific region, mainly to monitor 
transmission and spread, have provided information on 
virus evolution during outbreaks. In Sarawak, viral 
activity has increased every 3 years since 1997. This 
pattern is closely associated with increases in community 
incidence of HFMD.55 Regular cyclical epidemics have 
also been seen in Fukushima Prefecture, Japan.57 Such 
cyclical activity is assumed to relate to the availability of 
new birth cohorts of children who have not been exposed 
to the virus.73,74 Prediction of the epidemic potential of 
particular genotypic subgroups has proved difficult, 
although some differences in virulence, judged by size of 
associated epidemics, exist.
Shifts in subgroup dominance have been reported in 
Sarawak and Vietnam.5,13,55 In Japan and Taiwan subgroups 
of the B and C viruses have caused epidemics at different 
times (table 2).46,47,75 By contrast, in the Netherlands group B 
vimses were predominant before 1986, but since 1987 
dominance has shifted to group C viruses; cross- 
neutralisation among the group B but not group C viruses 
is a possible explanation, although experimental data seem 
not to support this theory.3,76"78 Older subgroups of EV71 
have been circulating and causing low levels of disease for 
many years, whereas some of those in newly described 
subgroups, such as B5, possess antigenicity distinct from 
other viruses and might, therefore, have the potential to
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cause very large outbreaks/'7'1 Although outbreaks have so 
far been confined to the Asia-Pacific region, increasing 
rates of travel mean that every region could be at risk.
Recombination
Recombination events occur frequently within enterovirus 
species/ and recombination between EV71 viruses, and 
occasionally between EV71 and other enteroviruses, such 
as coxsackievirus types A 16 and A 8, has also been 
reported/80 Since recombination most often involves 
non-structural gene regions or untranslated regions, the 
use of PCR that amplifies the VP1 gene region is thought 
to be robust for diagnosis.
Pathogenesis
Viral determinants of virulence
The factors that determine whether EV71 infection will 
be asymptomatic or lead to HFMD or severe neurological 
disease are unknown. For polioviruses, the 5' untranslated 
region and VP1 genes contain virulence determinants.26 
Several studies have, therefore, examined the relevant 
nucleotide sequences or the whole genome to compare 
isolates from fatal and non-fatal cases, but most isolates 
have been identical or nearly identical.81'82 The frequency 
of CNS disease and other severe complications of EV71 
infection has varied between Asian outbreaks, which 
suggests differences in virulence of subtypes. However, 
comparisons of outbreak data have been hampered by 
differences in study designs and viral diagnostic 
capabilities.
Perhaps the strongest data that determinants of strain 
virulence have key roles in the pathogenesis of severe 
neurological disease come from outbreaks in 
Perth, Australia, and Sarawak. In Perth, in 1999, 
subgroups B3 and C2 were both circulating.45'70 C2 viruses 
linked to the Taiwan epidemic of 1998 were almost 
exclusively isolated from children with severe neurological 
disease, and only one isolate came from a case of 
uncomplicated HFMD.45,70 By contrast, B3 viruses, which 
were similar to those from the Sarawak 1997 epidemic, 
were isolated mainly from children with uncomplicated 
HFMD, aseptic meningitis, or those with neurological 
complications, none of whom died.8 In two discrete 
epidemics in Sarawak in which either B4 or B5 viruses 
were predominant, a study of 277 children with EV71- 
associated HFMD showed that B4viruses were less likely 
than B5 viruses to cause CNS infection or be part of a 
family cluster.81
Dual infection
During the 1997 EV71 B3 virus outbreak in Sarawak, an 
adenovirus type 21 was isolated in the patients who died 
and in some with acute flaccid paralysis.4,84 The virus was 
detected at autopsy in sterile sites, such as cerebrospinal 
fluid and brain and heart tissue, in more patients than 
EV71. This finding led to the suggestion that death was 
related to dual infection,4 but subsequent detailed
studies, including longitudinal studies from Sarawak, 
have found no evidence of adenovirus 21 infection in 
other HFMD or neurological cases. Dual infection with 
EV71 and other viruses, including dengue and 
Japanese encephalitis, has been reported.83 Furthermore, 
adenovirus 21 has not been isolated in Sarawak 
since 1997.
Host susceptibility
Various factors could affect pathogenesis, especially 
partial cross-protective immunity from previous 
outbreaks, which might partly explain why young age is 
a risk factor for severe disease.73,7485 One genetic study in 
Taiwan reported that H LA-A3 3 is associated with 
increased susceptibility to EV71 infection, although the 
role of MHC remains unknown.86 The researchers 
noted that HLA-A33 is more frequent in Asian 
populations than in white populations, which might 
explain the high number of EV71 epidemics in Asia. 
They suggested also that HLA-A2, in a mechanism yet 
to be defined, could be linked to the risk of 
cardiopulmonary failure in patients with EV71.86 The 
CTLA4 gene is an important regulator of T-cell 
cytotoxicity, and it has a role in the regulation of an 
immune response. In a study of 78 children with 
EV71 infection in Taiwan, those with meningo­
encephalitis had a higher frequency of G/G genotype at 
position 49 of exon 1 in this gene, than those without 
meningoencephalitis and controls.87 However, a 
subsequent study found no such association.86
Pathophysiology of severe disease
Virus entry and spread
EV71 is transmitted predominantly via the faeco-oral 
route, but can also spread through contact with virus- 
contaminated oral secretions, vesicular fluid, surfaces or 
fomites, and in respiratory droplets.1 As with other 
enteroviruses, initial viral replication is presumed to 
occur in the lymphoid tissues of the oropharyngeal cavity 
(tonsils) and small bowel (Peyer’s patches), with further 
multiplication in the regional lymph nodes (deep cervical 
and mesenteric nodes), giving rise to a mild viraemia. 
Most infections are controlled at this point and remain 
asymptomatic. Further dissemination of enteroviruses to 
the reticuloendothelial system (liver, spleen, bone marrow, 
and lymph nodes), heart, lung, pancreas, skin, mucous 
membranes, and CNS coincides with the onset of clinical 
features. For EV71, viral shedding from the throat can 
occur up to 2 weeks after an acute EV71 infection, and 
virus can be isolated from stool for up to 11 weeks.88
Epidemiological and experimental studies suggest that 
polioviruses can invade the CNS system through a 
disrupted blood-brain barrier or retrograde axonal 
spread along cranial or peripheral nerves. For EV71, 
studies in mice and assessment of the distribution of 
virus and inflammation in fatal human cases implicate 
the latter route.88'91
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Pathological findings
CNS inflammation predominantly affects grey matter 
of the spinal cord and the whole medulla oblongata, 
including the dorsal nucleus of the vagus,
Figure4 Pathological findings in enterovirus 71 encephalitis
(A) Parenchymal inflammation (arrow) and perivascular cuffing in the the medulla. Severely inflamed areas show
(B) oedema (asterisk) and (C) neuronophagia (arrows). (D) More-subtle inflammation can be seen in the motor 
cortex, with mild perivascular cuffing (arrow) and parenchymal inflammatory cells (circle). (E) Numerous 
CD68-positive macrophages/microglia (arrows). (F) A CD8-positive lymphocyte adjacent to a neuron (arrow).
(G) Viral RNA in the anterior horn cells of the spinal cord (arrows). (H) Viral antigens in the neuronal body and 
process in the hypothalamus. (I) Adjacent section of the same neuron that was positive for viral RNA, and (J) 
adjacent section that was positive for antigen. Stains: haematoxylin and eosin (A-D), immunohistochemistry/ 
peroxidase/DAB (E, F), and ISFI/nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (G). Original 
magnifications: x4 (A), xlO(B and D), x40 (C and F), and x20 (G). Modified from the Journal of Neuropathololgy and 
Experimental Neurology,® with permission ofWolters Kluwer.
tractus solitarius, the nucleus, and reticular formation. 
The hypothalamus and subthalamic and dentate nuclei, 
and to a lesser degree motor cortex of the cerebrum, are 
also involved (figure 4).17’54'90'92-94 Inflammatory changes 
were absent in cerebellar cortex, thalamus, basal 
ganglia, peripheral nerve, and autonomic ganglia. 
Histopathological changes, characterised by perivascular 
cuffs, variable oedema, neuronophagia, and microglia 
nodules, are similar to those in encephalitis caused by 
other viruses.’5 However, virus inclusion has not been 
observed, and viral antigens and RNA can be seen in 
only a few neuronal processes and phagocytic cells.90
Severe pulmonary oedema and heart failure
Although fulminant pulmonary oedema is preceded by 
and closely associated with CNS involvement, its cause 
is unclear, especially whether neurogenic pulmonary 
oedema, cardiac dysfunction, increased vascular 
permeability, and cytokine storm contribute (figure 5).
Neurogenic pulmonary oedema classically follows head 
injury. In these cases, raised intracranial pressure is 
thought to be important, but the pathogenesis is not 
completely understood. Experimental studies suggest that 
the hypothalamus, vasomotor centres of the medulla, and 
nuclei in the cervical spinal cord are important; lesions to 
various nuclei in these regions can increase activity along 
the sympathetic trunk, resulting in severe systemic and 
pulmonary hypertension and pulmonary oedema.90 
Damage to brainstem nuclei in poliomyelitis is thought to 
lead to pulmonary oedema of neurogenic origin.97 Thus, 
when severe pulmonary oedema was first seen in 
EV71 encephalitis along with brainstem inflammatory 
changes, oedema was thought to be neurogenic. Post­
mortem examination and MRI studies of children with 
EV71 brainstem encephalitis showed extensive 
inflammation of grey matter of the spinal cord and the 
whole medulla oblongata.1754909’94 The observations of 
hyperglycaemia and leucocytosis were also postulated to 
be due to increased sympathetic discharges.98
Severe systemic and pulmonary hypertension is 
not always seen in children with EV71-associated 
pulmonary oedema.99",0, This disparity might arise 
because the changes in vascular pressures in neurogenic 
pulmonary oedema are only transient.90 Some 
commentators have argued that cardiac dysfunction is a 
major contributor to the pulmonary oedema. Although 
no histological or virological evidence of viral myocarditis 
is seen in patients with EV71 infection, raised 
concentrations of cardiac-specific troponin I suggest a 
degree of cardiac damage.18 54101 102 An echocardiographic 
study in 11 children with EV71 brainstem encephalitis 
showed that cardiac function was impaired, indicated by 
substantially lowered left-ventricular ejection fractions.101 
Two children whose cardiac output was supported with a 
left-ventricular assist device survived, whereas all the 
others died.101 In a separate report the same researchers 
described very high concentrations of norepinephrine
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and epinephrine in three of the 17 children with left- 
ventricular dysfunction.10'
Although patients with EV71 infection do not have 
myocardial inflammation, histological examination of 
cardiac ventricular tissue biopsy samples from six fatal 
cases and one survivor revealed notable coagulative 
myocytolysis. myofibrillar degeneration, and cardio- 
myocyte apoptosis, which are the characteristic features of 
catecholamine-associated cardiotoxic effects.10110* Thus, 
high catecholamine concentrations caused by brainstem 
encephalitis are purported to have a direct effect on cardiac
function, as well as to cause pulmonary oedema via raised 
pulmonary pressures.
The other potential contributor to pulmonary oedema, 
increased vascular permeability, might arise secondary to 
the systemic inflammatory response. Several studies have 
examined cytokine and chemokine profiles in 
EV71 patients with brainstem encephalitis: concentrations 
of interleukins IB, 6,10, and 13, tumour necrosis factor a, 
and interferon y are all significantly higher in patients 
with EV71 with pulmonary oedema than in those without. 
Several of these cytokines are mediators of increased
? Viral entry via blood-brain barrier 
? Viral entry via spinal neural route
Ma)or pathway
ttSVR; ttSBP; ft HR
Cardiomyocyte apoptosis
Acute LV dysfunction
Massive catecholamine release
Cardiac damage
Strong CNS inflammatory response
Virus entry into CNS
Brainstem encephalitis
Severe EV71 infection
Cytokine storm
Strong systemic inflammatory response
Systemic viral sepsis
Increased pulmonary vascular permeability
Acute pulmonary oedema 
(haemorrhage)
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Figure S'- The postulated pathogenesis of enterovirus-71-associated acute pulmonary oedema
EV71-enterovirus 71. CNS-central nervous system. SVR-systemic vascular resistance. SBP-systemic blood pressure. HR=heart rate. LV=left ventricular.
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vascular permeability.1115'107 High concentrations of several 
chemokines in plasma, including 10 kDa-interferon-y- 
induced protein, monocyte chemoattractant protein, 
monokine induced by interferon y, and interleukin 8, 
have been reported in children with brainstem encephalitis 
and pulmonary oedema.108 Children with oedema also 
had depleted lymphocyte populations, especially 
CD4, CDS, and natural killer cells.87 107 Thrombocytosis, 
neutrophilia, and hyperglycaemia are all thought to reflect 
a systemic inflammatory response.105,107 Cytokines in the 
cerebrospinal fluid are less studied than those in blood, 
but in one study patients with encephalitis complicated 
by oedema had high concentrations of interleukin lb, 
compared with those who had encephalitis alone.105
The development of pulmonary oedema in patients 
with EV71 encephalitis seems to be strongly associated 
with dysregulation of systemic and CNS inflammatory 
responses. This relation has formed at least part of the 
basis for anti-inflammatory therapy with intravenous 
immunoglobulin, and the approach does seem to be 
effective.83,99,100-111
The exact mechanism for pulmonary oedema in 
EV71 encephalitis is unclear. Neurogenic mechanisms 
secondary to brainstem inflammation seem to be 
important, but pathologically similar changes are seen 
in other encephalitides, such as Japanese encephalitis, 
without pulmonary oedema being such a prominent 
feature. Cardiac dysfunction and the effects of the 
systemic inflammatory response on the vascular 
endothelium may also make important contributions. 
In-vivo models, including those in mice and non­
human primates, have replicated some of the features 
of severe EV71 disease, such as neuroinvasion with 
inflammatory changes, but none has yet been able to 
reproduce the severe systemic features, such as 
pulmonary oedema.S0''J1,112'm
Prospects for control
Surveillance and social distancing
The only measures available for disease control are public 
health approaches. Since early intervention can lessen the 
spread of the virus, many countries in the Asia-Pacific 
region, including Japan, Malaysia, Singapore, Taiwan, 
and Vietnam, have implemented heightened surveillance 
for EV71.15,55,50,115,116 HFMD has now become a notifiable 
disease in many countries in the region.116 However, since 
other enteroviruses, such as coxsackievirus types A 8, 
A 10, and A 16, can cause HFMD, concurrent virological 
surveillance is necessary. This approach can also provide 
invaluable molecular epidemiological data that might 
help to track the spread of the virus across the region.
Outbreak control measures are primarily targeted at 
interrupting virus transmission person to person and 
through contact with contaminated surfaces, toys, or 
fomites. Health education, therefore, focuses on 
personal hygiene and good sanitation, including 
frequent hand washing, proper disposal of soiled
nappies, and disinfection of soiled surfaces with 
chlorinated (bleach) disinfectants.
The transmission of enteroviruses, including EV71, is 
most efficient in crowded settings and, therefore, most 
countries in the region, including Malaysia, Singapore, 
Taiwan, Hong Kong, and China, have adopted social 
distancing measures, such as closures of childcare 
facilities and schools, and cancellation of public functions 
involving children,115110 Little systematic research has been 
done to assess the effectiveness of such measures, but one 
study from Singapore seemed to show some benefit.115 
However, the optimum timing for implementation—as 
soon as an HFMD outbreak is reported or after it is 
confirmed to be caused by EV71—is unclear. In addition, 
the effectiveness of distancing measures, which have 
substantial socioeconomic implications, is uncertain. If 
EV71 is like other directly transmissible viruses, such 
controls will decrease the peak incidence of disease, but 
the outbreak could be prolonged and, therefore, the overall 
number of cases might not be lowered (Cardosa MJ, 
unpublished; figure 6). Transmission of the virus within 
families rather than the peer-group at school could lead to 
increased incidence of severe cases, as the inoculum 
concentration is thought to be higher.85 Data from clinical 
and epidemiological studies are needed to guide public 
health decisions.
Vaccine development
No vaccines against EV71 exist, but by analogy with 
poliomyelitis, vaccination probably offers the best option 
for disease control. One limitation in EV71 vaccine 
development is the lack of a good mouse model of human 
disease. Adult mice are resistant to infection. Although 
suckling mice are susceptible, by the time immunity 
develops after inoculation, the animals have matured and 
become resistant to infection. One way around this issue 
is to vaccinate female adult mice, allow them to become 
pregnant, and then measure litres of protective maternal 
antibodies transferred to offspring, as judged by 
protection against lethal infection.117
In human beings the target population should be 
young children, especially those younger than 3 years, 
because they are the most susceptible to severe disease. 
One important issue is whether vaccines derived against 
one EV71 genetic subgroup will provide cross-protection 
against all others; available data are contradictory.76"78 
Several comprehensive reviews on the development of 
EV71 vaccine candidates have been published.118,119 Various 
types of vaccines are being investigated, including 
inactivated whole-virus, live attenuated, subviral particle, 
and DNA vaccines. All types are in early stages of 
development, with the most advanced undergoing 
preclinical trials in mice and non-human primates.
Candidate inactivated vaccines include those derived in 
Taiwan from the B4 viruses EV71-075 and EV71-0117, 
which are highly immunogenic, and from EV71-1207, 
which is a C2 virus and is less immunogenic. In one
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Figure 6: Comparison of data from sentinel surveillance centres on effects of public health interventions on hand, foot, and mouth disease in Sarawak, 
Malaysia, in 2003 and 2006
The public health response was limited in 2003, but more-rigorous social distancing measures were encouraged in 2006.
study all these vaccines were more immunogenic in mice 
than recombinant VP1 protein or DNA vectored 
vaccines.1* Virus-like particles for EV71, which resemble 
the virus in appearance and capsid and protein structure, 
have been produced and purified as potential vaccines.121 
After immunisation of BALB/c mice, the particles 
induced potent and long-lasting humoral immune 
responses, reflected by high total IgG and neutralisation 
litres. Splenocytes collected from the immunised mice 
exhibited substantial cell proliferation and stimulated 
production of interferon y and interleukins 2 and 4, 
indicating the induction of T-helper-1 and T-helper-2 
immune responses. Immunisation of female mice 
conferred protection (survival up to 89%) to neonatal 
mice against virus challenge with a dose 1000 times that 
normally required to kill 50% of animals.121
A potential DNA vaccine has been developed by 
inserting the VP1 gene into the pVAXl vector, and 
transforming the constructs into Escherichia coli cells, 
followed by expression in a mammalian cell line.122 
Immunisation of mice with the DNA vaccine constructs 
resulted in the production of antibodies to VP1 IgG and 
neutralising antibody against EV71. Oral immunisation 
of female mice with an attenuated Salmonella enterica 
serovar Typhimurium expressing the VP1 gene, also 
proved protective in newborn offspring.121 Transgenic 
tomatoes expressing the VP1 protein have been 
developed. Incorporation of this protein in an oral 
vaccine led to the development of VPl-specific antibodies 
and evidence of cell-mediated immunity in BALB/c mice, 
and provided protection to offspring in neonatal 
challenge models.124
Linear neutralising epitopes from the VP1 capsid protein 
were identified in mice by raised concentrations of antisera 
against overlapping peptides from this protein, two of
which elicited neutralising antibody responses.125 One of 
these peptides, S P70, was especially potent, and comparison 
with sequences from other strains showed it was conserved 
among the different genotypic subgroups of EV71, which 
suggests it is a promising vaccine candidate.
A live attenuated strain of EV71, EV71(Sl-3), was derived 
from the genotype A prototype strain BrCr by genetic 
manipulation,126 on the basis of temperature-sensitive 
determinants of poliovirus type 1 vaccine strain, some of 
which are located in the 5' and 3' untranslated regions 
and the 3Dpol gene. Intravenous inoculation of 
cynomolgus monkeys led to the production of antibodies 
with cross-reactivity against a broad spectrum of EV71 
genotypes that survived challenge with intravenous 
virulent EV71 (BrCr-TR strain), which is lethal to non- 
immunised monkeys. However, the vaccine strain itself 
caused mild neurological symptoms (tremor) and entered 
the spinal cord, which indicated that further work on 
attenuation is needed.126
Among the various vaccine candidates, inactivated 
whole virus vaccines are in some ways the most ready to 
develop further, because the principles of vaccines based 
on inactive whole virus are well established. However, 
experience with vaccination against Japanese encephalitis, 
another major neurological infection in Asia, has shown 
that issues over cost and availability can limit the 
widespread uptake of vaccines in poor Asian countries. If 
a vaccine is to be used across the whole of Asia, it needs 
to be cheap, easily produced, and readily available.127
Conclusions
The increased size and frequency of EV71 outbreaks in the 
Asia-Pacific region over the past 12 years has been an 
important public health issue. Molecular epidemiological 
studies suggest that some viral genotypic subgroups seem
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to have massive potential for explosive epidemics, whereas 
others have more-indolent, low-level circulation. However, 
the biological determinants of these differences are poorly 
understood. The reasons for epidemiological differences 
between EV71 in the Asia-Pacific region and that in Europe 
and the USA are also unclear, as are the virological and 
host determinants of the wide-ranging clinical phenotypes 
in infected individuals. Although some animal models of 
neurological disease caused by EV71 are reasonable, a 
good model of cardiorespiratory dysfunction is urgently 
required to help understand pathogenesis better.
The public health measures currently used during 
EV71 epidemics are empirical and generic, have high 
socioeconomic impact and are not clearly effective. 
Further research is needed on virus transmission. The 
identification of several EV71 receptors might help in 
drug discovery. Several vaccine candidates are under 
development, but the logistical issues of how to reach 
their target paediatric populations remain important. 
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Clinical features, diagnosis, and management of 
enterovirus 71
Mong How Ooi, See Chang Wong, Penny Lewthwaite, Maiy Jane Cardosa, Tom Solomon
Although poliomyelitis has been mostly eradicated worldwide, large outbreaks of the related enterovirus 71 have been 
seen in Asia-Pacific countries in the past 10 years. This virus mostly affects children, manifesting as hand, foot, and 
mouth disease, aseptic meningitis, poliomyelitis-like acute flaccid paralysis, brainstem encephalitis, and other severe 
systemic disorders, including especially pulmonary oedema and cardiorespiratory collapse. Clinical predictors of 
severe disease include high temperature and lethargy, and lumbar puncture might reveal pleocytosis. Many diagnostic 
tests are available, but PCR of throat swabs and vesicle fluid, if available, is among the most efficient. Features of 
inflammation, particularly in the anterior horns of the spinal cord, the dorsal pons, and the medulla can be clearly 
seen on MRI. No established antiviral treatment is available. Intravenous immunoglobulin seems to be beneficial in 
severe disease, perhaps through non-specific anti-inflammatory mechanisms, but has not been tested in any formal 
trials. Milrinone might be helpful in patients with cardiac dysfunction.
Introduction
A global campaign has all but eradicated poliomyelitis 
from Europe, the Americas, and much of Africa and Asia. 
Over the past 10 years, however, the related enterovirus 71 
(EV71) has emerged across Asia, where it threatens to 
become what has been coined the new polio.1 The virus is 
a member of the enterovirus genus, which includes 
coxsackieviruses and echovimses, EV71 first appeared in 
California, USA, in the 1960s, and caused sporadic cases or 
small outbreaks of hand, foot, and mouth disease (HFMD), 
neurological disease, or both (table 1). In 1997, the virus 
caused an unexpectedly large and severe outbreak in 
Sarawak, Malaysia, with high mortality. Regular epidemics 
have since been seen in countries across the Asia-Pacific 
region, including an epidemic in Taiwan in 1998 that was 
thought to involve millions of people, and an outbreak of 
HFMD in China, during which nearly 500000 cases were 
reported.13’14'17'18'2225"30
During outbreaks, thousands of children can develop 
HFMD, and although most will have self-limiting illness, a 
small proportion can rapidly develop neurological and 
systemic complications that can be fatal. EV71 is, therefore, 
of major interest to neurologists, paediatricians, and 
specialists in infectious diseases, virology, and public 
health. In this Review we discuss clinical management, 
diagnosis, and treatment of EV71 disease. In a companion 
article in The Lancet Infectious Diseases,1' we examine the 
virology, clinical and molecular epidemiology, patho­
genesis, and public health implications of this important 
emerging virus.
Clinical features
EV71 infection has a wide variety of clinical 
manifestations, although CNS infection and HFMD are 
the two features most frequently seen.14
Mucocutaneous and respiratory manifestations
HFMD is a common childhood exanthema that is 
characterised by a brief, generally mild, febrile illness with 
papulovesicular rash on the palms and soles, and multiple
oral ulcers (figure 1). Herpangina, a closely related 
childhood enanthema, is characterised by febrile illness 
and the presence of multiple oral ulcers that predominantly 
affect the posterior of the oral cavity, including the anterior 
pharyngeal folds, uvula, tonsils, and soft palate. A classic 
coruse of HFMD generally occrus in older children with 
EV71, but in those aged 2 years and younger more- 
widespread and atypical rashes are frequently seen. Other 
features include upper respiratory tract infection, 
gastroenteritis, and non-specific viral rashes,32 and, 
especially in young children, exacerbation of bronchial 
asthma, bronchiolitis, and pneumonia.33 More than 20% 
of adult contacts in one Taiwanese outbreak had symp­
toms of an upper respiratory tract infection, but more than 
50% of infected adults remained symptom free.32
Neurological and systemic manifestations
As for other enteroviruses, EV71 can cause aseptic 
meningitis, acute flaccid paralysis, encephalitis, and 
other rarer manifestations (table 2).34 EV71 encephalitis is 
typically a brainstem encephalitis and, unlike most other 
enteroviruses, is frequently accompanied by severe 
cardiorespiratory symptoms, similar to those associated 
with poliomyelitis. These symptoms have been attributed 
to neurogenic pulmonary oedema, although the cause 
remains controversial.31
In a large prospective clinical study of several epidemics 
occurring over 7 years in Sarawak, 10-30% of children 
admitted to hospital with EV71-related HFMD also 
developed CNS complications.17'23 Brainstem encephalitis 
was the most frequent presentation, accounting for 58% of 
neurological manifestations, followed by aseptic meningitis 
(36%), and brainstem encephalitis with cardiorespiratory 
dysfunction (4%). Most children with CNS involvement 
also had features of HFMD, but a small proportion 
presented only with neurological features.17
Myoclonic jerks are seen more often in EV71 than in 
other enteroviruses, and could be an early indicator of 
neurological involvement, particularly in the brainstem.35 
This symptom has, however, also been reported in other
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Number of EV71 cases 
reported
Number of fatal cases reported Main clinical presentations
California, USA.1969-72’ 20 1 Encephalitis, meningitis, coxsackievirus-like illness
New York. USA. 1972' 11 0 Aseptic meningitis, encephalitis, HFMD (only one case)
Sweden, 19734 195 0 Aseptic meningitis, HFMD (some cases)
Bulgaria. 1975’ 70S 44 Aseptic meningitis, paralytic disease, including bulbar encephalitis
Japan, 1973.1977.1978* 1031 Some deaths, exact number unknown HFMD (in most patients), cerebellar encephalitis, meningitis, acute flaccid paralysis
New York, USA. 1977’ 12 0 CNS disease, HFMD, acute respiratory illness, acute gastroenteritis
Hungary. 1978* 323 laboratory confirmed 47 (unclear whether all due to EV71) Meningitis, encephalitis, poliomyelitis, HFMD (only four cases)
Australia, 1986’ 114 0 HFMD (in most cases), meningitis, encephalitis, encephalomyelopathy
Philadelphia. 1987K 5 0 Acute flaccid paralysis
USA, 1977-91" 193 laboratory confirmed Unknown 1985-89: paralysis, meningitis, encephalitis, rash, Guillain-Barre syndrome
Sarawak, Malaysia, 1997“ 2628 34 HFMD, aseptic meningitis, acute flaccid paralysis, cardiorespiratory dysfunction
Otsu, Japan. 1997'' 12 0 HFMD, herpangina, meningoencephalitis, encephalitis, meningitis
Taiwan, 1998“ 129106 78 Encephalitis, aseptic meningitis, pulmonary oedema or haemorrhage, acute flaccid 
paralysis, myocarditis
Kenya. 1999“ 8 0 Dermatitis, mucositis, myositis
Hyogo, Japan, 2000“ 60 1 HFMD, aseptic meningitis, cerebellar ataxia, acute flaccid paralysis, brainstem 
encephalitis
Sarawak. Malaysia. 2000“ 169 laboratory confirmed 2 HFMD, aseptic meningitis, acute flaccid paralysis, brainstem encephalitis
Singapore, 2000“ 3790 5 HFMD, neurological disease
Korea, 2000’’ Unknown 0 Aseptic meningitis, HFMD, herpangina, acute flaccid paralysis
Sarawak. Malaysia, 2003“ 107 laboratory confirmed 1 HFMD, aseptic meningitis, acute flaccid paralysis, brainstem encephalitis
Fukushima. Japan. 1983-2003* Unknown Unknown Unknown
Denver. USA. 2003’ 8 1 Meningitis, acute flaccid paralysis, fever, cardiopulmonary dysfunction
Southern Vietnam, 2005 173 laboratory confirmed 3 HFMD, aseptic meningitis, acute flaccid paralysis, brainstem encephalitis
Sarawak, Malaysia. 2006'' 291 laboratory confirmed 6 HFMD, aseptic meningitis, brainstem encephalitis
Denver, USA. 2005n 8 0 Meningitis, acute flaccid paralysis, fever, encephalitis
Brunei, 2006“ 1681 3 HFMD, neurological disease
Shandong. China. 2007“ 1149 3 HFMD, brainstem encephalitis, aseptic meningitis
Anhui, China. 2008“ 488955 128 HFMD, neurogenic pulmonary oedema
HFMD-hand, foot and mouth disease.
Table 1: Enterovirus 71 outbreaks worldwide, by country and year
viral CNS infections, including Japanese encephalitis, 
Nipah virus, subacute sclerosing panencephalitis, herpes 
simplex virus, HIV, and varicella-zoster virus. In addition, 
myoclonic jerks seen in many otherwise healthy young 
children, particularly when they are asleep, can occur 
spontaneously or be provoked by loud noises.
Seizures, if they occur at all in EV71 infection, are seen 
generally in children aged younger than 2 years and are 
short lived with good recovery of consciousness. Thus, 
they are likely to be febrile seizures rather than being 
caused by CNS involvement. Unlike other viral encepha- 
litides, recurrent and sustained seizures are very rare, 
which probably reflects the fact that EV71 is associated 
with a brainstem rather than a cortical encephalitis.
Brainstem encephalitis with associated pulmonary 
oedema has been the hallmark of EV71 CNS infection in 
Asia since the late 1990s.li,,z7,‘ This distinctive clinical 
syndrome is characterised by prodromal HFMD 
followed by a sudden deterioration that typically occurs 
after 3-5 days of fever. Children then develop acute and 
rapidly progressing cardiorespiratory failure, which
presents as shock and pulmonary oedema or 
haemorrhages. Without intensive care most children 
affected in this way will die before reaching hospital or 
within 24 h of admission.1218-2716
In the few studies where it has been possible to assess 
children with brainstem encephalitis, MRI and post­
mortem findings have correlated well, with both 
showing frequent involvement of the medulla oblongata, 
reticular formation, pons, and midbrain (figure 2).17'19 
Acute flaccid paralysis is the primary presenting feature 
in several neurological syndromes caused by EV71, 
including poliomyelitis-like anterior horn cell 
destruction (anterior myelitis), Guillain-Barre syndrome, 
and transverse myelitis. Anterior horn cell destruction 
is probably the most frequently seen of these syndromes, 
although it is generally less severe than that caused by 
polioviruses and has a higher recovery rate.14
During the 1998 Taiwan epidemic the severity of 
brainstem encephalitis was categorised into three 
grades: grade I, myoclonic jerks, tremor or ataxia, or 
both; grade II, cranial nerve palsies evident from eye-
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movement disorders (nystagmus, strabismus, or gaze 
paresis), facial weakness, and bulbar palsy (dysphagia, 
dysarthria and dysphonia); and grade III, acute onset of 
intractable, frequently fatal, cardiorespiratory failure.’6 
A separate clinical staging system (stages 1—4) has been 
used to help monitor the clinical course of EV71 
infection from febrile illness, to CNS involvement, to 
cardiorespiratory failure, and development of sequelae, 
and to aid management.4041 These systems are not, 
however, widely used, possibly because they are not 
always easy to remember and imply sequential 
progression, which does not always occur. The WHO 
Informal Consultation on Hand, Foot, and Mouth 
Disease, in Kuala Lumpur, Malaysia, in March, 2010, 
has proposed a simple clinical description of disease 
manifestation to describe the natural history of the 
disease, which will be published next year.
Diagnosis
During outbreaks of EV71, thousands of children develop 
symptoms (table 1). Most of them will have mild, self- 
limiting illness, but a small proportion of infected 
children rapidly develop severe and sometimes fatal 
neurological and systemic complications over days or 
even hours. In the past, many children with mild HFMD 
were originally cared for at home, but an increase in 
public awareness about the swift development of 
potentially fatal complications has led to many now being 
taken to hospital, and health services can easily become 
overwhelmed. A challenge for front-line clinicians is to 
recognise which patients are likely to deteriorate and to 
know which investigations give the best diagnostic yield.
Differential diagnosis
Childhood exanthema from a wide variety of causes can 
be confused with HFMD, particularly those seen with 
measles, rubella, and chicken pox (panel).42 Two 
particularly important causes to consider are 
meningococcus, because of the need for antimicrobial 
treatments, and dengue, because of the risk of developing 
dengue haemorrhagic fever, as severe forms require 
careful fluid resuscitation. Herpangina can be confused 
with aphthous ulcer and herpetic gingivostomatitis.
Of the many enteroviruses that can cause HFMD or 
herpangina, EV71 and coxsackievirus type A 16 are the 
most frequent, and both can cause epidemic disease. 
Coxsackievirus type A 16 is not generally associated with 
neurological disease,43 but the rash it causes is 
indistinguishable from that caused by EV71. However, 
other features can distinguish the two causes of HFMD. 
For example, studies from Sarawak and Taiwan show 
that children with EV71 are more likely to have a fever for 
longer than 3 days, with a peak temperature higher than 
38 • 5°C, lethargy, and myoclonus.23,44
Aseptic meningitis, which is a frequent neurological 
manifestation of EV71, must be distinguished from a 
broad range of other viruses, especially echoviruses and
Frequency
Purely neurological manifestations
Encephalitis, especially brainstem Frequent
Acute flaccid paralysis (anterior myelitis) Frequent
Encephalomyelitis Frequent
Aseptic meningitis Very frequent
Cerebellar ataxia Infrequent
Transverse myelitis Rare
Neurological and systemic manifestations
Brainstem encephalitis with cardiorespiratory failure Frequent
Manifestations indicative of immune-mediated mechanisms
Guillain-Barr£ syndrome Infrequent
Opsoclonus-myoclonus syndrome Rare
Benign intracranial hypertension Rare
Modified from McMinn,” with permission of John Wiley and Sons.
Table 2: Neurological syndromes associated with enterovirus 71 infection
other enteroviruses, adenoviruses, mumps, and 
occasionally Japanese encephalitis virus; partly treated 
bacterial meningitis and tuberculous meningitis should 
also be considered. Most patients with severe CNS 
disease due to EV71 also have features of shock and 
collapse. Septicaemia is, therefore, an important 
differential diagnosis. Other causes of encephalopathy 
might need to be excluded, particularly malaria. When 
acute flaccid paralysis is the predominant feature, the 
differential diagnosis includes poliomyelitis caused by 
wild-type polioviruses or vaccination, other enteroviruses, 
flaviviruses, rabies, Guillain-Barre syndrome, and 
bacterial toxins, such as diphtheria.
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Figure 2: MRI changes in enterovims-71-associated encephalomyelitis
T2 -weighted images of a child aged 10 months who had presented 3 months earlier with somnolence, tachycardia, 
tachypnoea. and coma, and who recovered consciousness but remained dependent on a ventilator. High signal 
intensity can be seen in (A) the posterior portion of the pons and medulla (green arrows) and anterior cervical cord 
(white arrows) on a sagittal section, and (B) in the two anterior horns of the cervical cords (green arrows) on an 
axial section. Modified from Shen and colleagues," with permission of the American Society of Neuroradiology.
Virological diagnosis
Laboratory diagnosis of EV71 is established primarily 
through virus isolation or molecular detection of the 
virus nucleic acid in appropriate clinical specimens. This 
approach is important to distinguish EV71 from other 
enteroviruses, such as coxsackievirus type A 16.
Choice of sample
Samples for laboratory investigation should be selected 
according to the disease manifestations. Possibilities 
include throat, rectal, and ulcer swabs, and samples of 
serum, urine, CSF, and fluid from vesicles. The 
sensitivity, specificity, and usefulness of findings vary 
according to the sample.4' In particular, virus detection in 
samples from sterile sites, such as vesicular fluid, CSF, 
serum, urine, or those gathered at autopsy, is more 
reliable than that in samples from non-sterile sites, such 
as the throat or rectum, where the presence of the virus 
might merely indicate coincidental carriage.
Viral shedding from the gastrointestinal tract (via the 
throat or rectum or in stools) might continue after 
complete resolution of the symptoms of EV71 infection, as 
it does for other enteroviruses. A study in Taiwan showed 
that EV71 can be detected in the throat up to 2 weeks after 
recovery from HFMD or herpangina, and in stools it can 
be detected up to 11 weeks after recovery.46 In addition, 
when an enterovirus is detected in non-sterile sites, it 
differs from that isolated in samples from sterile sites in 
10% of throat swabs and 20% of rectal swabs.45 In many of 
the sterile sites, however, the viral load is frequently very 
low, as for poliomyelitis; for example, virus is detected in 
0-5% of CSF samples from patients with neurological 
disease.‘■“•I7-2,47“51 The yield for serum is similarly low.17
Vesicular fluid, when present, is more useful, although 
care must be taken during collection (figure 3). Given the 
potential number of samples, laboratories can become 
overwhelmed. One study showed the most efficient 
approach was to examine throat swabs for all patients, 
plus swabs from at least two vesicles or from the rectum 
for patients with no vesicles.45
Virus isolation, serotyping, and nucleic acid detection 
The gold standard for diagnosis of enterovirus infection 
is virus isolation. Several human and non-human primate 
cell lines can be used, including rhabdomyosarcoma, 
which is most efficient, human lung fibroblast cells, and 
African green monkey kidney cells.4’ In rhabdomyo­
sarcoma cells, a characteristic cytopathic effect is observed 
typically 7-10 days after inoculation. To improve the yield, 
blind passage might be necessary before cytopathic effects 
become apparent. Once a cytopathic effect is observed, 
the virus is identified by neutralisation tests in intersecting 
pools of type-specific antisera, EV71-specific antisera, or 
by an indirect immunofluorescence assay with EV71- 
specific monoclonal antibodies.4’ A molecular serotyping 
approach has been developed by amplification of part of 
the VP1 gene of the cultured virus, use of PCR and pan­
enterovirus EV71-specific primers, and sequencing of the 
product.9 Several sets of primers directed at different 
regions of the VP1 gene of EV71 have been developed.5 9 52
EV71-spedfic primers are used to perform PCR directly 
on clinical samples. The advantage of this approach is that 
it is quicker than virus culture. Speed can be especially 
important given the explosive nature of some EV71 
outbreaks and the need for urgent public health 
interventions. The disadvantage is that only the vims 
looked for can be detected and, therefore, other unexpected 
causes will not be identified.52'55 DNA microarray is a 
powerful, although expensive, tool designed to detect 
multiple pathogen targets by hybridisation of pathogen- 
specific probes. Two groups have reported its use to 
distinguish EV71 and coxsackievirus typ>e A 16 infection in 
primary clinical specimens, with diagnostic accuracy of 
about 90%.5’-56
Serology
Serological diagnosis of an acute vims infection classically 
relies on a fourfold increase being shown in the 
concentrations of a specific neutralising antibody 
between the acute and convalescent phases.4’ In the case 
of EV71, however, very high concentrations of neutralising 
antibodies are frequently detectable within the first few 
days of illness, and thus such a difference will not be 
seen.4951 Furthermore, although homologous antibodies 
are produced when young children encounter their first 
enterovims infection, heterologous cross-reacting IgG 
and IgM antibodies are produced by older children and 
adults following repeated infection with different 
enterovims serotypes. The usefulness of this test, 
therefore, decreases with increasing age.
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A rapid IgM ELISA test for EV71 has been developed to 
try to overcome some of the current limitations of 
serological testing.57 The possibility of cross reactivity still 
remains an issue,5* and the duration of detectable EV71- 
specific IgM after an infection is also uncertain.
Other laboratory investigations
In mild EV71 disease, the full blood count and urea and 
electrolyte concentrations are generally normal, but in 
severe disease a raised white cell count with neutrophilia 
is frequently seen and hyperglycaemia might be present.47 
Creatine kinase concentration is sometimes raised in 
patients with cardiac involvement,59 and an increased 
cardiac troponin I level has been reported as a predictor 
of imminent cardiopulmonary failure in children with 
brainstem encephalitis.60 Pulmonary oedema, if present, 
will generally be obvious on chest radiographs; normal 
heart size indicates that the cause is not acute viral 
myocarditis or congenital heart disease. Electro­
cardiography frequently shows non-specific changes,59 
and continuous monitoring can demonstrate abnormal 
beat-to-beat variability, which can be predictive of 
imminent cardiovascular collapse.61 In children who are 
haemodynamically unstable and have tachycardia, 
hypotension, or pulmonary oedema, echocardiograms 
show generalised left ventricular hypokinesia, which 
might be accompanied by mitral regurgitation;57 
pericardial effusion is seldom seen.
The lumbar puncture is essential in children who are 
unwell and who have suspected CNS involvement. In 
some patients the clinical features, such as meningism 
or myoclonic jerks, clearly point to the CNS. In other 
children, however, especially those younger than 2 years, 
there may just be high fever, vomiting, or lethargy, but a 
lumbar puncture shows CNS disease. Mild lymphocytic 
pleocytosis of 10-100 cells per pL is typical, but 
occasionally there might be none.21 The ratio of glucose 
concentration in CSF to that in plasma is generally 
normal, but can be low.
Panel: Characteristics to consider in differential diagnosis of enterovirus 71 infection
Rash
• Viral infections: coxsackievirus type A16, and other enteroviruses,* measles,* rubella,* 
varicella-zoster virus,* human herpes viruses 6 and 7, parvovirus B19, dengue, 
flavivirus infections (especially haemorrhagic fever), alphavirus infections,
Epstein-Barr virus, primary HIV infection, and non-specific viral rashes
• Bacterial infections: meningococcaemia (Neisseria meningitides), scarlet fever 
(Streptococcus pyogenes), leptospirosis, relapsing fever (Borrelia recurrentis), Lyme 
disease (Borrelia burgdorferi), syphilis (Treponema pallidum), and typhus and other 
rickettsial infections
• Other disorders: scabies (Sarcoptes scabei),* drug reactions, allergies, and 
paraneoplastic syndrome
Aseptic meningitis
• Viral infections: echoviruses,* coxsackieviruses and other enteroviruses, herpes 
simplex virus type 2, HIV, mumps, flaviviruses, alphaviruses, and bunyaviruses, 
lymphocytic choriomeningitis
• Bacterial infections: partly treated bacterial meningitis, tuberculous meningitis, 
parameningeal bacterial infections, listeria (Listeria monocytogenes), syphilis, Lyme 
disease (Borrelia burgdorferi), Weil's disease (Leptospira spp), Mycoplasma pneumoniae
• Other disorders: drug reactions, fungal infections (eg, Cryptococcus spp, Candida spp, 
Aspergillus spp)
Flaccid paralysis
• Viral infections: poliomyelitis and other enteroviruses,* vaccine-associated paralytic 
poliomyelitis, flaviviruses (Japanese encephalitis virus, West Nile virus, tick-borne 
encephalitis virus), rabies, adenoviruses
• Bacterial infections: botulism, diphtheria
• Other disorders: intramuscular injection into buttock causing sciatic nerve damage, 
Guillain-Barre syndrome (especially acute motor axonal neuropathy)
Brainstem encephalitis
• Viral infections: poliomyelitis and other enteroviruses,* flaviviruses,* Nipah virus
• Bacterial infections: listeria (Listeria monocytogenes), tuberculosis (Mycobacterium 
tuberculosis), brucellosis (Brucella abortens), Lyme disease (Borrelia burgdorferi)
• Other disorders: paraneoplastic syndromes
The importance of the infections listed varies greatly according to the age and geographic location of the patient. "Especially
likely to be confused with symptoms of entervirus 71. Modified from Solomon,*' with permission of Oxford University Press.
Imaging
Although CT scanning can be helpful to exclude certain 
pathologies, it does not clearly identify EV71 encephalitis, 
where the pathology is mostly in the brainstem, as scans 
are almost always normal. Conversely, MRI shows 
characteristic high signal intensities on T2-weighted 
images in the dorsal pons and medulla, most of the 
midbrain, and the dentate nuclei of the cerebellum. 
Similar high-signal lesions can also be found in the 
anterior horn cells of cervical spinal cord (figure 2).1639 
The usefulness of these changes in terms of sensitivity, 
specificity, and positive and negative predictive value, 
however, has yet to be demonstrated. In children with 
acute flaccid paralysis, MRI typically shows unilateral 
high-signal lesions in the anterior horn cells of the spinal 
cord on T2-weighted images, and contrast-enhancing 
ventral root on Tl-weighted images.366263
Predictors of severe disease
Several clinical features and laboratory abnormalities 
have been associated with neurological and fatal EV71 
disease, but few have been prospectively validated.476064 
Young age at disease onset is associated with increased 
risk of severe disease.65 The results of a prospective 
clinical study of nearly 1500 children presenting to one 
hospital during three EV71 outbreaks in Sarawak over 
7 years showed that neurological involvement was 
strongly predicted by the presence of at least two of the 
following: peak temperature of 38- 5°C or more, fever for 
3 days or longer, and a history of lethargy.21 This study 
confirmed the findings from early retrospective studies. 
However, other early findings, such as an association 
between the absence of mouth ulcers and development 
of complicated or fatal disease,,7-66 were not confirmed. In 
a retrospective study, hyperglycaemia and leucocytosis
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Figure 3: Collection of vesicular fluid from palmar lesions for viralogical diagnosis of hand, foot, and mouth 
disease
(A) The hand should be gripped firmly to prevent movement, the skin stretched tight, and a small needle used to 
puncture the vesicle. (B) A clean swab is applied to collect the fluid released. The swab is placed into viral transport 
medium.
had been associated with fatal EV71 disease47 and were 
confirmed prospectively/1 but these are late symptoms 
that generally occur with fulminant disease and are not 
helpful clinical predictors of complications and death.'5
Not all children with CNS involvement in EV71 
infection will progress to cardiorespiratory collapse. The 
results of a small study involving 46 patients showed that 
children developed abnormal heart rate variability (an 
index of autonomic nervous system disease) about 7 h 
before the clinical onset of cardiorespiratory instability.6' 
The researchers proposed that screening of children with 
CNS involvement for this feature should be done to 
predict impending cardiorespiratory failure and allow 
timely initiation of appropriate interventions. Cardiac 
troponin I is a cardiac-specific biomarker for myocardial 
injury and is measured in patients with suspected acute 
coronary syndrome in adults. Raised concentrations of 
this protein have been observed in children with EV71 
infection, brainstem encephalitis, cardiac dysfunction, 
and pulmonary oedema,60 in some cases before the 
development of cardiopulmonary failure.60 Serial 
measurement of cardiac troponin I concentrations might, 
therefore, be helpful in identifying children at risk of left- 
ventricular failure. Measurement of heart rate variability 
and cardiac troponin I concentrations have not, however, 
become routine clinical practice in the management of 
EV71, probably because of the poor availability of 
technologically advanced equipment needed and the 
high cost, respectively. Even in wealthier Asian countries, 
such as Taiwan, these measures have not entered routine 
clinical practice. Overall, simple clinical parameters, such 
as length of illness, height of fever, and lethargy, are 
probably more useful indicators of potentially 
severe disease.
Treatment
No established antiviral treatments are available for EV71, 
and there are no specific clinical data on antiviral or 
ancillary treatments. Thus, recognition of which 
treatments might be appropriate remains a challenge for 
front-line clinicians.
Antiviral agents
Pleconaril is an antiviral drug that inhibits the entry of 
several enteroviruses into cells by blocking viral 
attachment and uncoating, and has been used in clinical 
trials of aseptic meningitis.67'6, This drug it is not, 
however, active against EV71.70 Several other capsid- 
function inhibitors have been investigated, and some 
have shown promising activities against EV71 in 
predinical studies.70 In-vitro and in-vivo studies show 
that both ribavirin and interferons might be useful,7'-72 
and RNA interference approaches are being explored.71-75
Intravenous Immunoglobulin
During the initial large outbreaks of EV71 in Asia, 
clinicians in Sarawak and Taiwan used intravenous 
immunoglobulin on the presumptive basis that it would 
neutralise the virus and have non-specific anti­
inflammatory properties.'7 44 Retrospective comparisons 
of patients who did and did not receive immunoglobulin 
suggest a benefit from this treatment if given early/1-76 For 
example, among children with EV71 assessed in Sarawak 
over three seasons, 204 (95%) of 215 survivors who had 
severe CNS complications had received intravenous 
immunoglobulin treatment, typically once there was 
evidence of severe disease, such as tachycardia or poor 
perfusion or altered consciousness, compared with only 
one (11%) of nine fatal cases (odds ratio 148-36, 95% Cl 
16 • 34-6609 • 04, p<0 • 0001)/' Analysis of cytokine profiles 
before and after immunoglobulin treatment showed 
substantial reductions in concentrations of some 
proinflammatory cytokines in patients with EV71 if they 
had encephalitis with autonomic dysfunction, but not if 
they had less severe disease.76-80 Intravenous immuno­
globulin has, therefore, become more routinely used for 
the treatment of severe EV71 disease, and in Taiwan has 
been introduced into the national treatment guide­
lines.17 21-40-4'-8' Uncertainty remains, however, over whether 
this expensive human blood product treatment is really 
effective, and randomised, placebo-controlled, phase 2 
trials are needed. Such trials would be logistically and 
ethically challenging to establish because the treatment 
is so widely used, and would require careful design with 
surrogate endpoints of disease progression, such as 
failure of resolution of tachycardia.
Milrinone
Milrinone is a cyclic nucleotide phosphodiesterase 
inhibitor currently used in the treatment of congestive 
heart failure. Inhibition of phosphodiesterase subtype III 
by this cardiotrophic agent results in an increase in 
intracellular concentrations of cyclic AMP, which in turn 
leads to increased cardiac output and decreased peripheral 
vascular resistance. The results of a small, non- 
randomised, retrospective assessment of 24 children 
with EV71-induced pulmonary oedema showed that those 
treated with milrinone had reduced tachycardia and 
lower mortality than those who did not receive this
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drug.8'*82 Peripheral white cell and platelet counts and 
plasma interleukin 13 concentrations were also lower,82 
which might indicate an immunomodulatory effect of 
the drug. A clinical study examining efficacy of milrinone 
is said to be ongoing.83
Fluid balance and inotrope support
In routine paediahic practice, the most common cause 
of shock and peripheral shut down is hypovolaemia and 
dehydration, for example after gastrointestinal infection. 
These disorders are treated with rapid fluid resuscitation. 
When similar approaches were used in the early EV71 
outbreaks in Asia, however, they frequently precipitated 
pulmonary oedema. After it became clear that impaired 
cardiac function is an important contributor to shock, 
clinicians were more judicious in their use of intravenous 
fluids and used inotrope support. Fluid management 
should, whenever possible, be guided by measurement 
of central venous pressure. In Taiwan, management 
algorithms based on this approach seem to have 
improved outcome.7<i
Outcomes
Studies up to 7 years after infection show that children 
who present with aseptic meningitis generally have good 
outcomes, although parent and teacher reports indicate 
that the incidence of symptoms similar to those in 
attention deficit-hyperactivity disorder is 20% among 
children who have recovered from EV71 CNS infection, 
compared with 3% for matched controls.84 Approximately 
a fifth of children with severe neurological disease, 
including encephalitis, poliomyelitis-like paralysis, and 
encephalomyelitis, have sequelae, particularly focal limb 
weakness and atrophy.63*85*86 Cerebellar disorders are 
observed in about 10% of patients after moderately severe 
brainstem encephalitis, including cranial neuropathies, 
myoclonus, tremor, and ataxia. Of those, however, only a 
quarter with severe brainstem encephalitis associated 
with fulminant cardiorespiratory failure make a full 
neurological recovery.65*86 Common sequelae include focal 
limb weakness and atrophy, swallowing difficulties 
requiring nasogastric feeding, central hypoventilation, 
facial nerve palsies, seizures, and psychomotor 
retardation.
Conclusions
Over the past 12 years, EV71 has evolved from being a 
rare and sporadic cause of HFMD to a cause of major 
and regular epidemics across the Asia-Pacific region and 
| a disease frequently associated with severe and sometimes 
fatal neurological complications. Across Asia a range of 
diagnostic techniques is used. Standardisation via some 
form of laboratory network with proficiency panels to 
allow comparison of laboratory findings and ensure 
quality control might prove useful. Reliable ways of 
predicting who will develop HFMD and who will have 
' neurological complications and which patients with CN S
involvement are at risk of disease progression are still 
lacking. Intravenous immunoglobulin is now used 
presumptively for severe EV71 infection in many Asian 
countries, even though there are almost no data on its 
efficacy and this treatment is expensive. Evidence-based 
clinical practice guidelines for diagnosis and treatment 
would considerably help the management of this 
emerging neurological infectious disease.
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